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ABSTRACT 
Background: Group B Streptococcus (GBS) is the leading cause of neonatal sepsis and 
meningitis. Currently, the UK recommends against universal antenatal screening to prevent 
early-onset GBS disease (EOGBS, <7 days). Key gaps around GBS natural history, harms 
from screening and a lack of high-quality data to prove screening effectiveness make it 
difficult to ensure the benefits of GBS screening outweigh the harms. There is also a wider 
gap on policy-making processes for screening. The overall aim of this thesis is to address these 
gaps and examine whether the UK should introduce universal GBS screening as a result.  
Methods: In addition to a literature review, I used two approaches: systematic review/meta-
analysis and ecological trend analysis. The systematic reviews synthesised evidence on the 
screening policy-making processes, mechanisms of EOGBS and adverse events from 
intrapartum antibiotic prophylaxis (IAP) to prevent EOGBS. In the absence of RCTs, I 
combined ecological data on the benefits and harms of GBS screening, then analysed their 
trends across time compared with other prevention strategies in regression analyses adjusting 
for context differences.  
Results: Evidence from 17 countries showed that most GBS screening recommendations were 
not developed by screening organisations and it is not known whether screening principles 
and the likely unseen harms of GBS screening were considered. Seventeen studies revealed 
that we do not fully understand the natural history of why some mothers, but not others, 
transmit GBS to their neonates, or which neonates will develop EOGBS. There was consistent 
evidence that heavy bacterial load was associated with transmission and progression to 
EOGBS. Neonates colonised with serotype III were also twice as likely to develop EOGBS 
compared with serotype Ia and II. However, the evidence was old and at high risk of bias. The 
selective culture test at 35 to 37 weeks gestation is not an accurate predictor of EOGBS and 
at least 99% of screen-positive and treated mothers (and their neonates) would be over-treated. 
Seventeen observational studies and 13 RCTs showed a wide range of potential harms from 
IAP, including cerebral palsy, functional impairment and antibiotic resistance. However, there 
was little high-quality and applicable evidence to quantify the frequency of adverse events. 
The three ecological trend analyses combining data from 59 geographical areas showed that 
EOGBS incidence decreased by approximately 0.02 per 1,000 livebirths per year in areas that 
most recently reported GBS screening, whereas it increased by approximately 0.01 to 0.02 per 
1,000 livebirths in areas most recently reporting risk-based prevention. Areas that recently did 
not have GBS prevention displayed conflicting EOGBS trends. By contrast, there was no 
evidence that screening impacted annual early-onset sepsis trends compared with other, or no 
prevention strategies; however, this study did not have a sufficient sample size. The was no 
harmful impact of GBS screening on LOGBS trends compared with other, or no prevention. 
There was also no evidence that screening increased early-onset E. coli incidence and the 
percentage of GBS cases resistant to clindamycin and erythromycin, compared with risk-
based or no prevention; again, these analyses did not have a sufficient sample size. The 
findings of these studies must be treated with caution as some results may be due to low 
statistical power and others were unstable across analyses. The findings also contain numerous 
limitations as covariates were poorly collected in most countries. Therefore, the evidence on 
the benefits and harms of universal GBS screening remains inconclusive.  
Conclusion: GBS infection is an important health condition and its persistence, poor 
screening tests and the IAP harms stress the need for a better understanding of the natural 
history of GBS and more effective prevention. Evidence on the harms and benefits of GBS 
screening is limited, therefore, screening should not be introduced in the UK. Ecological trend 
analysis was not an adequate method to inform GBS screening decisions, however, it may be 
useful for screening decisions on other conditions.
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1. INTRODUCTION 
In this chapter, I will introduce the main issues underpinning this PhD thesis and describe the 
structure of my thesis. In Chapter 2, I will provide a detailed review of the background 
literature surrounding the thesis and in Chapter 3, I will introduce the thesis aims and 
objectives. 
1.1 Health problem  
Streptococcus agalactiae, or Group B Streptococcus (GBS), is a gram-positive bacterium that 
was first recognised as a serious child health concern in the 1960s and 1970s.1 Since then, 
GBS has remained the leading cause of neonatal sepsis and meningitis in the United Kingdom 
(UK) and other developed countries.2, 3 Early-onset GBS disease (EOGBS) in the first six days 
of life accounts for around 60% to 70% of neonatal GBS disease and originates from GBS 
passing from mothers to their neonates during labour.3 It is not known why 36.4% of mothers 
colonised with GBS pass it on to their neonates or why 1% to 3% develop EOGBS.4  
The incidence of EOGBS in the UK is approximately 0.57 per 1,000 livebirths,5 which equates 
to approximately 443 neonates every year. EOGBS progresses rapidly, presenting with sepsis 
in 63% of cases, meningitis in 13% and pneumonia in 24%.5 Ten percent of EOGBS cases 
will die as a result,6 though the most recent surveillance reported a case fatality rate of 5.2% 
in the UK.5 Neonates who survive with EOGBS can suffer from long-term 
neurodevelopmental abnormalities in around 8.7% or 15.8% of cases.7 8 EOGBS meningitis, 
in particular, can lead to long-term neurological impairment in up to 50% of cases.9 Although 
EOGBS is relatively rare, it is an important health condition as it can lead to long-term and 
fatal consequences.  
1.1 GBS prevention treatment  
The current recommendation to prevent EOGBS is to offer antibiotic prophylaxis during 
labour to mothers at risk of having a neonate with GBS.1, 3 With vaccinations currently in 
development and licensure awaiting, intrapartum antibiotic prophylaxis (IAP) treatment is the 
only prevention option. A Cochrane review of all randomised controlled trials (RCTs) 
assessing the effectiveness of IAP found that it reduced the incidence of EOGBS by 83% 
compared with no treatment.10 However, the evidence was at high risk of bias making the 
estimate uncertain.10 Nevertheless, the current IAP recommendation is intravenous penicillin 
(or ampicillin in the US and Italy) given as soon as possible after the onset of labour and then 
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every four hours until delivery.11-14 For mothers allergic to penicillin, second-line treatment 
recommended in the UK was intravenous clindamycin, 13 however, this has changed in the 
new guidelines published in September 2017 to cephalosporin.15 If a woman has a history of 
severe allergy to beta-lactams vancomycin is recommended. Similarly, in the United States of 
America (US) since 2010, the first alternative is intravenous cefazolin followed by 
clindamycin.14 
1.2 GBS prevention strategies 
There are different prevention strategies to identify women at risk of having a baby with 
EOGBS in order to offer IAP. The UK adopts risk-based prevention, whereby women who 
present with known EOGBS risk factors in labour, such as maternal GBS colonisation, 
bacteriuria, a previous baby with GBS disease or intrapartum fever are offered IAP.12, 13 There 
are currently no high-quality studies on the effectiveness of risk-based prevention. Under risk-
based prevention in the UK, EOGBS incidence has not decreased, but instead, has increased 
from 0.48 to 0.57 per 1,000 livebirths.5 The risk-based prevention strategy has also been 
criticised as above 30% of EOGBS cases without risk factors are excluded from prevention.5 
To increase the identification of pregnant women colonised by GBS an alternative strategy is 
universal antenatal screening. This mainly involves culturing rectal and/or vaginal swabs from 
all pregnant women and offering IAP to those with positive screening results. Testing is 
administered at 35 to 37 weeks gestation as culture takes 24 to 48 hours to process and the 
results would not be available in time to treat in labour. Observational evidence, at high risk 
of bias, reports that the odds of EOGBS is 55 to 75% lower during periods of screening 
compared with historical periods of risk-based or no prevention.16, 17 There has been no RCT 
assessing the effectiveness of GBS screening on the morbidity and mortality of EOGBS 
making it increasingly difficult to calculate the impact of screening. Concerns have also been 
raised about the potential harms from widespread IAP under screening, including increases in 
antibiotic resistance,18 neonatal infections caused by gram-negative bacteria (as a result of 
selection pressure) and changes in the neonatal microbiota leading to long-term health 
problems.4, 19, 20 Widespread IAP may also cause a maternal predisposition to Clostridium 
difficile infection21 maternal anaphylaxis14 and the increased medicalisation of labour.4, 13 
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1.3 UK GBS screening recommendation  
In the UK, screening programmes are national, and the UK National Screening Committee 
(NSC) is tasked with providing triennial evidence-based recommendations about whether or 
not to introduce nominated screening programmes. To reach a decision, the UK NSC assesses 
the evidence against internationally recommended screening criteria.22 In 2012, the UK NSC 
reviewed the evidence for universal GBS screening, concluding that, it is difficult to ensure 
that the benefits of screening would outweigh the harms due to evidence gaps around key 
screening criteria.23 In particular, there was no evidence about why some neonates develop 
EOGBS, and others do not (natural history), nor the frequency and severity of screening 
associated IAP harms. Furthermore, a lack of RCT evidence inhibited information on the 
effectiveness of screening. 
1.4 Chapter summary 
EOGBS is an important health condition, and with the increasing rate of EOGBS in the UK, 
an effective prevention strategy is required to reduce the morbidity and mortality that neonates 
suffer as a result. Universal GBS screening is a potential strategy to prevent EOGBS, however, 
there is a need to address the current gaps in the evidence base in order to assess whether it 
should be introduced in the UK.  
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2. BACKGROUND  
In this chapter, I will examine the literature on EOGBS and the strategies to prevent it, 
particularly universal screening. This will involve the key issues of GBS epidemiology and 
natural history, IAP treatment and its effectiveness, GBS prevention strategies, screening as a 
concept, universal GBS screening and the evidence on the benefits and harms from universal 
screening.  
2.1 Data sources  
Much of this chapter is informed by the 2016 UK NSC evidence review on the policy of 
universal GBS screening,24 which I successfully led with the help of my supervisors and a 
multi-disciplinary team of experts. The team included public health and screening experts, 
infectious diseases consultants, clinical microbiologists, gynaecologists and systematic 
reviewers and meta-analysts. While the overarching objectives of the review were set by the 
NSC, I led the design of the specific research questions and the methodology to address them. 
I also performed the searches, study selection, data extraction and report writing. My 
supervisors and other team members contributed their technical expertise by reviewing and 
advising me throughout. Some of the team members were also involved with study selection, 
data extraction and report writing. 
For the 2016 NSC review, I conducted comprehensive literature searches in well-known and 
recommended electronic databases: Medline, Medline In-process, Embase and the Cochrane 
Library, from January 2012 to 21st April 2016. I applied a comprehensive search using the 
following MeSH and text terms that I combined with the Boolean operator OR: Streptococcus 
agalactiae/, group b adj streptococc* and Streptococc* agalactiae. I also searched Public 
Health England for published reports, unpublished data from the British Paediatric 
Surveillance Unit (BPSU) and unpublished data from Mothers and Babies: Reducing Risk 
through Audits and Confidential Enquiries (MBRRACE-UK). As the NSC review was only 
from 2012 to 2016, for the purposes of this chapter, I have supplemented the literature review 
with evidence published before 2012 or after 2016 if it was of higher quality.  
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2.2 The health problem 
2.2.1 Natural history 
GBS is a gram-positive commensal bacterium that principally colonises the gastrointestinal 
and genitourinary tract in approximately 30% of healthy adults.25, 26 GBS colonisation can be 
persistent, transient or intermittent.27 As a natural reservoir for GBS is the genitourinary tract, 
GBS can colonise the vagina during pregnancy and labour. Globally, GBS colonisation in 
pregnant women varies and, in developed countries, GBS has been identified from vaginal 
and/or rectal swabs in between 10% and 30% of women tested.28, 29 A recent meta-analysis of 
78 studies including 73,791 pregnant women across 37 countries estimated a global 
prevalence of 17.9% (95% confidence intervals [CI] 16.2 to 19.7).30 The highest incidence 
was reported in Africa (22.4%, 95% CI 18.1 to 26.7), followed by the Americas (19.7%, 95% 
CI 16.7 to 22.7), Europe (19%, 95% CI 16.1 to 22), and southeast Asia (11.1%, 95% CI 6.8 
to 15.3). In the UK, maternal GBS colonisation is estimated at 21%,31 although prevalences 
of 14%,32, 4 19%33 and as high as 29%34 have been reported. Differences in prevalences could 
be attributable to socio-demographic factors, such as the ethnic make-up of the participants, 
the geographical location, as well as the methodology used. For example, culturing swabs 
from the vagina and rectum with a selective culture medium, compared with a vagina-only 
swab and/or a standard culture medium, can increase the detection of GBS.35 However, in the 
recent meta-analysis, differences in the timing of specimen collection in pregnancy or 
selective culture methods did not explain heterogeneity.30  
When a pregnant woman is vaginally colonised during labour, a meta-analysis estimated that 
there is a 36.4% (95% CI 28.1 to 45.0) risk that GBS can be transmitted to her neonate, either 
through the neonate passing the colonised birth canal or GBS ascending in utero.4 Rates 
around 50% have also been reported.3, 36 The majority of the colonised neonates will be 
asymptomatic. However, 3.0% (95% CI 1.6 to 4.7) of colonised neonates will suffer from 
GBS in the first six days of life,4 although rates as low as 1% have also been reported.3 The 
natural history of GBS is summarised in Figure 1 on a hypothetical cohort of 718,126 term 
pregnant women. The estimates for each point in the natural history pathway are based on the 
best available data, however, they do contain uncertainties. For example, the estimate for the 
risk of EOGBS in colonised neonates is calculated from a small number of cases pooled from 
non-UK studies published between 1979 and 1998, therefore, the estimate may not be 
applicable to the UK today.4 The risk of EOGBS in colonised term neonates may also be lower 
than 1.6% as the burden of EOGBS is lower in term compared to preterm neonates. Indeed, 
the total number of term EOGBS cases in  Figure 1 (916/718,126, 1.28 per 1,000 term 
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livebirths) is much higher than the enhanced surveillance estimates in section 2.3.1. Therefore, 
these estimates should be used cautiously for a sense of scale but not as exact estimates.  
The natural history of GBS in the gastrointestinal and genitourinary tract is poorly understood. 
In particular, the reasons why 36% of colonised mothers transmit GBS to their neonates, while 
the other 64% do not, or the reasons why, in 1% to 3% of GBS colonised neonates, the 
commensal becomes a pathogen causing invasive GBS disease, are largely not known. As for 
many other pathogens, the polysaccharide capsule appears to be important. There are 10 GBS 
capsular serotypes – Ia, Ib, II-IX.25, 26, 37 Types Ia, Ib, II, III and V are more commonly 
responsible for GBS disease,38-43 with 80.3% of neonatal GBS disease within six days 
attributed to serotypes III and Ia.39 Isolates of GBS that are not typeable on capsular serotyping 
are also found to be less associated with invasive disease, supporting the association of the 
capsule with virulence. Interestingly, a study in South Africa exploring the temporal changes 
in invasive GBS serotypes found a 9.4% increase in the incidence of serotype Ia and a 7.4% 
decrease in serotype III invasive disease.44 Although there were some changes in serotype 
distribution, both serotypes Ia and III were still the most dominant across time. In the UK, 
serotype III is the most commonly reported serotype in neonatal GBS disease (60%) followed 
by Ia (17.2%).5 The number of serotype III cases increased from 2000/01 to 2014/15, 
mirroring an increase found in disease incidence.5 
Congruent with this is the evidence, summarised in a recent systematic review, that low levels 
of GBS serotype-specific capsular antibody levels are associated with increased risk of GBS 
disease in neonates. However, the reviewers found substantial heterogeneity in assay methods 
and a lack of standardised reference ranges for functional antibody levels.45 Recently, a study 
in Gambia also found that no infant was colonised with GBS above a serotype-dependent 
antibody threshold, and that a higher antibody concentration was also associated with 
clearance of GBS between birth and 60 to 89 days.46  
A number of other virulence factors such as resistance to antimicrobial peptides, factors for 
immune evasion and pore-forming toxins have been proposed in laboratory and clinico-
epidemiological studies as important in the pathogenesis of GBS disease.47-49 The majority of 
these have little or no clinical or experimental evidence to confirm their role. A clonal 
complex, known as CC-17 has been described as hypervirulent in a number of geographical 
locations, with enhanced risk of disease in the neonate and higher rates of meningitis.41, 40, 50, 
51A CC-17 specific surface protein of GBS, which promotes attachment to intestinal and 
meningeal cells, has been described as an important determinant of hypervirulence.52 It has 
also been demonstrated that sequence types do not always follow serotypes.51  
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2.2.2 Clinical presentation and prognosis  
An invasive GBS diagnosis is most commonly confirmed by culture of the organism from 
blood, cerebrospinal fluid or another sterile site. Invasive GBS disease in the neonate is 
separated into early-onset GBS (EOGBS) and late-onset GBS (LOGBS). EOGBS occurs 
during the first six days of life (although definitions can vary across countries), with the 
majority of cases occurring within the first day of life.25, 26 The most recent estimate in the UK 
reported that approximately 67% of EOGBS cases present within the first 24 hours.5 EOGBS 
cases progress rapidly with the majority presenting with sepsis, pneumonia and meningitis; in 
in rare cases, bone and joint involvement occur.25, 26 In the UK, the relative proportion of cases 
with each type of morbidity has been remained stable between 2000/01 and 2014/15; 63% 
present with sepsis, 23% to 26% with pneumonia and 11% to 13% with meningitis.5 The 
clinical symptoms of EOGBS are not very specific to this pathogen but neonates could be 
irritable, lethargic, feed poorly or present with respiratory disease.53 
Conversely, LOGBS presents between seven and 89 days of life and is associated with 
localised infections, particularly meningitis.25, 26 In the UK, the percentage of LOGBS cases 
presenting with meningitis decreased from 43% to 28.9%.5 While maternal colonisation is the 
direct cause for EOGBS, LOGBS is predominantly caused by perinatal, nosocomial and 
community sources.3 The remaining review will focus more heavily on EOGBS as it is 
amenable to maternal prevention strategies. 
Further to the initial morbidity, EOGBS can result in death and disability. Without treatment, 
case fatality rates from EOGBS in the 1970s were reported at 20 to 50%. This has substantially 
declined to 10% or lower as a result of antibiotic treatment.25, 26, 1 Therefore, neonates with 
symptoms of EOGBS should be tested for culture confirmation and treated with intravenous 
antibiotics as soon as possible.  
For GBS survivors, there is the risk of chronic neurodevelopmental sequelae, particularly from 
meningitis. Eastwood et al. (2014) found that 8.7% of surviving EOGBS cases had abnormal 
neurodevelopment although it was uncertain whether the sequelae were related to GBS or 
prematurity.7 In Japan, a study found that 15.8% of surviving EOGBS cases and 33% in 
EOGBS meningitis cases had neurological sequelae, with no difference in preterm and term 
neonates.8 In another Japanese study, sequelae were observed in 11.3% of EOGBS cases, with 
around 30% suffering neurological sequelae from EOGBS meningitis. The neurological 
sequelae included one or more of the following: brain atrophy, cerebral infarction, cerebral 
palsy, mental retardation/developmental delay, diabetes insipidus, encephalomalacia, hearing 
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impairment, hydrocephalus, seizure disorder and visual impairment.54An earlier study in the 
UK showed that, after GBS meningitis, 50% had neurodevelopment impairment at five years 
of age. Of the 98 neurological meningitis cases, 13% had severe disability, 17% had moderate 
disability and 18% had mild disability.9 A study in the US in 2012 found that GBS meningitis 
resulted in 25% of cases having mild to moderate impairment while 19% had severe 
impairment.55 Relatedly, a recent published meta-analysis reported a pooled relative risk (RR) 
of 4.99 (95% CI 3.17 to 7.86) for low IQ (less than 70) as well as developmental delay in 
survivors of bacterial meningitis, compared with controls.56  
 
2.3 GBS Epidemiology  
2.3.1 Incidence and mortality  
Despite prevention, treatment and management efforts, GBS remains the most important cause 
of neonatal sepsis and meningitis. Globally, a meta-analysis of data from 2000 onwards, 
estimated that the incidence of neonatal GBS is 0.53 per 1,000 livebirths (95% CI 0.44 to 
0.62), although this is likely an underestimate.6 The GBS burden varies geographically, with 
the highest incidence per 1,000 livebirths found in Africa (1.21), followed by the Americas 
(0.67), Europe (0.57), Eastern Mediterranean (0.35), Western Pacific (0.15) and very low 
estimates in Southeast Asia (0.016).6 EOGBS incidence is estimated at 0.43 per 1,000 
livebirths (95% CI 0.37 to 0.49), double the incidence of LOGBS (0.24).6 EOGBS incidence 
is the highest for Africa and lowest for Southeast Asia (see Table 1).6   
Table 1. Incidence of early onset group B Streptococcus per 1000 livebirths by region6 
Region Incidence of early onset group B Streptococcus 
Africa 0.53 (0.15 to 0.92) 
Americas 0.50 (0.43 to 0.57) 
Europe 0.45 (0.34 to 0.56) 
Southeast Asia 0.11 (0.012 to 0.220) 
 
The burden of GBS differs by country. In the US, multi-state, population-based active 
surveillance reported that the incidence of EOGBS per 1,000 livebirths was 1.7 per 1,000 
livebirths in the early 1990s but is now around 0.23 per 1,000 livebirths in 2015.14, 57 It is 
important to note that these estimates are of culture-proven EOGBS and although this is the 
primary and standard outcome of interest, the more recent figures during periods of antibiotic 
prevention are likely to underestimate the true burden of the EOGBS due to antibiotics given 
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to women. The presence of the antibiotics in the blood of neonates could prevent the isolation 
of GBS from neonatal blood in the laboratory, despite the organism being present. LOGBS 
rates from the 1990s until 2015 has remained between 0.3 and 0.4 per 1,000 livebirths.14 In 
the 1990s, it was estimated that approximately 7600 cases of GBS cases occurred in the US, 
with 310 deaths.3 In Alberta, Canada, EOGBS increased from 0.15 per 1,000 livebirths in 
2003 to 0.34 per 1,000 livebirths in 2013.58 In Europe before 2000, the EOGBS incidence per 
1,000 livebirths was 3.35 in Czech Republic,59 0.2 to 0.3 in Denmark,60 0.6 to 0.7 in Finland,61, 
62 0.69 to 4.5 in France,63, 64 0.11 to 0.54 in the Netherlands,65, 66 0.46 in Norway,67 2.4 in 
Spain,68 and 5.4 in Vienna.69, 1 Since then, EOGBS incidence rates have been 1.96 per 1,000 
livebirths in Czech Republic,59 0.19 in the Netherlands,66 0.46 in Norway,70 0.33 in Spain,68 
and 0.47 in Germany71 In Australia and New Zealand, the incidence of EOGBS was 1.43 per 
1,000 livebirths in 1993, which reduced to 0.25 in 2001.72 The lower incidence rates reported 
more recently are attributed to prevention and treatment strategies.  
In Africa, a recent meta-analysis estimated a high EOGBS incidence of 1.3 per 1,000 livebirths 
(95% CI 0.81 to 1.90) despite methodological limitations that would lead to an 
underestimation.73 A small recent study of 500 women in Nigeria reported an incidence of 
2.00 per 1,000 livebirths, while, in Kenya, a study of 7,967 women reported a rate of 0.76 per 
1,000 livebirths in the hospital, but a reduced rate of 0.13 using a population denominator.41 
As indicated, the incidence of EOGBS is relatively lower in Asian countries, for example, a 
recent study in Japan, reported a rate of 0.09 per 1,000 livebirths.54 In Malaysia, the EOGBS 
incidence per 1,000 livebirths was reported at 0.26, in India 0.15 to 0.17 and in Bangladesh 
0.10.74 In Thailand, EOGBS incidence was 0.27 per 1,000 livebirths in 1996 but 0.10 in 
2001.75 Across Latin America, in Brazil, EOGBS incidence was reported at 0.39 to 1.0 per 
1,000 livebirths and recently 0.90 per 1,000 livebirths.76 In Mexico, it was reported at 0.60 per 
1,000 livebirths.74  
In the UK, single centre studies in England reported neonatal GBS incidence rates of 0.5 to 
1.4 per 1,000 livebirths through the 1990s.77-79 In 2000/01, enhanced surveillance across the 
UK and the Republic of Ireland reported a neonatal GBS incidence of 0.72 per 1,000 livebirths 
(568 cases), EOGBS incidence of 0.48 per 1,000 livebirths (377 cases) and LOGBS incidence 
of 0.24 per 1,000 livebirths (191 cases).80 The enhanced surveillance was reproduced for 
2014/15 and the authors found an increase in the GBS burden. The neonatal GBS incidence 
across all five countries in the British Isles was 0.94 per 1,000 livebirths (856 cases), EOGBS 
incidence was 0.57 per 1,000 livebirths (518 cases) and LOGBS incidence was 0.37 per 1,000 
livebirths (339 cases).5 EOGBS incidence in the latest survey varied slightly across the 
different countries with the lowest incidence in the Republic of Ireland (0.45 per 1,000 
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livebirths) and the highest in Northern Ireland (0.64 per 1,000 livebirths). The incidence of 
both EOGBS and LOGBS has increased from the 2000/01 survey with the biggest increase 
observed in Scotland (from 0.21 to 0.49 per 1,000 livebirths). While these are the best 
available data in the UK, the enhanced surveillance studies were only at two points in time 
(14 years apart), thus, it is not clear how the incidences might fluctuate year by year. The 
authors of the surveys have also mentioned that the observed increase in the EOGBS incidence 
might be, in part, due to technical improvements in the increased awareness of neonatal GBS, 
increased case ascertainment and bacterial culturing practices. Nevertheless, voluntary annual 
surveillance collected by Public Health England between 2000 and 2010 has also shown that 
EOGBS incidence increased from 0.28 to 0.41 per 1000 livebirths and LOGBS increased from 
0.11 to 0.29 per 1,000 livebirths.81 Again, the limitations of focussing the surveillance to 
culture-proven EOGBS may underestimate reported incidences.  
The global mortality rate of neonatal GBS disease has been estimated at 9.6% (95% CI 7.5 to 
11.8%), EOGBS at 12.1% and LOGBS at 6.8%.6 Case fatality of neonatal GBS was three 
times higher in low-income countries at 12.6% compared with high income countries at 4.6%.6 
Case fatality rates of EOGBS have been reported at around 4.7% in the US,82, 8% in Finland,61 
4.3% in Germany,71 6.6% in Portugal83 and 4.5% in Japan.54 In the UK, the enhanced 
surveillance study found a case fatality rate of 5.2%; a statistically significant decrease from 
10.6% in 2000/01 (p=0.01).5 Data from MBRRACE-UK reported that, in 2014, there were 17 
GBS-related neonatal deaths within 7 days of life, 13 of whom had GBS as a primary cause 
of death and four who had GBS as a co-factor of death among 777,764 livebirths. This equates 
to a rate of 2.2 per 100,000 livebirths and 1.72% (17/991) of all early neonatal deaths.84 
Related to GBS mortality is the burden of GBS related stillbirths, which has been relatively 
less researched. A systematic review searching the literature up to 2015, concluded that the 
incidence of GBS related stillbirths varied substantially between 0.04 to 0.9 per 1,000 births 
between studies.85 The proportion of stillbirths associated with GBS varied between zero to 
12.1% across studies. In the UK, data from MBRRACE for 2014 identified 31 GBS related 
stillbirths among 780,979 total births corresponding to a rate of 0.04 per 1,000 total births and 
0.96% of all stillbirths.84 GBS was reported as the primary cause of death in 24 cases and as a 
co-factor of death in seven cases. 
2.3.2 Risk factors 
There are a number of maternal, obstetric and neonatal risk factors that increase the risk of 
EOGBS disease. Some of these factors are well-defined and provide an important 
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understanding into the development of EOGBS. Other factors are not clear due to 
contradictory results in the literature and the interrelated relationships between them, making 
them less helpful to direct clinical management.3 It has been well-established and 
internationally reported that babies born preterm and colonised with GBS are at an increased 
risk of developing EOGBS as their immune systems are immature.35, 3, 6, 86, 87 Daniels et al. 
(2009) report that the pooled incidence of EOGBS disease from five studies showed that 40% 
of cases were preterm, which gave a 5.5 times higher risk for preterm compared with term 
neonates.35 In a case-control study, the odds of having GBS for preterm neonates was 10.4 
(95% CI 3.9 to 27.6).88 Indeed, the recent enhanced surveillance in England and Wales 
reported that EOGBS incidence was inversely associated with gestational age at birth 
decreasing from 4.42 per 1,000 livebirths before 28 weeks to 0.41 per 1,000 livebirths after 
37 weeks of gestation (see Table 2).5 Overall, 21.9% of EOGBS were preterm (37 weeks). 
Prematurity was also an independent risk factor for EOGBS mortality. Case fatality decreased 
from 47.1% in neonates born before 28 weeks of gestation to 2.8% in neonates born after 27 
weeks (see Table 2).5 Low birthweight, related to prematurity, is also inversely related to 
EOGBS incidence.87 For example, EOGBS incidence in the enhanced surveillance was 2.24 
per 1,000 livebirths in neonates weighing less than 1500g,  1.17 in neonates 1500 to 2499g 
and 0.43 in neonates born 2500g and above.5  
Table 2. EOGBS incidence and mortality by gestational age at birth in England and Wales5 
Gestational 
weeks 
EOGBS 
cases 
  
EOGBS incidence per 
1,000 livebirths (95% 
CI) 
Number of EOGBS 
deaths 
Case fatality 
rate 
<28 14 4.42 (2.42 to 7.40) 8/17 47.1% 
28-36 68 1.27 (0.99 to 1.61) 7/77 9.1% 
≥37 283 0.41 (0.36 to 0.46) 9/321 2.8% 
All 343 0.46 (0.41 to 0.51) 24/415 5.8% 
EOGBS early-onset GBS, GBS group B Streptococcus 
Vaginal GBS colonisation has been identified as an important risk factor for EOGBS. In one 
study, GBS colonised women had a 29 times higher likelihood of EOGBS compared with 
women who were not colonised.89 In a case-control study where birthweight and birth time 
were controlled for, Heath et al. (2009) reported that compared with uncolonised mothers, 
vaginal colonisation increased the risk of GBS by OR 8.47 (95% CI 3.73 to 19.22) (74% 
EOGBS).88 In the study, it was not clear at what point GBS colonisation was assessed and this 
is important as GBS colonisation can be transient and intermittent. Nevertheless, GBS 
colonisation remained a statistically significant risk factor in the multivariable analysis (odds 
ratio [OR] 6.88, 95% CI 2.77 to 17.1). Heavier GBS colonisation, in particular, has been more 
strongly associated with EOGBS than light colonisation.90, 91  
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Another important risk-factor for EOGBS is the premature or prolonged rupture of 
membranes. It is argued that the prolonged rupture of membranes increases the risk of GBS 
colonisation and disease by increasing the opportunity and likelihood of GBS infection 
ascending in utero.35, 92 However, it is also argued that GBS may be causing the prolonged 
rupture of membranes.35, 92 Recently, Surve et al. (2016) demonstrated in a rat model that, 
GBS produces membrane vesicles, which lead to chorioamnionitis and damage to the 
membrane resulting in preterm birth or fetal death.93 The rupture of membranes for more than 
18 hours prior to delivery has been associated with a 25.8 (95% CI 10.2 to 64.8) times higher 
risk of EOGBS in one study.94 However, in the case-control study by Heath et al. (2009), 
prolonged rupture of membranes ( 18 hours) had an OR of 2.69 (95% CI 1.67 to 4.34) for 
GBS disease in the unadjusted analysis, which lost statistical significance in the multivariable 
analysis (OR 1.82, 95% CI 0.99 to 3.35).88 The latest enhanced survey found that 31.7% of 
EOGBS cases had prolonged rupture of membranes ( 18 hours, term and preterm), 9.6% had 
preterm prolonged rupture of membranes ( 18 hours) and 11.4% had preterm, pre-labour 
rupture of membranes.5 The current understanding of prolonged rupture of membranes is 
limited, especially the differences in the association of preterm, term and preterm pre-labour 
rupture of membranes with GBS.95  
Neonates born to mothers suffering from intrapartum fever or pyrexia are also at an increased 
risk. In their case-control study, Heath et al. found that intrapartum fever was associated with 
GBS even in multivariable analyses (OR 2.16 for every °C increase in maximum temperature, 
95% CI 1.32 to 3.53).88 In the recent survey, 19.3% of EOGBS cases had intrapartum fever. 
In the US, a case-control study, matched for gestational age, also found that intrapartum fever 
increased the odds of EOGBS (OR 4.1, 95% CI 1.2 to 13.4).96 
In addition to these key risk factors, Heath et al. (2009) found that women having their first 
baby, GBS bacteriuria during pregnancy, an epidural during labour, having one or more 
vaginal examinations during labour, emergency intervention during labour, infection after 
delivery, foetal tachycardia, foetal distress, foetal blood sampling during labour or maternal 
post-delivery antibiotics also increased the risk of EOGBS in univariable analyses.88 In the 
multivariable analysis, besides maternal GBS colonisation and intrapartum fever, maternal 
infection after delivery also remained statistically significant (OR 4.17, 95% CI 1.12 to 15.4). 
Other studies have similarly found that black ethnicity, teenage maternal age, and history of 
miscarriage increased the risk of EOGBS.97, 98 However, when birthweight is controlled for, 
these factors do not remain statistically significant, probably as a result of the association 
between low birthweight and these factors.88, 96  
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Despite these associations, there have been varied results on how prevalent the risk factors are 
or how many EOGBS cases have risk factors. An observational study found that among GBS 
cases, 67% had at least one risk factor and 44% had two or more risk factors.99 Another study, 
in Rome, found that only 17.4% of GBS cases had risk factors,100 and a UK HTA study found 
no association between the presence of a risk factor and neonatal colonisation.35 In the US, 
risk factors were found in 49% of EOGBS cases.96 In the most recent enhanced UK survey it 
was found that, depending on which risk factors were considered, there were 59% to 65% of 
EOGBS cases whose mothers had no risk factors and 52% to 63% of EOGBS deaths had no 
risk factors.5 
One systematic review has explored country-level determinants of neonatal GBS disease.6 The 
authors found that studies having less than 20% of infants with GBS who had low birthweight 
decreased the odds of GBS infection compared with 20 to 39% (OR 0.51 9% CI 0.32 to 0.81). 
Countries with low gross national income had higher odds of GBS compared with high gross 
national income, however, this was not statistically significant. Intrapartum antibiotic 
prophylaxis use, skilled attendance at delivery, site of delivery and specimen type were not 
related to neonatal GBS disease. In the analysis on EOGBS alone, no use of prophylaxis had 
2.20 times higher odds of EOGBS compared with those that did (95% CI 1.59 to 3.40). The 
incidence of EOGBS was 0.23 per 1,000 livebirths in studies with any intrapartum antibiotic 
prophylaxis compared with 0.75 per 1000 livebirths in studies with no intrapartum antibiotic 
prophylaxis.  
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GBS Group B Streptococcus, EOGBS early-onset GBS, NICE National Institute for Health and Care Excellence, 
NPV Negative predictive value, PPV Positive predictive value, RCOG Royal College of Obstetricians and 
Gynaecologists 
a. Term pregnant women available for screening at 35-37 weeks: cohort based on 776,352 livebirths in the 
UK in 2014 (Office for National Statistics [ONS], 2015).101 Of all livebirths, 7.5% delivered < 37 weeks 
(applied from England and Wales ONS, 2015)102 and removed from cohort. Assumes no stillbirth, 
multiple births or miscarriages in third trimester.  
b. 21% GBS maternal carriage in the UK.31 
c. Carriage in labour: Estimates were approximately 60.6%, 78.6% & 67.4% for PPV, and 96.7%, 93.5% 
& 89.5% for NPV.103-106 An average estimate of PPV of 75% and NPV of 95% was used. 
d. GBS colonisation in neonates: 36.4% GBS transmission from women positive for GBS intrapartum;4 1% 
from uncolonised women.35  
e. EOGBS disease based on transition rate from neonatal colonisation to EOGBS disease: 1.6% colonised 
neonates taken as the most appropriate.4 Three percent gives an estimate of 1,718 cases (2.4/1000), which 
is almost five times the number of cases seen in the UK in all pregnancies, therefore the lower confidence 
interval from the meta-analysis is used instead.  
f. Maternal risk factors: 37% had at least one RCOG risk factor; 33% had at least one risk factor based on 
NICE guidelines.5  
g. Mortality in this review: 2.8% taken as most appropriate.5  
h. Short-term morbidity in this review: Meningitis: 13.2%; Sepsis 63.1%; Pneumonia 23.7%5 
i. Long-term disability in this review: 8.7-15.8% of surviving EOGBS cases.7, 8  
 
Figure 1. Natural history of GBS on a hypothetical cohort of 718,126 term pregnant women  
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2.4 Detection of maternal GBS colonisation 
The most frequently used and recommended method for detecting maternal GBS colonisation 
is bacterial culturing as it is considered the definitive approach.28, 107 Bacterial culturing 
involves taking swabs from pregnant women and plating them on blood agar plates, where 
GBS grows forming white colonies surrounded by β-haemolysis areas if a woman is colonised 
with GBS, followed by tests to confirm the identity of GBS.35 If GBS colonies grow, the 
woman would be diagnosed as positive for GBS colonisation and if they are absent, the woman 
would be diagnosed as negative.  
The site of swab, timing of swab and use of selective enriched media can vary the sensitivity 
of the detection of GBS colonisation.86 The currently recommended test in the UK is a 
selective enriched culture of rectovaginal swabs.107 The recommendation for swabbing sites 
are rectal and vaginal as studies have found that they are more sensitive than other sites or one 
of these sites alone, increasing detection by 40%.28 Using a selective enrichment broth before 
plating compared with standard plating can also increase the isolation of GBS by inhibiting 
the growth of competing organisms. Although its necessity has been questioned,35 there is 
evidence showing that selective enrichment can increase detection by 50%.108 The most 
widely used enrichment media is Lim broth with Todd-Hewitt base, nalidixic acid and colistin 
before plating on blood agar.35 Finally, as culture tests take 24 to 48 hours to process, culture 
testing cannot be offered at the point of treatment in labour as results would not be available 
in time to treat. Thirty-five to 37 weeks has been selected as the time to test for GBS using 
culture, in order to balance the changes in colonisation status with sufficient time to obtain 
results. Therefore, culture testing only detects babies born at term or nearly at term, missing 
the majority of preterm pregnancies, who have a higher incidence, morbidity and mortality of 
EOGBS. 
Studies investigating the test accuracy of selective enriched GBS culture focus on the positive 
predictive value (PPV) of culture at 35 to 37 weeks to detect maternal GBS carriage at birth; 
however, the outcome of interest in a prevention programme would be EOGBS. Using the 
number of EOGBS cases from the enhanced survey and the number of term pregnancies from 
the Office for National Statistics,5, 101, 102 in the 2016 GBS NSC review, I calculated the 
positive predictive value for antenatal culture detecting EOGBS. If enriched culture testing at 
35 to 37 weeks was a perfect test with 100% uptake, the PPV of the test would be 0.2% 
(350/150,806) for detecting EOGBS in the neonate.24 The incidence of EOGBS in this study 
was during a period of intrapartum antibiotic prophylaxis prevention and this could 
underestimate the PPV. The PPV of selective enriched culture testing at 35 to 37 weeks 
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detecting EOGBS can also be calculated by combining studies which estimate each point in 
the natural history pathway from Figure 1. In 150,806 women colonised in the third trimester 
(21% of 718,126), 659 neonates would go on to develop EOGBS without treatment. This 
would increase the PPV to around 0.4% (659/150,806). This figure is based on the best 
available data for each point in the natural history pathway, however, as noted above, it does 
contain uncertainties. Furthermore, this rate does not account for the proportion of multiple 
births, nor does it remove elective caesarean sections or women with maternal risk factors 
who would not benefit from the screening test. With these PPVs, around 99.6% or 99.8% of 
the women positive for GBS colonisation at 35 to 37 weeks would be over-detected.  
There are no agreed test accuracy values for antenatal selective enriched culture detecting 
maternal GBS colonisation at birth, and a range of values have been reported. A systematic 
review found that the ability of a selective rectovaginal culture at 35 to 37 weeks to predict 
maternal GBS colonisation at birth using rectovaginal culture as the reference standard was 
reported in two prospective studies.104 The reported PPVs were 67.4%103 and 78.6%,106 and 
the negative predictive values (NPVs) were 96.7%103 and 93.5%.106 Recent but small studies 
show similar PPVs of 71.7%,109 72.8%,110 77.0%111 and 89.1%112 and NPVs of 91.2%112 and 
94.9%.109 To summarise the varying ranges, approximately 20 to 30% of pregnant women 
who test positive for GBS at 35 to 37 weeks test negative during labour. The largest study 
since the systematic review looking at the accuracy of culture in routine clinical practice in 
the US reported a lower PPV of 60.6% and an NPV of 89.5%.105 It is difficult to ascertain the 
reason for the change in colonisation status between 35 to 37 weeks and birth as it could be a 
result of false test results at 35 to 37 weeks or because of natural fluctuations in GBS 
colonisation during late pregnancy.  
Due to the restrictions in culture methods, rapid tests have been developed that can be 
administered during labour and can include women in preterm labour. Of all the available 
rapid tests, real-time polymerase chain reaction (PCR) testing is the most promising.35 In real-
time PCR, after taking the rectovaginal swab (enriched or standard), the DNA is extracted by 
targeting specific areas of the bacterial chromosome by primers. The DNA then undergoes 
logarithmic iterative amplification to identify whether there is any evidence of GBS DNA.35 
In older real-time PCR tests, first the swab has to be prepared by extracting the DNA from it 
and adding the primer and polymerase. To ensure biases and false results are avoided, positive 
and negative controls for each kit are also prepared.113, 35 All three samples are then placed 
into the real-time PCR machine where the target DNA for GBS is amplified and the presence 
of GBS is analysed from fluorescent signals.113, 35 More recently, the GeneXpert GBS PCR 
(Cepheid) has automated the process of DNA extraction, amplification and detection. The 
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rectovaginal swab is inserted into a single-use cartridge that contains the PCR reagents and 
controls which goes into the machine to process and analyse.114-116 The results for any of the 
real-time PCR tests present as negative, positive or inhibitory (inconclusive and patient needs 
to be re-tested). The average time to complete a real-time PCR test is 40 to 50 minutes.116, 117 
An early systematic review of real-time PCR studies from 1996 to 2005 found a median 
sensitivity of 96% and specificity of 98% across two studies using intrapartum culture as 
reference standards.117 Since then, compared with intrapartum culture, reports of real-time 
PCR sensitivity have ranged between 62.5% and 100%, specificity between 84.6% and 100%, 
PPVs between 65% and 100% and NPVs between 92.3% and 100%.118 A literature review in 
2015 specifically on GeneXpert GBS compared with intrapartum culture, found eight studies 
reporting good sensitivity of the test, which was superior to antenatal culture.116 Sensitivity 
ranged between 83.3% and 98.5%, specificity between 64.5% and 99.6%, PPVs between from 
90.9% and 97.8% and NPVs between 95.2% and 99.7%. Since the reviews, studies in France, 
Brazil and Demark have similarly found that real-time PCR had better test accuracy than 
antenatal culture when intrapartum culture was used as the reference standard.119-121 The 
largest of the three studies, on 902 women in Denmark, reported a sensitivity of real-time PCR 
of 83%, specificity of 97%, PPV of 78% and NPV of 98%.120 Again, the outcome of interest 
in a GBS prevention programme is EOGBS although real-time PCR studies use intrapartum 
culture as the reference standard.  
There are some practical limitations of real-time PCR that restricts their use. Firstly, real-time 
PCR is much more expensive than enriched selective culture. A cost-effectiveness analysis 
reported that real-time PCR was less cost-effective compared with culture,122 although this 
was an older version of real-time PCR and studies are needed on the latest available 
technology. In addition, the test needs to be simple for it to be administered and interpreted 
by midwives or nurses and would require training and additional support. Quality assurance 
of point of care tests remains an important issue. One of the studies investigating PCR was 
operated by midwives and found a sensitivity of 85%, specificity of 96.5%, PPV of 85.7% 
and NPV of 96.3% compared with intrapartum culture, with no difference between the 
performance of antenatal culture at 35 to 37 weeks and real-time PCR.123 In addition to these 
feasibility concerns, real-time PCR cannot determine antibiotic sensitivity which directs the 
choice of antibiotic to use for treating women who are allergic to penicillin.124 Culture testing 
is currently the only method to determine antibiotic susceptibility and, as indicated earlier, 
culture testing cannot be performed with sufficient time to direct antibiotic selection if GBS 
colonisation was only identified by real-time PCR in labour. It is estimated that approximately 
9% of women, identified as culture-positive for GBS, are allergic to penicillin.125 Without 
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testing antibiotic sensitivity, these women and their neonates could be put at risk making 
culture methods a compulsory pathway for them. Therefore, even though guidelines have 
incorporated rapid testing into the maternal GBS colonisation testing guidelines,118, 14 this is 
in addition to antenatal culture testing, which remains the main recommendation and is most 
frequently utilised. Real-time PCR is not currently recommended in the UK.116, 15  
 
2.5 Intrapartum antibiotic prophylaxis for EOGBS prevention  
With no vaccination currently available, the widely recommended prevention for EOGBS is 
intrapartum antibiotic prophylaxis (IAP).3, 1 GBS vaccination is the most promising prevention 
strategy for GBS disease as it would not only prevent EOGBS, but also LOGBS, and possibly 
miscarriage, stillbirths and preterm delivery related to GBS and have greater feasibility in low-
resource settings.27 Advances have been made in the development of a GBS vaccine, however, 
they are still being trialled and regulatory licence for a vaccination is eagerly awaited.27, 3, 126    
IAP treatment involves administering IAP to eligible mothers at risk of vertical GBS 
transmission in order to prevent GBS vertical transmission and EOGBS disease.  Giving IAP 
to at-risk mothers was first demonstrated to be effective in reducing EOGBS in 1986.127 The 
current recommendation for IAP is intravenous penicillin (or ampicillin in the US) given as 
soon as possible after the onset of labour and then, every four hours until delivery. Second-
line treatment for mothers allergic to penicillin varied across countries.13, 14 In the UK, until 
September 2017, intravenous clindamycin was recommended.13 However, in the latest 
guideline published in September 2017, the recommendations have been modified due to the 
evidence of increasing clindamycin resistance.15 If a woman has a history of allergy to beta-
lactams that is not severe, i.e. does not have a history of anaphylaxis, angioedema, respiratory 
distress or urticaria, a cephalosporin is recommended. If a woman has a history of severe 
allergy to beta-lactams, vancomycin is recommended instead. Similarly, in the US since 2010, 
intravenous Cefazolin is the first alternative, followed by clindamycin if there is a history of 
anaphylaxis, respiratory distress, urticaria or angioedema after penicillin or cephalosporin.14   
A Cochrane review of three randomised controlled trials (RCTs) assessing the effect of IAP 
found that IAP substantially reduced the incidence of EOGBS (risk ratio [RR] 0.17, 95% CI 
0.04 to 0.74) and the incidence of probable EOGBS (RR 0.17, 95% CI: 0.03 to 0.91) by around 
83%, compared with no treatment.10 IAP did not reduce the incidence of all-cause mortality, 
mortality from GBS infection or mortality from other bacteria. Due to the high risk of bias 
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identified in the three small RCTs more than 20 years ago, the authors concluded that there 
was no valid information to inform clinical practice. While this is the best available evidence, 
findings from two observational studies have suggested that the timing and duration of IAP 
had an impact on its effectiveness, with rates of EOGBS and clinical sepsis higher in mothers 
who received IAP for less than 4 hours compared with those who received it for four or more 
hours.128, 129 Furthermore, patients who received substandard IAP of clindamycin due to 
reported penicillin-allergy also showed a reduced effectiveness of IAP. 128 As the studies were 
observational, the results may be due to bias from detection bias and confounding variables. 
Better quality evidence is required to address the effectiveness of IAP, although RCTs may 
not be feasible when IAP has become the recommended treatment. 
 
2.6 EOGBS prevention strategies 
Different strategies are used across countries to identify eligible women at risk of having a 
baby with EOGBS in order to treat them with IAP. One strategy is risk-based prevention, 
whereby women who present with risk factors such as those identified in Section 2.3.2, are 
offered IAP in labour.35, 1 As GBS maternal carriage is a pre-requisite for EOGBS disease, an 
alternative strategy is universal antenatal screening. Screening principally involves using the 
selective enriched culture test of recto-vaginal swabs from all pregnant women at 35 to 37 
weeks and offering IAP to those with positive results.35, 1  If feasible, national guidelines have 
suggested the use of rapid testing.14, 118 It is important to note, that in most cases, screening is 
applied in addition to risk-based prevention. Therefore, women with antepartum or 
intrapartum risk factors would be offered IAP irrespective of screening results.14 As mentioned 
above, screening at 35 to 37 weeks would miss the majority of preterm births who have a 
higher burden of GBS disease. For these women or women with missing results,14 IAP is either 
offered automatically or based on other risk-factors.35  
A third strategy is a combination of the risk-based prevention and universal screening, 
whereby women are tested in pregnancy and only if they then present with a risk factor in 
labour are they offered IAP. If there is no risk factor present, IAP is not offered.35 In Australia, 
there is one national guideline stating either a risk-based or screening prevention strategy be 
implemented across hospitals and a review indicated that across the country different 
strategies are implemented.130  
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2.6.1 Risk-based GBS prevention strategy 
In the UK, risk-based prevention was first introduced in 2001 by the GBS Working Group of 
the Public Health Laboratory Service.131 The Royal College of Obstetricians and 
Gynaecologists (RCOG) endorsed the recommendations in 2003, 2012 and most recently in 
September 2017.13, 15 In 2012, the National Institute for Health and Clinical Excellence (NICE) 
developed their guidelines for intrapartum antibiotics also following a risk-based strategy.12 
Women presenting with intrapartum fever, incidental GBS colonisation. GBS bacteriuria, a 
previous baby with invasive GBS disease or chorioamnionitis are offered IAP.12, 13 Previously, 
IAP was not recommended for pre-labour rupture of membranes in term or preterm mothers 
or for preterm labour,12, 13 although NICE guidelines did suggest considering IAP for preterm 
pre-labour and prolonged rupture of membranes but not for term rupture of membranes or 
preterm birth alone.12 In the most recent RCOG guidelines in 2017, IAP is now recommended 
for women in confirmed preterm labour.15 In addition, if GBS was detected in a previous 
pregnancy, enriched selective culture testing is recommended in late pregnancy with IAP 
offered if the result is positive.15 
The Netherlands,66 New Zealand,132, 133 Denmark,134 Norway135 and Sweden136 all recommend 
risk-based prevention. However, guidelines in New Zealand, Sweden and Denmark state that 
women with preterm labour with evidence of imminent labour and women with prolonged 
rupture of membranes should also be offered IAP.133, 134, 137 In the Netherlands, if women 
present with preterm labour or prolonged rupture of membranes, a culture is taken and IAP is 
offered if the results are positive.138  
There are currently no high-quality studies on the effectiveness of risk-based prevention. 
Population surveillance shows that in the UK EOGBS incidence appears to have increased 
under risk-based prevention from 0.48 in 2000/01 to 0.57 per 1,000 livebirths in 2014/15, 
although mortality has decreased from 10% to 5%.5 A criticism of the risk-based prevention 
strategy is that approximately 30 to 40% of cases without risk factors are excluded from 
prevention. The enhanced survey found that the 2012 national GBS prevention guidelines 
provided by the RCOG and NICE, which are based on the presence of at least one clinical risk 
factor, only identified 35.4% to 41.3% of UK and Irish EOGBS cases.5 Only 44% of those 
women with RCOG risk factors were then treated with IAP; 50% received IAP for less than 
two hours and only 25% received IAP for at least four hours. Among EOGBS deaths, 37% 
had at least one RCOG risk factor for IAP and 48% had at least one NICE risk factor. Of the 
EOGBS deaths, only one woman had received IAP in labour. The percentage of EOGBS cases 
born at term with no RCOG or NICE risk factors was 63% and 67% respectively. Similarly, 
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60% to 70% of 10 EOGBS deaths in neonates born after 35 weeks had no NICE or RCOG 
risk factors respectively, while 56% to 67% of nine EOGBS deaths in neonates born after 37 
weeks of gestation had no risk factors.5 These are the EOGBS morbidities and mortalities that 
the current risk-based strategy would not be able to prevent. Similarly, in the Netherlands 
EOGBS has increased from 0.10 per 1,000 livebirths in 1987 to 0.19 per 1,000 livebirths in 
2011, though it is not clear whether this could be an increase in reporting66 and another study 
reported a decrease from 0.54 in 1997/98 to 0.36 per 1,000 livebirths in 1999 to 2001.65  
By contrast, in New Zealand, the incidence of EOGBS has more than halved under risk-based 
prevention from 0.5 per 1,000 livebirths in 1998/99139 to 0.23 per 1,000 livebirths in 2009 to 
2011.140 In Denmark, there was a decrease of EOGBS incidence from 2.27 per 1,000 livebirths 
in 2002 to 1.30 per 1,000 livebirths in 2010.141 Similarly, in Sweden the incidence of EOGBS 
decreased from 0.40 per 1,000 livebirths in 2006 to 2008 to 0.30 per 1,00 livebirths in 2009 
to 2011,136 while in Norway it has remained steady.70 It is possible that the difference in trends 
between the UK and the Netherlands and the remaining countries are a result of treating 
preterm births with EOGBS. Preterm births have an increasing burden of GBS and it can be 
hypothesised that treating all could have a substantial impact. Now that the RCOG guidelines 
recommend treating all preterm births, the impact this has on EOGBS incidence in the UK 
may shed some light on the differences.  
While the trends of EOGBS are informative about the effects of risk-based prevention on 
EOGBS incidence, they are observational in nature, which means it is possible that they are a 
result of factors within or beyond the prevention programme. For example, there could be 
differences in GBS awareness, adherence to guidelines or the management of neonates across 
time that could contribute to the trends. The low adherence to the risk-based prevention policy 
in the UK makes it difficult to identify its impact, particularly as the reasons for the low 
proportion of women with indication receiving IAP, are not known. As there were no 
contemporaneous control groups, it is not known how the EOGBS rates would have fluctuated 
over time without risk-based prevention.  
2.6.2 Universal GBS screening 
Screening as a concept 
An alternative strategy to increase the detection of GBS in pregnant women is universal 
antenatal screening. Before discussing the adoption and effectiveness of universal GBS 
screening, it is important to understand health screening as a concept and prevention 
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programme. Health screening is a public health service in which members of a defined 
population who do not perceive that they are at risk of a disease are offered a test to identify 
individuals who can be diagnosed in a timely way and treated primarily to reduce the risk of 
mortality and severe morbidity from the disease, via early diagnosis.142-144 While screening is 
favoured as a valuable tool in disease prevention, since the 1960s there has been a recognition 
that all screening programmes cause harms.  The potential benefits of screening are better 
prognosis and less radical treatment for some individuals, reassurance for others and more 
cost-effective care. The potential harms from screening include hazards of the screening and 
diagnostic tests, side effects from the treatment, anxiety, time and financial burden to the 
patient, false reassurance and the opportunity cost of spending resources on a screening 
programme instead of other services.145 For individuals with false positive results, the anxiety 
and complications from testing would be unnecessary as they were not actually at risk of the 
disease. Similarly, screening can also cause over-diagnosis and overtreatment, whereby 
individuals are true positives for latent conditions, however, these latent conditions would 
never become symptomatic. Again, the testing and treatment could be invasive, cause severe 
adverse physical and psychological harm and would be unnecessary.146, 142, 144 Many of these 
harms would also be concealed once a screening programme is implemented. 
To ensure that benefits of screening outweigh the harms to an asymptomatic population, it is 
essential to undertake a robust evaluation of screening programmes prior to implementation.144 
To do so systematically, Wilson and Jungner developed 10 criteria to assess screening 
programmes for any disease.147 The criteria were: important condition, with a recognisable 
latent phase, whose natural history is known, available and acceptable treatment, available 
facilities, a suitable and acceptable test, agreed policy on whom to treat as patients and 
screening to be cost-effective and continual. Policy-makers and academics in different 
countries have accepted these criteria and modified them to incorporate evidence-based 
healthcare, quality assurance, consumer choice, the advent of genetic screening and 
accountability.148 For example, the NSC had developed these principles into a 22-item list of 
criteria,22 which they have now modified into a 20-item list.149 It is not currently known which 
criteria policy-makers use within other countries or how they are evaluated.  
Equally, there has been limited discussion about the systems or structures responsible for 
screening within countries. For criteria to be valuable, countries need to have screening 
systems that encourage the implementation of evidence-based screening decisions. There has 
been limited discourse on the optimum system to ensure screening care reflects evidence-
based decisions. It has been proposed that there should be one national organisation to make 
national screening recommendations and decisions and to implement national screening 
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programmes.142, 143, 150 However, the financing and structure of general health systems can 
affect the structure for screening.148, 142, 150 Countries that have decentralised screening policies 
usually have general health systems that are decentralised, insurance-based, autonomous and 
less regulated. On the other hand, countries that have national agencies for the decision-
making and implementation of screening are more likely to have tax-based general health 
systems and greater regulation.151 In the UK, the NSC is nationally responsible for making 
screening recommendations and for implementing the recommended programmes. Within 
other countries, we do not know which organisations assess screening programmes for their 
introduction, decide whether or not to introduce screening programmes or implement 
screening programmes as a result. 
Screening for GBS 
Many countries internationally recommend and adopt universal GBS screening. The first 
national guidelines were recommended by the Centers for Disease Control and Prevention 
(CDC) in the US in 1996.152 In this guideline, the CDC recommended that a risk-based strategy 
or universal screening be adopted. The CDC revised its guidelines in 2002 recommending 
universal screening only,86 which was then reinforced in 2010.14 After the CDC guidelines 
were published, many countries developed universal GBS screening guidelines.130, 1 In the 
Americas, Canada and Argentina introduced screening guidelines.153-155 Across Europe: 
Belgium,156, 157 Czech Republic,158, 59 France,159 Germany,160 Italy,161 Poland,162 Spain163 and 
Switzerland164 also reported screening guidelines, while in Asia: Hong Kong165 and Japan166 
have reported screening guidelines. 
In the UK, the NSC developed the screening policy for GBS by assessing the scientific 
evidence against the international screening criteria. They recommended against introducing 
universal GBS screening (see Section 2.6.5). In the other countries, it is not clear what the 
responsibility is of the organisations which made the policy for GBS screening within each 
country nor the processes used to make the policy. In the US, GBS screening guidelines were 
made by the CDC which is a public health institution whose goal is to protect health and safety 
by controlling and preventing disease. They developed guidelines in conjunction with experts 
from relevant disciplines and provided a report outlining an epidemiologic basis for 
prevention protocols, summarised results of clinical trials demonstrating IAP efficacy and 
examined the limitations of different prevention strategies. In 2002, the CDC stated that the 
recommendation was based on available evidence and expert opinion where evidence was 
lacking. Similarly, in 2010, clinical and public health representatives revaluated the 2002 
guidelines on the basis of available evidence and expert opinion when evidence was 
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insufficient. We do not know whether there are organisations responsible for screening in the 
US or other countries that may have made GBS screening guidelines.  
Clinical Effectiveness  
As with risk-based prevention, there is only observational evidence investigating the 
effectiveness of universal GBS screening on morbidity and mortality. Without RCT evidence 
it is difficult to calculate the impact of screening due to confounding variables. In 
investigations of screening this is even more problematic due to the bias of the healthy 
screenee effect, where individuals who opt for screening are healthier and more likely to heed 
medical advice compared with those who do not opt for screening, as well as the problem of 
over-diagnosis and over-treatment, whereby individuals who might have been positive at 35 
to 37 weeks would have never been at risk of having a neonate with EOGBS.144 Efforts to 
undertake an RCT have been made, and whilst it would be possible, it would require a very 
large sample size. At the beginning of this research project, a previous RCT proposal had not 
been executed due to the large sample size requirements. The authors calculated that for an 
RCT in the UK a sample size of 540,000 pregnant women would be required,167 which is 
approximately 70% of the annual UK birth population. RCTs in other developed countries (or 
the possibility of an international multicentre study) may also be difficult as the public in 
countries with universal screening might consider it unethical not to receive screening and 
would do so independently, contaminating the trial.  
Nevertheless, there are increasing reports from several countries that have implemented 
universal screening. These observational studies compare EOGBS incidence during periods 
of universal screening to historical controls (no screening and/or risk-based strategy) that 
precede the universal screening periods. There is a high risk of bias from this kind of approach 
as data are collected retrospectively, participants in the study and the control period are not 
contemporaneous and confounding factors are not usually adequately considered. 
Consequently, the results could be due to other factors in the population that may have 
changed between the two periods of comparison, for example, the number of women with risk 
factors or the serotype distribution. Another limitation is that many studies report the rate of 
all EOGBS and not in term births alone, the population eligible for screening. Many of these 
preterm births would not have been screened and their reduction could be a result of routine 
IAP administration. Combining all of the results together blurs the effect of screening.  
Since the US introduced IAP guidelines, EOGBS has decreased from 1.7 per 1000 livebirths 
during the 1990s to 0.23 in 2015.57, 168 However, the largest decreases occurred during the 
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period in which both strategies were recommended, making it difficult to attribute all the 
decrease to universal screening. As an indication of guideline implementation, in 1997, 28% 
of hospitals across eight states adopted universal screening, 20% adopted risk-based strategies, 
4% adopted both strategies, and 42% did not have a policy.169 Recently, Schrag et al. (2016) 
reported a reduction in EOGBS sepsis incidence from 0.27 in 2005 to 0.22 in 2014 during 
screening recommendations (p=0.02).87   
A systematic review in 2011 including eight observational studies from the US (four studies), 
Austria, Australia, Italy and Switzerland compared the rate of neonatal GBS sepsis before and 
after the introduction of universal screening.16 The incidence of neonatal GBS sepsis was less 
common during universal screening compared with risk-based (OR 0.25, 95% CI 0.16 to 0.37) 
or no prevention (OR 0.43, 95% CI 0.25 to 0.73). However, this review has been heavily 
criticised. In addition to the limitations identified above, discrepancies have been detected in 
the data extracted from the included reviews, rendering the meta-analysis potentially 
unreliable.23 It has also been noted that the review did not thoroughly consider clinical 
heterogeneity and differences between studies, such as the timing and method of screening, 
which can influence the validity of the meta-analysis.23 Another systematic review in 2013 
pooled nine studies from Turkey, Australia and the US (seven studies) comparing risk-based 
prevention to screening from 2000 to 2013. They also found that the odds of EOGBS under 
risk-based prevention were higher than under screening (OR 0.45, 95% CI 0.37 to 0.53). This 
review did analyse EOGBS in term births only (three studies, 27,630 livebirths) finding that 
the odds were still higher under risk-based prevention compared with universal screening (OR 
0.45, 95% CI 0.36 to 0.57). While the heterogeneity as assessed by χ2 (chi-squared) tests was 
adequate for meta-analysis, the influence of the heterogeneity was not further assessed in 
sensitivity analyses or meta-regression. Furthermore, most of the studies in the meta-analyses 
were observational cohort studies with no adjustment for confounding factors, therefore, the 
risks of potential healthy screenee bias and confounding variables still apply. Finally, although 
combining the data from the studies and finding consistent results across them strengthens the 
evidence, there were only two countries outside of America. As most of the data were from 
the same country, there is a risk that population differences within the US could be 
contributing to the result, questioning their generalisability.17 
Since the systematic reviews, recent studies have consistently shown a decrease in EOGBS 
incidence during the era of universal screening compared with the era without any screening. 
However, the results are inconsistent when comparing screening with the era of a risk-based 
strategy. In the US, Bauserman et al. (2013) found lower odds of developing EOGBS 
(denominator admissions to neonatal intensive care units [NICUs]) during universal screening 
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compared with the risk-based or screening prevention period in an adjusted analysis (OR 0.69 
95% CI 0.59-0.80). Factors adjusted for were gestational age, sex, race, inborn status, 5-
minute Apgar, ventilator support on first postnatal day, prenatal steroid exposure, prenatal 
antibiotic exposure and mode of delivery. By contrast, Ecker et al. (2013) found that EOGBS 
incidence decreased after risk-based prevention (from 2.06 to 0.96 per 1,000 livebirths) but 
did not reduce further after the introduction of universal screening (1.11 per 1,000 
livebirths).170 In the UK, a study in one maternity unit found that EOGBS incidence fell from 
0.99 per 1,000 livebirths in the risk-based period to 0.33 per 1,000 livebirths during the 
screening period; however, this did not reach statistical significance (p=0.08).34 The authors 
acknowledged that several maternal characteristics were different between the two periods. 
Mothers during the screening period were older, a higher proportion had a caesarean section 
and white other ethnicity and a lower proportion were of black ethnicity. There was also a low 
rate of IAP in the carrier population. The authors suggested that factors beyond the screening 
programme may have influenced the reduction in EOGBS. In Hong Kong, Ma et al. (2017) 
found that EOGBS incidence did decrease in the era of universal screening (1 per 1,000 births) 
compared with the era of risk-based prevention (0.24 per 1,000 births, p<0.001).171  
Findings on the impact of universal GBS screening on the mortality from EOGBS are also 
inconsistent. The two recent studies in the US found no change in EOGBS mortality between 
the eras with and without universal screening. Bauserman et al. (2013) found a case fatality 
rate of 4% in both periods while Ecker et al. (2013) found that the case fatality rate in all early-
onset infections was 11.4% under no prevention, 15.5% under risk-based prevention and 
13.6% under screening.172, 170 By contrast, a study in Hungary reported decreased EOGBS 
mortality rates from 19.5% (29/149) to 1.6% (1/63) after the introduction of screening.173  
A concern identified in these studies is their focus on culture-confirmed EOGBS, which may 
lead to the changes in EOGBS incidence that actually reflect a decrease in the likelihood of 
GBS being detected by culture due to IAP usage. As a result, this would overestimate the 
impact of GBS screening and widespread IAP. Internationally, there has been a suggestion for 
studies to explore all-cause early-onset sepsis, however, the results have been contradictory. 
One US study found that there was an average annual percent decrease in neonatal sepsis 
hospitalisations for term infants during 1996 to 2001 when risk-based prevention or universal 
screening were recommended (-3.6%, 95% CI -5.1 to 2.0%), and this did not change after 
2002 when only universal screening was introduced.174 Using a proxy for early-onset sepsis 
(term infants diagnosed with sepsis during delivery with admission and discharge within ten 
days of birth), they found no trend between 1988 and 2006. The first multi-state population 
study exploring the rates of neonatal sepsis in the US under universal screening found that 
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rates of early-onset sepsis have remained stable at around 0.76 to 0.77 per 1,000 livebirths.175 
Recently in Brazil, early-onset sepsis incidence decreased from 1.9 to 1.3 cases per 1,000 
livebirths after the introduction of screening prevention compared with no prevention, 
however, this was not statistically significant.176 Schrag et al. (2005) similarly found stable 
rates of early-onset sepsis in 2005 and 2014 at around 0.77 and 0.79, respectively.87  
Recently, an expert group assembled by the UK NSC estimated the impact of culture-based 
screening in addition to risk-based prevention in the UK by developing a model of the best 
available evidence.177 They estimated that 30,666 women would receive antibiotics in labour 
which would prevent 70 cases of EOGBS during risk-based prevention compared with no 
prevention. Under screening and risk-based prevention, a further 96,260 women would 
receive IAP and this would prevent an additional 52 to 57 cases of EOGBS, the prevention of 
three deaths and four cases of severe disability. With screening, an additional 1,675 to 1,854 
women would have to receive IAP to prevent one case of EOGBS and 24,065 to 32,087 to 
prevent one death from EOGBS. This result is similar to Angstetra et al. (2007) who found 
that that 1,191 women would require IAP treatment to prevent one case of EOGBS (95% CI 
813–3,272).178 Although this model uses the best available evidence and expert input, there is 
a level of uncertainty because of the limitations and associated gaps in the evidence used to 
develop the model. These gaps, identified throughout this review, are around the natural 
history of GBS, the test accuracy of culture and the effectiveness of IAP.  
Overall, there are increasing numbers of observational studies assessing the effectiveness of 
their screening programmes compared with their previous prevention strategies. However, 
these results are not only inconsistent across studies, they are also fraught with serious 
methodological limitations, which prevents the identification of the impact of universal GBS 
screening. RCT evidence is required to quantify the impact of screening on GBS outcomes, 
however, at the time of this thesis, RCT evidence was not looking promising due to feasibility 
and ethical issues.  
2.6.3 Harms from widespread IAP treatment 
The authors have raised concerns about the potential harms from the use of IAP and the 
increase of IAP under screening. However, the occurrence of harmful outcomes from IAP and 
their clinical significance has not been well explored. Firstly, widespread IAP could increase 
antibiotic resistance. GBS remains almost universally susceptible to penicillin,14 although 
there are recent reports in Ethiopia and Italy with evidence of penicillin resistance in GBS 
isolated from pregnant women.179-181 However, these are small studies and/or have 
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methodological limitations in their susceptibility testing methods, thus, larger studies with 
robust methods are needed to confirm this in pregnant women and neonates. By 2005 in the 
US, 0.2% of GBS isolates had reached the upper level of susceptibility for beta-lactams.182, 18 
A number of mutations in the bacterial cell wall have been associated with reduced penicillin 
susceptibility, but their clinical significance is not known. In Japan, 5% to 15% of GBS 
isolates are reported to have reduced penicillin susceptibility;183 approximately half of these 
are susceptible under European breakpoints and came from populations where chronic 
antibiotic exposure is likely to be common (due to chronic respiratory disease). The clinical 
significance of increased minimum inhibitory concentrations close to breakpoint is uncertain.  
Resistance to clindamycin and erythromycin has increased in the last 20 years.81, 14 In countries 
adopting universal screening, reported rates of resistance have been higher compared with 
countries with risk-based prevention though no formal comparison has been performed. In the 
US where universal screening is adopted, EOGBS resistance to erythromycin was reported at 
48% and resistance to clindamycin was reported at 27% in 2010,57 whereas in 2010 in the UK, 
where risk-based prevention is adopted, erythromycin resistance was reported under 15% in 
EOGBS81 and clindamycin resistance was reported at 9% though this included all GBS 
cases.184 However, in Australia, where either risk-based prevention or universal screening is 
recommended, reported resistance rates in invasive GBS strains were low at 6.4% for 
erythromycin and 4.2% for clindamycin resistance, which did not increase between 1982 to 
2001 and 2002 to 2006.185 In 2014/15, invasive neonatal GBS isolates reached a resistance 
rate of 15.9% for clindamycin, 23% for erythromycin and 15.7% for both clindamycin and 
erythromycin in the UK (any pathogen resistant to clindamycin is expected to be resistant to 
erythromycin, but the converse is not necessarily true).5 This was an increase from 2000/01, 
where there were 3% of neonatal GBS isolates resistant to clindamycin, 6% to erythromycin 
and 2% to both.80  A recent meta-analysis found that most GBS isolates from pregnant women 
were susceptible to penicillin, ampicillin and vancomycin, while the pooled resistance to 
clindamycin and erythromycin was 27% and 25%, respectively.186 Resistance rates for both 
clindamycin and erythromycin were highest in Asia (47% and 46% respectively) followed by 
America (20% and 14% respectively), Africa (18% and 14% respectively), Oceania (15% and 
8% respectively) and  Europe (11% for both). In general, most countries in Asia and Africa 
do not have GBS prevention programmes, therefore, it would seem that resistance patterns do 
not follow IAP prevention. However, the resistance patterns may instead reflect unregulated 
antibiotic use in these regions. Without knowing the prevention strategy in the specific centres 
in the meta-analysis, it is difficult to assess their impact. There may also be other factors 
besides screening and widespread IAP that could be contributing to the differences between 
regions and across time within countries.  
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Widespread IAP may also increase neonatal infections caused by gram-negative bacteria as a 
result of selection pressure on the organisms causing infection, though results are 
contradictory.32, 19 Escherichia coli (E. coli) is the most common gram-negative bacterium 
causing invasive neonatal disease and there is evidence indicating that neonatal sepsis from 
E. coli may have increased since the introduction of GBS screening. Bizzarro et al. (2008) 
found that early-onset E. coli in very low preterm births (<1500g) increased from 2.83 per 
1,000 admissions during no prevention to 7.12 per 1,000 admissions during risk-based 
prevention to 10.22 per 1,000 admissions during screening in the US.187 Similarly, Stoll et al. 
(2002) reported that the rate of early-onset E. coli infections increased from 3.2 to 6.8 per 
1000 livebirths over time in low birthweight infants between 1998 to 2000 in the US. Other 
studies have found that IAP increased the odds of early-onset E. coli infection in univariable 
analyses but not in multivariable analyses when other factors, such as gestational age, were 
accounted for.188, 189 On the other hand, more recent studies have found that early-onset E. coli 
has remained stable from the period of ‘either prevention’ to the period of screening at 1.4 per 
1,000 admissions,172 and during screening only at around 0.2 per 1,000 livebirths.87 In 
Australia and New Zealand, early-onset E. coli has seen a statistically non-significant decrease 
from 1992 to 2001 during either or risk-based prevention.72, 190 Again, any changes in before 
and after studies are difficult to attribute to screening alone.  
There is evidence that antibiotic usage may cause changes in neonatal microbiota that could 
lead to long-term health problems. Disturbances in the microbiota have been associated, 
though not causally, with asthma, obesity, diabetes, and autism.191, 32, 192, 27 There has been 
evidence showing that intrapartum antibiotics are associated with alterations in the microbiota 
of women and children.193, 194 For example, intrapartum penicillin was associated with lower 
relative proportions of Lactobacillus spp. in treated women compared with those who were 
not treated (13.1% vs 88.1%).195 However, GBS itself can also affect the microbiota 
composition.195  
Antibiotic use in mothers may also predispose them to Clostridium difficile infection, a well-
recognised complication of antibiotic treatment that is increasingly being observed in the post-
partum population.21 Maternal anaphylaxis may also occur in the pregnant women being 
treated, which, although very rare, can be fatal for both mother and neonate.14 Although 
figures are based on limited evidence, an estimate of anaphylaxis associated with penicillin 
use in labour is one in 10,000 and fatal anaphylaxis is estimated in one in 100,000 patients.196 
One study between 2003 and 2004 found no maternal anaphylaxis in 2,432 women who were 
treated with IAP.197 Since 2008, the CDC has noted one case of maternal anaphylaxis in which 
an emergency caesarean section was performed. Both mother and child survived, however, 
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the child suffers from severe neurological damage.198, 14 A positive screening culture could 
also increase anxiety for the mother, family and medical staff, increase the medicalisation of 
labour and reduce the patient choice in birthing options.32, 13 These harms would be 
unnecessary in false positive and over-diagnosed cases who would not have had a neonate 
with EOGBS in the absence of treatment. Studies in prenatal screening indicate that false 
positive results could have a lasting effect of anxiety.199, 200 In another study, half of clinicians 
felt that IAP caused additional stress to mothers and families and anxiety to physicians and 
the floor staff.201  
2.6.4 Cost effectiveness of GBS prevention 
There have been two key studies about the cost effectiveness of GBS prevention strategies in 
the UK, both concluding that screening and risk-based prevention are not cost-effective under 
the NHS willingness to pay threshold. The first was published in 2007 and determined the 
cost-effectiveness of 14 different prenatal strategies including doing nothing, risk-based 
prevention, antenatal culture screening, PCR screening and vaccination.32 The authors 
concluded that vaccination was the most cost-effective strategy, followed by culture screening 
of women without risk factors assuming that preterm and high-risk groups (including elective 
caesarean section) were treated. Risk-based prevention was not cost-effective. They also 
concluded that all cost-effective options involved treatment of all preterm and high-risk 
groups. The model has a list of limitations, possibly as a result of being one of the first detailed 
studies on the topic. GBS experts have commented that there were some concerning 
assumptions, which could decrease screening cost-effectiveness, such as using culture positive 
(and not negative) infection, which overestimates IAP effectiveness, potentially 
overestimating the effectiveness of IAP itself (taken as 99% although, as indicated above, a 
Cochrane review found that IAP was around 83% effective), using a low rate of GBS maternal 
colonisation of 12% which would increase the number of women screened with no benefit and 
excluding the harms of IAP such as that on antibiotic resistance.167, 23 They have also identified 
that the authors excluded some fundamental issues, for example, they did not account for the 
wider costs of observation and testing of babies whose mothers were screen positive but did 
not receive adequate IAP, the increase in exposure to medical interventions during labour and 
community midwifery input, which has consequences for staffing and size of units and a 
reduction in labour choices.167, 23  
The most recent cost-effectiveness analysis of GBS prevention in the UK, identified that 
compared with doing nothing, antenatal culture screening costs £23,444 per quality-adjusted 
life year (QALY).122 Antenatal culture screening was more cost-effective than risk-based 
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prevention, however, both approaches were above the NHS willingness to pay threshold of 
£20,000 per QALY. The cost-effectiveness of screening compared with risk-based prevention 
was finely balanced with variability in the findings. The sensitivity analysis showed that if 
you do not administer IAP to all women who deliver before the screening test at 35 to 37 
weeks, risk-based prevention is more cost-effective than culture screening. Risk-based 
prevention is also more cost-effective than culture screening if the costs of a culture test 
increased by £0.87. However, a key limitation of the cost-effectiveness analyses is that the 
models are based on uncertain evidence on the clinical effectiveness of GBS screening and 
IAP treatment (as discussed above), which makes the assumptions and findings on the costs 
and benefits uncertain. 
2.6.5 UK NSC screening recommendations 
In 2012, the UK NSC reviewed the evidence for universal screening.23 There were 22 UK 
NSC screening criteria at the time, three of which relate solely to genetic mutations and are 
not relevant to GBS screening. Essentially, the screening criteria examine four things: 1) the 
seriousness, epidemiology and natural history of the condition, i.e. if the condition moves 
from asymptomatic to an illness; 2) is the test accurate, acceptable and able to separate those 
with a problem from those without it; 3) is the treatment available, effective and acceptable; 
and 4) does the programme do more good than harm at a reasonable cost. The NSC concluded 
that universal screening should not be offered as there was insufficient evidence to ensure that 
the benefits of screening would outweigh the harms (see Table 3 for a summary against the 
key criteria).  
In particular, they identified the following important gaps in evidence, which made it difficult 
to weigh up the benefits and harms of universal screening. Firstly, there was a lack of 
information about why GBS colonisation status changes from 35 to 37 weeks to birth, which 
women transmit GBS to their babies and which babies will suffer from GBS disease and why. 
There was also a lack of evidence on the harms of IAP treatment, limited evidence on the 
effectiveness of screening on EOGBS, early-onset sepsis and the overall harms from screening 
and widespread IAP. In 2016, the UK NSC updated their review to fill in some of these gaps. 
As this thesis was a part of the 2016 NSC review, it will be considered in the discussion 
chapter of the thesis (Chapter 15). Nevertheless, there continues to be increased pressure to 
introduce a universal antenatal GBS screening programme in the UK in addition to the current 
risk-based strategy.   
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Table 3. Summary of the 2012 UK National Screening Committee review key findings23 
Criterion Judgement Explanation 
1. The condition should be an 
important health problem. 
Met EOGBS is an important health condition, as 
although it is relatively uncommon, 
consequences can be long-term and severe and 
fatal.  
2. The epidemiology and natural 
history of the condition, including 
development from latent to 
declared disease, should be 
adequately understood and there 
should be a detectable risk factor, 
disease marker, latent period or 
early symptomatic stage. 
 
Partly met The natural history of GBS is poorly 
understood – we do not understand why GBS 
colonisation status changes from 35 to 37 
weeks to birth, nor do we understand which 
women transmit GBS to their babies nor 
which babies will suffer from GBS disease nor 
why. We also do not fully understand the 
long-term morbidities of EOGBS. There is 
evidence to support the association of risk 
factors with GBS disease, especially with GBS 
colonisation and intrapartum fever, when other 
factors were adjusted. However, evidence on 
how many GBS-colonised or EOGBS babies 
have maternal risk factors varies. 
5. There should be a simple, safe, 
precise and validated screening 
test. 
Not met Antenatal culture has a moderate ability to 
predict GBS colonisation status in labour. 
There are no post-screening methods to 
narrow down which mothers, colonised with 
GBS, are at greatest risk. Screening at 35 to 37 
weeks would also miss out preterm deliveries 
before 37 weeks (who have a higher burden of 
GBS mortality).  
10. There should be an effective 
treatment or intervention for 
patients identified through early 
detection, with evidence of early 
treatment leading to better 
outcomes than late treatment. 
Partly met A Cochrane review found RCT evidence that 
IAP reduces culture-confirmed and probable 
EOGBS but not neonatal mortality. However, 
the RCTs were small, of poor quality, and 20 
years old. Therefore, the authors concluded 
that IAP is not supported by conclusive 
evidence.  
13. There should be evidence from 
high quality Randomised 
Controlled Trials that the screening 
programme is effective in reducing 
mortality or morbidity.  
Not met There are no RCTs assessing screening 
effectiveness for reducing EOGBS mortality 
or morbidity, and sub-optimal observational 
evidence makes it difficult to quantify the 
benefits and harms of screening compared 
with risk-based prevention.  
15. The benefit from the screening 
programme should outweigh the 
physical and psychological harm 
(caused by the test, diagnostic 
procedures and treatment). 
Uncertain The literature did not report about the harms 
from screening and treatment, such as 
antibiotic resistance and long-term health 
problems from changes in the neonatal 
microbiota. 
16. The opportunity cost of the 
screening programme should be 
economically balanced in relation 
to expenditure on medical care as a 
whole (i.e. value for money).  
Not met There were no new cost-effectiveness studies 
since the previous review in 2008.  
EOGBS early-onset GBS, GBS group b Streptococcus, IAP intrapartum antibiotic prophylaxis, RCT randomised 
controlled trial  
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2.7 Conclusions 
This review presents an exploration of the literature pertaining to EOGBS disease and the 
strategies to prevent it. With an incidence of 0.57 per 1,000 livebirths and mortality rate of 
5.2%, EOGBS is an important health condition in the UK. There are some well-defined risk 
factors of EOGBS, with preterm births and low birthweights at particularly high risk. 
Regarding the natural history of GBS, it is still not fully understood why some mothers, but 
not all, transmit GBS to their neonates. Nor is it known which neonates will develop the 
disease.   
Risk-based prevention in the UK has not managed to stabilise or decrease the incidence of 
EOGBS, although risk-based prevention in other countries has shown decreases. The evidence 
on risk-based prevention is based on observational before and after studies making it difficult 
to assess its impact. Estimates in the UK show that only 44% of women with risk factors are 
treated with IAP; 50% receive IAP for less than two hours and only 25% receive IAP for at 
least four hours before delivery. The low adherence to the risk-based prevention policy makes 
it difficult to identify its impact, particularly as the reasons for the low proportion of women 
with indication receiving IAP are unknown. In addition, a substantial proportion of EOGBS 
cases do not have any risk factors. Estimates show that 63% to 67% of EOGBS cases and 56% 
to 67% of EOGBS deaths born at term have no maternal risk factors indicative of IAP 
treatment. 
An alternative strategy to increase the detection of women at risk of having a neonate with 
EOGBS is universal GBS screening in addition to the risk-based prevention. Screening is a 
precarious tool that can only be powerful through evidence-based and careful implementation. 
As maternal GBS colonisation is a pre-requisite for EOGBS disease, the selective enriched 
culture test is recommended to detect maternal colonisation. However, this test which is 
administered at 35 to 37 weeks of gestation is not an accurate predictor of EOGBS disease, 
with only somewhere between 0.2% to 0.4% being correctly identified. A more accurate and 
practical test is required, however, the lack of evidence on the natural history of GBS inhibits 
this venture.  
Despite IAP being the recommended preventative treatment for EOGBS worldwide, the 
effectiveness of IAP is uncertain due to the high risk of bias in the evidence. Equally, the 
effectiveness of universal screening is difficult to assess as there is no RCT and the 
observational evidence is at high risk of bias and inconsistent. However, an RCT for EOGBS 
prevention would require a large sample size. Furthermore, the harms from screening and 
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widespread IAP treatment are not well-studied or documented even though over 99% of tested 
women would be over-treated. As a result, it is difficult to quantify the benefits and harms of 
screening and treatment.  
Despite increasing pressure in the UK to introduce universal GBS screening in addition to 
risk-based prevention, it is not recommended due to the gaps in the evidence base summarised 
below. EOGBS infection is an important health problem and more research is required to 
understand and prevent neonatal invasive disease. 
 
2.8 Key areas requiring further research 
 Research is needed to more fully understand the current gaps in the evidence related 
to EOGBS and the implications this has for whether universal GBS screening meets 
international standards to introduce a screening programme.  
 There is a need to explore why some mothers transmit GBS to their neonates and why 
some colonised neonates develop EOGBS. This will help to understand if we can 
reliably predict which mothers colonised with GBS will have a neonate with EOGBS.  
 There is also a need to explore the current data on the adverse events from IAP in 
order to inform the balance between the benefits and harms from GBS treatment.  
 To measure the overall benefits and harms of introducing a universal GBS screening 
programme would require RCT evidence. However, as RCTs would require a large 
sample size, an alternative method may be needed to assess this.  
 Finally, data are needed regarding how different countries assess screening 
programmes, such as universal GBS screening, and how decisions are made to 
introduce them.  
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3. RESEARCH AIMS AND OBJECTIVES 
3.1 Research gap and thesis rationale 
As discussed in Chapter 2, in 2012, the UK NSC recommended against introducing a universal 
GBS screening programme after assessing the evidence against their screening criteria. The 
NSC identified the following three key gaps in the literature: the uncertainty of the evidence 
on the effectiveness of GBS screening due to a lack of RCT data, a lack of evidence on the 
natural history of GBS and a lack of evidence on the harms from IAP treatment and the overall 
screening programme.23 In this thesis, I address the three research gaps, examine whether the 
evidence now meets the criteria and recommend whether the UK should introduce a universal 
GBS screening programme. Each of these research gaps is discussed below. 
There is considerable uncertainty about the clinical effectiveness of universal GBS screening 
as there has been no RCT on the impact of screening on GBS morbidity and mortality. 
However, when this thesis began, efforts to conduct an RCT to inform the benefits and harms 
of GBS screening had not been executed due to the large sample size requirements. With 
increasing political and media pressure for the UK to follow in the footsteps of other countries 
and implement screening, the NSC may require a method for estimating the effectiveness of 
GBS screening in the absence of RCT data. GBS is the leading cause of neonatal infections 
and death, causing severe morbidity and mortality for a small proportion of neonates. It is 
critical that the UK and other countries apply the most effective, and evidence-based 
prevention strategies for GBS that will result in more benefit than harm to mothers and their 
neonates. In the absence of RCT data, it has been suggested that careful data collection and 
the use of historical and coexisting controls from different regions should be utilised to make 
screening decisions.202 The best available data for universal GBS screening have been 
collected from those countries that have implemented programmes across the world. Using 
these data could contribute towards our understanding of the beneficial and harmful outcomes 
associated with GBS screening programmes compared with no prevention and risk-based 
prevention strategies.  
To determine the transferability of a public health intervention such as screening, programme 
outcomes cannot be crudely transferred from one country with the expectation that they will 
occur in another. Interventions are dependent on their context or their “social, political and/or 
organisational setting”.203 p119 Contextual factors describing a country’s economy, health 
system, and population can impact the effectiveness of an intervention.204-206 To transfer the 
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evidence on the effectiveness of a GBS screening intervention from one country to another 
would require an adjustment for the contextual differences. This approach would not only 
assist in decision-making for GBS screening, but could also provide a broader solution on 
evidence-based decision-making for other diseases, rare or otherwise, where RCTs may not 
be possible. Using this approach may also help low and middle-income countries make 
evidence-based screening decisions without spending resources on screening trials. Screening 
programmes and their outcomes in high-income countries could be transferred to low and 
middle-income countries by adapting the approach and estimating the impact for their context. 
This would allow low and middle-income countries to optimise the allocation of scarce 
resources.  
The second research gap was about the harms from IAP treatment. Treatment harms are 
crucial to decision-making on whether or not to recommend a screening programme, as they 
inform the basic information required to determine the balance between the benefits and harms 
of screening. As indicated in Chapter 2, IAP would be given to over 150,000 pregnant women 
and their babies every year, of whom over 99% will be unnecessarily treated, therefore, it is 
particularly important in this context. The 2012 NSC GBS report concluded that this evidence 
has never been reviewed. It is necessary to synthesise the evidence on the adverse events to 
mothers and their children after IAP treatment in order to identify the implications this may 
have for universal GBS screening programmes worldwide.  
Likewise, better information is required on the natural history of GBS. As discussed in Chapter 
2, we do not know why vertical GBS transmission occurs in approximately 36% of cases or 
why 1% to 3% of colonised neonates progress to invasive EOGBS disease. Understanding the 
natural history of a condition is crucial to finding a valid target for testing and detection of 
individuals at high risk of a disease. This information could allow identification of the best 
points in time that GBS screening should take place, the GBS carriers at most risk of EOGBS 
who should be targeted, and whether there are other mechanisms that could be used for GBS 
screening tests and procedures. Again, the 2012 NSC GBS report concluded that this evidence 
has never been reviewed. It is important to examine the evidence on the factors associated 
with GBS transmission and EOGBS in GBS-colonised women in order to identify how they 
might affect a universal GBS screening programme in the UK and abroad.  
Finally, preliminary research for this thesis highlighted that there was a paucity of information 
about the policy-making processes used to decide on whether, or not, to introduce screening 
programmes. Within the literature and amongst screening policy-makers, little is known about 
the screening infrastructure, criteria or decision-making methods used across the world. The 
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way in which countries make these decisions not only has implications on whether GBS and 
other screening programmes are introduced in various countries but it also enables us to learn 
from other countries’ practices. This would expand the current understanding on worldwide 
screening practices and would also contribute insights on the international GBS screening 
policies and how they were made. As a result, policy-makers can ensure they are operating to 
the best international standards when making screening recommendations. 
 
3.2 Overall aim of research 
The overall aim of this thesis is to investigate whether the UK should commence a universal 
GBS screening programme by addressing the three key research gaps identified in the 2012 
NSC review. To provide a solution for the uncertainty of screening effectiveness from a lack 
of RCT data, I will analyse international trends on the benefits and harms related to universal 
GBS screening, to underpin national (UK) and international policies on universal GBS 
screening programmes. I will investigate whether the trends of the benefits and harms related 
to universal GBS screening across countries with different prevention programmes, can be 
adjusted for country-level differences in ecological trend analyses, to make screening 
decisions. To investigate the natural history and factors associated EOGBS and the adverse 
events from IAP treatment, I will synthesise the current evidence in the literature. I will also 
synthesise the current evidence to explore the screening policy-making procedures used in 
different countries.  
 
3.3 Research questions and objectives 
The specific research questions are listed below and the objectives are summarised in Table 
4:   
1. What are the screening systems and policy processes used in different countries to 
develop health screening policy for conditions such as GBS? 
2. Are bacterial load and/or bacterial molecular markers associated with GBS vertical 
transmission, and progression from neonatal GBS colonisation to EOGBS? 
3. What, and how frequently, are the adverse events experienced by the mother and/or 
her child after receiving intrapartum antibiotic prophylaxis treatment? 
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4. Adjusting for country-level differences, what is the international impact of GBS 
screening on the trend of annual EOGBS incidence across time compared with other 
prevention strategies? 
5. Adjusting for country-level differences, what is the international impact of GBS 
screening on the trend of all-cause early-onset sepsis incidence across time compared 
with other prevention strategies? 
6. Adjusting for country-level differences, what is the international impact of GBS 
screening on the trends of annual early-onset Escherichia coli and LOGBS 
incidences, and the percentages of clindamycin and erythromycin resistance in early-
onset and neonatal GBS disease across time compared with other prevention 
strategies? 
 
Table 4. Research objectives 
No Objective Study design Chapter 
1 To examine how different countries make screening policy for GBS 
and other conditions. 
Systematic 
review 
5 
2 To examine the association between bacterial load, bacterial 
molecular markers and GBS transmission and EOGBS disease 
Systematic 
review and 
meta-analysis 
6 
3 To assess the risk of adverse events experienced by women or 
children after intrapartum antibiotic prophylaxis treatment. 
Systematic 
review  
7 
4 To examine the trends and estimate the potential impact of GBS 
screening on annual EOGBS incidence across time compared with 
other prevention strategies. 
Ecological time 
trend analysis 
using linear and 
multi-level 
regression 
11 
5 To examine the trends and estimate the potential impact of GBS 
screening on annual all-cause early-onset sepsis incidence across 
time compared with other prevention strategies. 
Ecological time 
trend analysis 
using linear 
regression 
12 
6 To examine the trends and estimate the potential impact of GBS 
screening on potential harmful outcomes such as early-onset E. 
coli, LOGBS, and clindamycin and erythromycin resistance in 
early-onset and neonatal GBS disease across time compared with 
other prevention strategies. 
Ecological time 
trend analysis 
using linear 
regression 
13 
E. coli Escherichia coli, EOGBS early-onset GBS, GBS Group B Streptococcus, LOGBS late-onset GBS  
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3.4 Thesis structure 
This thesis is broadly composed of two sections of research based on the methodology used: 
systematic review and meta-analysis (part II) and ecological trend analysis (part III). The 
remaining sections (part I and IV) cover the thesis as a whole. The thesis includes 15 chapters. 
 Part I covered the introduction and research aims of the thesis as a whole.  
Chapter one introduced the thesis. 
Chapter two summarised the review of the current literature related to neonatal GBS and 
screening. 
Chapter three explained the research rationale and listed the research aims and the objectives 
of the thesis as a whole. 
 Part II comprises three systematic reviews and meta-analyses of the current evidence.  
Chapter four discusses the objectives, rationale and overview of the implemented 
methodology in part II of the thesis. I provide the methodology of each systematic review in 
the chapters that follow as the details vary between reviews. 
Chapters five, six and seven present the methods, results and discussion of the findings from 
the systematic review on the systems and processes for health screening policy-making 
(chapter five); the systematic review and meta-analysis on the bacterial load and bacterial 
molecular markers associated with neonatal GBS (chapter six); and the systematic review on 
the adverse events after IAP treatment (chapter seven).  
 Part III comprises three ecological trend analysis studies on the benefits and harms 
of GBS screening.  
Chapter eight introduces the rationale, aims and objectives of part III of this thesis.  
Chapter nine details the methodology of the ecological trend analyses covered in part III of 
this thesis. As I applied the same methodology for all three ecological trend analysis studies, 
I present it together in this chapter.  
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Chapter ten presents the overview and general characteristics of the data collected from the 
three ecological trend analysis studies, as they were collected from the same survey. This 
includes a description of the overall outcomes, predictors and covariates collected as well as 
information about the geographical area from which the data originate. 
Chapters eleven, twelve and thirteen present the results and discussion of the findings from 
the ecological trend analysis studies on the impact of universal GBS screening on EOGBS 
(chapter eleven); early-onset sepsis (chapter twelve); and adverse outcomes such as 
LOGBS, early-onset E. coli and clindamycin and erythromycin resistance (chapter thirteen) 
across time, compared with other prevention strategies.  
Chapter fourteen presents a summary of the findings from the ecological trend analysis 
studies covered in part III of the thesis, the strength and limitations of the methodology and 
the research and policy implications. As the aim, objectives and methodology for each of the 
three studies were similar, so were the strengths, limitations and implications. Therefore, I 
present this discussion for all of the studies together in this chapter. 
 Part IV comprises the discussion and conclusion of the overall thesis.  
Chapter fifteen summarises and discusses the findings of this thesis from each review and 
study, assesses the strength and limitations of the methods of the thesis overall and offers 
research and policy recommendations for universal GBS screening overall.   
Antenatal screening for group B Streptococcus in the UK	
	 42
PART II.     SYSTEMATIC REVIEWS ON 
CURRENT EVIDENCE   
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4. RESEARCH AIMS & METHODOLOGY  
4.1 Research aims   
The research aim for this part of the thesis is to address three of the four key gaps listed in 
Chapter 3 in order to aid decision-making on whether the UK should introduce GBS screening: 
the screening systems and policy processes, the natural history of GBS and the harms from 
IAP treatment. The specific research questions are:  
1. What are the screening systems and policy processes used in different countries to 
develop health screening policy for conditions such as GBS? 
2. Are bacterial load and/or bacterial molecular markers associated with GBS vertical 
transmission, and progression from neonatal GBS colonisation to EOGBS? 
3. What, and how frequently, are the adverse events experienced by the mother and/or 
her child after receiving intrapartum antibiotic prophylaxis treatment? 
  
4.2 Methodology rationale  
To address these aims, I carried out three systematic reviews: one to explore the international 
screening systems and processes (objective 1), one to identify the factors associated with GBS 
transmission and EOGBS disease (objective 2) and one to identify the harms associated with 
IAP treatment (objective 3). A systematic review is a “review of a clearly formulated question 
that uses systematic and explicit methods to identify, select, and critically appraise relevant 
research, and to collect and analyse data from the studies that are included in the review”.207 
A meta-analysis is “the process of combining the quantitative results of separate (but similar) 
studies by means of formal statistical methods”.208 p17 
The many strengths of using systematic reviews and meta-analyses to answer a research 
question have been well documented.209 Systematic reviews allow existing information to be 
efficiently integrated, they involve explicit methods which limit bias and allow information to 
be scientifically integrated, they increase the power and precision of estimates from meta-
analytical methods and they allow the generalisability and consistency of individual study 
findings to be established.209 Systematic reviews are useful for clinicians and other 
practitioners to keep up-to-date with literature in the field, enable economists and decision-
analysts to estimate key variables and outcomes and aid policy-makers to develop 
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guidelines.209 Another important purpose of performing systematic reviews is that they can be 
the first step in directing future research and motivating the effort and resources to for primary 
studies to further the field,210, 208 as “researcher[s] can use the review to identify, justify, and 
refine hypotheses”.209 In addition, they can ensure that a research idea does not venture down 
a path that has already been explored and does contribute to advancing the field.209  
I specifically chose systematic reviews for objectives 1 to 3 for these theoretical and practical 
reasons. This is coherent with the recommendation that “research methods should follow 
research questions in a way that offers the best chance to obtain useful answers”.211 p18 
Research questions 1 to 3 were research areas where the literature had not been previously 
synthesised and the status of the evidence in these fields was not known. Therefore, it was 
important to answer these questions to move the research in the right direction and avoid 
replicating previous work and wasting resources. For example, reviewing the harms from IAP 
could direct future projects and did direct research question 6 in this thesis about some of the 
harms that need to be measured. Secondly, the systematic reviewing method was the most 
pragmatic and efficient option. For example, researching the harms of IAP in a primary study 
would have required a follow up period beyond the scope of a PhD thesis. Likewise, 
interviewing policymakers on their systems and criteria would have been a waste of resources 
when this information was available but had not yet been collated.  
For the systematic reviews on the natural history of GBS (objective 2) and the harms of IAP 
treatment (objective 3), I prioritised quantitative methods and meta-analysed the findings as 
far as possible, since they were the most appropriate to address the research questions. For 
interventions such as screening, robust estimates are required to indicate the numbers of 
different groups of patients who would be affected by the condition and the number who 
would experience a morbidity and mortality harm from the intervention. To estimate the 
frequency of these outcomes, quantitative methods are the most appropriate. On the other 
hand, for the systematic review on the screening systems and policy processes (research 
question 1) I used a narrative synthesis in texts and tables as these data were narrative in their 
nature.  
In the following chapters (5, 6 and 7), I will provide the detailed methodology, such as the 
search strategies, data extraction and quality appraisal for each systematic review separately, 
as they differ across the reviews.   
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5. INTERNATIONAL POLICY-MAKING SYSTEMS AND 
PROCESSES FOR POPULATION HEALTH 
SCREENING 
5.1 Introduction 
As described in Chapter 2, there has been a recognition that, while screening programmes can 
be valuable in disease prevention, they can also cause harms. The benefits of screening are 
better prognosis and less radical treatment for some individuals, reassurance for others and 
more cost-effective care. The potential harms from screening include anxiety, false 
reassurance, the hazards of the screening and diagnostic tests, the side effects from the 
treatment, the time and financial burden to the patient and the opportunity cost of spending 
resources on a screening programme instead of other services.145 For individuals with false 
positive results, the anxiety and complications from testing would be unnecessary as they were 
not actually at risk of the disease. Similarly, screening can also cause over-diagnosis and 
overtreatment, whereby individuals are true positives for latent conditions, however, without 
screening, these latent conditions would never become symptomatic. Again, the testing and 
treatment could be invasive, cause severe adverse physical and psychological harm and would 
be unnecessary.146, 142, 144 Many of these harms would also be concealed once a screening 
programme is implemented. 
To ensure that benefits of screening outweigh the harms to an asymptomatic population, it is 
essential to undertake a robust evaluation of screening programmes prior to implementation.144 
As discussed in Chapter 2, to do so systematically, Wilson and Jungner developed 10 criteria 
to assess screening programmes for any disease.147 The criteria were: important condition, 
with a recognisable latent phase, whose natural history is known, available and acceptable 
treatment, available facilities, a suitable and acceptable test, agreed policy on whom to treat 
as patients and screening to be cost-effective and continual. Policy-makers and academics 
across different countries have accepted these criteria and adapted them to incorporate 
consumer choice, quality assurance, accountability, evidence-based healthcare, and the advent 
of genetic screening.148 For example, at the time of this review, the NSC had developed these 
principles into a 22-item list of criteria. However, it is not currently known which criteria 
policy-makers use within other countries or how they are evaluated. 
Equally, there has been limited discussion about the systems or structures responsible for 
screening within countries. For criteria to be valuable, countries need to have screening 
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systems that encourage the implementation of evidence-based screening decisions. It has been 
proposed that there should be one national organisation to make national screening decisions 
and implement national screening programmes.142, 143, 150 However, the financing and structure 
of general health systems can affect those for screening.148, 142, 150 Countries that have 
decentralised screening policies usually have general health systems that are decentralised, 
insurance-based, autonomous and less regulated.  On the other hand, countries that have 
national agencies for the decision-making and implementation of screening are more likely to 
have tax-based general health systems and greater regulation.151 In the UK, the NSC is 
nationally responsible for making screening recommendations and for implementing the 
recommended programmes. Within other countries, we do not know which organisations 
assess screening programmes for their introduction, decide whether or not to introduce 
screening programmes or implement screening programmes as a result. 
Consequently, we neither know which organisations made the policy for GBS screening 
within each country nor the processes used to make it. As shown in Chapters 2 and 3, the NSC 
developed the GBS screening policy in the UK. After assessing GBS against their screening 
criteria, they recommended against GBS screening as there was little information on the 
natural history of GBS, poor accuracy of the culture test, a lack of RCT evidence on screening 
effectiveness and a lack of information about screening harms. As shown in Chapter 2, GBS 
screening guidelines were made by the CDC for the US.86, 152, 14 In 1996 they developed 
guidelines in conjunction with experts from relevant disciplines and provided a report 
outlining an epidemiologic basis for prevention protocols, summarised results of clinical trials 
demonstrating IAP efficacy and examined the limitations of different prevention strategies. In 
2002, the CDC stated that the recommendation was based on available evidence and expert 
opinion where evidence was lacking. Similarly, in 2010, clinical and public health 
representatives revaluated the 2002 guidelines on the basis of available evidence and expert 
opinion when evidence was insufficient. We do not know whether there are organisations 
responsible for screening in the US or other countries that may have made GBS screening 
guidelines.  
There has been limited discussion about how screening policy decisions are developed across 
countries for GBS and other conditions. The structures and processes used to make GBS 
screening policies may have implications on whether GBS screening is in use or not. This 
information is useful for later comparison of the impact of GBS policies across countries in 
part III, Chapters 8 to 13. Beyond GBS, it is also useful to know the systems and processes 
used to make screening decisions for any condition. Having incomplete policy-making 
systems or processes that do not examine screening programmes rigorously may lead to the 
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introduction of disorganised, unsuccessful and expensive programmes, which have physical, 
financial and emotional harms, with little benefit.146, 142, 144 There has been no systematic 
comparison of the screening systems that have been established, nor of the screening criteria 
developed nor the other policy-making processes used in each country. A better understanding 
of worldwide practices could help uncover the optimal systems needed to ensure that every 
person is receiving evidence-based screening care. Therefore, in this chapter I will explore the 
systems and processes used to make screening policy worldwide. 
I will first present the aim and specific objectives of the review, followed by the methods used 
to search and extract the data and then report the results. Finally, I will discuss the principal 
findings compared with previous literature, the strengths and limitations of the review and the 
research and policy implications. 
 
5.2 Aims and objectives 
The aim of this chapter is to examine how different countries make population health 
screening policy for GBS and other conditions. The objectives are to examine the systems 
responsible for: 
a) developing screening policy recommendations; 
b) making a decision on whether or not to introduce screening programmes; and 
c) implementing screening programmes. 
In addition, I will explore the processes used to develop the policy recommendation on 
population health screening. The policy processes that I will specifically explore are: 
d) the screening criteria; 
e) the methodologies to synthesise evidence for criteria; and 
f) the procedures used to reach a final decision on whether or not to recommend a 
programme. 
The findings of this chapter have been reported to a UK NSC meeting, the Department of 
Health’s triennial independent review of the UK NSC processes and have been provided as 
written and oral evidence to the UK House of Commons Science and Technology 
Committee’s Inquiry on Health Screening. 
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5.3 Methods 
As discussed in Chapter 3, I chose systematic review methodology to address the objectives 
of this chapter. The systems and processes used to make screening policies within countries 
had never been previously synthesised or collated. I decided to find out what is publically 
available before using a more labour and resource intensive methodology. I planned and 
reported this systematic review according to recommendations from the Preferred Reporting 
Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) 2009 statement.212 
However, I adapted the systematic review processes to suit the needs of this review. 
In particular, the data for this review were largely from grey literature as opposed to medical 
and health science journal databases. Although I started the search strategy with these 
databases, this was primarily to find grey literature sources where I could then find the 
information about the screening systems and the policy-making processes. I developed a 
framework that first searched electronic databases for the policies developed for the screening 
of GBS. I then searched the full-texts and reference lists of abstract-included papers for 
organisations that made the GBS screening policy. Thereafter, I searched the organisations’ 
websites for information on the structures or processes they used to make screening policy on 
any health condition or screening programme (see Figure 2). Therefore, I extracted and 
synthesised the majority of the data from the policy manuals and the webpages of policy-
making organisations, in addition to some journal articles containing relevant information 
addressing my aims. The justification for this decision was that the required information was 
not available in electronic databases, but electronic databases were needed to find, 
systematically, the sources where this information was available. Further details are provided 
below. 
Compared with systematic reviews, I did not assess the quality of the data found and extracted 
for the review. This was not necessary as the data I extracted were descriptive in nature. It was 
also not feasible to do this as the data were in different formats, ranging from journal articles 
to policy manuals and website information, for which quality assessment tools were not 
appropriate. 
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GBS group B Streptococcus  
Figure 2. Framework for the methodology used in the health screening policy-making review 
5.3.1 Search strategy and selection criteria 
I conducted a literature search on electronic bibliographic databases MEDLINE (Ovid), 
EMBASE (Ovid), Science Citation Index Expanded (Web of Science) and the Applied Social 
Sciences Index and Abstracts (ProQuest) from 1996 to 29 November 2013, as 1996 was the 
first year that GBS screening was nationally recommended.1 I developed a search strategy 
with input from the authors, an information specialist, and had the strategy reviewed by the 
2014 Department of Health working group for the independent review of the UK NSC. To 
address all aspects of the objectives, in the final strategy, I combined three sets of search terms 
using both text words and Medical subject headings (MeSH) terms through Boolean operators 
OR within each set and then AND to combine the sets. The first set was made up of search 
terms for GBS, the second set was made up of search terms for screening, and the third set 
was made up of search terms for policy (see Appendix 1 for complete search strategies). 
As shown in Table 5, I included titles and abstracts that satisfied the following criteria for full-
text and reference list examination: the population was pregnant women or women in labour, 
the intervention was population-based screening policy for GBS and one of the outcomes 
likely reported in full-texts or reference lists were policy-making processes or the 
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organisations that made the screening recommendation. After I searched the full-text and 
reference lists of the abstract-included articles, I only included full-text articles for synthesis 
if the outcomes included sufficient information about policy-making processes. However, for 
articles that provided the screening organisation in the full-text or reference list, but did not 
have information about policy-making processes, I extracted the name of the screening 
organisation. After extracting all screening organisations’ names, I then searched for these 
organisations on the Internet. Once I found the screening organisations’ websites, I searched 
the websites to find policy documents with information on the screening structures and 
processes for assessing any health condition (see Table 6). Overall, I excluded articles 
published before 1996, articles that did not contain sufficient information on screening 
processes, were abstracts or letters. 
Table 5. Selection criteria for articles in the electronic databases for the review on health 
screening systems and policy-making processes 
Component Title and abstract electronic database search 
Study design Any study design, to identify as many countries and organisations as 
possible. The study design would not impact or bias the information 
on the policy-making organisation or processes.  
Participants Pregnant women or women in labour.  
Intervention Population-based screening policy or recommendation for the 
prevention of neonatal GBS. 
Comparator None or any comparator used for comparison with the intervention.  
Outcome Description of policy-making processes.  
Type, Year, and Language 
of publication 
Any type of report including primary and secondary studies, reviews, 
opinions and consensus statements. 
All languages. 
1996 onwards. 
GBS Group B Streptococcus  
Table 6. Selection criteria for policy documentation from screening organisation websites for the 
review on health screening systems and policy-making processes 
Component Policy documentation from screening organisation website 
Study design Any design used to describe policy-making processes.  
Participants Any population or health condition. 
Intervention Population-based screening policy or recommendation for any health 
condition. 
Comparator No comparator or any comparator. 
Outcome Policy-making processes. 
Type, Year, and Language 
of publication 
Any report, policy documentation, manual or guideline. 
Any language. 
1996 onwards. 
 
Finally, I invited screening policy experts from around the world, as identified by the UK NSC 
and my supervisors, to identify any further useful documentation on policy-making systems 
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and processes across countries. I also searched websites of the European Commission, 
European Council, European Observer and the World Health Organization for articles on 
screening policy-making systems and processes. 
5.3.2 Study selection and data management 
I downloaded identified, electronic database references to bibliographic management software 
(Endnote X5) and de-duplicated them. A second-reviewer and I independently screened the 
titles, abstracts and full-texts of all identified records using the selection criteria in Table 5 
(screening level I). I then obtained full-text reports of all potentially relevant records identified 
at screening level I and, along with the second-reviewer independently examined them for 
screening organisations as well as information on policy-making processes in the full-text and 
the reference lists (screening level II). The second reviewer and I independently extracted the 
names of screening organisations from the abstract-included articles and included full-text 
articles that had sufficient information about policy-making processes. Finally, the second 
reviewer and I independently searched for the organisations’ websites and searched the 
websites for policy documentation using selection criteria in Table 6. We resolved any 
disagreements over inclusion/exclusion at screening level I and II, the inclusion of screening 
organisations and policy documentation from the organisation websites by discussion, 
involving a third reviewer where necessary. I documented the study flow and reasons for 
exclusion of papers in a PRISMA study flow diagram.212 For any articles or documents that 
were not in English, I attempted to translate them informally using computer software. 
5.3.3 Data extraction 
A second reviewer and I independently extracted relevant data using an a priori defined 
extraction sheet piloted and refined before implementation (see Appendix 2). We cross-
checked each other’s data extraction forms and resolved any disagreements by discussion and, 
where necessary with the involvement of a third reviewer. The extracted data included: author, 
title, year, condition, country, level of recommendation, screening organisation and authority, 
screening criteria and how they are used, evidence synthesis methodologies and how a final 
recommendation is reached. 
5.3.4 Quality assessment 
I did not assess the quality of the data found as all of the information was descriptive in nature. 
The articles did not involve any methodology that would affect the resulting information. 
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Furthermore, the information was found in various formats, some in peer reviewed journals, 
some in policy manuals, and some on different webpages of the websites. In addition, some 
were in English sand some were translated informally. Therefore, it would not have been 
feasible to judge or compare the quality of information. 
5.3.5 Data synthesis 
I systematically and narratively synthesised the data in text and tables. To examine health 
screening systems, I tabulated the screening organisation in each country along with the level 
of responsibility for making the recommendation, decision-making, and implementation of 
screening programmes within that country (e.g. national or regional). Based on preliminary 
work, I anticipated that I would find professional medical bodies that make screening 
recommendations but that are not screening bodies themselves. I state these organisations in 
the results but I do not describe their processes. To examine the screening criteria used in 
different countries, I first tabulated each criterion produced by Wilson and Jungner,147 and 
then analysed the use of that item for each country. As I identified those criteria used in 
countries that were additional to Wilson and Junger’s original list, I tabulated the criteria and 
assessed them for inclusion in the remaining countries. To assist in the comparability of 
criteria across countries, I only tabulated the information used in the statement of each 
criterion and did not include the detailed paragraphs describing the criterion or details in the 
other sections of the manual. Finally, for countries that did not explicitly use criteria, I 
extracted information from their policy-making processes. I narratively synthesised evidence 
synthesis methodologies and the procedure for deciding a recommendation in each country in 
text. A second reviewer also independently tabulated for screening systems and criteria and 
cross-checked the text synthesis for the evidence review methodologies and the decision-
making processes. I discussed any discrepancies with the second reviewer with the 
involvement of a third author where necessary. 
 
5.4 Results 
5.4.1 Study selection 
Figure 3 shows the flow of study selection. From the electronic database search, the second 
reviewer and I identified 436 unique records. After screening, we excluded 265 records and 
assessed 171 full-text articles for inclusion as well as searching the full-texts and reference 
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lists for screening organisations. We subsequently excluded 166 articles, which resulted in 
including five articles. From the reference checking of 171 articles and organisational 
websites, we identified 31 documents and experts identified 12 further documents. We did not 
identify any documents from international health organisations. Overall, 48 articles met the 
inclusion criteria and were included in the synthesis.14, 11, 156, 157, 155, 159, 213-215, 132, 216-224, 166, 225-
227, 22, 138, 228-230, 163, 231-238, 151, 239, 143, 240-246, 150 
 GBS group B Streptococcus 
Figure 3. Flow diagram on the selection of studies for objective 1 
5.4.2 Characteristics of documents 
There were 42 documents that covered screening policy-making in one country or 
international organisation alone and six documents that covered more than one country.238, 151, 
143, 240, 246, 150 Ten documents were informally translated into English from Czech,220 Dutch,227, 
138, 234 German,214, 233 Italian,223 Spanish219, 163 and Swedish.243 Table 7 shows the screening 
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policy-making systems and processes found for 17 countries and two international 
organisations. The screening organisations found in all countries were responsible for 
developing screening policy for all conditions and were not restricted to GBS. The exception 
was for Belgium, the Czech Republic and Japan where there were only professional medical 
societies, thus, we did not extract their processes. Only cancer programmes were covered by 
the National Screening Observatory in Italy and the Screening Subcommittee in Australia. 
There was information on screening systems for 15 countries (objectives a, b and c), on criteria 
for 14 countries and two international bodies (objective d), on evidence synthesis 
methodologies for 11 countries (objective e) and on decision-making information for eight 
countries (objective f).  
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Table 7. Screening policy-making systems and processes found across countries and international 
bodies 
Country or 
Organisation 
Conditions 
covered 
Was a 
screening 
organisation 
found? 
Were 
criteria 
found? 
Were evidence 
synthesis 
methodologies 
found? 
Were decision-
making 
processes 
found? 
Countries 
Australia221, 222, 228, 
229, 245, 150 
Cancer, GBS, 
General 
Yes Yes Yes, but unclear No 
Belgium215, 156, 157 GBS Yes No Yes, but unclear No 
Canada216, 217, 155, 230, 
150 
General, GBS Yes Not used Yes Yes 
Czech Republic220  GBS No No No No 
Denmark238, 239, 143, 
241 
General Yes Yes Yes No 
Finland238, 143, 225 General Yes Yes Yes No 
France159, 213, 143 General, Early 
neonatal 
bacterial 
infection 
Yes Yes Yes Some 
Germany214, 143, 233 General, GBS Yes Yes Yes, but unclear Yes 
Italy11, 223, 143 Cancer, GBS, 
General 
Yes Yes Yes, but unclear No 
Japan166 Obstetrical 
practice 
No No No No 
Netherlands151, 227, 
138, 234 
General, 
Genetic 
screening, GBS 
Yes Yes Yes No 
New Zealand132, 226, 
244, 229, 150 
General, GBS Yes Yes Yes Some 
Spain219, 143, 163 General, GBS Yes Yes Yes No 
Sweden238, 151, 143, 243 General Yes Yes Yes Yes 
Switzerland237, 232 General, GBS Not in use  Not used Not used Not used 
UK238, 151, 142, 143, 22, 
230, 150, 246 
General, GBS Yes Yes Yes Yes 
US218, 224, 150, 235, 236, 
14 
General, GBS Yes Not used Yes Yes 
International organisation 
WHO231 Non-
communicable 
disease 
- Yes No No  
Council of the 
European Union239, 
242 
Cancer - Yes No No 
GBS group B Streptococcus, UK United Kingdom, US United States of America, WHO World Health 
Organization consultation group on methodology of non-communicable disease screening 
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5.4.3 Screening systems (objectives a, b and c) 
There was a national organisation in 14 countries that was responsible for providing screening 
recommendations to varying extents (Table 8). In 2010, officials had been considering the 
creation of a national screening body in Switzerland, however, there was no screening 
organisation as yet. With the exception of Spain, all screening bodies made some form of 
evidence-based screening recommendations at the national level. In Spain, regional authorities 
were permitted to make screening recommendations that the Ministry of Health had to approve 
before introduction. 
The decision-making and implementation of screening recommendations was at the national 
level in the UK, New Zealand and the Netherlands. In the other 11 countries, these 
responsibilities were delegated to the regional, local, or municipal bodies and via insurance 
schemes. In France, Germany and Belgium, decisions to introduce screening programmes 
were applied at the national level, however, the responsibility to implement them was 
delegated to lower levels. In Canada, Sweden and Australia, both the decision to introduce 
and implement screening programmes was devolved to the regional or local level. In Finland, 
Italy and Denmark, the national screening organisation asked municipal and regional 
authorities to introduce screening programmes with differing amounts of authority. Lower 
level authorities were obligated to introduce some screening programmes but did not have to 
introduce others. In the US, decision-making was previously delegated to the individual states 
and health insurance plans (including Medicare, Medicaid and the Veterans Health 
Administration), as guideline recommendations and coverage decisions were separated. 
Thereafter, under the Affordable Health Care Act, screening programmes that the United 
States Preventive Services Task Force (USPSTF) recommended with a grade A or B (see 
Section 5.4.6 below for grading) had to be covered by health insurance plans. Screening 
programmes not recommended by the USPSTF Health plans could still be covered by 
insurance plans. Therefore, in the US, Finland, Italy and Denmark, lower level bodies were 
able to introduce screening programmes not endorsed in national recommendations. 
GBS screening recommendations or policies across many countries were not developed by 
the national screening agencies identified above. In Australia, the Czech Republic, Germany, 
Italy, Japan, the Netherlands, New Zealand, Spain and Switzerland, GBS screening 
recommendations were developed by professional medical societies, such as obstetrics and 
gynaecology societies. The screening organisations in these countries did not have a GBS 
recommendation on their website. In Belgium, GBS screening recommendations were 
developed by the Ministry of Health, however, it was not clear whether the Ministry was 
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responsible for developing other screening recommendations as well. In the US, the CDC, a 
national disease prevention agency, developed the GBS screening recommendation, however, 
it is the USPSTF that is nationally responsible for screening. The USPSTF does not have a 
recommendation on GBS screening. The national screening agency in France did make the 
GBS recommendation, however, this recommendation was dated before the publication date 
for the policy manual to assess screening programmes. Only the GBS recommendations in 
Canada and the UK were made by the national screening organisation. 
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Table 8. Screening systems across countries 
Name Organisation Recommendation  Decision-making Implementation 
Other GBS screening 
recommendations 
Australia 
The Screening Subcommittee, 
Australian Population Health 
Development Principal 
Committee National  Regional  Regional 
Royal Australian and New Zealand 
College of Obstetricians and 
Gynaecologists  
Belgium Superior Health Council National National Local  
Canada 
Canadian Task Force on 
Preventative Health Care  National Regional Regional 
Canadian Strategy for Cancer Control: 
Screening Working Group 
Society of Obstetricians and 
Gynaecologists of Canada (SOGC)  
Canadian Paediatric Society 
Czech Republic  
Czech Gynaecological and Obstetrical 
Society 
Denmark  National Board of Health National/Regional National/ Regional Regional  
Finland  
National Screening Committee, 
Ministry of Health and Social 
Affairs National/Municipal National/Municipal  Municipal   
France  Haute Autorité de Santé National National  
Local through health 
insurance  
Germany  The Federal Joint Committee National National  
Regional through 
health insurance 
Working Group of the scientific 
medical professional societies 
Italy  National Observatory Screening National National/ Regional Regional 
GBS Prevention Working Group of 
Emilia-Romagna. 
Japan      
Japan Society of Obstetrics and 
Gynaecology Japan Association of 
Obstetricians and Gynaecologists  
Netherlands  
The Health Council  
National Institute for Public 
Health and the Environment National National National 
Dutch Organisation of Obstetrics and 
Gynaecology  
Dutch Association of Paediatrics 
(NVK)  
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Name Organisation Recommendation  Decision-making Implementation 
Other GBS screening 
recommendations 
New Zealand  
National Screening Advisory 
Committee  
National Screening Unit  National National National 
Royal Australian and New Zealand 
College of Obstetricians and 
Gynaecologists  
Spain  
Ministry of Health, Social 
Services and Equality Regional Regional Regional 
Spanish society of obstetricians and 
gynaecology  
Sweden  
The National Board of Health and 
Welfare National Local Local  Switzerland Considering national recommendation and decision-making organisation Swiss society of neonatology  
UK  
UK National Screening 
Committee National National National 
Royal College of Obstetricians and 
Gynaecologists 
US  
United States Preventive Services 
Task Force National 
National coverage 
for a set of 
conditions 
Regional: health 
insurance National: 
Medicare, Medicaid, 
Veterans Health  
Centers for Disease Control and 
Prevention 
American College of Obstetricians and 
Gynaecologists 
American Academy of Paediatrics  
GBS group B Streptococcus, UK United Kingdom, US United States of America, Recommendation: geographical coverage for screening recommendation, Decision-making 
geographical coverage for decisions to introduce screening, Implementation: geographical level that screening programme is implemented.
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5.4.4 Screening criteria (objective d) 
Not every country used explicitly set criteria. The US and Canada did not use a checklist of 
criteria but have developed an analytic framework with a set of key and contextual questions. 
The framework and associated questions can be tailored for each individual review. For the 
purposes of this review, I extracted the key questions and examples of the contextual questions 
provided in the manuals. However, other aspects of screening may also be assessed given the 
tailored approach. Similarly, I only found general guidelines required for the assessment of 
screening before programmes were introduced for Finland, Germany and Italy. Although I 
synthesised these areas, it is worth noting they were broader and more general relative to other 
countries. Finally, the Council of the European Union used the Council of Europe 
recommendations and Wilson and Jungner’s criteria,239 so I extracted the Council of Europe 
recommendations. 
Specifically for the US, Harris et al. (2001) described key questions in more detail than those 
stated in the 2008 USPSTF manual.224 Harris et al. described some sub-questions within each 
key question stated in the USPSTF manual. These were: 
- what is the prevalence of disease in the target group? 
- Is there significant variation between examiners in how the test is performed? 
- In actual screening programmes, how much earlier are patients identified and treated? 
- Does treatment work under ideal, clinical trial conditions? 
- How do the efficacy and effectiveness of treatments compare in community settings? 
- How similar are people diagnosed clinically to those diagnosed by screening? 
- Are there reasons to expect people diagnosed by screening to have even better health 
outcomes than those diagnosed clinically? 
- Is the test acceptable to patients? 
I only extracted the key questions stated in the manual into Table 9, not the sub-questions 
mentioned in Harris et al. 
Overall, I classified criteria across 13 countries and two international bodies into 44 items (see 
Table 9). The criteria that were most frequently used were from Wilson and Jungner’s list.147 
All countries used criteria covering test quality and the cost-effectiveness of the screening 
programme. Countries cited test quality in different ways. The majority stated that the test 
should be appropriate or suitable but others mentioned that the test should be accurate, 
efficient, valid, precise, reliable and reproducible, safe, sensitive and specific and have known 
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predictive values. Other commonly used criteria developed by Wilson and Junger were 
understanding the natural history and epidemiology of the condition and the condition having 
a detectable disease marker, early symptomatic stage, latent period or risk factor. Commonly 
used criteria that were not on Wilson and Jungner’s list were that the overall benefits from the 
screening programme should outweigh the harms and that there should be scientific evidence 
to provide screening effectiveness. 
The differences in criteria across countries often did not mirror the differences in the screening 
systems. There were two criteria that did differ between countries with national compared 
with devolved decision-making. Ten countries with devolved decision-making stated 
scientific evidence to prove screening effectiveness, however, none required RCT evidence. 
By contrast, only countries with national decision-making stated the need for RCT evidence 
to prove screening effectiveness: the UK required RCT data, New Zealand ‘ideally’ required 
RCT data, and France required RCTs or international consensus. The second criterion only 
used in countries with devolved decision-making but not in those with national decision-
making was ‘clarifying organisational aspects (to achieve national equivalence)’. 
There were some criteria recommended by the international organisations that were not 
applied in any country as far as I identified and other criteria that were only used by one or 
two countries. The most prominent of these criteria were focussed around quality assurance 
and genetic considerations. The Council of Europe recommended to correct or stop screening 
programmes if quality assurance standards are not met. They also recommended that early 
diagnosis outside of organised screening programmes should also be subject to quality control, 
which was only considered by Italy. 
There were some infrequently used criteria addressing genetic screening, which were only 
applied in the UK and Spain. Both the UK and Spain assessed a criterion used to clarify the 
subset of mutations to be covered by screening. The UK also stated that genetic mutation 
programmes should to be acceptable to people identified as carriers and to other family 
members and that the natural history of people with carrier status should be understood. 
Relatedly, the Council of Europe stated that neonatal screening could only be justified if the 
intervention is of direct health benefit to the child but this was not in use in any country I 
identified. 
Other infrequently used criteria were focussed around ethical issues (research consent, 
managing individuals with high risk of disease, and consequences of test results) and 
implementation issues (stakeholder involvement, public pressure, accountability). 
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5.4.5 Evidence synthesis methodologies (objective e)  
In all 10 countries, scientific evidence was searched to assess a screening programme against 
the screening criteria, or the analytical framework and key questions in Canada and the US. 
An evidence synthesis review of scientific literature was performed in these countries by an 
expert scientific body that was independent of the screening organisation. In the UK, however, 
the NSC’s information specialist first conducted a knowledge update of the relevant research 
and, on the basis of that, the NSC director decided whether a full external review was required. 
Only the full external review would be conducted by an independent expert.22 In all countries, 
screening organisations invited stakeholders, such as healthcare professionals, patient and 
carer groups and groups involved in developing public health or screening guidelines to 
participate in the evidence synthesis and decision-making process. Stakeholders played a 
larger role in Canada,217 the US236 and Denmark,241 helping to formulate the framework and 
questions to be addressed in the evidence review. 
Countries that do not always make national decisions (Canada,216, 217 Sweden243 and the US235, 
236) and France,213 assessed the quality of evidence in reviews using specified tools. Canada 
and Sweden used the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) Working Group methodology,247 where the quality of evidence is graded in two 
steps. First, a grade is assigned to the quality of evidence for the combination of studies for 
each important outcome in question, then a grade is assigned for the quality of evidence across 
all the outcomes, which results in a grade for the evidence base on the whole screening 
programme. The US has developed similar methods to GRADE, where the quality of each 
study is examined and then combined to examine the quality of evidence for each key 
question, then the quality of evidence for the key questions is combined to assess the quality 
of evidence for the entire screening programme.235, 236 France stipulated key critical appraisal 
questions and endorsed appraisal tools to examine specific study types within the criteria for 
screening tests, programme effectiveness and economic assessment.213 
In many countries, once evidence reports were completed they would be externally reviewed 
for quality assurance. Screening bodies consulted peer reviewers and experts in the field 
(Canada,217 Denmark,241 France,213 the Netherlands,227 New Zealand226, 244 the US236), partner 
organisations that were liaising federal agencies and primary care societies (Canada,217 and 
the US236), public health bodies (Sweden243 and Spain219), stakeholders (Denmark)241 and the 
general public (the UK22 and Sweden243). 
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5.4.6 Decision-making processes (objective f)  
Screening organisations in six countries stated that they would hold a meeting where members 
could discuss the criteria and key issues in the evidence and consultation, to reach a decision 
on whether, or not, to recommend screening. It was not clear whether there was a structured 
procedure for this in the UK, New Zealand and Sweden. A vote would be taken in Canada,217 
Germany233 and the US,236 with a quorum set for the level of agreement needed in the US and 
Canada. 
Canada,217, 216 Sweden243 and the US235, 236 that do not always make national screening 
decisions, as well as France213 that does make national screening decisions, would grade 
recommendations according to the quality of evidence. For Canada and Sweden, 
recommendations were graded weak, where benefits of the intervention probably outweigh its 
harms or vice versa, or strong where benefits of the intervention outweigh its harms or vice 
versa, following GRADE methodology. In the US, the grades were from A, B, C, D, and I, 
and were related to the certainty of the evidence and magnitude of the net benefit (benefits 
minus harms) for a programme. For example, grade A was a programme with high certainty 
that there is substantial net benefit while grade D is a programme with moderate or high 
certainty that the harms outweigh the benefits or the service has no benefit. Grade I is a 
programme where you cannot determine balance of benefits and harms as the evidence is of 
poor quality, conflicting or lacking. Where screening recommendations are graded A and B, 
the USPSTF recommends offering the programme and where recommendations are graded C, 
the USPSTF only recommends offering the programme if there are other considerations in 
support of offering services in an individual patient. The USPSTF discourages offering 
recommendations graded D and advises that, if services graded I are offered, the uncertainty 
about the balance of benefits and harms should be understood by the patients. 
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Table 9. Screening criteria used across countries and international bodies 
No Criteria Item 
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Condition 
                1 Suitable or well-defined candidate for screening   X  X     X    X X  
2 Condition should be an important health problem X X  X    X X  X X X X  X 
  a. Burden of condition – Incidence & prevalence   X  X X        X X  
  b. Mortality and morbidity       X          X 
  c. Socioeconomic impact      X          X 
3 The epidemiology and natural history of the condition, including development from 
latent to declared disease, should be adequately understood 
X X X X  X   X  X X X X X X 
  a. Known strength of association between intermediate outcomes and clinically relevant 
outcomes for the condition 
  X           X   
  b. Is pseudo disease present in the apparently diseased population?              X   
4 There should be a detectable risk factor, disease marker, latent period or early 
symptomatic stage  
X X X X   X X X  X X X X  X 
5 All the cost-effective primary prevention interventions implemented as far as practicable.      X     X  X    
6 If the carriers of a mutation are identified as a result of screening, the natural history of 
people with status should be understood, including the psychological implications. 
            X    
7 Current clinical practice   X           X   
 Test     X            
8 Suitable test or examination  X  X X   X X  X  X    X 
  a. Test should be simple      X     X  X  X  
  b. Test should be precise              X    
  c. Test should be accurate   X           X   
  d. Test should be sensitive and specific   X X           X  X 
  e. Predictive values of the test should be evaluated  X  X            X 
  f. Test should be valid  X  X  X     X  X    
  g. Test should be safe  X         X  X  X  
  h. Test should be reliable and reproducible      X   X  X      
  i. Test should be efficient    X       X      
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9 The test and [further investigation] should be acceptable to the population [Swe] X X  X  X   X  X X X   X 
10 The distribution of test values in the target population should be known and suitable cut-
off level defined and agreed on whom to categorize as “screen positive" "screen 
negative”  
 X           X  X  
11 There should be an agreed evidence based policy for each group following disclosure of 
screening results: 
                
 a. On further diagnostic investigation and support of individuals with a positive test 
result and on the choices available to those individuals 
 X  X  X     X  X  X X 
  b. Providing information about negative screening tests  X               
12 If the test is for mutations the criteria used to select the subset of mutations to be covered 
by screening, if all possible mutations are not tested, that should be clearly set out. 
          X  X    
13  New technologies for screening/and or intervention              X   
Treatment     X            
14 There should be an effective treatment or intervention to benefit premature mortality, 
benefit quality of life, or alter the course of the disease for patients identified through 
early detection  
 X X   X X   X   X  X X 
  a. Evidence of early treatment leading to better outcomes than late treatment      X  X   X X X X  X 
  b. Treatments available that make a difference in intermediate outcomes when the 
disease is caught early, or detected by screening 
             X   
15 There should be an accepted treatment X X  X     X   X    X 
16 The treatment must be accessible  X        X      X 
17 The treatment must be available  X              X 
18 There should be agreed evidence based policies and referral systems covering which 
individuals should be offered treatment and the appropriate treatment to be offered  
X X  X  X   X  X  X  X X 
  b. There needs to be an established policy for the management of individuals who are 
identified as being at high risk of developing the disease or condition  
 X               
19 Clinical management of the condition and patient outcomes should be optimised in all 
health care providers prior to participation in a screening programme 
          X  X    
Programme                 
Effectiveness     X            
Antenatal screening for group B Streptococcus in the UK	
	 66
No Criteria Item 
W
&
J
 
 
A
u
s
 
 
C
a
n
a
 
D
e
n
 
 
F
i
n
 
 
F
r
a
 
 
G
e
r
 
 
I
t
a
 
 
N
e
t
h
 
 
N
Z
 
 
S
p
a
 
 
S
w
e
 
 
U
K
 
 
U
S
 
a
 
W
H
O
 
E
U
b
 
20 Have scientific evidence of screening programme effectiveness (reduces morbidity and 
mortality) 
 X X   X   X X X X  X  X 
  a. High quality RCT evidence that screening programme is effective in reducing 
mortality or morbidity  
         X   X    
  b. Have evidence from experimental studies                X 
 c. Where screening is aimed solely at providing information to allow the person being 
screened to make an “informed choice”, there must be evidence from high quality trials 
that the test accurately measures risk. The information must be of value and readily 
understood 
            X    
21 Cost-effectiveness X X X X X X X X X X X X X X X X 
  a. All other options for managing the condition should have been considered to ensure 
that no more cost effective intervention could be introduced or current interventions 
increased within the resources available.  
     X       X   X 
  b. Cost effective to encourage high coverage.  X               
 Planning and implementation                  
22 Respond to a recognised need  X       X        
23 Have a clear definition of the objectives of the programme, the roles and responsibilities, 
the expected health benefits, and the financing required from the outset 
 X       X       X 
24 Identify the target population which stands to benefit from screening  X       X  X     X 
25 Patient values and preferences included in screening policy-making    X              
26 Case-finding should be a continuing process and not a ‘once and for all’ process with a 
clearly defined and optimal interval 
X X X X  X   X     X  X 
  a. Ages when screening should be stopped              X   
27 Public pressure for widening the eligibility criteria for reducing the screening interval 
and for increasing the sensitivity of the testing process, should be anticipated. Decisions 
about these parameters should be scientifically justifiable to the public. 
            X    
    Organisation, Infrastructure, Workforce, and facilities                 
28 Relevant programme organisational aspects should have been clarified (to achieve 
national equivalence) 
   X X   X    X     
  a. Staff training    X            X 
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  b.  Awareness programmes should be organised for target population and health 
professionals 
     X          X 
  c. The programme should integrate a coherent set of education, training, practice, test, 
care, clinical services, and programme management 
 X       X        
29 Adequate workforce, facilities, education, organisation and infrastructure for testing, 
diagnosis, follow-up assessment, treatment and programme management should be 
available prior to the commencement of the screening programme  
X X  X  X X  X   X X  X X 
30  Registration system - a database capable of providing a population register for people 
screened and health information collected for the programme  
 X  X    X        X 
  a. A detailed description of test result dissemination    X    X        X 
31 Feasible programme within the health system     X     X X X    X 
32 A detailed description of the steering committee     X             
33 Involve multiple disciplines and professions        X         
34 The governance structure at the government level should be accountable to society, in 
terms of both the overall performance of the programme and the implications for society 
               X 
      Monitoring and quality assurance                 
35 There should be a plan for managing, monitoring and evaluating the screening 
programme 
 X X   X   X  X X X   X 
36  An agreed set of quality control and assurance standards to minimise potential risks of 
screening 
 X    X  X X  X  X   X 
  a. Activity of early diagnosis done outside of organised screening programmes must be 
subjected to a quality control enabling the assessment of the adequacy and results.  
       X         
  b. A limited number of the appraisal criteria and indicators should be validated; they 
should be chosen at the design stage and be based on the results of the literature review 
or the opinion of a panel of experts 
     X           
  c. If quality assurance standards are not met in the long term it should be possible for the 
screening programme to be corrected and, if this is not possible, stopped. 
               X 
     Acceptability and ethical issues                 
37 There should be evidence that the complete screening programme (test, diagnostic 
procedures, treatment/ intervention) is clinically and socially acceptable to health 
professionals and the public. 
         X X   X    
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38 There should be evidence that the complete screening programme (test, diagnostic 
procedures, treatment/ intervention) is ethically acceptable to health professionals and the 
public. 
    X   X  X X X X    
  a. An evaluation of the ethical and psychological consequences for the examinees    X             
        i. An evaluation of the consequences of "false positive" and "false negative" test 
results/experience of overdiagnosis  
   X             
  b. An evaluation of stigmatisation    X             
39 Promotion of human rights, including upholding the principles of autonomy and 
confidentiality 
 X    X   X       X 
40 Promote equity and access to screening for the entire target population, regardless of 
socio-cultural and economic availability 
 X X   X  X X      X X 
41 Informed choice: Evidence-based information, explaining the consequences of testing, 
investigation and treatment, should be made available to potential participants to assist 
them in making an informed choice  
 X  X  X  X X   X X   X 
 a. If the programme is provided as a service and conducted also for research purposes, 
the decision to make available personal medical data stemming from the screening 
programme for research purposes should be taken freely, without undue pressure 
               X 
42  Neonatal screening can only be justified if the intervention is of direct health benefit to 
the child. Otherwise, screening should be postponed until the child can decide for itself. 
               X 
43 If screening is for a mutation the programme should be acceptable to people identified as 
carriers and to other family members 
            X    
Overall benefits versus harm                 
44 The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and treatment) 
 X X   X  X X X X X X X  X 
  a. Frequency and severity of harms of workup / screening test   X           X   
  b. Harms of treatment              X   
W&J Wilson & Jungner, Aus Australia, Can Canada, Den Denmark, Fin Finland, Fra France, Ger Germany, Ita Italy, Neth Netherlands, NZ New Zealand, Spa Spain, Swe Sweden, 
UK United Kingdom, US United States of America, WHO World Health Organization consultation group, EU Council of Europe 
a. No screening criteria b. The Council of Europe
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5.5 Discussion 
5.5.1 Principal findings 
In this systematic review, I reported the policy-making systems and processes for population 
health screening programmes across 15 countries and two international organisations. I found 
systems and processes for the screening of any conditions in 14 of the 15 countries and only 
for GBS in one country. The principal findings are as follows. A national body has been 
established in several countries that assesses the scientific evidence for a screening programme 
against a list of screening criteria to create screening policy recommendations (objective a). 
Even Canada and the US, which did not have a list of criteria, resonated the principles of 
screening criteria in their evidence review processes (objective d). Nevertheless, there were 
differences in the national screening organisations’ degree of influence to implement the 
screening decisions across countries (objective b and c). As screening decisions could be 
decided at a local or regional level, there were organisations beyond the screening 
organisations that made screening recommendations. Crucially, for GBS, few screening 
recommendations across countries were developed by the organisation nationally responsible 
for assessing screening. There was also a divergence in countries’ choices of the screening 
criteria used, little of which mirrored the differences in health systems. The important 
concerns here were that different countries required different levels of scientific evidence, few 
countries had criteria around genetic conditions, and none had criteria around ceasing 
programmes, all of which could be valuable. 
There were screening bodies across 14 countries that had the responsibility to make national 
screening recommendations and they did so using systematic policy-making processes that 
the organisations had developed (objective a). The screening organisations conducted 
thorough evidence reviews of scientific literature that incorporated screening principles 
beyond Wilson and Jungner’s list to ensure that the recommended programmes offer more 
benefit than harm.147 From the information that was available, these reviews also critically 
appraised the evidence and quality assured their reviews using external input (objective e). 
The decision on whether or not to recommend a screening programme was reached by 
discussion amongst the members of the organisation which incorporated the screening 
principles, evidence available, as well as its quality (objective f). However, once these national 
screening recommendations were formulated, they were not enforced in all countries. 
Screening recommendations became regulations that required national implementation only 
in some countries. In other countries, the recommendations were similar to best practice 
guidelines, and local and regional health authorities could decide all or some of the screening 
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programmes for their citizens (objective b and c). Therefore, screening practices may vary 
within countries. 
Relatedly, a key finding was that the screening recommendations for GBS were made by 
medical professional societies and other organisations not nationally responsible for screening 
in 15 of the 17 countries. The only countries with GBS screening reviewed by the screening 
organisation were Canada and the UK. In the majority of the countries, recommendations were 
produced by professional medical societies while in the US they have been developed by the 
CDC, which is a preventative health organisation but not the USPSTF which is responsible 
for screening nationally. Whether these organisations took the key screening principles into 
account is not known and may have serious implications on whether the critical and likely 
unseen harms of GBS screening have been considered. Similarly, in France and Belgium, it is 
not clear whether the national organisation that made the GBS recommendation took 
screening principles into account. Whether these societies and organisations assessed GBS 
screening using rigorous and systematic evidence-based methods that are free from bias and 
incorporated screening principles remains unknown. 
There was a divergence in the specific screening criteria that were utilised across countries 
(objective d). One of the most important criteria was that different countries required different 
levels of scientific evidence. Unlike the UK, many countries including Australia, Canada, 
Denmark, Finland, Germany, Italy, the Netherlands, Spain, Sweden and the US did not 
specifically require RCT evidence to prove screening effectiveness in reducing morbidity and 
mortality. Canada, Sweden and the US may fulfil this need with the use of GRADE or similar 
tools for quality appraisal and strength of recommendation. Sweden also mentioned RCT 
requirements in the detail of their manuals but not explicitly in their statements.243 The 
difference in the evidence approach between countries may reflect the decision-making 
structures for screening within the countries. Requiring RCT evidence may be more 
appropriate in countries where national screening decisions are similar to regulations, whereas 
GRADE methodology may be more appropriate in countries where the recommendations are 
guidelines that regional or local health authorities decide to follow. This is because GRADE 
provides a clear and comprehensive method to rate the quality of evidence and the strength of 
recommendation that can be used by authorities to decide the programmes that should be 
introduced. This difference could have implications on whether a programme is introduced, 
or not, as organisations in some countries may accept observational evidence as satisfactory 
and recommend a programme whereas organisations in other countries may not. Evidence 
other than RCT could overestimate the benefits of screening due to study design biases (see 
Section 5.5.4). 
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Another striking criterion that was not utilised in any country was the requirement where, if 
quality assurance is not met, the screening programme should be stopped. Sweden stated in 
their manual, that there should be criteria of when to stop a programme but this was not 
reflected in their criteria statement and how this should be done was not mentioned.243 Finally, 
only Spain and the UK covered criteria related to genetic conditions, which have some 
different considerations to other screening programmes. For example, as identified in these 
countries, there are ethical implications to wider family members who would not be screened 
but would be identified as carriers as well as the ethical implications of the unintended 
revelation of mutations not screened for as part of the programme. 
 
5.5.2 Comparison with previous literature 
There has been little literature on the policy-making systems or processes of screening. In 
particular, there has been no detailed comparison of the screening criteria used in different 
countries. Andermann et al. (2008) summarised 54 screening criteria lists proposed since 
Wilson and Jungner’s criteria and found that, the additional and newer criteria reflected 
developments in healthcare such as accountability, consumer choice, evidence-based 
healthcare, quality assurance and the advent of genetic screening.148 However, Andermann et 
al. did not identify which criteria were used by policy-makers within countries or how the 
criteria were evaluated. Identifying the criteria actually used for policy-making in countries, I 
found that they have indeed been extended to cover advances of ethical considerations, 
implementation issues and scientific effectiveness. However, there was little evidence of 
genetic criteria utilised in countries. As indicated above, the UK and Spain have progressed 
in this respect. Following the completion of this review, I found that in the Netherlands, a sub-
committee for the Health Council provided a separate list of screening criteria for assessing 
genetic screening programmes.248 Likewise, in the US, recommendations for genetic screening 
are developed by the Evaluation of Genomic Applications in Practice and Prevention 
initiative, which integrate USPSTF processes for appraisal and evaluation.249  
Previous literature comparing screening policy-making processes in different countries 
includes: a literature review on the comparison of decision-making processes for newborn 
screening in New Zealand, the US, the UK and Australia,250 a literature review on the links 
between health technology assessments and health policy for three specific screening 
programmes in nine European countries,151 a commentary of screening practices in six 
European countries143 and an unpublished summary of screening processes in the UK, the US, 
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Australia, New Zealand and Canada.150 Using systematic review processes and covering 15 
countries, similar to these reviews, I found that screening decision-making and 
implementation varied across countries and that, in many countries the decision is made at the 
regional or local level.240, 150, 151 As indicated by many authors, this difference in the screening 
process is often a result of the structure and financing of general health systems.148, 240, 150 In 
countries where health systems are insurance-based or heavily decentralised and are 
autonomous, screening practices are less regulated and are less likely to have national 
decision-making or national implementation of screening programmes. On the other hand, in 
tax-based health systems, governments are found to have more control and regulation of 
screening policies.151 There has been little discussion about the screening system required to 
ensure that every person is receiving screening care that reflects the national evidence-based 
recommendation. There has been a suggestion that there should be one body in each country 
that is responsible for screening recommendation, decision-making and implementation.143, 240 
Likewise, it is recommended that decision-making to introduce screening programmes should 
be made at the national level to ensure that only the correct programmes are introduced in the 
correct way and that there is consistency across the country.246 However, similar to this review, 
it is recognised that although a country may have a national recommendation, it may not be 
utilised adequately or appropriately.142  
Compared with other reviews, I also found that processes to make screening policy are based 
on Wilson and Jungner’s screening criteria, involve evidence reviews and stakeholder 
engagement.151, 250 However, the more detailed comparison in this review showed that there 
are differences in the way in which criteria are used and the level of evidence required for 
meeting the evidence requirements. In addition, there are recommendations in the literature 
that ongoing screening programmes should be regularly evaluated to ensure that the 
programme is performing and delivering the expected outcomes as this may lead to changes 
in the programmes or stopping the programmes.246 In this review, I found that there were no 
criteria in place on how this should be done.  
 
5.5.3 Strengths and limitations 
This systematic review was the first examination on the systems and processes used across 
countries to develop policies on population health screening. I used innovative methods 
prioritising the reference list search that resulted in meeting the objectives of the review. By 
extensively searching the trail of reference lists to the organisation websites and thoroughly 
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searching them allowed me to capture as much data as possible. I made an effort to translate 
documents not in English allowing more data capture across countries. Furthermore, I invited 
a panel of international experts who identified further documentation within their countries of 
expertise, as well as UK based experts who additionally reviewed the search strategy and the 
findings of the review, assuring its quality. I also enlisted a second independent reviewer to 
sift, extract and synthesise all of the information to maintain the quality of the review. 
However, findings must be considered in light of some limitations. While I searched 
extensively to find the correct screening organisations and processes, I may not have found 
all organisations responsible for screening within countries. For example, countries such as 
Australia, Belgium, and Italy where only one or few conditions were covered, there may be 
other screening organisations that I did not find. Similarly, my search strategy may have 
missed screening organisations outside the countries I did find. My search only resulted in 
countries from Australasia, North America, and Western Europe. In the literature, there have 
been no screening organisations reported in Asia, Africa, Eastern and Central Europe or South 
and Central America.151, 251 However, like some of the screening organisations that were found 
in the grey literature, organisations in these countries may also not be in the published domain. 
Similarly, policy processes and websites are updated constantly and as the search was 
performed in 2013, systems and processes may already have changed. Finally, although my 
primary interest was GBS, and I chose it as the condition to use in the search strategy, I may 
have found more countries and organisations with another condition. 
There are also some limitations in the data extraction process. As I only tabulated explicitly 
mentioned criteria, for the US and Canada that did not use a criteria list approach, I may have 
missed some information that is not included in the key questions yet may still be included in 
the review process. However, as a tailored approach was used in the US and Canada, it was 
difficult to compare them with the remaining countries that did use criteria lists. While I 
attempted to translate documents not in English, these were informal translations generated 
by computer software, which means there could have been some errors in the translations. 
Due to resource constraints, this was the only option to include this information in a 
meaningful way. Related to this, I did not contact organisations to request further information 
in English or further documentation that may not have been easily accessible even in English. 
This may have resulted in further information or documentation. Lastly, I only extracted 
processes for screening organisations and did not extract the policy-making processes by other 
organisations, the majority of which made the GBS recommendations. Consequently, the 
methods used to make the GBS recommendations across countries are not known. 
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5.5.4 Research and policy implications 
Having robust evidence-based policy development processes that critically scrutinise 
screening programmes and effective systems that allow evidence-based decisions to be 
applied, is essential to have safe and successful screening programmes. Having incomplete 
policy-making systems or processes that do not examine screening programmes rigorously 
may lead to the introduction of disorganised, unsuccessful and expensive programmes, which 
have physical, financial and emotional harms, with little benefit.146, 142, 144 The screening 
systems and policy-making processes I have identified in this review can be adopted by 
governments in countries with and without screening bodies in order to implement health 
screening programmes safely within their contexts. Indeed, this review was used in the UK to 
ensure that the screening processes measure up to international standards and to identify areas 
for improvement. However, the methods used by committees to make final screening 
recommendation decisions are not as well understood. To explore this, interviews with key 
members of the screening organisations could inform the discussions that occur in practice. In 
addition to international policy-making standards, I have identified specific implications from 
the key differences across countries, which indicate potential concerns and scope for 
improvement for screening policy-making. 
Firstly, countries need screening systems that encourage evidence-based screening decisions 
to be implemented. In countries where decision-making is at the local or regional level, 
citizens in some areas may not be receiving evidence-based screening care as national 
evidence-based recommendations do not have to be followed. This is especially a risk as 
screening recommendations are also produced by medical societies, which authorities may 
choose to adopt. However, these recommendations may not necessarily be developed around 
screening principles or account for screening harms. Studies have shown differences between 
expert opinion and research evidence. For example, Antman et al. (1992) found that 
professional recommendations on acute myocardial infarction therapies in review articles or 
textbooks frequently contradicted the evidence from meta-analyses of trials.252 Similarly, a 
systematic review demonstrated that clinicians overestimate the benefits of screening and 
underestimate the harms253  possibly based on their clinical experiences.254 This is a particular 
risk for the case for GBS screening, where most recommendations have been made by clinical 
organisations and it is not clear if they have used internationally recognised screening criteria. 
As the criteria require that all the effects of a programme (harms as well as benefits) are 
examined, they ensure, as much as possible, that the introduction of a GBS screening 
programme to hundreds of pregnant women and their children would bring more benefit than 
harm. The next research step would be to examine the processes used by these organisations 
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and compare them with the processes used by screening organisations. Future researchers may 
also wish to examine the screening policy-making processes used by local and regional 
authorities and the degree to which national recommendations are adhered to in countries with 
decentralised decision-making. 
Secondly, the difference in evidence requirements for RCTs versus the use of GRADE 
between countries is a complex aspect of policy-making process. Countries using GRADE 
may need to be cautious. Using levels of evidence lower than RCTs to assess screening 
programmes could overestimate the benefits of screening due to the inherent biases of lead 
and length time and the healthy screenee effect in observational studies.144 Equally, RCTs are 
not always feasible and, therefore, not always applied. For example, in the UK, the NSC 
decided to recommend new conditions on the newborn inherited metabolic screening 
programme despite no availability of RCT evidence. The rarity of the conditions prevents 
RCT data. Therefore, the requirement for RCT is a complicated matter and flexibility may be 
required. However, agreement is needed on the circumstances where the RCT criterion is 
necessary and where it is not. In addition, a clear acceptable level of evidence should be set 
out for when RCT evidence is not available. 
Thirdly, criteria to cease screening programmes would be influential and should be considered 
by countries as a way to assess and stop a programme if the evidence on the balance between 
benefits and harms changes. It is exceedingly difficult to assess the harms of screening 
programmes once they have been introduced and even more difficult to stop them, due to the 
popularity paradox.144 For example, emerging evidence of reduced benefits and increased 
overtreatment have been recently identified for mammography screening compared with 
previous estimates. This means that there is now an uncertainty about the balance between the 
benefits and harms of the breast cancer screening programme.255, 256 There is a strong dispute 
as to whether a sufficient level of evidence is still available to continue the breast cancer 
programme. Establishing conditions or criteria, such as the level of evidence or quality 
assurance standards, could provide a systematic method to reconsider or cease screening 
programmes until there is better evidence or assurance. Such processes could safeguard 
citizens during times of uncertainty and ensure they are offered robust evidence-based 
screening. This is a serious policy-making gap that requires process development. 
Finally, policy-makers may wish to develop their processes for genetic screening 
recommendations. Countries need to prepare for the genomic era that is fast approaching and 
involves additional considerations that differ from those for screening other conditions. For 
example, implications for family members who may also be identified as carriers and the 
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identification of mutations related to other conditions not tested for as part of the screening 
programme. Three approaches have been reported in this chapter: 1) adding genetic criteria in 
to the list of criteria for all conditions and using all of the same processes to evaluate genetic 
conditions, 2) using a distinct list of genetic criteria to evaluate genetic programmes separate 
from the general list, or 3) using a separate organisation to evaluate and make genetic 
recommendations.  
While screening policy-making across countries has undoubtedly come a long way since 
Wilson and Junger’s list of criteria, there are still areas for improvement. Research and policy-
makers can use the findings of this review to benchmark the systems and processes in their 
country against the international processes and invest in the development of reducing the 
remaining gaps. 
 
5.6 Conclusions for this chapter 
 Countries recognise the need for national screening organisations and robust 
evidence-based processes for making health screening policy. Governments have 
established systems and evidence-based processes to make screening policy. 
 However, there are some concerns about the capacity of these systems to introduce 
the recommendations. There may be a disconnect between national evidence-based 
screening recommendations and the requirement to introduce them, which could leave 
a citizen not receiving the best available screening care. 
 This is particularly important as the majority of international GBS screening 
recommendations have not been developed by the national screening organisations. 
Devolved health authorities may choose to implement these guidelines although they 
may not have incorporated screening principles or accounted for screening harms. 
When comparing GBS across countries in the remainder of this thesis (and generally 
in research or clinical practice), it is imperative to bear this context in mind. 
 To ensure that screening programmes are safely offered on robust evidence, countries 
should either have minimum study design requirements or apply GRADE 
methodology, according to their context.  
 Countries should incorporate genetic screening considerations into their criteria or 
processes as they were currently lacking in their preparedness for the genomic era. 
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 Finally, to ensure that implemented programmes remain safe, countries should 
address how to correct or stop screening programmes if the evidence becomes 
uncertain or the quality assurance can no longer be guaranteed.
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6. BACTERIAL LOAD AND BACTERIAL MOLECULAR 
MARKERS ASSOCIATED WITH GBS VERTICAL 
TRANSMISSION AND EOGBS DISEASE 
6.1 Context of this chapter 
In 2016, with the help of my supervisors, I enlisted a team of clinical and methodological 
experts and submitted an application to undertake the UK NSC evidence review on the policy 
of universal GBS screening.24 I was successfully commissioned to lead this work and this 
chapter presents one part of the evidence review on the bacterial load and/or molecular 
markers predictive of neonatal GBS. While the overarching objectives of the review were set 
by the NSC, I led the design of the specific research questions and development of the research 
protocol outlining the methodology for the systematic review reported in this chapter. I also 
conducted the searches, study selection, data extraction and report writing. My supervisors 
and other team members contributed their technical expertise by reviewing and advising me 
throughout. Their expertise included public health screening, infectious diseases, 
microbiology, obstetrics and gynaecology and systematic reviewing and meta-analyses. Some 
of the team members also conducted the second-reviewing of the systematic review processes. 
My supervisor (OU) conducted the initial meta-analysis for the UK NSC review and I then re-
ran the meta-analysis and conducted the sensitivity analyses.  
 
6.2 Introduction 
As discussed in Chapter 2, little is known about the natural history of GBS colonisation and 
EOGBS. We know that a prerequisite for EOGBS is maternal GBS colonisation of the 
gastrointestinal and/or genitourinary tract. There have also been estimates on how many 
women and neonates are affected in the natural history pathway from maternal GBS 
colonisation to EOGBS. However, there is, as yet, a poor understanding on the mechanisms 
influencing the natural history pathway. We do not know why vertical GBS transmission 
occurs in 36% of cases,4 or why 1% to 3% of colonised neonates progress to invasive EOGBS 
disease.3, 257, 4 In particular, there are limited data about the pathogenic factors associated with 
GBS vertical transmission and development of EOGBS. While a number of virulence factors 
have been proposed to be important in the pathogenesis of GBS disease in laboratory studies,49, 
48 their importance in clinical settings is not clear. As shown in Chapter 2, the polysaccharide 
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capsule of GBS appears to be important, with GBS capsular serotypes Ia, Ib, II, III and V more 
frequently responsible for GBS disease.38, 40, 39, 41-43 Clonal complex CC-17 has also been 
associated with disease in the neonate,50, 51, 40, 41 as has the maternal GBS bacterial load.91, 90  
Studying the mechanisms that increase or decrease the risk of vertical transmission and 
development from neonatal colonisation to EOGBS may have vital implications for GBS 
screening. As shown in Chapters 2 and 5, understanding the natural history of a condition 
from a latent to symptomatic phase is one of the key screening criteria across countries. 
Without knowing the reasons why some women transmit GBS and why some neonates 
develop EOGBS, it is difficult to find a good target for testing. As shown in Chapter 2, the 
currently recommended culture test at 35 to 37 weeks is not an accurate predictor of EOGBS 
in the neonate. As only approximately 0.2% or 0.4% would be correctly identified (see 
Chapter 2), a large proportion of women would be over-treated with antibiotics. The harms of 
widespread IAP are not known but could include increases in: gram-negative infections, 
antibiotic resistance, maternal anaphylaxis, microbiota disruption that could lead to long-term 
health problems, and the medicalisation of labour.32, 23, 13 Data on the mechanisms associated 
with GBS vertical transmission and EOGBS could allow identification of: the GBS carriers at 
most risk of EOGBS who should be targeted for treatment; the best points in time that 
screening should take place; and whether there are other mechanisms that could be used for 
GBS screening tests and procedures.  
Consequently, better information on the natural history of GBS could allow more efficient 
screening strategies. However, this literature has not been previously synthesised and the 
status of this evidence in not known. This research is critical as part of assessing whether the 
UK should introduce a screening programme for GBS. Therefore, in this chapter I will explore 
the evidence about the bacterial load and the bacterial molecular markers associated with GBS 
transmission and EOGBS, in order to identify the implications this may have for a screening 
programme in the UK (objective 2).  
I will first present the aim and specific objectives of the review, followed by the methods used 
to search, appraise and analyse the data and then report the results. Finally, I will discuss the 
principal findings compared with previous literature, the strengths and limitations of the 
review and the research and policy implications. 
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6.3 Aims and objectives 
The aim of this chapter is to identify, appraise and meta-analyse the evidence on the bacterial 
load and the bacterial molecular markers associated with GBS transmission and EOGBS 
disease to inform the natural history of GBS.  The objectives are to examine whether there is 
a bacterial load and/or bacterial molecular markers associated with the transition of GBS from: 
a) Maternal GBS colonisation in pregnancy to neonatal GBS colonisation; 
b) Maternal GBS colonisation in labour to neonatal GBS colonisation; 
c) Maternal GBS colonisation in pregnancy to neonatal early-onset GBS disease; 
d) Maternal GBS colonisation in labour to neonatal early-onset GBS disease; and 
e) Neonatal GBS colonisation to neonatal early-onset GBS disease. 
 
6.4 Methods 
As discussed in Chapters 3 and 4, I chose systematic review and meta-analysis methodology 
to address the objectives of this chapter. Evidence on the mechanisms associated with the 
natural history of GBS had not been previously synthesised and the status of the evidence was 
not known. It was important to answer this question to move research in the right direction 
and avoid replicating previous work and wasting resources. I reported this systematic review 
according to recommendations from the PRISMA-P 2015 statement.210 The protocol is 
registered at the International Prospective Register of Systematic Reviews (PROSPERO): 
CRD42016037196.   
6.4.1 Search strategy  
I conducted comprehensive electronic literature searches in well-known and recommended 
databases: MEDLINE (Ovid), MEDLINE In-Process & Other Non-Indexed Citations (Ovid), 
EMBASE (Ovid), Cochrane Library: Cochrane Database of Systematic Reviews, CENTRAL, 
DARE and HTA databases (Wiley), and Science Citation Index Expanded (Web of Science) 
from inception to 10th October 2016. I applied an extensive search with no date limit to 
capture as much data as possible. To address all aspects of the objective, in the final strategy, 
I combined three sets of search terms using both text words and MeSH terms through Boolean 
operators OR within each set and then AND to combine the sets. The first set was made up of 
search terms for GBS, the second set was made up of search terms for neonate or pregnancy, 
and the third set was made up of search terms for bacterial load or molecular markers. I limited 
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the strategy to humans as this was the population of interest, and to the English language, as I 
did not have the time or resources to translate studies in other languages (see Appendix 3 for 
complete search strategies). Although excluding non-English studies could introduce selection 
bias,258-260 the impact of this is not clear in the literature, with some reviews showing that it 
does not affect results.261, 262 Furthermore, methodologists have suggested that the impact of 
language bias has reduced recently as a result of the move towards publishing in English.263  
To reduce reporting bias, a second reviewer and I searched the reference lists of all included 
studies and relevant systematic reviews identified from the electronic databases. In addition, 
I enlisted subject area experts, through the help of the UK NSC, to cross-check the included 
studies and identify any further references not captured by the search. The team members of 
this project also cross-checked the included studies. 
6.4.2 Study eligibility criteria 
Study inclusion criteria 
I included studies that satisfied the following criteria: 
Study design: prospective or retrospective cohort studies and nested case-control studies. If 
the search did not result in a sufficient number of these studies, I included case series with 
≥50 patients. If a sufficient number of studies was still not found, I included case series with 
≥10 patients. I avoided case series as far as possible, as results from such studies do not have 
control groups, making it difficult to interpret whether the risk factor is associated with GBS 
transmission or EOGBS compared with those that do not have the risk factor.  
Participants: culture-confirmed GBS colonised mothers or colonised neonates across any 
setting. Mothers had to be tested for GBS after the onset of the third trimester using vaginal 
or rectal swabs and selective or standard culture. Neonates had to be tested soon after birth 
using any surface culture. Selective culture inhibits the growth of competing organisms and 
increases the sensitivity of GBS culture, however, standard culture is also acceptable.107 I 
included studies where some participants met the inclusion criteria, and some met the 
exclusion criteria, if participants meeting the inclusion criteria could be separated or 
participants that met the exclusion criteria were fewer than 10% of the study population. 
Interventions/Exposures: any bacterial load or individual bacterial molecular marker 
evaluated for association with risk of neonatal GBS colonisation or neonatal early-onset GBS 
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disease. The criteria for exposures was intentionally wide to capture as many bacterial markers 
as possible.  
Comparators/Controls: any bacterial load or individual bacterial molecular marker used as 
the reference categories for exposures. 
Outcome: occurrence of GBS colonisation in neonates less than seven days after birth 
confirmed by surface culture, or neonates diagnosed with early-onset GBS disease less than 
seven days after birth. GBS less than seven days is considered to be passed from mother to 
neonate, while GBS more than seven days can also be transmitted from other sources.3 To 
avoid bias from the contamination of GBS from other sources, I excluded GBS more than 
seven days. 
Type and Language of publication: full-text report in the English language. 
Study exclusion criteria 
I excluded studies that fulfilled the following criteria: 
Study design: To reduce bias, I excluded intervention studies where participants received an 
intervention that interferes with GBS transmission or transition such as IAP as well as studies 
conducted in the context of IAP. I also excluded, cross-sectional studies, ecological studies 
and case-reports.  
Participants: pregnant women tested for GBS before the third trimester, as GBS carriage can 
transition in pregnancy and colonisation before the third trimester is too distant from the 
outcome.  
Outcomes: economic evaluation and/or cost-effectiveness outcomes, diagnostic accuracy 
outcomes, complications of GBS such as disability and mortality (including case-fatality).  
Type and Language of publication: abstracts, reviews (systematic or non-systematic), 
editorials, letters, books, consensus statements and opinions. I excluded reviews as sources of 
primary data but I used them to identify the original studies contributing the evidence. I 
excluded all publications in any other language than English.  
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6.4.3 Study selection and data management 
I downloaded identified references to bibliographic management software (Endnote X7) and 
de-duplicated them. A second-reviewer and I independently screened the titles and abstracts 
of all identified records (screening level I). I then obtained full-text reports of all potentially 
relevant records identified at screening level I and the second reviewer and I assessed them 
independently using the same study eligibility criteria (screening level II). We resolved any 
disagreements over inclusion/exclusion at screening level I and II by discussion and involved 
a third reviewer where necessary. I documented the study flow and reasons for exclusion of 
full-text papers in a PRISMA study flow diagram.210 
6.4.4 Data extraction  
A second reviewer and I independently extracted relevant data using an a priori defined 
extraction sheet piloted and refined before implementation and cross-checked each other’s 
forms (see Appendix 4). The extracted data included study characteristics (year of publication, 
country of origin, study design, sample size, sampling strategy, study period), participant 
characteristics (maternal or neonatal GBS colonised participants, GBS confirmation methods), 
details of bacterial load or molecular marker (description, reference categories, 
measurements), outcomes (GBS neonatal colonisation or disease, measurement) and the 
results for the association between bacterial molecular marker or bacterial load and GBS 
neonatal colonisation or EOGBS disease. Where data permitted, I estimated any missing 
statistical parameters of importance (e.g., OR, RR) and variability measures (e.g., 95% CI, p-
values). I denoted all calculated or derived data as ‘calculated’. 
6.4.5 Quality assessment 
The second reviewer and I independently appraised the risk of bias for each included study 
using the Quality in Prognosis Studies (QUIPS) tool.264 The QUIPS tool is a published and 
validated quality assessment tool. I chose QUIPS as it is specifically designed to assess the 
risk of bias in prognostic factor studies, therefore, explicitly accounting for biases that arise 
from this study design. The QUIPS tool includes assessment of risk of bias for six domains: 
patient selection, study sample attrition, prognostic factor measurement, outcome 
measurement, confounding and statistical analysis and reporting. According to responses to 
prompting items, each of the six domains is rated as high, moderate or low risk of bias.  
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The second reviewer and I discussed the quality appraisals and resolved any disagreements 
by discussion, with the involvement of a third reviewer where necessary. I tabulated the 
individual item-specific quality assessment ratings for each study.  
6.4.6 Data synthesis 
Meta-analysis was only possible on the serotypes associated with progression from neonatal 
GBS colonisation to EOGBS, due to the heterogeneity in the definition of bacterial load levels 
and only one study on the other molecular markers. As there were no summary measures (such 
as RRs and 95% CIs) reported in the respective studies and only raw numbers and proportions 
were reported, I calculated the RR along with 95% CIs for each study, which were pooled in 
the meta-analysis. I compared a separate RR comparison for the proportion of colonised 
neonates who developed EOGBS for each serotype versus another. I only meta-analysed 
serotypes that were included in at least two studies. Due to anticipated between-study 
differences in the methods, EOGBS definitions and countries where studies were conducted, 
I used a random effects model to pool the RRs across individual studies.265 A random effects 
meta-analysis assumes that the estimates of the exposure effect can vary across studies 
because of differences between the studies.265 Therefore, the pooled result represents the mean 
RR in a random distribution of true effect sizes. On the other hand, a fixed effects model 
assumes that there is no heterogeneity and there is one true effect of the exposure, which is 
the same across all individual studies.266 Although the studies were reasonably comparable in 
the exposures used and the patient characteristics, there were slight differences in the 
definitions of the outcome and the culture media used. Therefore, the random effects model 
was more appropriate.  
I assessed the heterogeneity between the studies by inspecting forest plots and the I2 statistic 
where a value of less than 50% was interpreted as low to moderate heterogeneity.267, 268 I 
determined the stability of the meta-analysis results in sensitivity analyses. One sensitivity 
analysis only included the cohort studies, another only included studies explicitly using sterile 
site culture and another only included studies not explicitly using selective culture. Finally, I 
performed a leave-one-study-out sensitivity analysis, which evaluates the influence of 
individual studies by estimating the pooled analyses in the absence of each study.269  
The meta-analysis on neonatal GBS serotypes were pooled from two cohort studies and one 
case-controlled study. Meta-analysis on observational studies has been controversial, partly, 
because of the diversity in study designs. Researchers have cautioned that interpreting a meta-
analysis of different study designs can be problematic as the heterogeneity between them 
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could bias the results.270-272 However, others have argued that it is useful and possible to pool 
observational studies if: the different designs are addressing the same question of interest;273, 
271, 270 the heterogeneity is carefully assessed between the studies;273, 271, 270 and a random 
effects model is used.273 For the meta-analysis in this chapter, the studies were answering the 
same question on the neonatal GBS serotypes in one group of participants that had EOGBS 
and another group of participants that were only colonised on surface sites. As discussed with 
clinical and microbiology experts, the studies were similar in their populations, exposures and 
health conditions, and all of the studies were at equally high risk of bias as none accounted for 
any confounding variables in their study design. I chose a random effects model because of 
the anticipated heterogeneity and deemed the heterogeneity as adequate using the methods 
described above. I also conducted sensitivity analyses to assess the heterogeneity in study 
design and other methodology. Therefore, a meta-analysis combining the two study designs 
was appropriate, with the acknowledgment that the findings are not adjusted for confounding 
variables.  
For the remaining studies, where results could not be combined using meta-analysis due to 
clinical heterogeneity, I synthesised the results narratively. I displayed the results of individual 
studies in tables and texts as appropriate, to enable a succinct summary of the evidence. For 
the majority of these studies, summary measures were not reported, therefore, I calculated 
ORs for case-control studies and RRs for all other study designs. I performed all analyses in 
Stata version 14 (Stata Corp, College Station, Texas). 
 
6.5 Results 
Figure 4 shows the flow of study selection. From the search, there were 1,107 unique records, 
four of which were from grey literature. Upon screening, we excluded 1,029 records and 
assessed 78 full-text articles for eligibility. We subsequently excluded 59 studies (see 
Appendix 5 for excluded full-text studies with reason) and this resulted in seventeen articles 
that met the inclusion criteria, which were included in the synthesis.274-278, 103, 279-287, 90, 39 
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Figure 4. Flow diagram on the selection of studies for objective 2 
6.5.1 Characteristics of studies 
The studies differed in their study designs, bacterial factors, population and the definition and 
measurement of GBS colonisation and EOGBS (see Table 10). Two studies were case-control 
studies,277, 286 and the remaining were cohort studies. Nine studies were on vertical 
transmission of GBS colonisation (objectives a and b),274, 280, 103, 281, 284, 285, 276, 282, 283 five were 
on maternal colonisation to EOGBS disease (objectives c and d),281, 285, 276, 282, 283 and eight 
were on transition of neonatal GBS colonisation to EOGBS (objectives e).275, 277, 286, 287, 90, 279, 
278, 39 There were 13 studies published before 1990,275, 280, 276, 281, 103, 279, 283, 284, 278, 282, 286, 287, 90 
two during the 1990s,277, 285 and two after 2000.274, 39 There were six studies examining 
serotype,274, 275, 277, 286, 287, 39 and 11 examining bacterial load.276, 278, 103, 279-285, 90 EOGBS 
diagnostic criteria strictly required a positive culture from a normally sterile site in some 
studies, whereas in other studies it was also defined as positive urine or surface culture in the 
presence of symptoms of systemic EOGBS disease.  
Records after removing duplicates 
(n =1107) 
Records screened  
(n = 1107) Records excluded  (n = 1029) 
Full-text articles evaluated 
for eligibility  
(n = 78) 
Full-text articles excluded 
(n = 61) 
Studies included in data synthesis  
(n = 17) 
Additional records found through 
other sources  
(n =4) 
Records identified through database 
search 
(n =1754) 
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6.5.2 Risk of bias of included studies 
The overall evidence from included studies had poor methodological quality as assessed by 
the QUIPS tool (see Figure 5).264 None of the studies were at low risk of bias in all six domains. 
In 10 of 17 studies (59%), risk of bias was high in two or more domains and in 4 of 17 studies 
(24%), risk of bias was high in one domain. The domain with the greatest risk of bias was 
study confounding. Thirteen of the seventeen studies (76%) were at high risk because the 
study designs did not account for key potential confounders.274, 279-281, 283, 284, 287, 90, 276, 277, 103, 278, 
39 The remaining four studies were at moderate risk as there was information on some, but not 
all, confounding factors.275, 282, 285, 286 Nine studies (53%) were at high risk of selection bias 274-
277, 280, 281, 90, 278, 103 and the remaining eight studies were at moderate risk,286, 287, 279, 282-285, 39 as 
the recruitment methods were not fully stated and/or baseline characteristics were not 
adequately described. Two studies were at high risk of bias for the statistical analysis and 
reporting domain103, 280 and eight were at moderate risk,275, 286, 277, 278, 281, 282, 285, 276 as there was 
selective reporting and/or insufficient reporting of the number of cases in each prognostic 
group.  
Of the five studies on the serotypes associated with progression from neonatal GBS 
colonisation to EOGBS, two were at high,275, 277 and three were at moderate287, 39, 286 risk of 
bias for study participation, while three were at high,277, 287, 39 and two were at moderate risk 
of bias for study confounding.275, 286 One of these studies was also at high risk of bias for 
prognostic factor measurement,275 and one for outcome measurement as there was no 
information provided on the definition and measurement of EOGBS or serotyping 
procedures.39 The study on the serotypes associated with GBS transmission from mother to 
neonate had high risk of bias for study participation and study confounding.274 Similarly, the 
risk of bias for study confounding in bacterial load studies was high in nine of the 11 studies279-
281, 283, 284, 90, 276, 278, 103 and moderate in the remaining two studies.282, 285 Six of these studies 
were also at high risk of bias for study participation280, 281, 90, 276, 103, 278 while five were at 
moderate risk.279, 282-285 One bacterial load study had high risk of bias for study attrition and 
outcome measurement276 and two had high risk of bias for statistical analysis and reporting.103, 
280 Only prognostic factor measurement was at low risk of bias across all bacterial load studies. 
The study on C-protein antigen was at high risk of bias for study participation and study 
confounding, as well as moderate risk of bias for statistical analysis and reporting.277 
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Figure 5. Quality assessment across included studies, according to the QUIPS tool264 
 
 
0 2 4 6 8 10 12 14 16 18
Study Participation
Study Confounding
Study Attrition 
Statistical Analysis and Reporting
Prognostic Factor Measurement 
Outcome Measurement
Study Participation Study Confounding Study Attrition Statistical Analysis and Reporting
Prognostic Factor 
Measurement Outcome Measurement
Low 0 0 8 7 14 10
Moderate 8 4 8 8 2 5
High 9 13 1 2 1 2
Quality Assessment
Antenatal screening for group B Streptococcus in the UK	
	 89
Table 10. Characteristics of studies 
Study  
Country 
Design Participant characteristics and GBS culture method Definition and measurement of 
outcome 
Serotype 
Maternal GBS colonisation to neonatal GBS colonisation or EOGBS  
Al-Sweih 2005274 
Kuwait 
Prospective 
cohort study  
124 women colonised with GBS on vaginal-anorectal swabs in labour (Selective 
culture) 
Neonates colonised with GBS on surface 
swabs at unspecified time (Selective 
culture) 
Neonatal GBS colonisation to EOGBS disease 
Baker 1973275 
US 
Cohort study  66 neonates: 54 asymptomatic neonates colonised with GBS on surface culture at 
mean age of 13.8 hours (Selective culture), 13 neonates with EOGBS disease 
(one patient in both groups) 
EOGBS disease: ≤ 10 days (all infants 
developed symptoms in the first five 
days of life) 
Baker 1974286 
US 
Case control 
study  
Neonates (numbers unclear): 53 asymptomatic neonates colonised with GBS on 
surface swabs at <3 days, 15 neonates with EOGBS meningitis, Not known 
number of neonates with EOGBS sepsis 
EOGBS sepsis (clinical symptoms and 
pre-mortem blood cultures or post-
mortem heart and lung cultures in 
neonates with pneumonia) or meningitis 
(CSF culture) ≤5 days  
Chun 1991277 
US 
Case-
controlled 
study 
121 neonates: 74 asymptomatic neonates colonised with GBS at birth on surface 
swabs, 47 EOGBS sepsis 
EOGBS sepsis: < 7 days, blood and CSF 
culture 
Embil 1987287 
Canada 
Prospective 
cohort study   
55 strains from 54 neonates: 42 asymptomatic neonates colonised with GBS on 
surface swabs within 1 hour of birth (Selective culture), 12 symptomatic GBS  
Symptomatic EOGBS < 3 days  
 
Madzivhandila 
201139  
South Africa 
Prospective 
cohort study 
525 neonates: 389 neonatal isolates colonised on surface swab shortly after birth 
(Standard culture), 136 neonates with invasive EOGBS 
EOGBS: < 7 days, blood and CSF 
culture 
Reaction to C-protein 
Neonatal GBS colonisation to EOGBS 
Chun 1991277 
US 
Case-
controlled 
study  
121 neonates: 74 asymptomatic neonates colonised with GBS at birth on surface 
swabs, 47 EOGBS sepsis 
EOGBS sepsis: < 7 days, blood and CSF 
culture 
C protein ß antigen gene 
Neonatal GBS colonisation to EOGBS 
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Study  
Country 
Design Participant characteristics and GBS culture method Definition and measurement of 
outcome 
Chun 1991277 
US 
Case-
controlled 
study  
121 neonates: 74 asymptomatic neonates colonised with GBS at birth on surface 
swabs, 47 EOGBS sepsis 
EOGBS sepsis: < 7 days, blood and CSF 
culture 
Bacterial load: Number of positive sites 
Maternal GBS colonisation to neonatal GBS colonisation and EOGBS 
Hoogkamp 1982280 
Netherlands 
Prospective 
cohort study  
46 women colonised with GBS on throat, nose, vagina, cervix, rectum, and 
midstream urine swabs in labour (Selective culture)  
Neonates colonised with GBS on surface 
swab at < 6 hours of birth (Selective 
swab) 
Neonatal GBS colonisation to EOGBS 
Dillon 1987278 
US 
Prospective 
cohort study 
1448 neonates colonised with GBS on surface culture within 1 hour of birth 
(Selective culture) 
EOGBS: < 3 days, symptoms and blood, 
CSF, urine, and other clinical specimens 
Pass 197990 
US 
Prospective 
cohort study 
290 neonates colonised with GBS on surface swabs 1-2 hours after birth 
(Selective culture) 
EOGBS: blood and CSF culture 
Bacterial load: Number of colony counts per plate 
Maternal GBS colonisation to neonatal GBS colonisation and EOGBS 
Easmon 1985103 
England 
Prospective 
cohort study 
140 women colonised with GBS on vaginal swabs in labour (Selective and 
standard culture) 
38 neonates colonised with GBS on 
surface culture within 24 hours of birth 
and/or on discharge from hospital 
(Selective culture) 
141 women colonised with GBS on rectal swabs in labour (Selective and 
standard culture) 
39 neonates colonised with GBS on 
surface culture within 24 hours of birth 
and/or on discharge from hospital 
(Selective culture) 
Hoogkamp 1982280  
Netherlands 
Prospective 
cohort study  
46 women colonised with GBS on throat, nose, vagina, cervix, rectum, and 
midstream urine swabs in labour (Selective culture)  
Neonates colonised with GBS on surface 
swab at < 6 hours of birth (Selective 
swab) 
Neonatal GBS colonisation to EOGBS 
Gerards 1985279 
Netherlands 
Cohort study  68 neonates: 47 neonates colonised with GBS on surface swabs immediately 
after admission to NICU (Selective culture), 21 EOGBS 
EOGBS: < 7 days sepsis symptoms with 
GBS cultured from normally sterile 
culture  
66 neonates:  47 neonates colonised with GBS on surface swabs immediately 
after admission to NICU  (Selective culture), 19 probable sepsis 
Probable sepsis symptoms with surface 
culture but no culture from sterile site 
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Study  
Country 
Design Participant characteristics and GBS culture method Definition and measurement of 
outcome 
Bacterial load - Colony-forming units (CFU) per ml 
Maternal GBS colonisation to neonatal GBS colonisation and EOGBS 
Jones 1984281 
US 
Prospective 
cohort study 
130 women colonised with GBS on vaginal swabs at labour (Selective culture) Neonates colonised with GBS on surface 
swabs at unspecified time (Selective 
culture)  
Jones 1984281 
US 
Prospective 
cohort study  
130 women colonised with GBS on vaginal swabs at labour (Selective culture) EOGBS:  2 neonates were blood culture 
positive,  
Probable EOGBS: 1 had symptoms and 
surface culture positive 
Persson 1986284 
Sweden 
Secondary 
analysis 
combined 
with a 
prospective 
cohort study  
64 women colonised with GBS on urine swab in labour (Selective culture) 12 neonates colonised with GBS on 
surface culture < 5 days (Selective 
culture) 
Sensini 1997285 
Italy 
Prospective 
cohort study  
260 women colonised with GBS on lower vaginal swabs in labour (Selective 
culture) 
108 neonates colonised with GBS on 
surface culture before first bath 
(Selective culture) 
1 neonate with EOGBS sepsis < 24 
hours , blood culture and sepsis 
symptoms  
Bacterial load - Other 
Maternal GBS colonisation to neonatal GBS colonisation and EOGBS 
Boyer 1983276 
US 
Prospective 
cohort study  
207 women colonised with GBS on vaginal swabs in labour who gave birth to 
209 neonates (Selective culture) 
Neonates colonised with GBS on surface 
swabs in the delivery room  
EOGBS  
Morales 1986  
US283 
Untreated 
control group 
of RCT 
 
128 women colonised with GBS at labour identified by a rapid slide 
coagglutination test on selective vaginal culture  
59 term neonates colonised with GBS on 
surface swabs at delivery  
3 GBS sepsis in term neonates 
Positive body fluid 
Morales 1987282 
US 
Prospective 
cohort study 
48 women colonised with GBS in labour identified by latex agglutination on 
selective vaginal culture 
17 preterm neonates colonised with GBS 
on surface swabs on admission to NICU 
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Study  
Country 
Design Participant characteristics and GBS culture method Definition and measurement of 
outcome 
48 women colonised with GBS at labour identified by latex agglutination on 
selective vaginal culture 
13 preterm neonates with GBS sepsis, 
blood, CSF, or urine culture, and 
oropharynx cultures with radiographic 
and clinical signs of infection  
CSF cerebrospinal fluid, EOGBS early-onset GBS, GBS group B streptococcus, NICU neonatal intensive care unit, NT non-typeable, US United States of America  
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6.5.3 Serotypes  
Maternal GBS colonisation to neonatal GBS colonisation  
Only one study reported information on the serotypes associated with GBS transmission from 
mother to neonate. Al-Sweih et al. (2005)274 found that mothers colonised with serotype Ia 
(5/11, 45%) and serotype V (13/27, 48%) on vaginal-anorectal swabs were more likely to 
transmit GBS than colonised mothers with serotype III (11/33, 33%), serotype Ib (1/3, 33%), 
serotypes not typeable (7/22, 32%), and the remaining serotypes. The calculated RR for the 
comparison of the proportion of women colonised with serotype V against the proportion of 
women colonised by all other serotypes who had a neonate with EOGBS, was not statistically 
significant (13/27 [48%] vs 31/97 [32%] respectively, RR 1.51 95% CI 0.93 to 2.45).  
Progression from neonatal GBS colonisation to EOGBS 
Five studies provided data on the association between serotypes and the development of 
EOGBS from neonatal GBS colonisation.275, 277, 286, 287, 39 Two studies could not be meta-
analysed as the required data were not available for the following reasons. Baker et al. (1973) 
reported that serotype III was more frequent in EOGBS cases than in asymptomatic 
colonisation. However, in this study the number of participants in the asymptomatic group 
was inconsistently reported, therefore, the number with each serotype could not be 
calculated..275 Similarly in Baker et al. (1974), there was inconsistent reporting in the number 
of participants with GBS sepsis (reported as 51, 56 and 62 participants), therefore, the findings 
were unreliable and the numbers with each serotype could not be calculated.286  
Meta-analysis results 
The meta-analysis pooled the data from two cohort studies and one case-controlled study.277, 
287, 39 Figure 6 summarises the pooled RRs for the development of EOGBS by GBS serotype, 
and Appendix 6 shows the forest plots for the individual and pooled RRs for each GBS 
serotype comparison. Overall, neonates colonised by serotype III had a moderately higher risk 
of developing EOGBS. Neonates colonised by GBS serotype III had a higher risk of 
developing EOGBS than neonates colonised by GBS serotype Ia (pooled RR 1.51 95% CI 
1.12 to 2.03, three studies, 439 neonates) (see Figure 6). Of 261 neonates colonised by GBS 
serotype III, 37.5% (n=98) developed EOGBS compared with 25.3% (n=45/178) colonised 
by GBS serotype Ia. The results of the individual RRs showed that only one of the three studies 
had statistically significant results for this comparison (see Appendix 6).39 The I2 statistic for 
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this analysis was 0.0% indicating no heterogeneity in the effect of GBS serotype on the risk 
of EOGBS. This might have been due to the large contribution from one study.39  
Neonates colonised by GBS serotype III were twice as likely to have developed EOGBS as 
neonates colonised by GBS serotype II (pooled RR 1.95 95% CI 1.10 to 3.45, three studies, 
355 neonates) (see Figure 6). Among 94 neonates colonised by GBS serotype II, 20.2% (n=19) 
developed EOGBS compared with 37.5% (n=98/261) colonised by GBS serotype III. Similar 
to the comparison with serotype Ia, the results of the individual RRs showed that only one of 
the three studies had statistically significant results for this comparison (see Appendix 6). The 
I2 statistic for this analysis was 31.7% indicating low to moderate heterogeneity (i.e. less than 
50%). There were no other statistically significant results in the risk of developing EOGBS in 
neonates colonised by other pairwise comparisons of GBS serotype.  
Comparisons must be read from right to left. The pooled estimate is located at the intersection of the column-
defining serotype and row-defining serotype. The statistically significant results are underlined and in bold.  
Figure 6.  Pooled risk ratios of early-onset group B Streptococcus by serotypes in neonates 
Sensitivity analysis  
The sensitivity analysis results are shown in Appendix 7. Including only the two cohort studies 
and excluding Chun et al.’s (1991) case-control study277, 39 did not change any of the results. 
Neonates colonised with serotype III were still at increased risk of EOGBS compared with 
neonates with serotype Ia (pooled RR 1.59 95% CI 1.13 to 2.24, 377 neonates) and II (pooled 
RR 2.75 95% CI 1.46 to 5.21, 295 neonates). All of the remaining serotype comparisons 
remained statistically non-significant. Including only the two studies that explicitly required 
a diagnosis of EOGBS to be sterile culture positive OR did not explicitly require selective 
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culture (i.e. excluding Embil et al., 1978)287 showed that neonates colonised with serotype III 
were still at higher risk of EOGBS compared with serotype Ia (pooled RR 1.49 95% CI 1.09 
to 2.02, 416 neonates). However, the difference in the risk of EOGBS in neonates colonised 
with serotype III compared with serotype II was no longer different (pooled RR 1.87 95% CI 
0.86 to 4.03, 332 neonates). All other results remained the same.  
Due to the few studies available for meta-analysis, the leave-one-out sensitivity analysis was 
partly completed in the other sensitivity analyses above. Removing Embil et al.’s (1978) study 
changed the results of serotype III versus serotype II but removing Chun et al.’s (1991) study 
did not change the results. When Madzivhandila et al. (2011) was removed, all results became 
statistically non-significant (III vs Ia: pooled RR 1.37 95% CI 0.81 to 2.34; III vs II: pooled 
RR 1.47 95% CI 0.84 to 2.60; see Appendix 7). This was likely as this study had the largest 
contributing sample size for neonates colonised with serotype III and had the only statistically 
significant individual RRs when comparing serotype III with Ia or II.  
6.5.4 Bacterial load 
Eleven studies reported on bacterial load.276, 278, 103, 279-285, 90 The definition of bacterial load 
differed across studies. The number of positive culture sites was investigated in four 
studies,278, 280, 90 the number of colonies on a plate in two,103, 280 a combination of number of 
colonies and positive sites in one,279 GBS colony-forming units (CFU) in three,281, 284, 285 the 
number of hours by which a rapid slide coagglutination test identified GBS in two282, 283 and 
selective versus standard culture in one.276 The statistical results of the studies where they 
were provided or calculated, are shown in Table 11.  
Number of colonies per plate 
There were three studies reporting on the numbers of colony counts on a plate and, generally, 
they found that the risk of GBS transmission and EOGBS rises with the number of colonies 
per plate. Hoogkamp-Korstanje et al. (1982) found that heavy colonisation (87% 
transmission) was associated with GBS transmission more often than moderate (50% 
transmission) or light (30% transmission) colonisation.280 Heavy colonisation was defined as 
greater than 50 colonies, moderate as 10 to 50 colonies, and light as less than 10 colonies using 
selective culture on nose, throat, vagina, cervix, rectum and mid-stream urine swabs in labour. 
Easmon et al. (1985) defined presence of GBS colonies only on enriched culture medium, 
fewer than 10 colonies on direct plating, 10 to 50 colonies on direct plating, and greater than 
50 colonies on direct plating.103 They reported the bacterial load results separately for rectal 
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and vaginal swabs. However, the labelling of the data in the paper was unclear and could not 
be interpreted.  
Gerards et al. (1985) combined the number of colony counts with the number of sites and 
created the following criteria: heavy colonisation as three or more sites with more than 50 
colonies per plate, moderate colonisation as fewer than three sites with more than 50 colonies 
or three or more sites with less than 10 or 10 to 50 colonies and light colonisation as fewer 
than three sites with less than 10 or 10 to 50 colonies.279 Among the eight infants with heavy 
colonisation, 50% (n=4) had EOGBS, 50% (n=4) had probable sepsis (but no confirmatory 
culture from a normally sterile site), and none had asymptomatic colonisation. Among the 35 
neonates with moderate colonisation 42.8% (n=15) had EOGBS, 31.4% (n=11) had probable 
sepsis and 25.7% (n=9) had asymptomatic colonisation. Among the 44 neonates with light 
colonisation 4.5% (n=2) had EOGBS, 9.1% (n=4) had probable sepsis, and 86.4% (n=38) 
were asymptomatically colonised. They also found that neonates colonised with more than 50 
colonies of GBS were more likely to have EOGBS than neonates with less than 50 colonies. 
Sites swabbed were nose, throat, external auditory meatus (canal), eyes, umbilicus, skin and 
rectum immediately after admission to NICU. 
Number of colonised sites 
Equally, there were three studies reporting the number of colonised sites, and they found that 
the risk of GBS vertical transmission and EOGBS increased with a larger number of colonised 
sites. Hoogkamp-Korstanje et al. (1982) compared the risk of GBS vertical transmission in 
women with one (light) versus two or more (heavy) colonised sites.280 The sites swabbed were 
vagina, cervix, rectum, midstream urine, throat and nose. Women with heavy colonisation 
were 2.5 times more likely to have a neonate with GBS than women with light colonisation 
(91% vs 36%, RR calculated from percentages given 2.53 95% CI 1.93 to 3.31). Two studies 
compared the association of one to two colonised sites (light) versus three to four (heavy) 
colonised sites in neonates, and all found a higher risk of EOGBS in neonates with heavy 
compared with light colonisation (Pass et al., 1979: 8% [n=7/91] vs 0.5% [n=1/199], RR 15.31 
95% CI 1.91 to 122.60; Dillon et al., 1987: 5% [n=20/403] versus 0.4% [n=4/1045], RR 12.97 
95% CI 4.46 to 37.70).278, 90 Sites swabbed in these studies were external canal, umbilicus, 
throat and anus within one to two hours of birth90 and external canal, umbilicus, oropharynx 
and rectum within an hour of birth.278 
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Colony forming units (CFU) 
There were three studies that investigated the CFU of GBS agreeing that the risk of vertical 
GBS transmission and EOGBS increases with CFU of GBS.281, 284, 285 Jones et al. (1994) 
plotted the CFU of GBS in mothers’ vaginas against CFU of GBS in neonates’ rectum and 
found a linear correlation (p<0ꞏ001).281 In addition, the authors found that mothers’ swabs had 
to contain a minimum of 102 GBS for the neonate’s swab to yield a positive result. Finally, 
they found that neonates colonised with ≥105 GBS on a rectal swab were delivered by mothers 
colonised with ≥3 x 104 GBS on a vaginal swab. On the other hand, the CFU of GBS of 
mothers’ vaginal swabs correlated poorly with neonates’ umbilical and nasopharyngeal 
cultures. In this study, three neonates developed EOGBS: two had blood culture positive 
sepsis and one was rectal culture positive and had respiratory distress. All three of the neonates 
had mothers that were heavily colonized (7.70x106, 6.62x107, and 2.5x106), however, only 
two of the neonates were heavily colonized themselves (7.02x105, 5.25x106). One neonate 
with blood culture positive sepsis was lightly colonised (<101). The authors explained that this 
neonate may have been cleaned before culture.  
Similarly, Sensini et al. (1997) defined light colonisation as 102 to 106 CFU/GBS ml and heavy 
colonisation as ≥106 CFU/GBS ml, finding that mothers with heavy colonisation were more 
likely to transmit GBS to their neonates (50% [n=74/148] vs 30% [n=34/112] RR 1.65 95% 
CI 1.19 to 2.28).285 Only one neonate developed EOGBS and the mother had light 
colonisation. Likewise, Persson et al. (1986) investigated CFU/GBS ml in the urine of 
mothers, and found that those with ≥104 CFU/GBS ml were six times more likely to transmit 
GBS to their neonates compared with mothers with <104 CFU/GBS ml (67% [n=6/9] vs 11% 
[n=6/55] RR 6.11 95% CI 2.52 to 14.81).284 
Other definitions 
Morales et al. (1986, 1987) examined bacterial load by a rapid slide coagglutination test and 
categorised colonisation as heavy if agglutination with GBS antigens was detectable within 
five hours of swab or light if agglutination was negative at five hours but positive at 20 
hours.282, 283 They found that heavily colonised mothers in labour who gave birth to term 
infants were twice times as likely to transmit GBS to their neonates as mothers who were 
lightly colonised (80% [n=24/30] vs 36% [n=35/98] RR 2.24 95% CI 1.63 to 3.09). Heavily 
colonised mothers who gave birth to preterm infants were thrice as likely to transmit GBS to 
their neonates as lightly colonised mothers (73% [n=8/11] vs 24% [n=9/37] RR 2.99 95% CI 
1.52 to 5.87).282 In 1986, Morales et al. found three cases of neonatal GBS sepsis (positive 
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body fluid culture) in term births, all of whom had heavily colonised mothers. In 1987, the 
group found that GBS sepsis in preterm neonates (including culture of blood, cerebrospinal 
fluid [CSF], urine and oropharynx cultures with radiographic and clinical signs of infection) 
was four times more likely in mothers colonised with heavy bacterial load compared with 
mothers colonised with light load (64% [n=7/11] vs 16% [n=6/37] RR 3.92 95% CI 1.66 to 
9.25).  
Finally, Boyer et al. (1983) categorised degree of colonisation as heavy if intrapartum vaginal 
culture was positive on direct plate as well as selective culture, moderate if intrapartum vaginal 
culture was positive on selective culture only, and light if intrapartum vaginal culture was 
negative but postpartum rectal or vaginal culture was positive.276 Neonatal colonisation was 
3.29 times more likely in heavily compared with light or moderately colonised mothers (64% 
[n=69/107] vs 20% [20/102] RR 3.29 2.17 to 4.99). Of the women who transmitted GBS to 
their infants, heavily colonised women were more likely to have neonates colonised at 
multiple sites (55%) compared with moderately or lightly colonised women (30%, p=0.04). 
Neonatal sites swabbed were throat, umbilicus, rectum, external ear and nasogastric aspirate. 
The authors reported four neonates with EOGBS, and all of the mothers were heavily 
colonised.  
6.5.5 C-protein antigen  
One study investigated whether asymptomatic GBS and EOGBS (blood and CSF culture) 
strains reacted to C-protein antiserum and four antigens: α, β, γ, δ.277 Chun et al. (1991) found 
that GBS isolates reacted to C-protein antiserum in 87% (n=41/47) of neonates with EOGBS 
and 73% (n=54/74) of asymptomatically colonised individuals, however, this difference was 
not statistically significant. The authors found that antigen δ was expressed more frequently 
in isolates from neonates with EOGBS (29%, n=12/41) compared with asymptomatically 
colonised neonates (19%, n=10/54). The other three antigens were found less often in EOGBS 
(α = 68% n=28/41, β = 17% n=7/41, and γ = 36.5%, n=15/41) compared with healthy neonates 
(α = 81% n=44/54, β = 28% n=15/54, and γ = 37% n=20/54). For these data, I did not calculate 
summary measures as more than one antigen can be expressed in one strain. When comparing 
antigen distribution among septic EOGBS and LOGBS with healthy neonates, the authors 
found a higher expression of α in healthy neonates, and of δ in septic neonates. However, this 
association was not independent of serotypes in multivariable analysis. 
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Table 11. Findings of bacterial load associated with GBS 
Reference 
Country 
Outcome 
reported 
Definitions of bacterial load  Number/
% with 
no event  
Number
/% with 
event 
Summary 
measure (95% 
CI) 
Factor 
adjusted 
for in 
analysis  
Number of positive sites 
Hoogkamp 
1982280 
Netherlands 
Neonatal 
GBS 
colonisation 
Maternal GBS colonisation 
Light: 1 site 
Heavy ≥2 sites  
 
64% 
9% 
 
36% 
91% 
RR of heavy: 2.53  
(1.93-3.31) 
(calculated from 
%) 
None 
Dillon 
1987278 
US 
EOGBS Neonatal GBS colonisation  
Light: 1-2 sites 
Heavy: 3-4 sites 
 
1041 
383 
 
4 
20 
RR of heavy: 
12.97  
(4.46- 3.70) 
None 
Pass 197990 
US 
EOGBS Neonatal GBS colonisation  
Light: 1-2 sites 
Heavy: 3-4 sites 
 
198 
84 
 
1 
7 
RR of heavy: 
15.31  
(1.91-122.60) 
None 
Number of colony counts per plate 
Hoogkamp 
1982280  
Netherlands 
Neonatal 
GBS 
colonisation 
Maternal GBS colonisation 
Light: <10 colonies 
Moderate: 10-50 colonies 
Heavy: >50 colonies 
 
70% 
50% 
13% 
 
30% 
50% 
87% 
Not calculated for 
heavy versus 
light/moderate as 
no raw numbers 
None 
Gerards 
1985279 
Netherlands 
EOGBS – 
culture 
proven 
Neonatal GBS colonisation  
Light: <3 sites positive that 
were <10 or 10-50 colonies 
per plate 
Moderate: <3 sites positive 
that were >50 colonies per 
plate OR  
≥3 sites positive that were 
<10-50 colonies per plate; 
Heavy: ≥3 sites positive that 
were >50 colonies per plate 
 
38 
 
 
9 
 
 
 
 
0 
 
 
2 
 
 
15 
 
 
 
 
4 
 
Moderate and 
heavy versus light: 
p<0.0005 
None 
Probable 
sepsis 
Neonatal GBS colonisation 
Light (as above) 
Moderate (as above) 
Heavy (as above) 
 
38 
9 
0 
 
4 
11 
4 
RR of heavy 
versus light and 
moderate: 3.13 
(2.06-4.76) 
None 
BACTERIAL LOAD - Colony-forming units (CFU) per ml 
Jones 
1984281 
US 
Neonatal 
GBS 
colonisation 
 
Continuous variable of 
maternal GBS colonisation 
from 102 to 108 colony counts 
See text See text Correlation 
between 
CFU/GBS ml in 
mothers’ vagina 
and neonates’ 
rectum: P<0.001 
None 
Persson 
1986284 
Sweden 
Neonatal 
GBS 
colonisation 
 
Maternal GBS colonisation 
Light colonisation: 
<104 CFU/ml in urine  
Heavy colonisation: 
≥104 CFU/ml in urine 
 
49 
 
3 
 
6 
 
6 
RR of heavy: 6.11  
(2.52-14.81) 
None 
Sensini 
1997285 
Italy 
Neonatal 
GBS 
colonisation 
Maternal GBS colonisation 
Light: 102-105 CFU/ml 
Heavy: 106 or greater 
 
78 
74 
 
34 
74 
RR of heavy: 1.65  
(1.19-2.28) 
None 
EOGBS Maternal GBS colonisation 
Light: (As above) 
Heavy: (As above) 
 
111 
148 
 
1 
0 
- - 
BACTERIAL LOAD - Other 
Boyer 
1983276 
US 
Neonatal 
GBS 
colonisation 
 
Maternal GBS colonisation 
Light: Negative intrapartum 
vaginal culture but positive 
postpartum rectal/vaginal 
culture 
Moderate: Positive intrapartum 
vaginal culture on selective 
broth enrichment only 
 
47* 
 
 
 
35 
 
 
 
10* 
 
 
 
10 
 
 
RR of heavy 
versus light and 
moderate: 3.29 
(2.17-4.99) 
None 
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Reference 
Country 
Outcome 
reported 
Definitions of bacterial load  Number/
% with 
no event  
Number
/% with 
event 
Summary 
measure (95% 
CI) 
Factor 
adjusted 
for in 
analysis  
Heavy: Positive intrapartum 
vaginal culture on direct plate 
as well as enrichment 
 
 
38 
 
 
69 
EOGBS Maternal GBS colonisation 
Light: (As above) 
Moderate: (As above) 
Heavy: (As above) 
 
57* 
45 
103 
 
0 
0 
4 
- - 
Morales 
1986283 
US 
Neonatal 
GBS 
colonisation 
Maternal GBS colonisation 
Light colonisation: 
Agglutination with GBS 
antigens was negative at 5 
hours but positive at 20 hours 
Heavy colonisation: 
Agglutination with GBS 
antigens was detectable within 
5 hours  
 
63 
 
 
 
6 
 
35 
 
 
 
24 
RR of heavy: 2.24  
(1.63-3.09) 
None 
GBS sepsis Maternal GBS colonisation  
Light colonisation: 
(As above) 
Heavy colonisation: 
(As above) 
 
98 
 
27 
 
0 
 
3 
 
- 
- 
Morales 
1987282 
US 
Neonatal 
GBS 
colonisation 
 
Maternal GBS colonisation 
Light colonisation: 
Positive latex agglutination 
identification at 20 hours but 
not at 5 hours 
Heavy colonisation: 
Positive latex agglutination 
identification at 5 hours 
 
28 
 
 
 
3 
 
9 
 
 
 
8 
RR of heavy: 2.99  
(1.52-5.87) 
None 
GBS sepsis Maternal GBS colonisation 
Light colonisation: 
(As above) 
Heavy colonisation: 
(As above) 
 
31 
 
4 
 
6  
 
7 
RR of heavy: 3.92  
(1.66-9.25) 
None 
% Percentage, CI confidence interval, EOGBS early-onset GBS, GBS group B Streptococcus, US United States of 
America  
*Two extra births: 57 infants from 55 mothers  
Numbers in italics calculated 
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6.6 Discussion 
6.6.1 Principal findings  
This is the first systematic review that has investigated whether bacterial load or bacterial 
molecular markers are associated with GBS transmission from mother to neonate, or 
progression from neonatal colonisation to EOGBS disease. The systematic review findings 
suggest that the natural history of maternal GBS colonisation, GBS transmission to neonates, 
and early-onset GBS disease has not been extensively researched and the study is still in its 
infancy. In addition to bacterial load, only three bacterial markers have been investigated. 
Furthermore, most of the evidence was considered at a high risk of bias and was relatively old 
(pre-2000). Bacterial load was consistently associated with GBS vertical transmission, and 
progression from asymptomatic colonisation to EOGBS regardless of its definition and 
measurement. The pooled comparison of serotypes in GBS colonised neonates showed that 
serotype III is more associated with EOGBS than other serotypes.  
Of all the evidence in this review, the finding with most confidence was the association 
between high bacterial load and GBS transmission or EOGBS. Although the studies were at 
high risk of bias and did not control for confounding variables, the association was evident 
across different definitions of bacterial load and across study settings. Women colonised with 
heavy GBS bacterial load (>50 colonies, >1 site, >106 CFU/GBS ml or identification at five 
hours on rapid test) were approximately two to three times more likely to have a neonate with 
GBS colonisation compared with mothers with lighter GBS bacterial load (<50 colonies, 1 
site, <106 CFU/GBS ml identification at 20 hours on rapid test). Neonates colonised with 
heavier compared with lighter GBS bacterial load (all definitions) were also at higher risk of 
developing EOGBS. While the association between bacterial load and vertical transmission 
of GBS colonisation (objectives a and b) and neonatal colonisation versus invasive EOGBS 
(objective e) was consistent, the evidence on the association between bacterial load and 
transition from maternal GBS colonisation to EOGBS was not as clear (objectives c and d). I 
was only able to perform statistical analysis on the data from Morales et al. (1987)282 where 
the risk of EOGBS was almost four times higher in infants who had mothers with heavy 
colonisation. However, the methods of measuring bacterial load in this study were non-
standard and the definition of EOGBS was not limited to sterile site culture. In other studies, 
neonates with EOGBS had mothers with light GBS colonisation. The uncertainty in these 
results is likely due to the small number of EOGBS cases in each study.  
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With respect to serotype, data were pooled between studies using an appropriate meta-analytic 
model, which resulted in quantitative estimates for the increased risk of serotype III. Neonates 
colonised with serotype III were approximately 1.5 to two times more likely to develop 
EOGBS than neonates with serotype Ia and II, respectively (objective e). However, the results 
of the sensitivity analysis showed that some studies may have undue influence on the pooled 
estimates. In particular, removing data from Madzivhandila et al. (2011) led to statistically 
non-significant results for both serotypes Ia and II compared with III. It is important to point 
out that there are many possible explanations for this finding. Madzivhandila et al. (2011) had 
the largest sample size of 525 neonates and this was the only study that showed a difference 
in the risk of EOGBS by serotype in the individual RR results.39 Therefore, it may be that the 
remaining studies lacked statistical power to detect any changes. As confounding variables 
were not adequately adjusted for, it may also be that specific population characteristics in the 
study setting for Madzivhandila et al. (2011) contributed to the findings. Similarly, removing 
the data from Embil et al. (1978) made the difference in the risk of EOGBS in neonates 
colonised by serotype III compared with serotype II lose statistical significance.287 In addition 
to a reduction in power (as a result of losing one out of three studies) explaining this finding, 
it may also be due to methodological differences between the two remaining studies from 
Chun et al. (1991)277 and Madzivhandila et al. (2011),39 as the I2 for this comparison was high 
at 63%.  
Finally, results on the reaction to C-protein antiserum and four antigens was only available 
from one study. Chun et al. (1991) found that reaction to C-protein was not associated with 
EOGBS compared with asymptomatic colonisation in neonates, neither was antigen type 
when serotype was accounted for (objective e).277  
Despite the evidence on the potential value of these factors to predict GBS colonisation or 
EOGBS, the risk of bias across the evidence was high or moderate. No study was at low risk 
of bias for all domains. The most serious limitation of the evidence was the potential bias from 
confounding factors. None of the seventeen studies adequately adjusted for all important 
confounding variables in their studies and the majority did not account for any confounding 
variables. Similarly, as I calculated the majority of the point estimates and confidence intervals 
(RRs, ORs, and 95% CIs) using unadjusted statistical analyses that did not control for potential 
confounders, the overall relationships identified in this systematic review could be partly, or 
completely, a result of confounding factors. The majority of the evidence was also published 
before the year 2000 and may have limited applicability to today’s context. For example, the 
standardisation of microbiological testing may be more robust in comparison with the settings 
in these studies and the distribution of the bacterial markers may have also changed. 
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Following confounding variables, selection bias was another substantial concern, as none of 
the studies were at low risk of selection bias. Selection bias occurs when there is a systematic 
error in the two groups being studied.288  Many studies did not provide information on how 
participants were selected or any demographic or clinical details about the participants in the 
exposed or unexposed groups. Therefore, the results from this review on the association 
between risk factor and GBS transmission or EOGBS could potentially be distorted by the 
inadequate selection of participants. Related to this, some studies did not report on the number 
or characteristics of patients who dropped out of the study or refused to participate. Although 
this is less likely to affect pathogenic factors studied in the review, there is the possibility that 
there are differences between those who participated, and those who did not, and the impact 
of this is not known.  
Overall, heavy bacterial load was the most convincing factor increasing the risk of GBS 
transmission or EOGBS because of the consistency across the studies. However, the evidence 
on bacterial load (and other bacterial markers) contains important uncertainties due to the high 
risk of bias.  
 
6.6.2 Comparison with previous literature 
Previous literature shows that serotype III, along with Ia, Ib, II and V is one of the most 
commonly identified invasive neonatal serotypes.3, 289, 38, 40, 290 Globally, it was found in a 
review that serotype III was indeed the most commonly identified invasive neonatal serotype 
in all world regions.6 It has been estimated that  80.3% of EOGBS disease is attributed to 
serotypes III and Ia.39 I found that, compared with serotype Ia and II, serotype III may actually 
be more frequently associated with EOGBS. A Gambian study recently found that serotype V 
was a predominant GBS colonising serotype in women/infant pairs.257 The authors also found 
that mothers with serotype III or V were more likely to have infants with the same serotype. 
In this review, I was unable to compare serotype V against serotype III or any other serotypes 
as only one study reported on serotype V.  
Within serotype III strains, studies excluded from this review because of antibiotic use or no 
asymptomatically colonised participants found that invasive strains were more likely to be 
ST-17 than colonising or non-invasive strains and more likely to give rise to early-onset 
disease than other sequence types.291, 292 The increased virulence of ST-17 has been 
demonstrated in laboratory experiments. Compared with other strains, ST-17 is more likely to 
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attach and invade decidual cells. 293 In particular invasive ST-17 strains are more likely to 
invade decidual cells than colonising strains, which are more likely to attach without 
invasion.293 Likewise, a CC-17 clone specific surface protein of GBS, which promotes 
attachment to intestinal and meningeal cells has been indicated as an important determinant 
of the hypervirulence of CC-17.52 Despite these findings, the complete mechanisms that make 
these serotypes of GBS hypervirulent are not fully understood. Furthermore, the invasive GBS 
serotype and sequence types may not be fixed and can change over time.44  
Similarly, the finding that heavy bacterial load is associated with GBS vertical transmission 
and EOGBS is in line with evidence on women with GBS bacteriuria. GBS bacteriuria is a 
surrogate for heavy maternal colonisation, and many studies have shown that women with 
GBS bacteriuria have a higher risk of EOGBS.294, 295, 86, 88 For example, Heath et al. (2009) 
found that GBS bacteriuria increased the odds of neonatal GBS disease by 5.55 (95% CI 1.47 
to 20.96). However, this was not statistically significant in multivariable analyses when other 
factors were adjusted for, therefore, it is important to account for confounding variables. There 
is also a more recent study (excluded as it was conducted in the context of IAP treatment) 
showing that heavy neonatal colonisation defined by the number of sites is more strongly 
associated with EOGBS than light load (25/1000 versus 4/1000, p<0.001).296 Lastly, other 
virulence factors such as resistance to antimicrobial peptides, factors for immune evasion, and 
pore-forming toxins have been suggested from laboratory studies.47 However, I did not find 
these mechanisms investigated in experimental or clinical studies, which are required to 
confirm their role.  
 
6.6.3 Strength and limitations 
This is the first attempt to systematically review whether bacterial load or bacterial molecular 
markers are associated with GBS transmission from maternal colonisation, or progression 
from neonatal colonisation to EOGBS. I applied an extensive search with no date limit to 
capture as much data as possible. I included microbiology, infectious disease and obstetrician 
and gynaecology expert input to review the methodology and the findings to ensure that the 
review made clinical sense. I also involved methodologists and meta-analysts to ensure the 
systematic review and meta-analysis processes were performed correctly according to best 
practice. Furthermore, I enlisted second reviewers to duplicate study selection and quality 
assessment as well as cross-check data extractions, in order to maximise the quality of the 
review and minimise any errors.210 
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However, there are some limitations that must be noted. I excluded studies in languages 
besides English, therefore, there is a possibility that I may have missed prognostic studies in 
non-English speaking countries. Examining the studies included in this review highlights that 
the majority of the studies were from the US followed by Europe. Only one study was from 
the Middle East and one was from Africa. Many countries were not represented and it is not 
clear whether such studies exist in these countries. This could increase selection bias and 
question the external validity of the findings. Similarly, as I did not contact the authors 
directly, I may have missed some information where it was missing or unclear in the study 
report. Doing so could have clarified the data and the study could have added more value to 
the review. 
As part of the exclusion criteria, I removed studies where participants were given IAP or 
studies conducted in the context of IAP. This decision was to reduce the bias from IAP 
interfering with the natural history of GBS transmission or progression to EOGBS. An 
unintended trade-off might have been that more recent studies were excluded as a result. As 
IAP is the recommended prevention for GBS, it may now be less feasible to study untreated 
women only. In the full-text sift, however, there were only four such studies. As there was a 
sufficient amount of data, I also excluded case-series and case-reports. Again, this could have 
increased the amount of data included from the literature as there are laboratory studies on 
small numbers of EOGBS cases. However, these studies have few conclusive implications for 
clinical practice as the exposed groups with disease cannot be compared with controls.272  
 
6.6.4 Research and policy implications 
The stubbornness of EOGBS combined with the harms from IAP underscore the need for 
more effective screening and/or prevention. With a large number of women who would be 
over-treated with IAP (due to the poor accuracy of antenatal culture) in addition to the growing 
list of potential harms associated with IAP, a more refined approach might be required. 
Antibiotic resistance, in particular, is a major international threat and, while GBS remains 
almost universally susceptible to penicillin,86 0.2% of GBS isolates had reached the upper 
level of susceptibility for beta-lactams in the US in 2005,182, 18 and 5% to 15% of GBS isolates 
were described to have reduced penicillin susceptibility in Japan.183 Clindamycin and 
erythromycin resistance has also been increasing in the last 20 years.14, 18, 297 Bacterial factors 
such as bacterial load, serotype, sequence type and the more precise isolate characterisation 
through genome sequencing, could provide innovative opportunities to target patients with 
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only the hypervirulent strains of GBS, limiting the risk of harmful outcomes from widespread 
IAP and potentially reducing under-treatment . Bacterial load is the most promising of the 
factors as, despite the dissimilar measurements, it was consistently associated with GBS 
transmission and EOGBS. However, the current evidence has important drawbacks as 
discussed in Section 6.6.1. 
To better understand the mechanisms of GBS and confirm that heavier bacterial load or GBS 
serotype III is determinant of EOGBS, larger and better-controlled studies are required. The 
identified factors could be studied separately and, in combination through risk factor models 
(possibly along with other clinical and demographic risk factors), in order to more accurately 
predict the mothers that will transmit GBS and have a neonate with EOGBS. Such a study 
may be challenging as IAP is the recommended treatment, however it may be possible that 
these risk factor associations and models could be investigated in prospective cohort or case-
control studies in contexts where IAP prevention is not adopted, for example, in Africa or 
Asia. It may also be possible to conduct retrospective studies on databases from countries that 
already have a GBS screening policy for pregnant women at 35 to 37 weeks. Analyses could 
be performed on women who were screen-positive but not treated. This may be a small 
proportion of all screen-positive women (treated mothers would have to be excluded) but 
combining data across years and across countries could potentially provide a large enough 
database for the statistical power required. It might also be worth systematically reviewing 
whether serotype, bacterial load and other factors are associated with the risk of GBS 
transmission and EOGBS in the presence of IAP.  
Although the findings from this review, particularly on heavy bacterial load but also on 
serotype III, could possibly be involved in guiding future prevention interventions, they 
cannot be currently used for clinical practice. Due to the uncertainties in the evidence, the 
factors identified can only be used as a starting point to guide future research on the 
mechanisms predictive of GBS vertical transmission and EOGBS. For now, it is still not 
known why some women transmit GBS to their neonates and why some neonates develop 
EOGBS, while others do not. Consequently, the screening criterion on the understanding of a 
condition’s natural history, which needs to be fulfilled for the introduction of GBS screening, 
remains unmet. 
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6.7 Conclusions for this chapter  
 Findings from this chapter have highlighted that serotype III and heavy bacterial load 
may be important factors associated with GBS transmission and EOGBS. However, 
most of this evidence is at high risk of bias, therefore, confounding variables might 
be distorting these associations.  
 Furthermore, most of the evidence has been published before the year 2000 and it is 
not clear whether findings are as applicable today as they were around 20 years ago.  
 More effective prevention and therapy are needed to combat the persistence of 
EOGBS and the harms from IAP treatment. Future prevention interventions could 
target particular serotypes or sequence types and high bacterial load.  
 In particular, there is good evidence to investigate the association of the bacterial load 
as it was strongly and consistently associated with GBS vertical transmission and 
EOGBS. 
 Beyond these bacterial factors, wider research on the mechanisms that underlie the 
natural history of GBS vertical transmission and EOGBS is essential for the 
development of new interventions. The factors identified here, in addition to other 
pathogenic, clinical and demographic risk factors (individually and in risk models) 
could be studied in large and robust cohort and case-control studies. 
 In the meantime, the screening requirement that the natural history of a condition 
should be known before a screening programme is introduced is not currently met, 
limiting the ability to find a more efficient screening programme.
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7. ADVERSE EVENTS IN WOMEN AND CHILDREN 
WHO RECEIVE INTRAPARTUM ANTIBIOTIC 
PROPHYLAXIS TREATMENT 
7.1 Context of this chapter 
Similar to Chapter 6, this chapter presents another part of the 2016 NSC evidence review that 
I led to assess the harms from IAP treatment.24 My contribution, along with the contribution 
of the NSC and the other team members was the same as Chapter 6. While the overarching 
objectives of the 2016 review were set by the NSC, I led the design of the specific research 
questions and development of the research protocol outlining the methodology for the 
systematic review reported in this chapter. I also conducted the searches, study selection, data 
extraction and report writing. My supervisors and other team members contributed their 
technical expertise as required and conducted the second-reviewing of the systematic review 
processes.  
 
7.2 Introduction 
As discussed in Chapter 2, IAP is the internationally recommended treatment of EOGBS 
prevention. The current recommendation for IAP is intravenous penicillin (or ampicillin in the 
US) given as soon as possible after the onset of labour and then every four hours until 
delivery.13, 14 Second-line treatment for mothers allergic to penicillin varies across countries.13, 
14 In the UK, until September 2017, intravenous clindamycin was recommended.13 However, 
in the latest guideline published in September 2017, the recommendations have been modified 
due to the evidence of increasing clindamycin resistance.15 If a woman has a history of allergy 
to beta-lactams that is not severe, i.e. does not have a history of anaphylaxis, angioedema, 
respiratory distress or urticaria, a cephalosporin is recommended. If a woman has a history of 
severe allergy to beta-lactams, vancomycin is recommended instead. Similarly, in the US 
since 2010, intravenous Cefazolin is the first alternative, followed by clindamycin if there is 
a history of anaphylaxis, respiratory distress, urticaria or angioedema after penicillin or 
cephalosporin.14   
A Cochrane review summarised that the clinical practice of IAP treatment is not supported by 
valid evidence, due to the high risk of bias in small RCTs more than 20 years ago. While the 
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use of IAP did reduce the incidence of culture-proven EOGBS (RR 0.17 95% CI 0.04 to 0.74) 
and probable EOGBS (RR 0.17 95% CI 0.03 to 0.91) compared with no treatment, it did not 
reduce the incidence of all-cause mortality, mortality from GBS or mortality from other 
infections.10 On the other hand, the evidence on the adverse events from IAP has not been 
previously reviewed. As discussed in Chapter 2, a range of harms have been suggested,23, 13, 32 
including maternal anaphylaxis, which although very rare, can be fatal for mother and 
neonate,14 neonatal infections caused by gram-negative bacteria,298, 19, 32 antibiotic 
resistance,299, 298, 86 neonatal microbiota changes that could lead to short and long-term health 
problems,191, 32, 192 Clostridium difficile infection in mothers,21 anxiety for the mother, family 
and medical staff and the medicalisation of labour.32, 13 
The harms from IAP treatment have been poorly documented and understood. This evidence 
is crucial to decide whether, or not, to recommend a screening programme, as it informs 
whether the programme does more good than harm. As indicated in Chapters 3 and 4, the 2012 
NSC GBS report concluded that, as this evidence has never been reviewed, this major 
screening criterion was not met. As stated in Chapter 2, in the case of GBS, IAP would be 
given to over 150,000 pregnant women and their babies every year, of whom over 99% will 
be over-treated, making the harms from treatment even more important in the context of GBS 
screening. Therefore, in this chapter, I will explore the evidence about the adverse events to 
mothers and their children after IAP treatment, in order to identify the implications this may 
have for a GBS screening programme in the UK (objective 3). 
I will first present the aim and specific objectives of the review, followed by the methods used 
to search, appraise and analyse the data and then report the results. Finally, I will discuss the 
principal findings compared with previous literature, the strengths and limitations of the 
review and the research and policy implications. 
 
7.3 Aims and objectives 
The aim of this chapter is to identify, appraise and meta-analyse the evidence on the adverse 
events experienced by women or children after intrapartum antibiotic prophylaxis treatment. 
I took a broad definition of adverse events to mean any adverse or harmful event experienced 
after IAP treatment. This included the impact on the microbiome as well as clinical outcomes. 
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The research objectives are to: 
a) Quantify the incidence of each reported adverse event in women who received 
intrapartum antibiotic prophylaxis compared with women who did not receive it; 
b) Quantify the incidence of each reported adverse event in neonates whose mothers 
received intrapartum antibiotic prophylaxis compared with neonates whose mothers 
did not receive it; 
c) Quantify the overall incidence of any reported adverse events in women who received 
intrapartum antibiotic prophylaxis compared with women who did not receive it; 
d) Quantify the overall incidence of any reported adverse events in neonates whose 
mothers received intrapartum antibiotic prophylaxis compared with neonates whose 
mothers did not receive it; and 
e) Identify any important gaps in the evidence on adverse events after intrapartum 
antibiotic prophylaxis.  
 
7.4 Methods 
As discussed in Chapter 4, I applied systematic review methodology to address the objectives 
of this chapter. Evidence on the harms of IAP treatment had not been previously synthesised. 
It was important to understand the status of the evidence, identify research gaps and determine 
the direction required for future research to avoid replication and wasting of resources. 
Furthermore, the harms from IAP could be experienced long-term and a primary study to 
investigate this was beyond the scope of my thesis. To ensure high standards were maintained, 
I reported this systematic review according to recommendations from the PRISMA-P 2015 
statement.210 The protocol is registered at PROSPERO: CRD42016037195. 
7.4.1 Search strategy 
I conducted comprehensive electronic literature searches in well-known and recommended 
databases: MEDLINE (Ovid), MEDLINE In-Process & Other Non-Indexed Citations (Ovid), 
EMBASE (Ovid), Cochrane Library: Cochrane Database of Systematic Reviews, CENTRAL, 
DARE and HTA databases (Wiley) and Science Citation Index Expanded (Web of Science) 
from inception to 16th October 2016. I initially piloted scoping searches and then iteratively 
adapted them with input from the team and recommended search filters to inform the 
development of the final search strategy.300, 301 In the final strategy, I combined three sets of 
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search terms using both text words and MeSH terms through Boolean operators OR within 
each set and then AND to combine the sets. The first set was made up of search terms for 
antibiotic prophylaxis, the second set was made up of search terms for labour and the third set 
was made up of search terms for adverse events. I limited the search to antibiotics for 
prophylactic purposes during labour. In preliminary searches, I discovered that some relevant 
articles did not include terms for adverse events. Therefore, I included terms for known 
adverse events from IAP such as antibiotic resistance or maternal anaphylaxis. To do this 
systematically, I used adverse events that are known from the literature,32, 28, 13, 23 and I enlisted 
subject area experts as suggested by the UK NSC for further terms. I applied an extensive 
search strategy with no date limit to capture as much data as possible, but I limited the strategy 
to humans as this was the population of interest, and to the English language, as I did not have 
the time or resources to translate studies in other languages (see Appendix 8 for search 
strategies). Although excluding non-English studies could introduce selection bias,258-260 the 
impact of this is not clear in the literature, with some reviews showing that it does not affect 
results.261, 262 Furthermore, methodologists have suggested that the impact of language bias 
has reduced recently as a result of the move towards publishing in English.263 
I also searched grey literature to reduce reporting bias. Along with a second reviewer, we 
hand-searched reference lists of all included studies and relevant systematic reviews that were 
identified from the electronic searches. In addition, subject area experts cross-checked the 
included studies to identify any further references not captured by the search. The team 
members of this project also cross-checked the included studies. 
7.4.2 Study eligibility criteria 
Study inclusion criteria 
I included studies that satisfied the following criteria: 
Study design: prospective or retrospective cohort studies, case-control studies and 
randomised controlled trials. If the search resulted in an insufficient number of these studies, 
I included case series with ≥50 patients. If the search still resulted in an insufficient number 
of studies, I included case series with ≥10 patients. I avoided case series as far as possible, as 
results from such studies do not have control groups for comparison, making it difficult to 
interpret whether an adverse event is actually more common in those who have undergone 
treatment. 
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Participants: intrapartum women and their children. 
Intervention: intrapartum antibiotics given to asymptomatic women for a prophylactic 
purpose only. The antibiotics could be for any prophylactic purpose and not GBS prevention 
alone, however, it had to be administered in labour. I also included studies in which women 
received antibiotics in labour, and then continued to receive antibiotics after labour for 
prophylactic purposes, so long as women remained asymptomatic. 
Comparator: placebo, no treatment or an alternative treatment for prophylactic purposes 
(comparison of one treatment to another). No comparator for case-series. 
Outcome: any adverse outcomes experienced by the mother or child. The criteria for 
outcomes was intentionally wide to capture as many outcomes as possible. 
Type and Language of publication: full-text primary studies published in the English 
language in medical and healthcare journals or in grey literature, such as organisational 
websites. 
Study exclusion criteria 
I excluded studies that fulfilled the following criteria: 
Study design: ecological studies, cross-sectional studies, case reports, before and after studies 
across different participants (e.g. population-level resistance studies). I excluded before and 
after studies as control participants are not contemporaneous, therefore, adverse outcomes 
could be a result of other factors other than IAP treatment. 
Participants: I excluded the following participants as they were not considered clinically 
similar enough to the population of women and children who would be receiving IAP for GBS 
prevention: a) pregnant women given antibiotics before labour; b) neonates given antibiotics 
after birth; c) pregnant women undergoing elective or emergency caesarean sections; and d) 
women with symptoms of infection such as intrapartum fever or prolonged rupture of 
membranes before IAP administration. I excluded women with symptoms of infections as this 
would contaminate the findings, making it unclear whether the adverse events are a result of 
the treatment or the infection. I included studies where some participants met the inclusion 
criteria, and some met the exclusion criteria, if participants meeting the inclusion criteria could 
be separated or participants that met the exclusion criteria were fewer than 10% of the study 
population. 
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Intervention: antibiotics given for any other purpose than prophylaxis. I excluded 
prophylaxis for caesarean sections as women and their children who have undergone 
caesarean sections may also contaminate the findings making it unclear whether the adverse 
events were a result of the caesarean section or the antibiotics. 
Outcomes: Studies reporting only economic evaluation and/or cost-effectiveness outcomes. 
Type and Language of publication: abstracts, reviews (systematic or non-systematic), 
editorials, letters, books, consensus statements and opinions. I excluded reviews as sources of 
primary data but used them to identify the original studies contributing the evidence. I 
excluded all publications in any language other than English. 
7.4.3 Study selection and data management 
I downloaded identified references to bibliographic management software (Endnote X7) and 
de-duplicated them. A second reviewer and I independently screened the titles and abstracts 
of all identified bibliographic records (screening level I). I then obtained full-text reports of 
all potentially relevant records identified at screening level I and the second reviewer and I 
assessed them independently using the same study eligibility criteria (screening level II). We 
resolved any disagreements over inclusion/exclusion at screening level I and II by discussion 
and involved a third reviewer where necessary. I documented the study flow and reasons for 
exclusion of full-text papers in a PRISMA study flow diagram.210 
7.4.4 Data extraction 
A second reviewer and I independently extracted relevant data using an a priori defined 
extraction sheet that I piloted and refined with team members before implementation (see 
Appendix 9). We crossed-checked each other’s data extraction forms and resolved any 
disagreements by discussion, involving a third reviewer if necessary. The extracted data 
included study characteristics (year of publication, author, country of origin, study design, 
study setting, sample size, sampling strategy, follow-up duration), participant characteristics 
(socio-demographic characteristics, study eligibility criteria, co-morbidities), details of the 
intervention (antibiotic type, route of administration, treatment dose, treatment duration, 
treatment indication), adverse outcomes (name and definition of outcomes, methods and 
measurements of adverse outcome, timings of measurements) and the result for the association 
between IAP and the adverse events, (numbers with event in treatment and control, OR, RR, 
RD, mean difference) and variability measures (e.g. 95% CI, p-values). Where data permitted, 
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I estimated any missing statistical parameters of importance (e.g., OR, RR) and variability 
measures (e.g., 95% CI, p-values) using methods outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions.263 I denoted all calculated or derived data as 
‘calculated’. 
7.4.5 Quality assessment 
The second reviewer and I independently appraised the risk of bias for each included study 
using the Cochrane Risk of Bias (RoB) tool for studies in which participants were randomised 
to either receive IAP or placebo/no treatment,302 and the Risk of Bias Assessment Tool for 
Nonrandomised Studies (RoBANS) for non-randomised studies.303 Both tools are published 
and validated. The RoBANS tool is based on the Cochrane RoB tool but adapted with 
questions and probes specific to observational study types. Therefore, the biases assessed 
across both tools are consistent. The tools include information on selection bias (sequence 
generation, allocation concealment OR sample population, confounding variables), 
performance bias (blinding, outcome assessment), detection bias (blinding, outcome 
assessment), attrition bias (incomplete outcome data) and reporting bias (selective outcome 
reporting). Each of these domains is assessed and classified as low, high or unclear risk of 
bias. 
The second reviewer and I discussed each quality appraisal and resolved any disagreements 
by discussion, involving a third reviewer where necessary. I tabulated the individual item-
specific quality assessment ratings for each study. 
7.4.6 Data synthesis 
I intended to perform meta-analyses using a separate random effects model for the likelihood 
of each adverse event and then a random effects model for the likelihood of any adverse events 
if data were sufficiently similar. However, as there was a range of different adverse events 
reported in the literature, using different drug regimens for different durations, on different 
populations, I concluded that there was too much clinical heterogeneity in the studies to pool 
the results. Instead, I narratively synthesised the results of the individual studies in tables and 
text to enable a succinct summary of the evidence. I used Stata 14 (Stata Corp, College Station, 
Texas) to calculate the summary measures such as RRs, ORs, and RDs, along with 95% CI 
where they were not calculated but data were available to do so. 
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7.5 Results 
7.5.1 Study selection 
Figure 7 shows the flow of study selection. From the search, there were 2,364 unique records. 
Upon screening, we excluded 2,102 records and there were 262 full-text articles for eligibility. 
Subsequently, we excluded 232 studies (see Appendix 10 for excluded full-text studies with 
reason) and this resulted in 30 articles that met the inclusion criteria, which were included in 
the synthesis.304-322, 296, 194, 323-328, 20, 329, 330 
 
 
Figure 7. Flow diagram on the selection of studies for objective 3  
Records excluded 
(n = 2102) 
Full-text articles 
excluded 
(n = 232) 
Studies included in data synthesis  
(n = 30) 
Additional records found through 
other sources 
(n =13) 
Records identified through database 
search 
(n =3625) 
Records after removing duplicates  
(n = 2364) 
Records screened 
(n = 2364) 
Full-text articles evaluated 
for eligibility 
(n = 262) 
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7.5.2 Characteristics of studies 
There were 14 cohort studies, 304-307, 309-311, 313, 316, 321, 296, 194, 20, 330 three case-control studies,308, 
314, 328 12 RCTs312, 315, 317-320, 322-326, 329 and one sub-study327 of an included RCT.326 There were 
nine studies investigating IAP for GBS prevention,304, 305, 308-311, 316, 194, 328 two for GBS 
prevention and other indications,313, 321 three for post-partum infection prevention,317-319 eight 
for preterm labour,312, 315, 320, 322-325, 329 two for neonatal sepsis prevention326, 327 and six that did 
not state the indication (see Appendix 11 for study characteristics).306, 307, 314, 296, 20, 330 There 
were some trials that reported outcomes of interest, such as neonatal and maternal infection, 
however, the aim of the trials was to investigate the benefit of IAP on these outcomes. If IAP 
was successful, it could decrease the outcomes. On the other hand, IAP could inadvertently 
increase these outcomes as it could lead to changes in the organism causing infections and/or 
antibiotic susceptibility.20, 298 In order to prevent reporting bias, I reported these outcomes 
irrespective of whether they were identified as harms or as benefits by the study. I have 
reported these outcomes separately at the bottom of the table in Appendix 11. 
7.5.3 Risk of bias of included studies 
Figure 8 shows the methodological quality of the included RCTs, as assessed by the Cochrane 
Risk of Bias tool.302 None of the RCTs were at low risk of bias across all domains. The largest 
risk of bias amongst the RCTs was in the selective outcome reporting domain; eight of 13 
RCTs (62%) were at high risk partially or exclusively because they did not pre-specify the 
definition and measurement of side effects in the methods but only reported them in the 
results.312, 315, 317-319, 325, 327, 329 The second greatest risk of bias was in the incomplete outcome 
data domain, where seven out of 13 (54%) RCTs were at unclear risk of bias as there were 
substantial missing data, for example, on the adverse events in the control group.317-319, 322, 325, 
326, 329 Finally, I found a number of other sources of bias across RCTs. This included data not 
presented,318, 319 relatively small sample sizes,323, 327 a lack of information on treatment 
regimens,315 a lack of details of intention to treat analysis329 and inaccuracies in the numbers 
provided for participant flow.325 
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Figure 8. Quality assessment across included randomised controlled trials, according to the 
Cochrane risk of bias tool302 
Similar to RCTs, there were no observational studies at low risk of bias across all domains of 
the RoBANS tool (see Figure 9).303 Confounding variables was the domain with the highest 
concern. Four of 17 (24%) studies were at high risk,304, 309, 313, 20 none at low risk and 13 (76%) 
at unclear risk of bias.305-308, 310, 311, 314, 316, 321, 296, 194, 328, 330 In these studies, some variables were 
reported or accounted for in the study design, but others such as prenatal antibiotics, caesarean 
sections and maternal risk factors were not. Similarly, the selection of participants domain 
was also unclear across nine out of 17 (53%) studies,305-307, 316, 296, 194, 328, 20, 330 as important 
baseline characteristics and/or how participants were selected, was not reported.  
 
Figure 9. Quality assessment across included observational studies, according to the RoBANS 
tool303 
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7.5.4 Adverse events associated with IAP (objectives a to d) 
The 30 studies assessed a range of neonatal and maternal outcomes (see Appendix 11). Below 
I present the findings on the key results of gut microbiota, antibiotic resistance, neonatal 
respiratory distress, neonatal bacterial infections, candidiasis, anaphylaxis and long-term 
adverse events. Findings on the remaining outcomes such as necrotising enterocolitis, 
Clostridium difficile bowel problems, Apgar scores, seizures, maternal infection, bleeding 
abnormalities and the impact on management and care can be found in Appendix 11. There 
was no evidence on anxiety, asthma, autism, obesity, supra-infections, methicillin-resistant 
Staphylococcus aureus, vancomycin-resistant enterococci, extended spectrum beta-
lactamase-producing organisms or carbapenem-resistant organisms. 
Gut microbiota 
Gut microbiota changes in babies have been associated with long-term health problems, 
including respiratory and metabolic conditions. Seven cohort studies compared the 
colonisation levels of various microbial groups at different points in time in infants whose 
mothers were treated with IAP with those who were not.304-307, 311, 316, 194 None of the studies 
were at low risk of bias for confounding variables and one was at high risk of selection bias.304 
The studies consistently revealed that IAP alters infant microbiota. There were differences in 
the relative composition and the colony forming units per gram (log CFU/g) of organisms in 
the gut of newborns whose mothers were treated with IAP with those who were not, at day 2, 
3, 6 to 7, 10, 30 and 90 (see Table 12 and Table 13 for results).305-307, 311, 316, 194 Two studies 
reported sample richness and biodiversity and found that, compared with controls, at days 6 
to 7 and day 30, infants whose mothers were treated with IAP had a less diverse microbial 
profile.305, 194 There was also a clear separation between the microbiota profiles of infants 
whose mothers were treated with IAP, compared with control infants, when plotted on 
principal coordinate analysis plots at days 6 to 7. However, these disappeared by day 30.305, 
194 Related to gut microbiota, Keski-Nisula et al. (2013) found that, compared with controls, 
neonates whose mothers were treated with IAP had a lower transmission of vaginal 
Lactobacillus-dominant mixed flora on oral surfaces (1 vs 13, OR 0.08 95% CI 0.007 to 
0.80).321 While the evidence of gut microbiota alterations was consistent, it is not clear if any 
of the alterations are related to clinical adverse events. 
Antibiotic resistance 
Six studies reported antibiotic resistance. Four were observational studies and two were RCTs. 
Of the RCTs, Gordon et al. (1995) reported zero out of 58 cases of multi-resistant bacterial 
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infections in mothers who were treated with IAP for preterm labour, however, they did not 
report on the number of cases in the control group.315 In another RCT, Roca et al. (2016) 
investigated resistance of GBS, Streptococcus pneumoniae (S. pneumoniae), and 
Staphylococcus aureus (S. aureus) to azithromycin in 829 mothers and 843 infants treated 
with azithromycin for neonatal sepsis prevention.326 They found azithromycin-resistant S. 
aureus in maternal breast milk at day 3, in newborn nasopharynx and maternal breast milk at 
day 6, in vaginal swabs at day 8 and in newborn and maternal nasopharynx and maternal breast 
milk at day 14 and day 28. They also identified azithromycin-resistant S. pneumoniae at day 
28 in the maternal nasopharynx only. This study was at an unclear risk of bias for incomplete 
outcome data. 
Of the four observational studies, two were case-control studies,308, 314 one was a prospective 
cohort study316 and one was a retrospective cohort study.20 There was a high risk of selective 
outcome reporting bias in Ashkenazi-Hoffnung et al. (2011),308 and a high risk of bias for 
confounding variables in Stoll et al. (2011).20 There was also an unclear risk of bias in the 
remaining studies for confounding variables,308, 314, 316 unclear risk of selection bias and bias 
in the measurement of exposures in Jaureguy et al. (2004)316 and Stoll et al.,20 as well as an 
unclear risk of bias for incomplete data in Stoll et al.20 
Glasgow et al. (2005) found that 39% (n=24/62) of infants whose mothers were treated with 
various IAP drugs (indication not stated) had ampicillin-resistant organisms compared with 
11% (n=13/120) of infants whose mothers were not treated (OR 5.7 95% CI 2.3 to 14.3).314 
They also found a difference in the ampicillin-resistant bacteria only causing urinary tract 
infections (OR 4.3 95% CI 1.6 to 11.7). Similarly, Stoll et al. (2002) found a higher number 
of mothers who received intrapartum ampicillin in the group of infants with ampicillin-
resistant strains of E. coli compared with the number of mothers who received IAP in the 
ampicillin-sensitive group (93% [n=26/28] vs 20% [n=1/5] p=0.01).20 In the two studies, it 
was not clear if the infants were treated with antibiotics before or after they were tested for 
antibiotic resistance. Ashkenazi-Hoffnung et al. (2011) did not report any differences in first 
generation cephalosporin resistance in E. coli (60% vs 22.7% p=0.21) or any bacteria causing 
late-onset serious bacterial infections (57% vs 26% p=0.19) when comparing 17 infants born 
to mothers treated with IAP for GBS prevention and 178 infants who were not.308 However, 
they did report a higher development of first generation cephalosporin-resistant urinary tract 
infections (75% vs 23.5% p=0.04). They also found no difference of ampicillin resistance in 
E. coli (100% vs 54.5% p=0.14) or any bacteria causing late-onset serious bacterial infections 
(85% vs 63% p=0.19) Finally, Jaureguy et al. (2004) investigated colonisation of amoxicillin-
resistant Enterobacteriaceae and aerobic and anaerobic gram-positive bacteria in the gut of 
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neonates whose mothers were and were not treated with IAP for GBS. They did not find any 
difference in the number of infants colonised with amoxicillin-resistant Enterobacteriaceae 
(40% [n=10/25] vs 48% [n=12/25], RR [calculated] 0.83 95% CI 0.44 to 1.56) and 
amoxicillin-resistant E. coli (24% [n=6/25], vs 44% [n=11/25] RR [calculated] 0.55 95% CI 
0.24 to 1.25).316 
Neonatal respiratory problems 
There were four RCTs investigating respiratory problems in infants whose mothers were, and 
were not, treated with IAP for preterm labour.312, 320, 322, 329 Two were at high risk of bias in 
selective outcome reporting and/or incomplete data.312, 329 None of the trials found a difference 
between the two groups for medication for chest problems, admission for chest problems, 
wheezing, ventilation or respiratory distress syndrome. 
There was one observational study investigating the risk of respiratory distress and discharge 
diagnosis of a respiratory disorder.296 The study had no domains at high risk of bias and 
accounted for a number of confounding variables, including comorbidities during labour. 
However, it was at unclear risk of selection and detection bias, and because it was 
observational, there could be other factors that are related to the risk of respiratory distress. 
The authors found a higher risk of respiratory distress (21% [n=44/213] vs 7% [n=95/1378] 
RR 2.62 95% CI 1.79 to 3.83) and discharge diagnosis of a respiratory disorder (7% 
[n=12/213] vs 3% [n=39/1378] RR [calculated] 1.96 95% CI 1.04 to 3.69) in the group treated 
with IAP for GBS. 
Candidiasis 
Two studies reported the relationship between IAP and candidiasis. Cox et al.’s (1996) RCT 
showed that 27 of 39 (69%) participants had symptomatic vulvovaginitis caused by Candida 
albicans after treatment for preterm labour with ampicillin and sulbactam followed by 
ampicillin-clavunate for five days.312 The authors did not report on the number of cases present 
in the control group, therefore, the RCT was at high risk of bias for the selective reporting and 
incomplete data domains. 
In a retrospective cohort study, Dinsmoor et al. (2005) studied neonatal and maternal 
candidiasis after IAP for GBS prevention and other indications.313 This study was at high risk 
of bias for confounding variables, as variables such as the administration of antenatal 
antibiotics were not accounted for. The measurement of exposure, blinding and selective 
outcome reporting domains were at unclear risk of bias. Finally, the diagnosis of thrush was 
Antenatal screening for group B Streptococcus in the UK	
	 121 
not confirmed by an examination but based on participant report and whether treatment was 
prescribed. The authors did not find a difference in neonatal thrush between the neonates 
whose mothers were and who were not treated (12% [n=21/173] vs 7% [n=18/262], OR 1.87 
95% CI 0.97 to 3.63). However, they did find a higher risk of maternal thrush in the treated 
group (13% [n=22/173] vs 6% [n=17/262], OR 2.1 95% CI 1.08 to 4.08). 
Neonatal infections 
As mentioned earlier, although the purpose of IAP is to reduce neonatal infection, an adverse 
event is that IAP can potentially increase neonatal infection because of the changes it can 
cause in the organism producing infections.20, 298 Here, I report all studies that investigated 
neonatal infection (whether as a benefit or adverse event). There were four RCTs,315, 322, 324, 329 
three case-control studies308, 314, 328 and one cohort study.20 
The four RCTs investigated neonatal infections when assessing the benefit of IAP in 
preventing preterm labour. Two of the trials had a high risk of bias,315, 329 and three had an 
unclear risk of bias,322, 324, 329 in one or more domain. Nadisauskiene et al. (1996) found a lower 
proportion of neonatal infections in infants whose mothers who were treated with IAP 
compared with those who were not (9% [n=4/44] vs 21% [n=38/58], RR [calculated] 0.14 
95% CI 0.05 to 0.36).324 The remaining RCTs did not find a difference in neonatal sepsis, 
meningitis, pneumonia, all infections or positive cultures between treated and untreated 
groups. 
Of the four observational studies, two had a high risk of bias in selective outcome reporting308, 
328 and one had a high risk of bias in confounding variables.20 Glasgow et al. (2005) found a 
higher proportion of late-onset bacterial infections in infants whose mothers were treated with 
IAP (indication not stated) compared with those who were not (60% [n=37/62] vs 44% 
[n=53/120], OR 1.96 95% CI 1.05 to 3.66).314 The relationship between IAP and infections 
was attributed to broad spectrum IAP as opposed to penicillin IAP, as when compared 
separately, only those treated with broad spectrum IAP compared with no broad spectrum IAP 
had a higher risk of infections (OR 4.95 95% CI 2.04 to 11.98). There was also a higher 
number of late-onset meningitis, omphalitis and bacteraemia without UTI in the treated group 
(OR 25.00 95% CI 1.8 to 346). 
By contrast, Stoll et al. (2002) found no difference in all-cause sepsis (2% [n=63/3,554] vs 
1% [n=21/1,893], OR 1.1 95% CI 0.6 to 1.8]) or E. coli early-onset sepsis (2% [n=58/3,554] 
vs 1% [n=26/1,893], OR: 1.0 95% CI 0.6 to 1.6) between neonates whose mothers were treated 
with IAP (indication not stated) and those who were not.20 There was a difference in early-
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onset E. coli sepsis with ampicillin when comparing IAP given within 72 hours of delivery 
compared with no IAP within 72 hours, however, this lost statistical significance when 
controlling for gestational age and the interval between membrane rupture and delivery. Total 
early-onset sepsis was also not associated with IAP use. Likewise, Sinha et al. (2003) did not 
find a difference in the proportion of bloodstream infections (RR 0.20 95% CI 0.011 to 3.6), 
pneumonia (RR 2.5 95% CI 0.43 to 14.0) or any infection syndrome (RR 1.0 95% CI 0.38 to 
2.9),328 and neither did Ashkenazi-Hoffnung et al. (2011) in late-onset serious bacterial 
infections (47% [n=8/17] vs 10% [n=17/178] OR per dose of IAP 5.1 95% CI 0.01 to 93.11).308 
The treatment in the both studies was IAP for GBS prevention. 
Anaphylaxis and other short-term side effects to antibiotics 
Eight RCTs investigating the effectiveness of IAP in preventing preterm labour or post-partum 
infection reported on anaphylaxis and other immediate side effects to antibiotics.317-319, 322, 323, 
325, 326, 329 There were five RCTs at high risk of bias317-319, 325, 329 and one at unclear risk of bias 
for selective reporting,323 and seven at unclear risk of bias for incomplete outcome data317-319, 
322, 325, 326, 329 and other sources.318, 319, 322, 323, 325, 329 
There were no differences in the side effects between treated and control groups in two RCTs. 
McGregor et al. (1986) found no differences in the number of women who suffered from 
nausea or vomiting (1/29 in each group)323 and Rajaei et al. (2006) reported no differences in 
nausea, vomiting, hot flushes, decreased deep tendon reflexes, emotional disturbances and 
drug intolerance between groups.325 Keuchkerian et al. (2005) and Svare et al. (1997) found 
more palpitations, flushes, nausea and vomiting322 and undefined side effects329 in treated 
compared with control groups, but these did not reach statistical significance (2/47 [4%] vs 
0/49 [0%]322 and 4/59 [7%] vs 1/51 [2%]329). 
Keettel et al. (1949, 1950), Kampikaho et al. (1993) and Roca et al. (2016) reported side 
effects in the treatment group only. Kampikaho et al. (1993) reported zero undefined side 
effects from streptomycin or penicillin (0/330 women).322 Keettel et al. (1949) reported seven 
mild urticaria (2%), two general urticaria (0.4%), five local allergic manifestations (1%) and 
no abscess formations (0%) in 465 treated participants, as well as relatively uncommon 
discomfort at the site of injections which was never severe or persistent.319 In 1950, Keettell 
et al. found one general urticaria (0.3%), one local allergic manifestation (0.3%) and no 
abscess formations in 382 treated participants.318 Roca et al. (2016) found one case of 
moderate urticaria and zero ‘adverse event/serious adverse events’ in 419 newborns whose 
mothers were treated.326 
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Long-term adverse events 
A factorial RCT by Kenyon et al. (2008) was the only study that specifically assessed the 
long-term effects of IAP. Kenyon et al. (2008) compared children aged seven whose mothers 
received any erythromycin (alone or with amoxicillin-clavulanate) with no erythromycin, and 
any amoxicillin-clavulanate with no amoxicillin-clavulanate (alone or with erythromycin).320 
This RCT had a low risk of bias in all main domains, however, there were key limitations in 
the ‘other biases’ domain. A large number of statistical analyses were conducted on a 
relatively small sample size, which could increase the probability of getting a statistically 
significant result due to chance. Outcomes were also parent-reported and children were not 
individually assessed. 
The authors found that IAP might be associated with serious consequences of cerebral palsy, 
functional impairment and bowel problems. The risk of cerebral palsy was higher in infants 
whose mothers were treated with any erythromycin compared with no erythromycin (3% 
[n=53/1,611] vs 2% [n=27/1,562], OR 1.93 95% CI 1.21 to 3.09) and in mothers who received 
any amoxicillin-clavulanate versus no amoxicillin-clavulanate (3% [n=50/1,587] vs 2% 
[n=30/1,586], OR 1.69 95% CI 1.07 to 2.67). A higher number of children who developed 
cerebral palsy were born to mothers who received both antibiotics (35/735) than to mothers 
who received erythromycin alone (18/785), amoxicillin-clavulanate alone (15/763) or double 
placebo (12/735) (OR 2.91 95% CI 1.50 to 5.65). Any erythromycin also increased the risk of 
bowel problems (4% [n=64/1,611] vs 2% [n=38/1,562], OR 1.66 95% CI 1.10 to 2.49) and 
functional impairment (42% [n=658/1,554] vs 38% [n=574/1,498], OR 1.18 95% CI 1.02 to 
1.37) compared with no erythromycin; amoxicillin-clavulanate did not. None of these effects 
were found for erythromycin or amoxicillin-clavulanate alone compared with placebo, which 
may be a result of insufficient power. The authors also investigated attention deficit 
hyperactivity disorder, behavioural problems, diabetes, education attainment and other 
development problems, but they did not find any differences between any of the treatment 
versus control groups. 
There was one observational study that followed children up to two years of age and 
investigated the relationship between IAP (indication not stated) and atopic dermatitis in a 
retrospective cohort study. This study was at unclear risk of selection bias as the response rate 
was only 43% and not all confounding variables were accounted for. Compared with no 
treatment, only participants whose mothers were treated with more than 24 hours of IAP were 
at a higher risk of atopic dermatitis (55% [6/11] vs 27% [100/364], RR 1.99 95% CI 1.13 to 
3.49). IAP for 0 to 4 hours, 4 to 12 hours or 12 to 24 hours was not associated with dermatitis.  
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Table 12. Qualitative composition of gut microbiota in IAP-treated and untreated infants 
Organisms Reference 
Year 
Infants (n) in each 
group 
Relative amount in microbiota composition (%) or infants (n) colonised 
Day 
1 2 3 6/ 7  10 30 
Phyla level 
All Arboleya 
2016 
IAP n=14 
Control n=13 
No 
difference 
     
Actinobacteria  Aloisio 
2016* 
IAP n=10 
Control n=10 
   IAP: 0.4% 
Control: 3.8% 
p<0.05 
  
Arboleya 
2016 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
   IAP: 0% 
Control: 17% 
p<0.001 
  
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 1% 
Control: 8% 
RR 0.13 (CI 0.02-0.98) 
 IAP: 7% 
Bacteriodetes Aloisio 
2016* 
 
IAP n=10 
Control n=10 
   IAP: 16% 
Control: 47.7% 
p<0.05 
  
Mazzola 
2016* 
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 21% 
Control: 36% 
RR 0.59 (CI 0.3-0.93) 
 IAP: 34% 
Control: 26% 
RR 1.31 (CI 0.85-2.01) 
Proteobacteria  Aloisio 
2016* 
IAP n=10 
Control n=10 
   IAP: 54.7% 
Control: 15.5% 
p<0.05 
  
Arboleya 
2016 
IAP n=14 
Control n=13 
     Higher % in IAP, 
p<0.001 
Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
   Higher % in IAP, 
p<0.062 
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Organisms Reference 
Year 
Infants (n) in each 
group 
Relative amount in microbiota composition (%) or infants (n) colonised 
Day 
1 2 3 6/ 7  10 30 
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 37% 
Control: 17% 
RR 2.18 (CI 1.32-3.60) 
 IAP: 28% 
Firmicutes Arboleya 
2016 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.01 
Mazzola 
2016* 
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 41% 
Control: 29% 
RR 1.14 (CI 0.96-2.08) 
 IAP: 30% 
Family level 
Bifidobacteriaceae Aloisio 
2016* 
 
IAP n=10 
Control n=10 
   IAP: 0.02% 
Control: 6.47% 
p<0.05 
   
Arboleya 
2015 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Comamonadaceae Arboleya 
2015 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Enterobacteriaceae Arboleya 
2015 
IAP n=14 
Control n=13 
     Higher % in IAP, 
p<0.05 
Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
   Higher % in IAP, 
p=0.044 
 IAP: 44% 
Control: 16% 
RR 2.75 (CI 1.67-4.54) 
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 35% 
Control: 17% 
RR 2.06 (CI 1.24-3.42) 
 IAP: 28% 
 
Jaureguy 
2004* 
IAP n=25 
Control n=25 
  IAP n=13 
Control n=16 
p=0.58 
IAP: 0%   
Lachnospiraceae Mazzola 
2016* 
IAP n=14 
Control n=13 
     IAP: 4% 
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Organisms Reference 
Year 
Infants (n) in each 
group 
Relative amount in microbiota composition (%) or infants (n) colonised 
Day 
1 2 3 6/ 7  10 30 
Leuconostaceae Arboleya 
2015  
IAP n=14 
Control n=13 
 Lower % in 
IAP, p<0.05 
    
Micrococcaceae Arboleya 
2015 
IAP n=14 
Control n=13 
    Lower % 
in IAP, 
p<0.05 
 
Propionibacteriaceae Arboleya 
2015 
IAP n=14 
Control n=13 
    Lower % 
in IAP, 
p<0.05 
 
Staphylococcaceae Arboleya 
2015 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Streptococcaceae Arboleya 
2015 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Veillonellaceae Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
     Lower % in IAP, 
p=0.035 
Unclassified 
Actinobacteria 
Arboleya 
2015  
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Unclassified Bacilli IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Unclassified 
Lactobacillales 
IAP n=14 
Control n=13 
     Lower % in IAP, p<0.05 
Genera level 
Bacteroides 
 
Jaureguy 
2004* 
IAP n=25 
Control n=25 
  IAP n=13 
Control n=7 
p=0.15 
   
Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
   IAP: 7% 
Control: 20% 
p=0.078 
  
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 13% 
Control: 32% 
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Organisms Reference 
Year 
Infants (n) in each 
group 
Relative amount in microbiota composition (%) or infants (n) colonised 
Day 
1 2 3 6/ 7  10 30 
RR 0.41 (CI 0.23-0.73) 
Bifidobacteria Jaureguy 
2004* 
IAP n=25 
Control n=25 
  IAP n=6 
Control n=12 
p=0.18 
   
Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
   IAP: 0% 
Control: 16% 
p=0.001 
 IAP: 6% (compared with 
day 7, p=0.025) 
Control: 6% 
Mazzola 
2016* 
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 1% or 0% 
Control: 5% 
 IAP: 6% (compared with 
day 7, p=0.013) 
Control: 19% 
RR: 0.32 (CI 0.13-0.76) 
Clostridia Jaureguy 
2004* 
IAP n=25 
Control n=25 
  IAP n=3 
Control n=10 
p=0.04 
   
Enterococci Jaureguy 
2004* 
IAP n=25 
Control n=25 
  IAP n=15 
Control n=17 
p=0.73 
   
Escherichia Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control n=7 
   IAP: 52% 
Control: 14% 
RR 3.71 (CI 2.21-6.25) 
  
Staphylococci Jaureguy 
2004* 
IAP n=25 
Control n=25 
  IAP n=21 
Control n=22 
p=1.00 
   
Streptococci Mazzola 
2016* 
Mixed-fed IAP n=6 
Mixed-fed Control n=6 
   IAP: 32% 
Control: 10% 
RR 3.2 (CI 1.66-6.15) 
 IAP: 8% (compared with 
day 7, p=0.042) 
Other microbial 
genus 
Aloisio 
2016* 
IAP n=10 
Control n=10 
   No differences   
* Group B Streptococcus prophylaxis; Numbers in italics are calculated 
CI confidence interval, IAP intrapartum antibiotic prophylaxis, p probability value, RR risk ratio,  
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Table 13. Quantitative composition of gut microbiota in IAP-treated and untreated infants 
Organism Reference 
Year 
Infants in each 
group (n) 
Log colony forming units per gram (CFU/g) 
Day 
3 6/7  30 90 
Family level 
Staphylococcaceae Arboleya 
2015  
IAP n=14 
Control n=13 
  Lower log cells/g in IAP, 
p<0.05 
 
Enterobacteriaceae Arboleya 
2015  
IAP n=14 
Control n=13 
  Higher log cells/g in IAP, 
p<0.05 
 
Jaureguy 
2004* 
IAP n=25 
Control n=25 
IAP: Med 8.4 (R 3.3-9.5) 
Control: Med 9.2 (R 3.3-9.8) 
p=0.18 
   
Genera 
Bacteroides 
 
Jaureguy 
2004* 
IAP n=25 
Control n=25 
IAP: Med 8.0 (R 6.3-10.3) 
Control: Med 7.9 (R 3.6-9.6) 
p=0.12 
   
Bifidobacteria Jaureguy 
2004* 
IAP n=25 
Control n=25 
IAP: Med 8.2 (R 4.3-9.5) 
Control: Med 8.5 (R 6.9-
10.3) 
p=0.10 
   
Arboleya 
2015  
IAP n=14 
Control n=13 
   Lower log 
cells/g in 
IAP, 
p<0.05 
Bifidobacterium 
spp. 
 
Aloisio 
2014* 
IAP n=26 
Control n=26 
 IAP: Mn 5.85 (R 3.24-7.79) 
Control: Mn 7.29 (R 4.12-
10.95) 
p=0.001 
  
Corvaglia 
2016* 
IAP n=35 
Control n=29 
 IAP: Med 6.01 (IQR 5.51-6.98) IAP: Med 8.41 (IQR 7.71-
8.80) 
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Organism Reference 
Year 
Infants in each 
group (n) 
Log colony forming units per gram (CFU/g) 
Day 
3 6/7  30 90 
Control: Med 7.80 (IQR 6.61-
8.26) 
p=0.000 
Control: Med 8.39 (IQR 7.96-
8.86) p=0.363 
Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control 
n=7 
 IAP: Med 5.86 
Control: Med 8.16 
p=0.005 
IAP: Med 7.72 (compared with 
day 7, p=0.035)  
Control: Med 8.62 
NS  
 
Mixed-fed IAP n=6 
Mixed-fed Control 
n=6 
 IAP: Med 5.81 
Control: Med 7.19 
p=0.03 
IAP: Med 8.50 (compared with 
day 7, p=0.036) 
Control Med 8.55 (compared 
with day 7, p=0.028)  
 
Clostridia Jaureguy 
2004* 
IAP n=25 
Control n=25 
IAP: Med 5.3 (R 4.3-5.8) 
Control: Med 6.2 (R 3.6-8.1) 
p=0.01 
   
Enterococci Jaureguy 
2004* 
IAP n=25 
Control n=25 
IAP: Med 8.3 (R 3.6-10.3) 
Control: Med 7.3 (R 3.3-9.5) 
p=0.78 
   
Lactobacillus spp. Aloisio 
2014* 
IAP n=26 
Control n=26 
 IAP: Mn 6.69 (R 5.40-8.93) 
Control: Mn 6.73 (R 5.45-8.20) 
NS 
  
Corvaglia 
2016* 
IAP n=35 
Control n=29 
 IAP: Med 5.56 (IQR 4.94-6.14) 
Control: Med 5.45 (IQR 4.81-
6.14) 
p=0.872 
IAP: Med 5.29 (IQR 4.68–
6.01) 
Control: Med 5.25 (IQR 4.60-
6.15) 
p=0.932 
 
Staphylococci 
 
Jaureguy 
2004* 
 
IAP n=25 
Control n=25 
IAP: Med 6.5 (R 3.6-8.0) 
Control: Med 7.0 (R 4.0-9.3) 
p=0.53 
   
Species 
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Organism Reference 
Year 
Infants in each 
group (n) 
Log colony forming units per gram (CFU/g) 
Day 
3 6/7  30 90 
Escherichia coli 
 
Aloisio 
2014* 
 
IAP n=26 
Control n=26 
 IAP: Mn 8.18 (R 4.09-12.70) 
Control: Mn 9.03 (R 5.61-
11.78) 
NS 
  
Bacteroides 
fragilis 
 
Aloisio 
2014* 
IAP n=26 
Control n=26 
 
 IAP: Mn 8.17 (R 4.68-11.99) 
Control: Mn 8.53 (R 5.22-
11.16) 
NS 
  
Corvaglia 
2016* 
IAP n=35 
Control n=29 
 IAP: Med 7.71 (IQR 5.80-9.33) 
Control: Med 7.75 (IQR 5.87-
9.61) 
p>0.05 
IAP: Med 7.36 (IQR 5.80-
9.09) 
Control: Med 8.51 (IQR 5.86-
9.37) 
p>0.05 
 
Clostridium 
difficile 
 
Aloisio 
2014* 
IAP n=26 
Control n=26 
 IAP: Mn 3.89 (R 3.12-4.80) 
Control: Mn 3.70 (R 2.85-5.46) 
NS 
  
Total bacteria Mazzola 
2016* 
Breast-fed IAP n=7 
Breast-fed Control 
n=7 
Mixed-fed IAP n=6 
Mixed-fed Control 
n=6 
 All groups: R 9.38-9.71  All groups: R 9.53-9.83  
 
 
Arboleya 
2015  
IAP n=14 
Control n=13 
  Higher log cells/g in IAP, 
p<0.05 
 
* Group B Streptococcus prophylaxis 
IAP intrapartum antibiotic prophylaxis, Mn mean, Med median, R range, IQR interquartile range, p probability value
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7.6 Discussion 
7.6.1 Principal findings 
This is the first systematic review investigating the evidence on adverse events experienced 
by the mother and/or her child after treatment with intrapartum antibiotic prophylaxis. There 
were a wide range of adverse events reported in 17 observational studies and 13 RCTs. 
However, there was little high-quality evidence to quantify the frequency of adverse events 
from IAP for neonatal GBS disease prevention (objectives a to e). There were three key 
findings. First, there was a substantial evidence gap around the long-term effects of IAP 
(objectives e). There was only one RCT, which reported a moderate effect of cerebral palsy, 
functional impairment and bowel problems at the age of seven, in infants whose mothers were 
treated with IAP. However, this RCT had limited applicability to GBS prevention. Second, 
there was consistent observational evidence that IAP for GBS prevention altered infant 
microbiota from 0 to 90 days of life. However, the clinical significance of this is not known. 
Thirdly, some observational evidence showed increased antibiotic resistance in infants whose 
mothers were treated with IAP. However, the evidence was at high or unclear risk of bias due 
to confounding variables, and these findings were not replicated in other studies. 
The best quality evidence was Kenyon et al.’s (2008) RCT which found the increased risk of 
bowel problems, cerebral palsy and functional impairment from IAP.  This study had a low 
risk of bias across major domains. However, the applicability of these findings is uncertain, 
as the drugs investigated were erythromycin or amoxicillin-clavulanate given for 10 days or 
until birth to a population in preterm labour.320 The drug recommendation for GBS IAP 
treatment is penicillin followed by a cephalosporin or clindamycin,13, 15 given for shorter 
durations, at or near, term labour. The effect sizes of the findings were also moderate, and 
with multiple statistical comparisons on the same population, the probability of a chance result 
is increased. Furthermore, the plausible biological mechanisms through which IAP can cause 
the development of cerebral palsy are not known. Despite the relatively higher methodological 
quality of this study, the findings may not be applicable to GBS prevention. 
On the other hand, studies with improved applicability that explicitly included IAP for GBS 
prevention found that IAP could alter gut microbiota, increase maternal thrush and increase 
neonatal respiratory distress. However, all of these studies were observational and at high or 
unclear risk of bias. These studies did not account for all of the important confounding 
variables, thus, results could be due to other factors. In addition, although there were consistent 
observational results on gut microbiota, populations in these studies were not followed to 
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clinical outcomes. Therefore, whether microbiota alterations from IAP are associated with 
short or long-term health problems is not known. 
The remaining evidence in all treated populations (GBS and/or other prevention) was 
inconsistent, as some studies showed differences while others did not. There was unclear risk 
of developing antibiotic resistance, Clostridium difficile bowel problems, necrotising 
enterocolitis and neonatal infections. Generally, the RCTs that investigated the effectiveness 
of IAP found no increase in the treated, compared with control groups, whereas the 
observational studies did find an increase. 
The results may have lacked consistency as the overall evidence across the studies was at high 
or unclear risk of bias in more than one domain. Eight (64%) of the RCTs were at high risk of 
bias for selective reporting, as many of the outcomes were not pre-specified or only reported 
in the treated group, while seven studies had unclear but serious risks of other biases. 
Furthermore, all but one of the trials aimed to investigate the effectiveness of IAP and might 
have contained investigator bias. None of the observational studies had a low risk of bias for 
confounding variables as 13 (76%) studies controlled some, but not all, important confounding 
variables, while the remaining four (24%) were at high risk. In these studies, key variables 
such as the proportion of women with maternal risk factors for infection or who were 
administered antibiotics during pregnancy, were not stated. 
As a result of the inconsistent and fairly inapplicable evidence base that was at high risk of 
bias, it is difficult to quantify the incidence of any one, or all, of the potential adverse events 
associated with IAP treatment for GBS prevention. 
 
7.6.2 Comparison with previous literature 
Below I discuss the previous literature in relation to the three key findings on the adverse 
events of microbiota changes, long-term severe consequences and antibiotic resistance. 
It has been suggested in the literature that early gut bacterial colonisation plays an important 
role in infants’ mucosal and immune system development.191, 32, 321, 192 Infant microbiome 
changes from antibiotics have been linked to autism, metabolic problems such as diabetes and 
obesity and respiratory problems such as asthma.191, 32, 192 For example, Cox et al. (2014) 
demonstrated gut microbiota changes that led to permanent abnormalities in the immunity and 
metabolism in mice as a result of low dose penicillin delivered after birth.331 Antibiotic 
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exposure repeatedly during infancy or before six months of age was also recently associated 
with an increase in body mass and height in healthy children.192 Although these studies relate 
to gut microbiota from antibiotic exposure, the antibiotics in these studies were not 
administered during labour. Therefore, it is not clear whether gut microbiota changes from 
intrapartum antibiotic exposure have these or any other clinical significance.  
In this systematic review, I found inconsistent evidence on the increase of antibiotic resistance 
after IAP. As shown in Chapter 2, the literature shows increases in the rates of antibiotic 
resistance in countries offering IAP for neonatal GBS prevention. In the last 20 years, both 
clindamycin and erythromycin resistance have increased.14 In the US in 2010, EOGBS 
resistance to erythromycin was reported at 48% and resistance to clindamycin was above 
27%.332, 18, 297 In the UK, in 2014/15, EOGBS resistance to erythromycin was reported at 23% 
and resistance to clindamycin was 16%; an increase from 6% and 3% respectively, since 
2000/01.5 However, clindamycin and erythromycin resistance in GBS strains isolated from 
pregnant women have shown increased rates across the world. The highest rates have been 
reported in Asia, followed by the Americas and Africa. Most Asian and African countries do 
not administer IAP, however, without knowing the contributing centres and their IAP policies, 
it is difficult to reach conclusions. While GBS remains almost universally susceptible to 
penicillin,86 0.2% of GBS isolates in the US in 2005 had reached the upper level of 
susceptibility for beta-lactams.182, 18 Similarly, in Japan, 5% to 15% of GBS isolates were 
reported to have reduced penicillin susceptibility;183 approximately half of which are 
susceptible under European breakpoints and came from populations where chronic antibiotic 
exposure is likely to be common (due to chronic respiratory disease). As discussed in Chapter 
2, there have been some studies showing penicillin resistance in GBS isolated from pregnant 
women including one in Italy where IAP is offered,181, 179, 180 however, these studies were small 
and had methodological limitations, therefore, require further research. All of the observations 
are also ecological in nature with no comparators, making it difficult to attribute them to IAP 
for GBS prevention as they could be due to other factors that occurred during those periods. 
The previous literature on the association between IAP and cerebral palsy (shown in Kenyon 
et al., 2008)320 is uncertain. The plausible biological mechanisms by which IAP can cause 
cerebral palsy are not known within the extant literature.333, 320 Further complicating this result 
is a second trial administering IAP for pregnant women with preterm rupture of the 
membranes (which was excluded because of potential confounding effects due to signs of 
infection) that showed no difference in the number of children who developed cerebral palsy 
in treated versus untreated women.334 Overall, the reason why cerebral palsy occurred in the 
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first study and if it would occur because of IAP for neonatal GBS prevention involving 
different drug durations and regimens, is uncertain. 
 
7.6.3 Strengths and limitations 
This was the first systematic assessment of the literature on the adverse events from IAP. I 
applied an extensive search strategy with no date limit to capture as much as data as possible. 
I also included reference checking of all included papers and relevant systematic reviews to 
capture grey literature. Furthermore, I had expert input from clinical microbiology, infectious 
disease and obstetrics and gynaecology to find any further literature I had not identified, and 
to review the methodology and the findings to ensure I maintained clinical significance. I also 
enlisted a second reviewer to duplicate and cross-check reviews processes including study 
selection, data extraction and quality appraisal to minimise any errors and maintain a high-
quality standard for the review. For quality appraisal, I considered and piloted different 
validated tools to ensure they met the needs of the review. Finally, where summary measures 
were not available for comparisons of outcomes, I calculated them to improve the 
understanding of the results. 
However, there are some limitations to the review around the search strategy, study eligibility 
and data extraction. Firstly, as my search strategy was broad and focused heavily on harms or 
adverse events search terms, I may not have found studies investigating outcomes that would 
potentially be adverse events, but were not indexed as such. This was the most efficient and 
effective strategy to find the appropriate studies, and I made an effort to find these studies by 
including the terms for IAP harms known to experts and known in the literature, searching 
reference lists and asking experts for any studies missed. Secondly, I only included studies for 
which full-texts were available in English, therefore, I might have missed adverse events 
reported in other languages. The majority of the studies included in this review were from the 
US and Europe, with one study from the Latin America, three from Africa and two from the 
Middle East. I did not identify studies from many countries, and it is not clear whether there 
are such studies in other countries. This could potentially increase selection bias and put the 
generalisability of the review findings at risk. 
Secondly, with respect to the study eligibility criteria for the study inclusion, I excluded 
studies on the adverse events from caesarean section prophylaxis due to differences in the 
regimens for caesarean prophylaxis compared with GBS prophylaxis and the potential 
confounding of the surgery itself. Similarly, I excluded studies where more than 10% of 
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women had risk factors for infection due to the confounding effect. Thus, I may have excluded 
harms in such studies that may also be relevant to GBS prophylaxis. However, I excluded 
these studies as it would have been difficult to form conclusions on whether the cause of the 
adverse event was IAP or the confounding variables. Similarly, I excluded case reports even 
though they might have identified more adverse events that occurred after IAP, for example 
from medical records. However, with no control group, it would have been difficult to reach 
conclusions about whether IAP would increase adverse events. 
Thirdly, regarding the data extraction process, there were some studies in which information 
was not provided, was unclear or numbers did not add up. In these cases, I did not contact the 
authors directly to clarify the data or provide the information required. Contacting them could 
have clarified the data and the study could have been more valuable to the review. Finally, I 
was unable to pool data that were extracted using meta-analysis due to the heterogeneity across 
the adverse events and the populations investigated. This meant that I could not meet the 
objectives of this review to quantify the incidence of each adverse event separately or 
combined. Instead, I narratively synthesised the data which identified that there are still 
important gaps in the evidence on the adverse events from IAP. 
Despite the limitations of this review, I used a broad search strategy, searched reference lists 
and experts did not identify further studies. Therefore, the findings of this review are 
representative and reflective of the evidence base on adverse events from IAP available at this 
time. 
 
7.6.4 Research and policy implications 
This review has implications on the widely recommended clinical practice of IAP treatment 
for maternal GBS carriage to prevent neonatal GBS disease.1 A Cochrane meta-analysis 
concluded that despite an 83% reduction in EOGBS incidence from IAP, IAP for maternal 
GBS colonisation is not supported by conclusive evidence due to a high risk of bias across 
RCTs.10 Given this uncertainty, and the uncertainty of the results in this review, it is 
increasingly difficult to determine whether the benefits of IAP for EOGBS prevention 
outweigh the harms to mothers and their children. To answer this question, well-designed and 
large RCTs are needed. However, as IAP is now the recommended treatment, it may no longer 
be possible for such a trial. An alternative might be to perform large, longitudinal and high-
quality observational studies across countries with widespread IAP that comprehensively 
control for confounding variables. In particular, long-term follow-up investigations are 
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required on the health consequences of early microbiota alterations from IAP. Without this 
information, it is not possible to understand the importance, if any, of early gut microbiota 
changes. 
In the meantime, expanding EOGBS prevention from risk-based strategies to universal GBS 
screening may increase the number of low risk women exposed to IAP. As identified in 
Chapter 2, the literature indicates that up to 30% of mothers positive in pregnancy become 
negative by birth, and only up to 3% of mothers colonised in labour have a neonate with 
EOGBS.4, 104 In the UK, approximately 150,800 pregnant women would be eligible for IAP 
every year, and without treatment, over 149,300 (99%) would not have a neonate with 
EOGBS. These women and their babies would be unnecessarily exposed to potential harm. 
This review indicates that the adverse events from IAP and their clinical significance are not 
well investigated. As a result, the balance between the benefits and the harms from expanding 
IAP administration in a GBS screening programme cannot be calculated. As observational 
evidence on universal GBS screening effectiveness is limited because of inherent biases,16, 14, 
17 an RCT on the effectiveness of GBS antenatal culture screening could inform on both the 
effectiveness and the harms of screening and IAP treatment. However, as indicated in 
Chapters 2 and 3, such an RCT would require a large sample size due to the low positive 
predictive value of the GBS antenatal culture test (0.2% to 0.4%). For now, the screening 
criterion that the benefits of screening and treatment should outweigh the harms remains 
unmet, as it is not clear if widespread IAP is safe to undertake.  
 
7.7 Conclusions of this chapter 
 The evidence on the adverse events from IAP treatment revealed a range of potential 
adverse events. However, the evidence base for IAP treatment specifically for 
neonatal GBS disease prevention is unclear, inconsistent and/or at risk of bias. 
 The key findings were consistent evidence from observational studies that IAP for 
GBS alters infant microbiota, and some inconsistent evidence that IAP increases 
antibiotic resistance. However, this evidence was at risk of bias and the clinical 
consequences of the microbiome alterations are not known. 
 There was also evidence from one long-term RCT which showed that IAP in preterm 
labour is associated with potentially severe consequences such as cerebral palsy. 
However, it has applicability concerns, unclear biological plausibility and was not 
duplicated in a similar RCT. 
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 These limitations prevent accurate conclusions on the frequency of adverse events 
from IAP treatment for neonatal GBS disease prevention. It is uncertain whether large 
scale IAP as a result of a universal GBS screening programme would be safe to 
undertake. Consequently, the requirement that the benefits of screening should 
outweigh the harms is not met. 
 Larger, longer and higher quality studies across countries with widespread IAP are 
needed to quantify adverse events from IAP treatment for neonatal GBS disease 
prevention.
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PART III. TIME TRENDS AND THE IMPACT OF 
GBS SCREENING   
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8. RESEARCH RATIONALE, AIMS AND OBJECTIVES 
As discussed in Chapters 2 and 3, one of the reasons the UK NSC recommended against 
universal GBS screening was that there was no RCT evidence to prove the clinical 
effectiveness of GBS screening on EOGBS morbidity and mortality. However, as EOGBS is 
a relatively rare condition with an incidence of 0.57 per 1,000 livebirths,5 a large sample is 
required to power an RCT. In such circumstances, an alternative to RCT evidence may be 
required to make screening decisions. Therefore, in this part of the thesis, I will investigate 
whether an alternative approach can inform the clinical effectiveness and harms of universal 
GBS screening. As demonstrated in Chapter 2, there has been growing evidence from 
countries that have implemented universal GBS screening, on the benefits and harms from 
screening. However, due to a high risk of bias from confounding variables, the same results 
may not necessarily be expected in the UK as there are different population, economic and 
health system contexts. Therefore, to estimate the benefits and harms of universal GBS 
screening, I will explore whether international data on GBS related outcomes in GBS 
screening programmes compared with other prevention strategies can be adjusted for country-
level differences in ecological trend analyses. 
The primary purpose of a universal GBS screening programme, or any EOGBS prevention 
strategy, is to reduce the morbidity and mortality of EOGBS disease in neonates. Therefore, 
in Chapter 11, I present an ecological trend analysis study that combines international data to 
explore the impact of universal GBS screening on the trends of annual EOGBS incidence 
compared with other GBS prevention strategies, adjusted for country differences. Despite 
EOGBS being the primary outcome of interest in screening programmes, there is a 
fundamental limitation of its use in research investigations. Focussing on cultured-confirmed 
EOGBS can overestimate the reduction in EOGBS incidence under screening. This is because 
antibiotics present in neonates’ blood increase the chance of false negative test results in the 
presence of infection.275, 18 Consequently, it has been suggested that early-onset sepsis (less 
than 7 days) must be assessed to investigate GBS screening. However, as indicated in Chapter  
2, the findings from different studies have shown conflicting results. Some studies show that 
neonatal sepsis incidence does not decrease under screening, whereas others show that it 
decreases under IAP prevention (screening or risk-based prevention) but not necessarily 
specific to screening.174, 175 It is vital to investigate the impact of GBS screening in reducing 
early-onset sepsis as this would result in a true and unbiased understanding of the effectiveness 
of GBS screening. In Chapter 12, I present an ecological trend analysis study that combines 
international data to explore the impact of universal GBS screening on the trends of annual 
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early-onset sepsis incidence compared with other prevention strategies, adjusted for country-
level differences. 
As identified in Chapters 2, 3 and 5, a necessary part of assessing screening in the UK and 
according to international screening standards is to examine the harms of screening in order 
to ensure that the benefits of screening outweigh the harms. As discussed in Chapter 2, in the 
case of GBS, IAP would be given to approximately 150,800 pregnant women and their babies 
every year, of whom over 99% will be over-treated, making the harms from the screening 
programme even more important in the context of GBS screening. Therefore, in Chapter 13, 
I present a final ecological trend analysis study that combines international data to explore the 
impact of universal GBS screening on the trends of some harmful outcomes of GBS screening 
and IAP treatment compared with other prevention strategies, adjusted for country-level 
differences. In Chapter 7, I summarised the current literature on the harms of IAP treatment. 
There were a range of potential harms identified in the literature, although most of the 
evidence is from small studies that are at high risk of bias. One of the key adverse events 
identified in this chapter was antibiotic resistance. The evidence about these outcomes was 
inconsistent across the literature and did not always involve GBS prophylaxis or GBS 
organisms. Another key adverse event was neonatal infection, where there was also 
inconsistent evidence that IAP treatment increases early- and late-onset neonatal infections. 
Although this is counterintuitive, widespread IAP can cause selection pressure and change the 
organisms causing infection. Therefore, it can lead to an increase in antibiotic resistant strains 
causing infection, particularly for late-onset disease, and can increase early-onset gram-
negative bacteria, of which E. coli is the commonest, as shown in Chapters 2 and 7. Therefore, 
in Chapter 13, I investigate the following potential harms of a GBS screening programme and 
the expansion of IAP treatment: LOGBS incidence, early-onset E. coli incidence, the 
percentage of EOGBS cases resistant to clindamycin and erythromycin and the percentage of 
all neonatal GBS cases resistant to clindamycin and erythromycin. I did attempt to investigate 
maternal anaphylaxis as it is a serious adverse event from IAP, however, due to the rarity of 
the condition the analyses would not have been possible.  
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8.1 Research aims and objectives 
The research aim of this part of the thesis is to investigate whether the international data on 
the benefits and harms of universal GBS screening, compared with other prevention strategies, 
can be adjusted for country-level differences using ecological trend analysis, to inform the 
clinical effectiveness of universal GBS screening. 
The research questions for each of the ecological trend analysis studies are: 
1. Adjusting for country-level differences, what is the international impact of GBS 
screening on the trend of annual EOGBS incidence across time compared with other 
prevention strategies? 
2. Adjusting for country-level differences, what is the international impact of GBS 
screening on the trend of annual all-cause early-onset sepsis incidence across time 
compared with other prevention strategies? 
3. Adjusting for country-level differences, what is the international impact of GBS 
screening on the trends of annual early-onset E. coli and LOGBS incidences, and the 
percentages of clindamycin and erythromycin resistance in early-onset and neonatal 
GBS disease across time compared with other prevention strategies? 
The specific research objectives are to: 
a) Describe the frequency of the GBS prevention strategy as well as the mean or 
frequency of the country-level covariates in general (irrespective of outcome); 
b) Describe the mean incidence of each outcome across time, geographical areas, world 
regions and GBS prevention strategies; 
c) Investigate the unadjusted relationship between universal GBS screening and the 
trend of each annual outcome (as stated above) across time compared with other 
prevention strategies, using linear regression; 
d) Investigate the unadjusted relationship between each country-level covariate and the 
mean outcome across time, using linear regression; 
e) Investigate the relationship between universal GBS screening and the trend of each 
annual outcome across time compared with other prevention strategies, using linear 
regression adjusted for the country-level covariates; 
f) Examine the stability of the adjusted relationship between universal GBS screening 
and the trend of each annual outcome across time compared with other prevention 
strategies in a range of sensitivity analyses, if the relationship was statistically 
significant; and 
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g) Investigate the multi-level unadjusted relationship between universal GBS screening 
and the trend of annual EOGBS incidence across time compared with other prevention 
strategies, using a multi-level growth curve model to account for the structure of the 
data. 
In Chapter 9, I describe the detailed methodology used to address the research questions and 
objectives. In Chapter 10, I summarise the data collected for all three studies, and in Chapters 
11, 12 and 13,  I explore the results and discuss the key findings and how they compare to 
previous literature for each study separately: Chapter 11 EOGBS, Chapter 12 early-onset 
sepsis, and Chapter 13 harmful outcomes (early-onset E. coli, LOGBS, and clindamycin and 
erythromycin resistance in early-onset and neonatal GBS disease). Finally, in Chapter 14, I 
summarise the results of all three studies, discuss the strength and limitations of the methods 
used in these studies and the research and policy implications.   
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9. METHODS 
I have reported the three ecological trend analysis studies using the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) statement.335   
9.1 Study design and rationale  
To address research questions 4 to 6, I used quantitative methodology. For interventions such 
as screening, robust estimates are required to indicate the numbers of different groups of 
patients who would experience a morbidity and mortality benefit or harm from the 
intervention. To estimate the frequency of these outcomes, I chose quantitative methods as 
they are the most appropriate. This is coherent with the recommendation that “research 
methods should follow research questions in a way that offers the best chance to obtain useful 
answers”.211 p18 
To formulate a screening decision, the UK currently fills out a screening flowchart to assess 
the trade-off between the benefits and harms of a screening programme to the population (see 
Figure 10). This flowchart, recommended in the literature,336 is filled in to show the numbers 
and percentages of people who would experience each possible consequence from a screening 
programme. This part of the thesis focuses on the intervention phase of the flowchart as the 
target population and the diagnostic accuracy of the sieve phase of the flowchart has already 
been researched and can be estimated from current literature while the sort phase of the 
flowchart does not exist in the case of GBS screening as there is no currently available 
diagnostic test. The UK NSC usually uses RCT evidence to fill in the flow chart. For GBS, 
most of the flowchart is based on evidence that is partly of fully biased and uncertain or 
unknown. However, in the absence of RCTs, I proposed to use adjusted international data 
from epidemiological ecological studies to estimate the benefits and harms of screening in the 
flowchart.  
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 Figure 10. Screening flow chart developed by Raffle and Gray,336 p78 and used by the UK 
National Screening Committee 
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I measured the benefits (objective 4 and 5) and harms (objective 6) of universal GBS screening 
to populations across countries in three epidemiological ecological trend analysis studies. 
Epidemiology is defined as “the study of the distribution and determinants of health-related 
states or events in specified populations, and the application of this study to the control of 
health problems”.337 Various methods exist to carry out epidemiological investigations; some 
studies are descriptive and are used to study disease distribution while others are analytical 
and used to study determinants of diseases.338 As epidemiological methodology enables 
assessment and control for the determinants of diseases at a group level, and allows the 
researcher to investigate groups of people,339 it was an appropriate alternative to RCT data to 
meet the objectives. 
Specifically, within epidemiological study designs, I chose the ecological study design. An 
ecological study is an observational study investigating the disease burden (exploratory 
design) or the association between diseases and exposures (analytic design at the level of the 
population or community).340, 341 Therefore, the unit of measure is the population and the 
disease rates and exposures are measured at the population level. Ecological studies not only 
allow geographical correlations between disease incidence rates and the prevalence of risk 
factors (multiple-group design), they also allow the analysis of trends in incidence rates over 
time (time-trend design), or a combination of place and time (mixed design). Although 
validating trends and changes in trends is difficult as it depends on observations made years 
ago, ecological studies can reveal the reality of trends with reasonable certainty.341 Indeed, the 
aim of research questions 4 to 6 were to assess the exposure of different population GBS 
prevention programmes on a population level over time and across countries. Furthermore, 
screening programmes are population level interventions or policies where the target level of 
inference is ecologic. Therefore, an analytical mixed design ecological study was appropriate. 
Furthermore, ecological analyses can enable the identification of unintended consequences of 
population interventions, which are not likely to be identified in individual level studies.340  
I decided to include a time-trend element in the comparison of the outcomes between 
populations as opposed to a cross-sectional snapshot comparison, as trends enable a more 
dynamic and reliable estimate of changes related to the effect of exposures such as a GBS 
prevention strategy. Time trend analyses are useful in describing long-term changes in a 
population, comparing one geographical area with another and studying effects specific to 
groups, such as public health interventions offered to the group.342, 343 These trends reveal facts 
related to the disease that can aid in making health-related public policies to decrease the 
population’s risk of the disease.344 Trends also help to monitor the progress made in a 
particular disease and evaluate the effectiveness of current intervention methods.344 By 
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assessing whether the slope of the incidence rates is increasing or decreasing, one can assess 
the progress of intervention methods such as GBS prevention strategies.344 While a 
comparison of one point in time estimates of diseases between countries that have different 
GBS prevention strategies can provide some indication about the differences in the 
effectiveness of the prevention strategies, it is not clear whether the rate in one year would be 
reflective of every year or how the rates might fluctuate between the years. By examining the 
trends over time, one can achieve a more accurate indication of the changes that can be 
expected under different prevention strategies, allowing predictions of future outcome rates.343 
This, in turn, can help assist in the planning of population prevention interventions.   
In planning for research questions 4 to 6, I also explored the feasibility of a retrospective, 
quasi-experimental study comparing the outcomes from maternity centres in England that 
implement different GBS prevention policies. A 2014 RCOG audit on practice to prevent 
EOGBS in hospitals in the UK identified four English hospitals that were reported to offer 
universal screening while the remaining offered risk-based prevention.345 I intended to match 
these ‘screening’ hospitals to hospitals that are similar in size and geographical location, but 
which did not offer universal screening. I would have compared the EOGBS rates between 
the ‘screening’ and ‘non-screening’ hospitals using the PHE’s GBS surveillance. However, 
when I contacted the hospitals that claimed to screen for GBS for more information, I found 
that they did not have a universal screening programme: one had provided an incorrect answer 
to the GBS audit, one only screened if a patient requested it and one only screened women 
with a clinical indication. With only one ‘screening’ hospital, there was insufficient power to 
proceed with this study.  
 
9.2 Study setting and participants 
As this was an ecological study, the unit of analysis was the geographical area that the 
institutions collecting data on the disease rates of interest were from. The study setting was 
international and I made an attempt to sample institutions from as many countries as possible 
so that the sample of geographical areas used in these studies could be representative. Initially, 
I attempted to collect national figures on any of the GBS screening benefits and harms (see 
Section 9.3 below). However, as data collection began, it became clear that, across many 
countries data were not available at this level. Therefore, I made the pragmatic decision to 
include data from institutions across countries at the regional, city or centre level. In addition, 
some of the regional and national data from the different institutions were based on mandatory 
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surveillance while others were voluntary. Due to these differences, I accounted for the 
geographical level and type of data in the analyses (see Section 9.3 below). For some countries 
or regions, multiple institutions provided data that covered the same outcomes for overlapping 
regions. To avoid double counting, I selected the institution with the widest coverage and/or 
the best quality data (i.e. mandatory instead of voluntary surveillance) for the area. If the main 
results were statistically significant, in one of the sensitivity analyses, I replaced the selected 
data source with the unselected data source to test the stability of the model (see Section 9.8).  
 
9.3 Variables and measurement 
The data for these studies included three components: the outcomes, the predictor, and the 
country or compositional covariates.  
9.3.1 Outcomes 
Altogether, there were eight outcomes across research questions 4 to 6.  The primary outcome 
for this project was the average annual change in the incidence rate of culture-confirmed 
EOGBS per 1,000 livebirths addressed in research question 4. I chose EOGBS as the primary 
outcome because this is the disease of interest that screening aims to prevent. The secondary 
outcome I addressed in research question 5 was the annual change in early-onset sepsis 
incidence per 1,000 livebirths. Early-onset sepsis was selected because measuring culture-
proven GBS alone may underestimate the incidence of sepsis due to GBS as IAP in the blood 
may prevent GBS from being isolated.275, 18  
The secondary outcomes I addressed in research question 6 to assess the harms from GBS 
screening and widespread IAP treatment were the annual changes in: early-onset E. coli 
incidence per 1,000 livebirths, LOGBS incidence per 1,000 livebirths, the percentage of 
EOGBS cases resistant to erythromycin, the percentage of EOGBS cases resistant to 
clindamycin, the percentage of all neonatal GBS cases resistant to erythromycin and the 
percentage of all neonatal GBS cases resistant to clindamycin. I chose early-onset E. coli 
because widespread IAP can lead to selection pressure on the organism causing disease and 
increase the rates of neonatal infection caused by gram-negative bacteria.32, 19 Investigating E. 
coli, which is the most common gram-negative bacterium causing neonatal infection,346 could 
provide an indication about whether GBS screening increases the rates of gram-negative 
bacteria causing early-onset infection compared with other prevention strategies. I chose 
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LOGBS because there is a suggestion that widespread IAP and resulting selection pressure 
may increase LOGBS cases.347, 348, 172 Finally, a concern of widespread IAP particularly in the 
era of antibiotic resistance, is that it can increase antibiotic resistance rates.32, 86, 23, 14 I chose 
clindamycin and erythromycin as they were the second-line drugs offered for IAP treatment 
for women who are allergic to penicillin.13, 86, 14 I did not investigate penicillin resistance as 
GBS remains almost universally susceptible to penicillin.86 
I collected annual rates of these outcomes from institutions across geographical areas and 
calculated an average annual change in the analyses as described in Section 9.8 below. 
Incidence rates per 1,000 livebirths were defined differently across institutions with respect to 
the number of days at onset of disease. EOGBS, early-onset sepsis, and early-onset E. coli 
varied between zero to two days and zero to seven days (zero to eight days for early-onset E. 
coli) and was also defined as vertical-onset or mother acquired. LOGBS ranged between two 
days onwards and five days onwards. Neonatal GBS varied between less than 28 days to less 
than 132 days. I accepted all definitions and accounted for the differences in definitions by 
adjusting for a categorical variable in the analysis that indicated the definition for the outcome.   
9.3.2 Time variable 
For each outcome, I recorded time as the year in which each observation was provided for 
each geographical area, i.e. for each observation, there was an associated year. In a minority 
of cases, some institutions provided the year as a range, in which case I chose the most recent 
year as arbitrary to avoid bias in choosing a specific year. I used this approach unless the 
months were provided for the data and it was known that the majority of the data came from 
an earlier year. In that case, I used the earlier year. For example, I used the year 2000 if the 
survey reported February 2000 to February 2001, however, I used 2001 if the survey only 
reported 2000 to 2001.  
9.3.3 Predictor variable 
The primary predictor variable of interest for research questions 4 to 6 was the most recently 
reported GBS prevention strategy recorded during the period for which outcome data were 
provided in each geographical area (country, region city or centre). It was a categorical 
variable with four categories: universal GBS screening (antenatal and/or rapid testing), risk-
based GBS prevention (based on any GBS risk factors), either a GBS screening or risk-based 
prevention strategy or no GBS prevention strategy.  
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Many institutions provided information about their prevention strategy, however, not all 
reported annually. As I did not have data on the GBS prevention strategy by year, I could not 
analyse them by year. I also considered categorising the variable into the change in prevention 
strategy that occurred for each geographical area, e.g. no prevention strategy to a risk-based 
prevention strategy for the UK, and no prevention strategy to ‘either prevention’ strategy to 
universal screening for the US. Again, because previous strategies were not always reported, 
this could not be accurately recorded. Finally, based on the dates reported by some institutions, 
as well as the dates reported on national GBS prevention guidelines, I created a variable for 
the most frequently reported GBS prevention strategy for each geographical area. This was 
not the most accurate predictor as many guidelines were provided at the country level and it 
was not possible to ascertain when the geographical area or individual hospitals within the 
geographical area may have begun implementing the guideline. For these reasons, the most 
recently reported GBS prevention strategy was the most reliable and least biased method of 
the available options. I used the most frequently reported strategy in the sensitivity analysis if 
the adjusted relationship between the most recently reported GBS prevention strategy and the 
outcome was statistically significant.  
9.3.4 Compositional variable 
In the epidemiological literature, inter-context differences in outcomes that are attributable to 
differences in group composition are referred to as compositional effects.349 Therefore, from 
this point forward in the thesis, I will refer to the country-level or contextual differences as 
compositional variables or covariates. In these ecological trend analysis studies, I adjusted the 
association between the GBS prevention strategy and the annual change in each of the eight 
outcomes for 17 compositional covariates. I selected each covariate, a priori, for a specific 
reason to account for geographic, economic, health system and population characteristics 
(related to EOGBS) as well as the methodological differences (see Table 14).  
The frequency of each compositional covariate varied as shown in the frequency column in 
Table 14. For some compositional covariates, there was only one value which was the same 
for each observational year for each geographical area, meaning that for each geographical 
area the data values did not differ across the years. This is because these data were either the 
most recently recorded data for the geographical area (e.g. prolonged rupture of membranes, 
intrapartum fever) or these data did not vary naturally across the years (e.g. world region, age 
of onset definition). For other covariates, data were available across years, therefore, the data 
values for each geographical area differ across years.     
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Table 14. Compositional covariates adjusted for in the ecological studies  
Category Covariate Variable type and categorical 
levels 
Frequency 
Geographic  Region Categorical: Asia, Europe, Latin 
America, North Africa and the 
Middle East, North America, 
Oceania, Sub-Saharan Africa 
Constant 
over time 
Economic Human development 
index 
Continuous  Annual 
rates 
Health System  % of skilled attendance 
at delivery 
Continuous  Annual 
rates 
Per capita government 
expenditure on health 
(PPP int $ [purchasing 
power parity 
international dollars) 
Continuous  Most recent 
rate 
Population % preterm births Continuous  Annual 
rates 
% low birthweights Continuous  Annual 
rates 
% caesarean section Continuous  Annual 
rates 
Fertility rate Continuous  Most recent 
rate 
Average maternal age Continuous  Most recent 
rate 
Multiple or twin births 
/1000 births 
Continuous  Most recent 
rate 
% maternal GBS 
colonisation 
Continuous  Most recent 
rate 
% prolonged rupture of 
membranes 
Continuous  Most recent 
rate 
% intrapartum fever Continuous  Most recent 
rate 
Most prevalent GBS 
serotype 
Categorical: Ia, Ib, III, V Most recent 
rate 
Methodological Type of surveillance Categorical: Mandatory/enhanced 
population surveillance, Voluntary 
population surveillance, Multiple 
centres, One centre 
Constant 
over time 
Geographical coverage Categorical: National, Regional, 
City/town wide, One centre 
Constant 
over time 
Age of onset definitions Categorical: Constant 
over time  EOGBS: 2/3 days or less, 5/6/7 days 
or less, vertical onset, not stated   
Early-onset E. coli: 2/3/4 days or 
less, 5/6/7/8 days or less, mother-
infected, not stated 
Early-onset sepsis: 2/3/4 days or 
less, 5/6/7 days or less, vertical 
onset or mother infected, not stated 
LOGBS: 2/3/4 to 28/90 days, 
5/6/7/8 to 13/27/28/30/60/90/365 
days 
48 hours to 6 days, not stated 
EOGBS early-onset group B Streptococcus, E. coli Escherichia coli, GBS group B Streptococcus, LOGBS late-
onset group B Streptococcus disease, % percentage 
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9.4 Data collection 
To access data for the outcomes within 194 countries recognised by the United Nations, I 
identified healthcare institutions in each country through systematic Internet and literature 
searches as well as the research team and the UK NSC’s international knowledge of all 
surveillance and public health institutions. I approached key institutions involved in 
surveillance related to maternity and childbirth, paediatric conditions, infectious disease and 
health-care in each country. To recruit institutions, I used the snowball sampling technique, 
in which a researcher makes initial contact with a group of participants relevant to the research 
topic and then uses these to establish subsequent contact with other relevant participants.350  
Once institutions were identified, I initially contacted them by email, explained the studies, 
their aims and the processes involved. I informed the institutions that participation was 
voluntary and that, because aggregate figures were required, the information was anonymous. 
If the institution was interested in participating, I sent the study information leaflet (see 
Appendix 12) to the relevant person in the institution. If they agreed to participate, I contacted 
the individual by telephone to discuss the project and asked them to email the annual aggregate 
data by filling in the survey questionnaire which was sent via email or in whichever software 
it was available. Once the data were received, I thanked the individual and addressed any 
questions.  
 
9.5 The questionnaire 
The self-completion questionnaire was available in Microsoft Word or Microsoft Excel format 
(see Appendix 13). Respondents were to complete the tables with data for the outcomes, 
predictor variable and compositional covariates available to them across different years for 
their geographical area. Questions included the following outcomes: the geographical area 
covered, the type of surveillance, the number of livebirths in the area, the number of early-
onset, late-onset, all neonatal GBS, E. coli, all-cause sepsis cases and their definitions and the 
number of GBS antibiotic resistance cases. The questionnaires also included the number or 
percentage of various risk factors such as preterm births, low birthweights, caesarean section, 
multiple births, prolonged rupture of membranes, intrapartum fever, maternal GBS 
colonisation as well as the GBS prevention strategy and the most prevalent GBS serotype. 
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9.6 Data collection for wider compositional covariates and 
variables unavailable from survey questionnaires  
I acquired data describing the wider aspects of each country’s economy, health system and 
population through international websites, including the World Health Organization, United 
Nations, the World Bank as well as through existing literature. In addition, if data on the 
compositional covariates were not provided in the surveys, I also collected these from the 
international websites. This means that for some lower level geographical areas such as 
regions, cities or centres, I assigned the data for the covariates from national level data 
obtained through international websites and literature. Table 15 shows the exact data source 
used for each covariate.  
Table 15. Data sources for compositional covariates  
No. Covariate Data source 
1 GBS maternal colonisation prevalence Kwatra et al. (2016)30 
2 Most prevalent GBS serotype Kwatra et al. (2016)30 
3 Preterm births Blencowe et al. (2012)351 
4 Low birthweights UNICEF & WHO (2004)352 
5 Caesarean section WHO353-356 
6 Multiple/twin births Developed countries: Pison et al. 
(2015)357 
Developing countries: Smits et al. 
(2011)358 
7 Fertility rate UN359 
8 Average maternal age UN360 
9 Skilled attendance at delivery WHO353-356 
10 Human development index UNDP361 
11 Per capita government expenditure on health 
(PPP int $) 
WHO362  
GBS group B Streptococcus, UN United Nations, UNDP United Nations Development Programme, UNICEF 
United Nations United Nations Children's Fund, WHO World Health Organization   
I used a similar process for the GBS prevention strategy (predictor variable) when it was not 
provided in the survey questionnaire. I assigned the GBS prevention strategy from the national 
GBS prevention guideline for geographical areas that did not provide information. 
Consequently, while this GBS prevention strategy might have been the national guideline for 
the country, it is not necessary that every hospital in the geographical area was administering 
the guideline.  
For the five compositional covariates where data were available across years (human 
development index, preterm births, low birthweights, fertility rate and skilled delivery), data 
were available for some years and were missing at random for other years. I statistically 
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imputed the years with missing data using multiple imputation (see Section 9.8). For example, 
for preterm births data were only available for years 2000, 2005 and 2010, so I, statistically, 
imputed data for the years in between. For some geographical areas, compositional covariate 
data were not available for any of the years, from either the survey or international websites. 
In these cases, I imputed data for the covariate from the closest neighbouring geographical 
area (sometimes another region and other times another country) in the dataset. This was the 
best approach as the variables that I statistically imputed using multiple imputation utilised 
data from the context of the geographical areas for which data were being inputted. In Chapter 
10, I have summarised the compositional variables and geographical areas for which I had to 
impute data from other countries and in Table 17, I have detailed them.   
 
9.7 Study size 
I calculated the sample size based on my aim to analyse the difference in the average change 
of annual EOGBS incidence per 1,000 livebirths (the primary outcome of interest) in 
geographical areas implementing one GBS prevention strategy compared with geographical 
areas implementing another. I calculated that a sample size of 63 incidence rate observations 
per GBS prevention group provided an 80% chance of detecting an average annual difference 
of 0.1 per 1,000 livebirths between two GBS prevention groups with 95% confidence.  
 
9.8 Data management and statistical analysis  
I manually entered data from the institutions into a Microsoft Excel sheet and then recorded 
data from the international websites and literature. I exported the Excel sheet into Stata 14.0 
(Stata Corp, College Station, Texas) where I performed all of the analyses. First, I cleaned and 
validated the data by checking for any inconsistencies using the ‘describe’ and ‘summarize’ 
Stata command for each variable, correcting any data errors and renaming and (re)coding 
variables into dummy variables as appropriate. Where data were missing, I imputed the values 
as described below. There were eight different outcomes and each outcome had its own 
imputation model and analysis model. Therefore, I separately followed the steps indicated in 
the sections below for each of the eight outcomes.  
The initial statistical plan of analysis for all of the studies involved imputing and analysing 
the data using repeated measures multi-level analyses in order to account for the hierarchical 
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structure of the data (outcomes for each year were nested in the geographical areas). I 
attempted to account for this multi-level structure when imputing the data for the missing 
observations in the five compositional covariates by using the Stata command ‘Realcom-
Impute’.363 However, due to the limited number of fully observed years, multi-level data 
imputation did not work and imputed values could not be generated. As multi-level imputation 
was not feasible neither was multi-level analysis.  
Alternatively, I applied linear regression analysis to analyse the trends in outcomes. 
Regression analysis has been discussed in the literature as a tool to predict trends343, 344 and 
has been previously utilised in other areas of public health and epidemiology to analyse trends 
across time.364-368 Furthermore, as the observations were at the ecological level, the required 
linear regression assumption that observations must be independent is not as problematic as 
the observations are not related to the same participants/individuals. For the primary outcome 
of EOGBS, in addition to the linear regression trend analysis, I modelled a repeated measures 
multi-level analysis. As the data in the analysis could not be multiple imputed to account for 
the hierarchical structure, I analysed a multi-level model on fully observed data only, known 
as the complete case analysis.369, 370 As there were few fully observed covariates, I only 
analysed an unadjusted multi-level model (with no compositional covariates).  
9.8.1 Multiple imputations for compositional covariates 
There were five annually reported covariates that had data available for some years but not 
for others. These were the percentages of preterm births, low birthweights, caesarean sections, 
skilled deliveries and the human development index. To avoid losing data and increase 
statistical power in each model, I used multiple imputation so that all observations (or years) 
of outcomes could be included. First, I calculated the amount of missingness in each of the 
covariates using the ‘misstable summarize’ Stata command, which calculates the number of 
observed and missing cases for each covariate.371 I then assessed the missingness mechanism. 
As the reason for missing data among these variables was that the sources only reported data 
for certain years and not for others, I concluded that data were missing at random. 
Nevertheless, I investigated the specific missingness mechanism using the ‘misstable patterns’ 
Stata command, which shows the patterns of the observed and unobserved observations for 
covariates with missing data across the dataset.371 Finally, I created a variable to identify 
whether a covariate was missing or observed using the ‘misstable sum, gen( _)’ Stata 
command. I then performed logistic regressions on each variable investigating whether the 
probability of each covariate with missing data was associated with the outcomes, predictors, 
and all compositional variables from the analysis model.372 This indicated whether the missing 
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values were missing completely at random (and unrelated to the other variable data) or missing 
at random (and dependent on other variables).369  
To impute the data for the covariates in each model, I used multiple imputation using chained 
equations (MICE). MICE fills in missing observations iteratively using a sequence of 
univariate imputation methods with fully conditional specification (FCS) of prediction 
equations.373, 374 MICE is a flexible approach that accommodates missingness patterns that are 
arbitrary.370, 375, 374 The specific MICE model was predictive mean matching (PMM); a semi-
parametric method that combines standard linear regression and nearest-neighbour imputation 
approaches, allowing the missing values to be imputed using the observed value with the 
closest predicted mean.370, 376 PMM is more robust than a fully parametric regression MICE 
model as it uses linear regression to obtain linear predictions and then randomly draws an 
imputed value from a set of nearest neighbouring donors with complete values. By drawing 
from the observed values, the advantage of PMM is that it preserves the distribution of the 
observed values.377 PMM was appropriate for the aims because the covariates with missing 
data were percentages whose parameters were bounded from 0-100% or 0.00-1.00. By using 
PMM, missing data were never outside these bounds and were, therefore, plausible. 
Furthermore, from an initial examination of the data, the covariates had particular skewed 
distributions that needed to be accounted for by the missing data. When using PMM, I set the 
number of nearest neighbours (to consider as donors) at 10 or ‘knn(10)’ based on the 
recommendation by Morris, White and Royston (2014).376  
For the multiple imputation models, the outcomes were the variables with missing data 
(preterm births, low birthweights, caesarean section, skilled delivery and the human 
development index) and the covariates that were regressed onto the outcome to obtain the 
missing values were: the relevant outcome of the analysis model (e.g. EOGBS, LOGBS, early-
onset E. coli or sepsis, etc.), the predictors of the analysis model (prevention strategy, year 
and the interactions between year and prevention strategy [see Section 9.8]) and every 
compositional covariate of the analysis model. It is recommended that the larger the missing 
data, the bigger the number of imputations.370 I set the number of imputations to 100 due to 
the small sample sizes of the fully observed data where only approximately 60 observation 
years had complete data for all the years for each of the covariates. I evaluated the sufficiency 
of using 100 imputations by assessing the convergence of imputations on post-imputation 
diagnostic plots for MICE (see paragraph below) and by assessing the largest fraction of 
missing information (FMI) in the analysis model. The rule of thumb is that M (number of 
imputations) ≥	100	x	FMI provides an adequate number of imputations for analysis.370  
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After running the imputation models, I used multiple imputation diagnostics to assess the 
reliability of the imputation. I used trace plots to ensure that convergence of the data was 
achieved, meaning that the algorithm used for data augmentation reached an appropriate 
stationary state.375 Trace plots show the estimated parameters against the iteration numbers 
for each of the five imputed variables. They allow judgement on whether the predicted values 
remain constant and do not show a trend, as well as the number of iterations it took to achieve 
a stationary phase.378, 375 To do this, I saved a trace file containing the mean and standard 
deviation of each variable in each iteration. I reshaped the data into time series and used the 
Stata command ‘tsline’ to plot the iteration on the x-axis and the predicted values on the y-
axis. If the data showed signs of not converging, I increased the number of iterations in the 
imputation model. Finally, I also examined the descriptive summary statistics for the imputed 
datasets and compared them with the original dataset.  
There has been an ongoing debate in the literature about whether data should be transformed 
and then imputed or vice versa to account for non-linear effects in the data.370, 379 For the data 
available to address objectives 4 to 6, I considered many methods and chose PMM which is 
one approach to alleviate effects of model misspecification.379 I considered the recommended, 
substantive model compatible FCS, which involves specifying the analysis model of interest 
and imputing each variable compatibly with the analysis model.379 However, with only 
approximately 60 observations being fully observed, the substantive model compatible FCS 
model did not work and valid imputed values could not be generated. Likewise, I also 
considered the ‘Just Another Variable’ approach,380 where data are first transformed and then 
imputed as just another variable. Again, because of the few initial observations, the 
relationships between the covariate with missing data and the outcomes were difficult to assess 
and transform because of issues such as collinearity. Furthermore, the relationships between 
the variables changed after imputation when more data were used for analyses. Therefore, 
PMM approach as the most appropriate for this context and I transformed the data after 
imputation. Indeed, PMM can provide results comparable with the results from the ‘Just 
Another Variable’ approach.370 Importantly, there was no missing data in the predictor 
variable of interest (interaction of year with prevention strategy) or the outcomes, and so the 
compositional covariates were transformed using the best available solution. The missingness 
data mechanism in these variables was also missing at random due to data collection and 
estimation in some years and not others, minimising the bias from imputation.  
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9.8.2 Descriptive analyses 
The descriptive statistics entailed exploratory analyses of the outcomes, predictors, and 
compositional covariate variables. I reported means and standard deviations for the continuous 
variables in tables and text (livebirths; EOGBS, early-onset E. coli, early-onset sepsis, and 
LOGBS per 1000 livebirths; percentage EOGBS and neonatal GBS resistant to clindamycin 
and erythromycin; percentage skilled delivery, preterm births, low birthweights, caesarean 
section, multiple births, maternal GBS colonisation, prolonged rupture of membranes, 
intrapartum fever; fertility rate, maternal age, per capita government expenditure on health, 
the human development index). I also described frequencies and percentages for the 
categorical variables in tables and text (GBS prevention strategy, region, most prevalent GBS 
serotype, type of surveillance, geographical coverage, age of onset definition). Finally, I 
tabulated the averages (mean and standard deviation [SD]) of the outcomes for each 
geographical area, year, world region and each GBS prevention strategy along with a 
scatterplot.  
9.8.3 Unadjusted linear regression analyses 
After analysing the descriptive statistics, I analysed the unadjusted relationship between each 
outcome variable and the predictor, most recently reported GBS prevention strategy, in 
separate linear regression models for multiple imputed data, using the Stata command ‘mi 
estimate: regress’. This command runs a linear regression on the multiple imputed data and 
estimates model parameters by adjusting coefficients and standard errors for the variability 
between imputations according to Rubin’s rules.381, 382, 373, 370  To investigate the difference in 
the average annual change in each outcome between areas that most recently reported 
screening with areas that most recently reported other GBS prevention strategies, I interacted 
the prevention strategy and the year and regressed this to the outcome per 1,000 livebirths or 
percentage. While the main effect of the year and prevention strategy were included in the 
model, the most important term was the interaction between year and GBS prevention strategy 
as this revealed the difference in the average annual change in the outcomes between screening 
compared with another GBS prevention strategy. I presented the analyses using the 
coefficients for each of the most recently reported GBS prevention strategies and their 95% 
CI and p-values. The coefficients show the difference in the average annual change in the 
outcome, between each GBS prevention strategy and the baseline prevention strategy. Most 
often, the baseline prevention strategy was universal GBS screening, however, for antibiotic 
resistance outcomes, the baseline was no prevention strategy, as I was interested in resistance 
rates in risk-based compared with no prevention.  
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To present the outcome trends across time graphically and aid the interpretation of the trend 
analysis for each of the most recently reported GBS prevention strategies calculated by the 
models, I used the STATA command ‘mimgrns’. ‘Mimgrns’ is the multiple imputation 
equivalent of the ‘margins’ post-estimation command for linear regression.383 Margins provide 
estimates of the outcomes that are calculated from predictions of a model for specified values 
of covariates.384 Once the margin estimates are generated, they can be plotted using 
‘marginsplot’. Using these methods, I obtained estimates for each outcome for each year under 
different GBS prevention strategies and was able to plot these trends graphically.  
For the compositional covariates, that were later used for adjustment purposes, I investigated 
the relationship between the covariate and the outcome per 1,000 livebirths or percentage 
itself, but not the trend. I analysed the unadjusted relationship between each outcome variable 
and each compositional covariate in separate linear regression models for multiple imputed 
data, using the same Stata command ‘mi estimate: regress’. I also presented these analyses 
using the coefficients and their 95% CI, as well as the p-values. The coefficients here show 
the differences in the mean outcome and not the trend. 
9.8.4 Adjusted linear regression analyses 
After the unadjusted analyses, I performed an adjusted linear regression for multiple imputed 
data to identify the independent association between the most recently reported GBS 
prevention strategies and the average annual change for each outcome, after statistically 
controlling for the compositional covariates. Using ‘mi estimate: regress’, I regressed the main 
effect of, and interaction between, year and GBS prevention strategy (to account for the trend 
in each prevention strategy) as well as the compositional covariates onto each outcome. I only 
included compositional covariates that were statistically significant at a probability level of 
p<0.20 in 2-sided t-tests in the unadjusted analyses. I chose a probability level higher than 
p<0.05, because adding covariates together in regression models can influence a covariate that 
was not associated with the outcome on its own, to become associated. 
To generate a minimal adjusted model, I used a backwards elimination process, whereby I 
removed covariates that had low explanatory power (in combination with the others) one at a 
time, only including variables that were statistically significant at p<0.05 in 2-sided t-tests. 
The exception was a list of covariates that I decided, a priori, were important adjustments that 
would be included in the final model even if they were not statistically significant at p<0.20 
in the unadjusted models or p<0.05 in the adjusted model. The a priori list for EOGBS and 
LOGBS consisted of: preterm births, low birthweights, maternal GBS colonisation, prolonged 
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rupture of membranes and intrapartum fever (as they are known strong risk factors of EOGBS) 
and the human development index, world region, surveillance type, geographical coverage, 
and outcome definition (to account for crucial limitations in the data collection methods). The 
a priori list for the analyses of the remaining outcomes was shorter as the sample sizes were 
considerably smaller, therefore, the model needed to be simplified. The list included: preterm 
births and low birthweights (as they are important risk factors), and the human development 
index, geographic region, surveillance type, geographical coverage and outcome definition (to 
account for crucial limitations in the data collection methods).  
Currently, the recommended methods for running regression diagnostics on multiple imputed 
data are to run the diagnostics separately for a few imputed datasets.370, 385 Therefore, I ran 
regression diagnostics for the minimal adjusted models separately for five imputed datasets to 
check that the residuals met the assumptions of linear regression. I used five datasets as this 
was sufficient to get consistent results. The diagnostic plots I created to check the assumptions 
were the residual-versus-fitted plots, kernel density plots, standardised normality plots (pnorm 
and qnorm) and augmented component-plus-residual plots.386 I tested these assumptions using 
Cameron & Trivedi’s Information Matrix-test387 and Breusch-Pagan/Cook-Weisberg test388, 
389 for heteroscedasticity, the linktest390 and ovtest391 for regression model specification and 
the variance inflation factor test (VIF test) for the collinearity of continuous covariates.386, 392 
When assumptions were not met, particularly for linearity, I transformed the covariates using 
the most appropriate transformation according to the relationship, the normality and the 
natural measurement of the covariate. Once linearity was achieved and all the assumptions 
were reasonable for the models, I re-ran the multiple imputed regression models with the 
transformed covariates. If the assumptions of heteroscedasticity or normality were not 
strongly supported in the diagnostic analyses, I calculated robust standard errors.393 If any 
compositional covariates were no longer significant at p<0.05 in the model with transformed 
data, I removed them (except those on the a priori inclusion list) and re-ran the regression 
diagnostics. This process continued until the regression assumptions were sufficiently met and 
minimal models were achieved.  
These adjusted minimal regression models on multiple imputed and then transformed data 
were considered the final models. I calculated the adjusted R2 for the final models, which 
informs the amount of variance accounted for in models, by using the Stata command ‘mi 
beta’ designed for models on multiple imputed data.394 Finally, I used the command ‘mi test’ 
to compare GBS prevention strategies with strategies other than the baseline.395 The regression 
equation for the models was:  
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YOutcome = αIntercept + β1 × Years + β2 × Prevention strategy + β3 × Years*Prevention 
Strategy+ βK × Compositional Covariate K… + ƐError 
Similar to the unadjusted analysis, the final adjusted models compared the average annual 
change of outcomes in each of the most recently reported GBS prevention strategies with the 
baseline prevention strategy (most often universal GBS screening, but no prevention strategy 
for antibiotic resistance outcomes, as stated above). I presented the adjusted differences in the 
average annual change of the outcome, by different GBS prevention strategies (adjusting for 
the compositional variables), using the coefficients for each GBS prevention strategy 
(compared with the baseline prevention strategy), along with their 95% CI and p-values. In 
addition, I also reported the adjusted R2 of the model. To present, graphically, the outcome 
trends for each GBS prevention strategy (adjusted for compositional covariates), I used the 
Stata command ‘mimgrns’ and ‘marginsplot’ (as described above). 
9.8.5 Sensitivity analyses 
When the average annual change of the outcome was statistically different (p<0.05) by most 
recently reported GBS prevention strategy in the final model, I tested the stability of the results 
in sensitivity analyses. This was especially necessary due to the anticipated differences in the 
data collected across geographical areas. I re-ran the final model with the following sensitivity 
changes: 
a. Restricting the analysis to outcome data that were from two or more centres (i.e. 
excluding data from one centre only). Data that are mandatory and large scale are more 
accurate than small centre-based studies, especially as the outcomes were relatively 
infrequent (e.g. EOGBS incidence is only around 0.5 per 1000 livebirths). Therefore, the 
larger the sample size coverage the more stable and accurate the incidence rates. Ideally, 
I would have restricted the data to the mandatory national or regional level only, however, 
this was not possible due to the limited data available at these levels. As an alternative, I 
excluded data from only one centre although this meant that voluntary data and data from 
a few centres only were included.  
b. Restricting models to data with the most appropriate definition of the outcome (e.g. 5/6/7 
days or less for early-onset and five days onwards for late-onset). As described in Chapter 
2, less than seven days is considered early-onset disease and attributed to maternal 
transmission, while seven to 98 days is considered late-onset and can be transmitted from 
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other sources.3 As the definitions of early-onset varied across geographical areas, I 
selected the closest definition to seven days and ran the final model with only the outcome 
data defined as such.  
c. Restricting models to geographical areas that provided four or more years of data. The 
number of years provided by institutions varied, with some that only provided data for 
one year. Only including areas with four or more years of data may be more accurate as 
the trends would be more stable. Therefore, a sensitivity analysis tested this. 
d. Restricting models to outcome data that were within the outer fences of a box plot (i.e. 
removing extreme box plot outliers). The box plot divides data into four boundaries based 
on the interquartile ranges (IQR): two are the inner fences and two are the outer fences. 
Outer fences are “Q1-3 IQR and Q3+3 IQR”, and any data points beyond these 
boundaries are considered extreme outliers.396 p2 Outer fence outlier data are usually the 
furthest away, even past the whiskers (inner fences) of a box plot.396 For this sensitivity 
analysis, I calculated the outer fences and removed those data lying beyond the outer 
fences on the right side of the distribution. The outer fence on the left side was less than 
zero even though the most extreme value on the left side could only be zero, therefore, 
there were no data to remove. Box plot outliers are only explanatory, thus, I only used 
them for the purposes of exploring the sensitivity of the models. I analysed the outer 
fence outliers as they are generally more accurate at identifying unusual distributions 
compared with inner fence outliers.396  
e. Restricting models to compositional variables where only less than 10% of the data were 
imputed from another country. Data from the same country are more accurate than those 
imputed from neighbouring countries, thus, I tested whether the results changed if only 
these variables were included. This meant including only the following compositional 
covariates: region, preterm births, low birthweights, surveillance type, geographical 
coverage and outcome definitions.  
f. Using only survey data for the compositional covariates (i.e. removing data from 
international websites, except naturally occurring wider covariates, such as the human 
development index that are only available from international websites). The 
compositional data from the survey questionnaires match the geographical area from 
where the outcome data were provided. On the other hand, data from the international 
websites may be averaged from many different regions across the entire country and may 
not reflect the context of the particular area the outcome data were from. For example, 
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data were provided for Emilia-Romagna, a region in the north of Italy that is known for 
having better economic and health indicators than the south of Italy.397, 398 Compositional 
data, averaged for Italy as a whole, may differ from the specific context of Emilia-
Romagna. In this analysis, I checked the impact of this difference on the results. I first 
re-ran multiple imputation on the survey data alone in order to impute missing 
observations. This included data that were previously missing and data that were now 
missing due to the removal of international website data. I then re-ran the final model on 
this new multiple imputed dataset.  
g. Using a different ‘most prevalent’ GBS serotype for geographical areas where more than 
one was reported from the data source. For the main model, I selected the serotype using 
the most commonly reported serotype across the years with provided data or the study 
with the largest sample size where more than one study was available in the literature. In 
this analysis, I selected the alternative serotype and re-ran the final model.  
h. Using alternative maternal GBS colonisation rates for geographical areas where more 
than one rate was available. Similar to the analysis for serotype, for the main model I 
selected the colonisation rate using the most commonly reported rate across the years 
with provided data or the study with the largest sample size where more than one study 
was available in the literature. For this sensitivity analysis, I selected the alternative lower 
and/or higher rates separately and re-ran the final model.  
i. Using alternative data sources for geographical areas where more than one institution 
provided data for overlapping areas. Similar to using survey data only, I first re-ran the 
multiple imputation on the alternative sources of data in order to impute missing 
observations. I then re-ran the final model on this new multiple imputed dataset to assure 
confidence in the results.  
j. Replacing the GBS prevention strategy that was the most recently reported (predictor 
variable) with the GBS prevention strategy that was the most frequently reported across 
the years with outcome data. As discussed in Section 9.3, I created a variable for the most 
frequently reported GBS prevention strategy for each geographical area using the dates 
reported by some institutions as well as the dates reported on GBS prevention guidelines. 
As mentioned in Section 9.3, although this was not the most accurate predictor, it was 
important to have a comparison between the use of the most recently reported GBS 
prevention strategy as the predictor variable with the most frequently reported one across 
the years.  
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9.8.6 Repeated measures multi-level analyses for EOGBS trends 
As mentioned above, I only performed the repeated measures multi-level analysis on the 
EOGBS data as it this was the primary outcome and was the study with statistically significant 
results. I ran a two-level linear growth curve model on the fully observed data in the EOGBS 
dataset using the STATA command ‘mixed’.399, 400 A growth curve model is a type of random 
slopes model with time as the x-axis and time observations clustered within individuals (or 
within geographical areas for the purposes of this study). Like other multi-level models, 
growth curve models allow the estimation of within and between differences, i.e. between 
geographical area differences and within geographical area differences.401, 402 The within-
geographical patterns of change are the time trends or growth curves.401 The EOGBS 
observation years (level 1) were nested within the geographical area from which the data 
originated (level 2). The outcome variable was the average change in annual EOGBS 
incidence per 1,000 livebirths and the predictor variable was the GBS prevention strategy.  
The growth curve model consists of fixed and random effects that display the trends of 
EOGBS incidence. The fixed effect represents the mean intercept of EOGBS incidence and 
the mean slope (or change) in the EOGBS incidence across the entire sample of geographical 
areas. On the other hand, the random effect represents the between-geographical area 
variability in the geographical area intercepts and slopes for EOGBS incidence.401 The model 
was a growth curve model with an interaction between the year and the most recently reported 
GBS prevention strategy as a fixed effect, year centred at 2005 (this was around the mean 
year) random at the level of the geographical area and no compositional variables in the model. 
As this was a complete case analysis (because multi-level multiple imputation did not work) 
and there were few fully observed covariates, I was unable to adjust for the compositional 
covariates. 
As per the linear regression analyses, I reported the differences in the trends of EOGBS 
incidence for each GBS prevention strategy compared with universal GBS screening (fixed 
effect) using their coefficients with their 95% CI. I also calculated margins for the models and 
plotted the trends graphically using margin plots as described above. In addition, I reported 
the between geographical area variance in the intercept at year 2005 (variability in the EOGBS 
incidence at year 2005 by geographical area) the slope (variability in the pattern of EOGBS 
incidence by geographical area), and the intercept-slope (the joint variability between the 
geographical area intercept and slopes). I also reported the within geographical area variance, 
which is the variability across the years within geographical areas.  
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9.9 Ethical approval  
This study was ethically approved by the University of Warwick Biomedical and Scientific 
Research Ethics Sub-Committee, BSREC reference: REGO-2014-777 (see Appendix 14). As 
the data provided were aggregated at the level of the centre, region, or country, they were 
anonymous and formal consent was not required. I clearly informed institutions of this on the 
study information sheet. I also told them to make a free decision, reassured them that that there 
would be no consequences if they chose not to provide data, and that they were free to 
withdraw their data at any time without giving any reason. I stored the aggregate data in a 
password protected laptop during the studies, and will store and archive the data as per 
University policy once the studies are completed.  
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10. GENERAL DESCRIPTION OF DATA COLLECTED 
FROM SURVEYS FOR OBJECTIVE 4 TO 6 
As discussed in Chapter 9, the data on the outcomes, the predictor and some of the 
compositional covariates for the three ecological trend analysis studies were collected by 
sending one survey across institutions worldwide. The remaining compositional covariates 
were collected from the same international sources (see Chapter 9 for more details on the 
methodology). As the data were collected using the same surveys and sources, in this chapter, 
I summarise an overview of the collected outcomes, predictors and covariates across the 
geographical areas. In some cases, the provided data covered geographical areas that overlap. 
In the chapters that follow, I summarise the outcomes, predictors and covariates only for the 
selected geographical areas with the best available outcome data (widest coverage or best 
surveillance type) for areas where data overlap. I then only use the areas excluded from the 
main analysis, in the sensitivity analysis. In the sections below, Table 16 and Table 17 I 
summarise the overall outcome, predictor and compositional data collected, the geographical 
areas that these data are from, the surveillance and geographical coverage and the sources for 
the compositional data. I also provide the average rates of the outcomes and the compositional 
variables. 
 
10.1 Data collected 
I advertised the study to 520 institutions across 167 countries. There were five identified 
institutions whose contact details I could not find (one covering Asia, one in India, one in 
Argentina and two in Slovakia) and two whose contact details did not work (one in Saudi 
Arabia and one in Brazil). Of the 520 institutions contacted, some of the institutions were 
international and covered more than one country. Altogether, 467 institutions did not provide 
data: 257 did not respond, 158 did not have available data, 29 did not have the availability, 
resources or had management issues, for example, were unable to obtain ethical approval from 
their institution altogether or by the time data collection ended, eight did not send data after 
initially agreeing to participate, seven either did not have their data ready yet or had yet to 
publish them so could not share, seven did not want to participate or did not want to share data 
and one required payment which was not possible. Six of the institutions that provided 
outcome data referred me to other institutions that covered the same geographical area to 
provide data on the compositional covariates. Of the six institutions suggested, three provided 
Antenatal screening for group B Streptococcus in the UK	
	 166 
data or referred me to the website to collect data myself, while one did not respond and two 
did not have the data. One institute covering Ontario and one covering Norway provided 
compositional covariate data and one online database covering England was suggested, from 
which I extracted data. 
Altogether, 53 institutions provided outcome data across 60 geographical areas. However, I 
excluded data from one institution in Hebei, China, as the denominator was the number of 
neonates in an NICU, instead of livebirths. This may over-represent the number of diseases in 
a population and not be comparable with data from other countries. This left 52 institutions 
across 59 geographical areas. One institution provided outcome data on three different 
geographical areas in South Africa (two different hospitals in Johannesburg and the township 
of Soweto) and one institution provided outcome data on six different geographical areas 
within the British Isles (England, Northern Ireland, Republic of Ireland, Scotland, Wales and 
the United Kingdom and Republic of Ireland combined). Table 16 shows the geographical 
areas for which I collected data for each outcome. There were EOGBS data from 55 
geographical areas, early-onset neonatal sepsis and early-onset E. coli data from 28 areas, 
LOGBS data from 47 areas, EOGBS clindamycin resistance from 23 areas, EOGBS 
erythromycin resistance data from 24, neonatal GBS clindamycin resistance from 17 areas 
and neonatal GBS erythromycin resistance from 19 areas. 
Table 17 shows the data source for each compositional covariate: survey data, international 
websites or imputed from neighbouring countries. There were five geographical areas or 
institutions from North America, four from Oceania, eight from Asia, 27 from Europe, eight 
from Latin America and the Caribbean, four from Sub-Saharan Africa and three from North 
Africa and the Middle East. Data for the human development index, skilled attendance at 
delivery, mean government expenditure on health and fertility rate were from international 
websites, and as such, were at the national level for each geographical area. Data for the 
average maternal age were from international websites for all areas, except six (Buenos Aires, 
Cordoba, Guangzhou, Kuwait, Macau and Mauritius) for which I imputed data from the 
closest neighbouring area. Data for preterm births were from the survey questionnaires for 23 
geographical areas and from international websites for 36 areas while data for low 
birthweights were from survey questionnaires for 27 areas and from international websites for 
32 areas. Data for caesarean sections were from survey questionnaires for 21 areas, from 
international websites for 36 areas and I imputed data from a neighbouring country for 
Singapore City. Data for multiple births were from international sources, except for 14 areas 
where the data were from surveys and 10 that I imputed from the nearest neighbouring area. 
Maternal GBS colonisation rates were from surveys for 25 areas, an international source for 
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25 areas and I imputed data from the closest neighbouring area for nine areas. Data on the 
most prevalent serotype were provided in surveys for 21 areas, from international sources for 
eight areas and I data from neighbouring areas for 30 areas. Data for prolonged rupture of 
membranes were from surveys for 17 areas and I imputed them from neighbouring areas for 
42 areas, while data for intrapartum fever were from surveys for 14 areas and I imputed them 
from neighbouring areas for 45 areas. Evidently, few data were available for prolonged rupture 
of membranes and intrapartum fever, however, as these compositional covariates were 
important for EOGBS, I imputed them from the other countries so that the models had some, 
rather than no, adjustment. 
 
10.2 General characteristics of the data 
There were 59 geographical areas across 42 countries. Data from 26 areas had national 
coverage, three had regional coverage, two had city or town wide coverage and the remaining 
were from one centre in a city or town. Data for 11 areas were from mandatory or enhanced 
population surveillance, nine from voluntary population surveillance, 11 from multi-centre 
surveillance and the remaining were surveillance from one centre. 
Table 16 shows the mean outcome rates for each geographical area (across the years) and a 
total mean rate across all geographical areas and years is provided below. Note that the total 
mean outcome rate provides an overview of the data collected, however, as some of the areas 
overlap, there may be double counting. Therefore, the overall mean outcome rates provided 
in the separate chapters are more accurate. The years ranged from 1989 to 2015 and the 
livebirths ranged from 414 to 4,316,233. The mean EOGBS incidence was 0.55 per 1,000 
livebirths (SD 1.48) and it ranged from 0.00 to 28.99 per 1,000 livebirths. Mean early-onset 
sepsis was 4.60 per 1,000 livebirths (SD 8.79), and it ranged from 0.00 to 72.46 per 1,000 
livebirths. Mean early-onset E. coli was 0.42 per 1,000 livebirths (SD 1.99), and it ranged 
from 0.00 to 28.99 per 1,000 livebirths. The mean LOGBS was 0.37 per 1,000 livebirths (SD 
1.37), ranging from 0.00 to 24.15 per 1,000 livebirths. The disease incidence rates of 0.00 per 
1,000 livebirths might be a result of diagnostic related issues, voluntary surveillance or too 
small a sample size to detect cases. The highest incidence rates of all of the disease outcomes 
across the board were in Mansoura city, Egypt. The mean percentage of EOGBS cases 
resistant to clindamycin was 15.57% (SD 29.22) and resistance to erythromycin was 19.22% 
(SD 30.08), both ranging from 0.00 to 100.00%. The mean percentage of neonatal GBS 
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resistant to clindamycin was 14.73% (SD 25.01) and the mean percentage of neonatal GBS 
cases resistant to erythromycin was 15.33 (SD 21.75), both ranging from 0.00 to 100.00%. 
Table 17 shows the averages for the predictor variable and the compositional covariates across 
geographical areas. Twenty-six centres, regions, or countries most recently reported a 
universal GBS screening programme, 22 reported a risk-based prevention strategy, three 
reported either a screening or risk-based strategy (two of which were Australia) and eight 
reported no prevention strategy. The mean human development index was 0.83 (SD 0.09), the 
mean percentage of skilled deliveries was 97.80% (SD 4.98) and the mean government 
expenditure on health was $3,502.46 (SD 2,268.15). The mean percentage of preterm births 
was 8.96% (SD 3.70), the mean percentage of low birthweights was 8.88% (SD 6.73) and the 
mean percentage of caesarean sections was 25.84% (SD 10.09). The mean fertility rate was 
1.83 per woman (SD 0.45), the mean maternal age was 26.39 (SD 3.21) and the mean multiple 
or twin birth rate was 17.29 per 1,000 livebirths (SD 12.44). The mean maternal GBS 
colonisation was 20.85% (SD 10.05, range 0.14 to 44%) and the most prevalent GBS serotype 
was serotype III. Finally, the mean percentage of prolonged rupture of membranes was 7.08% 
(SD 6.24) and the mean percentage of intrapartum fever was 1.51% (SD 2.30). 
In the following three chapters, I will focus separately on the results on each outcome.  
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Table 16. Outcomes collected for objectives 4 to 6 
No Area Country Surveillance type Geographical 
coverage 
Overall 
Years 
Mean 
Livebirths 
(SD) 
Mean 
EOGBS 
(SD) 
Mean early-
onset sepsis 
(SD) 
Mean 
early-onset 
E.coli (SD) 
Mean 
LOGBS 
(SD) 
Mean EOGBS 
clindamycin 
resistance (SD) 
Mean EOGBS 
erythromycin 
resistance (SD) 
Mean neonatal 
GBS clindamycin 
resistance (SD) 
Mean neonatal 
GBS erythromycin 
resistance (SD) 
1 Alberta Canada Mandatory/ Enhanced 
population 
Regional 2003-2013 47,896 
(4854.45) 
0.25 
(0.10) 
0.21 
(0.08) 
- 0.24 
(0.09) 
20.85 
(11.05) 
36.17   
(18.41) 
19.51 
(10.12) 
32.94 
(14.80) 
2 Australia Australia Multi-centre National 2008 847,783 0.38 - - - - - - - 
3 Australia Australia Multi-centre National 2002-2012 29,199.82 
(4802.03) 
0.38 
(0.16) 
2.24 
(0.51) 
0.34 
(0.12) 
0.20 
(0.12) 
- - - - 
4 Bangalore India Multi-centre City/town-wide 2013-2015 4,044.33 
(1605.77) 
0.15 
(0.26) 
5.68 
(0.72) 
0.00 
(0.00) 
0.07 
(0.11) 
- -  - 
5 Barcelona Spain One centre One centre in a 
city/town 
1996-2013 1,776.89 
(247.95) 
0.33 
(0.52) 
0.98 
(0.81) 
0.25 
(0.33) 
0.10 
(0.23) 
0.00 (0.00) 0.00  
(0.00) 
0.00 0.00  
(0.00) 
6 Brno Czech 
Republic 
One centre One centre in a 
city/town 
2010 6,415 0.31 - - 0.00 0.00 0.00 0.00 0.00 
7 Buenos Aires Argentina One centre One centre in a 
city/town 
1996-2013 6,473.22 
(923.54) 
0.14 
(0.20) 
0.68 
(0.32) 
0.13 
(0.12) 
- - - - - 
8 Canada Canada Voluntary population National 2000-2013 - - - - - 22.95 
(5.50) 
56.60  
(17.74) 
22.32 
(7.65) 
56.01  
(13.37) 
9 Canada Canada Voluntary population National 2011-2012 379,037.50 
(1,982.02) 
0.07 
(0.03) 
0.17 
(0.01) 
0.06 
(0.01) 
- 9.98 
(6.68) 
8.51  
(4.60) 
- - 
10 Cordoba Argentina One centre One centre in a 
city/town 
2013-2014 1,573 
(152.74) 
0 .00 
(0.00) 
6.12 
(4.80) 
0.00 
(0.00) 
0.00 
(0.00) 
- - - - 
11 Denmark Denmark Voluntary population National 1999-2013 63,296.47 
(3182.94) 
0.17 
(0.05) 
- - 0.13 
(0.05) 
27.10 
(28.39) 
26.80 
(27.26) 
23.48 
(29.13) 
24.79 
(28.82) 
12 Emilia-
Romagna 
Italy Mandatory/ Enhanced 
population 
Regional 2003-2013 38,686.09 
(2,477.04) 
0.26 
(0.07) 
0.61 0.13 0.30 
(0.10) 
23.81 16.67 - - 
13 England United 
Kingdom 
Mandatory/ Enhanced 
population 
National 2000, 2014 668,696 
(68,071.76) 
0.54 
(0.06) 
- - 0.31 
(0.08) 
- - - - 
14 England United 
Kingdom 
Voluntary population National 1998-2013 629,548.60 
(46,740.74) 
0.35 
(0.03) 
- 0.14 
(0.04) 
0.20 
(0.05) 
5.91   
(5.07) 
9.46   
(7.04) 
  6.44   
(4.88) 
8.79 
(6.48) 
15 Finland Finland Mandatory/ Enhanced 
population 
National 1995-2013 58,576.38 
(1,752.01) 
0.55 
(0.14) 
- - 0.25 
(0.09) 
- - - - 
16 Flanders Belgium Multi-centre City/town-wide 2004-2009 - 0.21 
(0.08) 
- - - - - - - 
17 France France Voluntary population National 1996-2013 570,199.50 
(57,015.64) 
0.36 
(0.19) 
- - 0.22 
(0.04) 
- - - - 
18 France France Voluntary population National 2007-2013 - - - - - 14.90   
(8.42) 
23.27 
(9.16) 
10.35  
(5.09) 
16.58 
(3.04) 
19 Guangzhou China One centre One centre in a 
city/town 
1997-2014 1,820.89 
(488.22) 
0.61 
(0.29) 
7.24 
(3.00) 
2.30 
(1.66) 
0.97 
(0.45) 
100.00   
(81.65) 
100.00  
(81.65) 
43.75   
(33.69) 
43.75 
(33.69) 
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No Area Country Surveillance type Geographical 
coverage 
Overall 
Years 
Mean 
Livebirths 
(SD) 
Mean 
EOGBS 
(SD) 
Mean early-
onset sepsis 
(SD) 
Mean 
early-onset 
E.coli (SD) 
Mean 
LOGBS 
(SD) 
Mean EOGBS 
clindamycin 
resistance (SD) 
Mean EOGBS 
erythromycin 
resistance (SD) 
Mean neonatal 
GBS clindamycin 
resistance (SD) 
Mean neonatal 
GBS erythromycin 
resistance (SD) 
20 Ho Chi Minh Vietnam One centre One centre in a 
city/town 
2011-2013 45,589.33 
(5,934.90) 
- - - 0.04 
(0.03) 
- - - - 
21 Johannesburg South Africa One centre One centre in a 
city/town 
2012 9,028 1.22 - - 1.22 - - - - 
22 Johannesburg South Africa One centre One centre in a 
city/town 
2012 11,894 0.67 - - 0.84 - - - - 
23 Kaunas Lithuania One centre One centre in a 
city/town 
2007-2013 3,524.86 
(194.83) 
1.13 
(0.50) 
5.18 
(2.15) 
0.81 
(0.30) 
0.79     
(0.90) 
- - - - 
24 Kingston Jamaica One centre One centre in a 
city/town 
1991-2010 2,744.69  
(360.63) 
0.69 
(0.40) 
2.59 
(1.03) 
0.18 
(0.40) 
0.33 
(0.31) 
- - - - 
25 Kuala 
Terengganu 
Malaysia One centre One centre in a 
city/town 
2006-2014 12,578.56  
(1141.11) 
0.26 
(0.25) 
0.93 
(0.42) 
0.02 
(0.03) 
0.03 
(0.04) 
3.17    
(8.40) 
19.05 
(26.23) 
3.17    
(8.40) 
19.73 
(27.69) 
26 Kuwait Kuwait One centre One centre in a 
city/town 
2005-2014 11,074.1  
(486.46) 
1.14   
(0.76) 
3.52 
(1.14) 
0.43 
(0.28) 
- 16.31   
(12.20) 
15.44 
(10.60) 
- - 
27 Macau China One centre One centre in a 
city/town 
2005-2014 2,667.70  
(697.83) 
0.64 
(0.70) 
0.84 
(0.77) 
0.08 
(0.17) 
0.68  
(0.66) 
66.67   
42.49 
33.33 
(57.74) 
79.17 
(21.08) 
17.78  
(16.78) 
28 Manila Philippines One centre One centre in a 
city/town 
2014 6,682 0.15 10.18 - 0.00 - - - - 
29 Mansoura 
city- Dakahlia 
Governorate  
Egypt One centre One centre in a 
city/town 
2014 414 28.99 72.46 28.99 24.15 16.67 25.00 18.18 27.27 
30 Mauritius Mauritius Mandatory/ Enhanced 
surveillance  
National 2013 12,986 1.46 - - 0.39 - 0.00 - 0.00 
31 Mexico City  Mexico One centre One centre in a 
city/town 
1995-2013 5,055.11  
(594.00) 
0.27 
(0.22) 
24.52 
(8.20) 
0.96 
(0.84) 
0.99 
(1.40) 
0.00  
(0.00) 
0.00  
(0.00) 
0.00  
(0.00) 
0.00  
(0.00) 
32 Netherlands Netherlands Voluntary population National 1995-2015 190,186.70  
(9,833.44) 
0.17  
(0.04) 
- 0.03 
(0.02) 
0.10 
(0.04) 
- - - - 
33 New Zealand New Zealand Multi-centre National 2002-2012 5,929.55  
(1891.91) 
0.96 
(0.44) 
3.00 
(0.82) 
0.54 
0.33 
0.68 
(0.51) 
- - - - 
34 New Zealand New Zealand Multi-centre National 1998, 2010 119,768   
(10,417.10) 
0.36 
(0.19) 
0.49 0.09 0.02 3.57 1.79 - - 
35 Northern 
Ireland 
United 
Kingdom 
Mandatory/ Enhanced 
population 
National 2000, 2004 24,866  
(2,207.59) 
0.69  
(0.06) 
- - 0.26  
(0.11) 
- - - - 
36 Norway Norway Mandatory/ Enhanced 
population 
National 1996-2013 59,343.44  
(1,936.13) 
0.44  
(0.12) 
- - 0.22 
(0.08) 
- - - - 
37 Ontario Canada Voluntary population Regional 1997-2013 135,098.60  
(4,563.32) 
0.27 
(0.06) 
- 0.003 
(0.003) 
0.08 
(0.03) 
- - - - 
38 Panama City Panama One centre One centre in a 
city/town 
1992, 2011 131,288    
(163,749) 
0.40  
(0.53) 
1.09 0.22 0.30 
0.40 
- - - - 
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No Area Country Surveillance type Geographical 
coverage 
Overall 
Years 
Mean 
Livebirths 
(SD) 
Mean 
EOGBS 
(SD) 
Mean early-
onset sepsis 
(SD) 
Mean 
early-onset 
E.coli (SD) 
Mean 
LOGBS 
(SD) 
Mean EOGBS 
clindamycin 
resistance (SD) 
Mean EOGBS 
erythromycin 
resistance (SD) 
Mean neonatal 
GBS clindamycin 
resistance (SD) 
Mean neonatal 
GBS erythromycin 
resistance (SD) 
39 Podgorica Montenegro One centre One centre in a 
city/town 
2012-2014 4,630.333  
(2,449.98) 
0.00 
(0.00) 
- - 0.00 
(0.00) 
- - - - 
40 Portugal Portugal Multi-centre National 2001-2007 109,472.90  
(4,266.57) 
0.24 
(0.13) 
- - 0.13 
(0.08) 
- - - - 
41 Portugal Portugal Multi-centre National 2008-2013 95,824.83  
(8,100.16) 
- 5.13 
(0.20) 
0.21 
(0.03) 
- - - - 30.19 
42 Republic of 
Ireland 
Republic of 
Ireland 
Mandatory/ Enhanced 
population 
National 2000, 2014 65,921.50  
(10,129.30) 
0.40  
(0.08) 
- - 0.27 
(0.02) 
- - - - 
43 Riga Latvia One centre One centre in a 
city/town 
2014 2,060 0.49 9.71 0.00 
(0.00) 
0.00 0.00 0.00 0.00 0.00 
44 Santo 
Domingo 
Dominican 
Republic 
One centre One centre in a 
city/town 
2011 18,000 2.33 - - 0.83 4.76 83.33 - - 
45 Sao Paolo Brazil One centre One centre in a 
city/town 
One centre in a 
city/town 
1991-2001, 
2007-2011 
8,671.19  
(4,906.72) 
0.44  
(0.24) 
- - 0.15 - - - - 
46 Scotland United 
Kingdom 
Mandatory/ Enhanced 
population 
National 2000, 2014 59,475.5  
(2,795.19) 
0.35  
(0.20) 
- - 0.32 
(0.15) 
- - - - 
47 Singapore 
City 
Singapore One centre One centre in a 
city/town 
2001-2014 2,658.64  
(399.24) 
0.26  
(0.40) 
- - - - - - - 
48 Slovenia Slovenia Voluntary population National 2009-2013 21,839   
(448.82) 
0.00 
(0.00) 
- - 0.00 
(0.00) 
- - - - 
49 Sofia Bulgaria One centre One centre in a 
city/town 
2009-2014 3,894.17  
(229.22) 
0.78  
(0.25) 
- - - 1.00  
(2.45) 
- - - 
50 Soweto South Africa One centre One centre in a 
city/town 
2004-2012  29,064.50  
(2,561.84) 
1.50  
(0.15) 
- - 1.20 
(0.13) 
0.39 
(0.88) 
5.74 
(4.32) 
0.23  
(0.51) 
3.41  
(2.66) 
51 Spain Spain Multi-centre National 1996-2012 96,036.63     
(13,710) 
0.50  
(0.31) 
1.35 
(0.51) 
- - - - - - 
52 St Augustine Trinidad and 
Tobago 
One centre One centre in a 
city/town 
1989, 
1990, 
1994, 
1996, 
1997, 
2000, 2002 
5,145  
(375.28) 
3.74  
(1.14) 
10.18 - - - - - - 
53 Switzerland Switzerland Multi-centre National 2011-2013 81,901  
(988.11) 
0.06  
(0.05) 
0.30 
(0.18) 
0.04 
(0.05) 
0.13 
(0.10) 
- - - - 
54 Tokyo Japan One centre One centre in a 
city/town 
2003-2013 1,627.73 
(192.70) 
0.39  
(0.63) 
1.05 
(0.92) 
0.12 
(0.26) 
0.12 
(0.26) 
25.00  
(50.00) 
0.00 
(0.00) 
16.67 
(40.82) 
0.00 
(0.00) 
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No Area Country Surveillance type Geographical 
coverage 
Overall 
Years 
Mean 
Livebirths 
(SD) 
Mean 
EOGBS 
(SD) 
Mean early-
onset sepsis 
(SD) 
Mean 
early-onset 
E.coli (SD) 
Mean 
LOGBS 
(SD) 
Mean EOGBS 
clindamycin 
resistance (SD) 
Mean EOGBS 
erythromycin 
resistance (SD) 
Mean neonatal 
GBS clindamycin 
resistance (SD) 
Mean neonatal 
GBS erythromycin 
resistance (SD) 
55 Tunis Tunisia One centre                            
One centre in a 
city/town 
2011-2013 3,818  
(115.17) 
1.14  
(0.32) 
- 0.18 
(0.31) 
0.00 
(0.00) 
100.00 60.00 
(56.57) 
- - 
56 United 
Kingdom and 
the Republic 
of Ireland 
United 
Kingdom and 
Republic of 
Ireland 
Mandatory/ Enhanced 
population 
National 2000, 2004 854,084.5  
(84,919.99) 
 
0.52  
(0.06) 
- - 0.31 
(0.09) 
- - - - 
57 United States 
of America 
United States 
of America 
Multi-centre National 1990, 
1993, 
1995, 
1997-2014 
384,732.30   
(95,631.70) 
0.53 
(0.43) 
0.56 
(0.22) 
0.19 0.33 
(0.03) 
26.09 47.83 21.64 49.71 
58 Wales United 
Kingdom 
Mandatory/ Enhanced 
population 
National 2000, 2014 
 
35,126  
(1,715.44) 
0.41 
(0.08) 
- - 0.35 
(0.16) 
- - - - 
59 Zagreb Croatia One centre One centre in a 
city/town 
2008-2013 4,254.50 
(102.26) 
0.35  
(0.13) 
3.23 
(2.52) 
0.27 
(0.23) 
0.00 
(0.00) 
0.00 0.00  
(0.00) 
0.00  
(0.00) 
0.00 
(0.00) 
E. coli Escherichia coli, EOGBS early-onset GBS, GBS group B Streptococcus, LOGBS late-onset GBS, SD standard deviation 
Notes:  
- The range of years covers the entire period given for the data overall, however, not all outcomes are available for all years 
- All outcomes per 1,000 livebirths, except resistance rates which are percentages 
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Table 17. Average population compositional variables for objective 4 to 6 
No Area Region GBS prevention 
strategy 
Mean 
HDI 
(SD) 
Mean 
skilled 
delivery 
(SD)  
Mean 
government 
expenditure 
on health (SD) 
Mean 
preterm 
births  
(SD) 
Mean low 
birthweights 
(SD) 
Mean 
caesarean 
section  
(SD) 
Mean 
fertility 
rate 
(SD) 
Mean 
maternal 
age  
(SD) 
Mean 
multiple or 
twin births 
(SD) 
Mean 
maternal 
GBS  
(SD) 
Most 
prevalent 
GBS 
strain 
Mean 
PROMs 
(SD)  
Mean 
intrapartum 
fever  
(SD) 
1 Alberta North America Screening 0.91 
(0.00) 
98.55 
(0.82) 
4,759 7.8  
(0.00) 
6.00 27.05 
(0.54) 
1.61 
(0.05) 
27.60 18.26 19.50 III 3.84 1.15 
2 Australia Oceania Either screening 
and risk-based 
- 99.00 4,191 7.6  
(0.00) 
6.00 32.00 1.95 30.50 16.20 24.50 III 16.15 7.60 
3 Australia Oceania Either screening 
and risk-based 
0.93 
(0.00) 
99.00 
(0.00) 
4,191 7.6  
(0.00) 
6.00 31.75   
(0.42) 
1.89   
(0.08) 
30.50 16.20 24.50 III 16.15 7.60 
4 Bangalore Asia None 0.62 
(0.00) 
67.00 
(0.00) 
215 2.05  
(0.76) 
6.62 
(2.10) 
63.93   
(1.35) 
2.48 
(0.00) 
19.90 10.93 0.13 III, Ia 7.06 1.36 
5 Barcelona Europe Screening 0.86 
(0.02) 
97.86  
(0.95) 
2,846 8.96 
 (0.99) 
3.78 
(1.49) 
24.91 
(3.11) 
1.30   
(0.07) 
29.30 17.20 14.60 III 4.23 1.57 
6 Brno Europe Screening 0.86 100.00 1,982 7.30 8.00 52.00 1.45 27.40 19.20 17.40 Ib 6.22 0.85 
7 Buenos Aires Latin America 
and the Caribbean 
Screening 0.81  
(0.03) 
98.94 
(1.16) 
1,725 7.65   
(0.49) 
7.00  
(0.00) 
25.89   
(3.23) 
2.47 
(0.11) 
22.10 15.02 9.40 Ib 0.03 0.08 
8 Canada North America Screening 0.90 
(0.02) 
98.86  
(0.95) 
4,759 
 
7.67   
(0.23) 
6.00  
(0.00) 
26.89   
(0.57) 
1.59   
(0.05) 
27.60 18.26 19.50 III 3.84 1.15 
9 Canada North America Screening 0.91 
(0.00) 
98.00 
(0.00) 
4,759 7.58 6.11 27.00 
(0.00) 
1.61 
(0.00) 
27.60 18.26 19.50 III 3.84 1.15 
10 Cordoba Latin America 
and the Caribbean 
Screening 0.83   
(0.00) 
100.00 
(0.00) 
1,725 8.83 
(1.13) 
7.00 
(0.00) 
47.96 
(4.01) 
2.35 
(0.00) 
22.10 15.02 16.03 Ib 0.03 0.08 
11 Denmark Europe Risk-based  0.91  
(0.03) 
97.43 
(1.16) 
4,552 6.47   
(0.25) 
5.00 
(0.00) 
20.86   
(0.20) 
1.78 
(0.05) 
28.40 21.15 37.90 III 15.86 0.30 
12 Emilia-
Romagna 
Europe Screening 0.87   
(0.00) 
99,82 
(0.40) 
3,126 7.44  
 (0.19) 
2.00   
(1.88) 
36.08   
(4.73) 
1.40 
(0.05) 
29.90 13.00 21.40 III 8.50 0.50 
13 England Europe Risk-based 0.87   
(0.00) 
99.00 
(0.00) 
3,311 7.40 4.00 21.50 1.79   
(0.18) 
29.90 14.77 21.00 III 0.25 0.13 
14 England Europe Risk-based 0.90   
(0.02) 
99.00  3,311 7.63 
 (0.61) 
6.63   
(0.18) 
22.93   
(2.19) 
1.80   
(0.11) 
29.90 14.77 21.00 III 0.25 0.13 
15 Finland Europe Either screening 
and risk-based 
0.88   
(0.01) 
99.89 
(0.31) 
3,604 5.61 
 (0.13) 
4.00 
(0.00) 
15.96   
(0.05) 
1.77 
(0.04) 
28.20 15.00 37.90 III 15.86 0.30 
16 Flanders Europe Screening 0.88    
(0.01) 
99.00 
(0.00) 
4,526 7.90 7.00 22.68   
(6.57) 
1.80 
(0.06) 
27.70 17.40 22.00 III 0.25 0.13 
17 France Europe Screening 0.88  
(0.02) 
97.86 
(0.95) 
4,334 6.40      
(0.30) 
7.00  
(0.00) 
20.71   
(0.40) 
1.91   
(0.09) 
28.60 16.30 15.40 III 0.25 0.13 
18 France Europe Screening 0.88  
(0.00) 
97.00 
(0.00) 
4,334 6.70 - 21.00 
(0.00) 
1.99   
(0.02) 
28.60 16.30 15.40 III 0.25 0.13 
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No Area Region GBS prevention 
strategy 
Mean 
HDI 
(SD) 
Mean 
skilled 
delivery 
(SD)  
Mean 
government 
expenditure 
on health (SD) 
Mean 
preterm 
births  
(SD) 
Mean low 
birthweights 
(SD) 
Mean 
caesarean 
section  
(SD) 
Mean 
fertility 
rate 
(SD) 
Mean 
maternal 
age  
(SD) 
Mean 
multiple or 
twin births 
(SD) 
Mean 
maternal 
GBS  
(SD) 
Most 
prevalent 
GBS 
strain 
Mean 
PROMs 
(SD)  
Mean 
intrapartum 
fever  
(SD) 
19 Guangzhou Asia Screening 0.69   
(0.05) 
96.61  
(3.97) 
646 10.37   
(6.39) 
5.66    
(5.77) 
15.59   
(16.00) 
1.52   
(0.03) 
22.60 7.90 7.10 III, Ib 17.87 1.36 
20 Ho Chi Minh Asia None 0.66    
(0.00) 
94.00 
(0.00) 
308 9.4 
(0.00) 
5.00 43.59   
(0.59) 
1.96 
(0.00) 
22.60 6.20 14.10 Ia 2.47 1.36 
21 Johannesburg Sub-Saharan 
Africa 
Risk-based 0.66 94.00 1,121 8.00 15.00 20.60 2.40 22.50 12.60 28.40 Ia 9.66 2.42 
22 Johannesburg Sub-Saharan 
Africa 
Risk-based 0.66    94.00 1,121 8.00 15.00 
 
20.60 2.40 22.50 12.60 28.40 III 9.66 2.42 
23 Kaunas Europe Screening 0.83   
(0.00) 
100.00  1,579 16.73 
(0.78) 
12.15 
(0.62) 
28.96   
(0.89) 
1.51 
(0.08) 
26.10 37.56 15.30 III 2.61 1.03 
24 Kingston Latin America 
and the Caribbean  
Risk-based 0.71  
(0.02) 
98.57  
(0.53) 
512 9.28 
(0.81) 
10.00  
(1.41) 
18.43 
(3.21) 
2.55 
(0.26) 
19.20 11.20 44.00 III 12.00 0.08 
25 Kuala 
Terengganu 
Asia Risk-based 0.77   
(0.00) 
99.00 
(0.00) 
1,579 12.30 12.18   
(1.68) 
16.00 
(0.00) 
2.01 
(0.05) 
22.30 11.00 14.10 Ia, III 2.47 1.36 
26 Kuwait North Africa and 
the Middle East  
Risk-based 0.81  
(0.00) 
99.00 
(0.00) 
2,375 10.60 8.00 30.32   
(2.63) 
2.35 
(0.21) 
22.90 18.25 12.94 Ib 9.66 2.42 
27 Macau Asia None 0.71  
(0.01) 
99.20 
(1.69) 
646 7.10 5.00  
(0.00) 
27.00 
(0.00) 
1.07 
(0.13) 
22.60 7.90 7.10 III 17.87 1.36 
28 Manila Asia Risk-based 0.67 73.00 287 18.89 28.76 28.00 3.04 23.10 9.28 14.10 Ia 2.47 1.36 
29 Mansoura 
city- 
Dakahlia 
Governorate  
North Africa and 
the Middle East 
None 0.69 92.00 539 12.08 14.49 24.15 3.38 22.90 17.70 30.00 V 9.66 2.42 
30 Mauritius Sub-Saharan 
Africa 
Risk-based 0.78 100.00 864 12.60 18.69 42.40 1.50 22.50 12.60 32.30 III, Ia 9.66 2.42 
31 Mexico City  Latin America 
and the Caribbean 
None 0.74   
(0.02) 
91.05 
(10.77) 
1,061 7.50 
(0.24) 
24.22 
(3.03) 
41.75   
(4.47) 
2.57 
(0.23) 
20.80 10.50 3.67 III 0.03 0.08 
32 Netherlands Europe Risk-based 0.91 
(0.01) 
100.00 5,601 7.63 
(0.35) 
6.00 15.64   
(0.39) 
1.71 
(0.07) 
29.20 18.60 22.90 III 0.25 0.13 
33 New Zealand Oceania Risk-based 0.91   
(0.00) 
96.55   
0.52 
3,405 7.45   
(0.21) 
6.00 24.05   
(0.09) 
2.06   
(0.08) 
27.70 15.50 21.70 III 16.15 11.55 
34 New Zealand Oceania Risk-based 0.91   
(0.00) 
95.00  
(2.83) 
3,405 7.40 6.00 23.60 1.83    
(0.32) 
27.70 15.50 21.70 III 16.15 11.55 
35 Northern 
Ireland 
Europe Risk-based 0.87 99.00  3,311 7.00 8.00 27.60 1.79 
(0.18 
29.90 14.90 21.00 III 0.25 0.13 
36 Norway Europe Risk-based 0.94   
(0.01) 
99.00 
(0.00) 
6,308 6.86 
(0.43) 
5.15   
(0.16) 
14.86   
(1.57) 
1.85   
(0.05) 
28.10 18.30 37.90 III 15.86 0.30 
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No Area Region GBS prevention 
strategy 
Mean 
HDI 
(SD) 
Mean 
skilled 
delivery 
(SD)  
Mean 
government 
expenditure 
on health (SD) 
Mean 
preterm 
births  
(SD) 
Mean low 
birthweights 
(SD) 
Mean 
caesarean 
section  
(SD) 
Mean 
fertility 
rate 
(SD) 
Mean 
maternal 
age  
(SD) 
Mean 
multiple or 
twin births 
(SD) 
Mean 
maternal 
GBS  
(SD) 
Most 
prevalent 
GBS 
strain 
Mean 
PROMs 
(SD)  
Mean 
intrapartum 
fever  
(SD) 
37 Ontario North America Screening 0.90    
(0.02) 
98.71  
(0.92) 
4,759 7.50 
(0.22) 
6.97 
(0.12) 
27.61   
(0.49) 
1.58   
(0.05) 
27.60 18.26 21.69 III 3.84 1.15 
38 Panama City Latin America 
and the Caribbean 
None 0.71   
(0.07) 
88.50  
(3.54) 
796 8.30 11.00 20.40 2.86   
(0.54) 
21.10 11.20 13.00 III 12.00 0.08 
39 Podgorica Europe Screening 0.80  
(0.00) 
100.00 
(0.00) 
926 5.65 
(1.77) 
6.40 
(0.60) 
41.72   
(23.38) 
1.71     
(0.00) 
25.50 25.90 15.46 Ib 6.22 0.85 
40 Portugal Europe Screening - 100.00 
(0.00) 
2,508 7.02   
(1.12) 
7.48 
(0.21) 
33.00 
(2.22) 
1.42 
(0.04) 
27.90 12.90 22.50 III 4.23 1.57 
41 Portugal Europe Screening 0.82   
(0.00) 
100.00 
(0.00) 
2,508 - - - 1.31 
(0.05) 
27.90 12.90 22.50 III 4.23 1.57 
42 Republic of 
Ireland 
Europe Risk-based 0.86 100.00 3311 5.6 6.00 26.00 1.90   
(0.02) 
28.90 15.50 25.60 III 0.25 0.13 
43 Riga Europe Screening 0.82 99.00 1,310 2.57 2.57 23.00 1.48 25.60 10.40 15.30 III 2.61 1.03 
44 Santo 
Domingo 
Latin America 
and the Caribbean 
None 0.70 98.00 1,454 16.00 18.00 56.00 2.53 20.30 11.20 44.00 III 12.00 0.08 
45 Sao Paolo Latin America 
and the Caribbean 
Screening 0.72 
(0.03) 
97.73 
(0.96) 
1,454 8.63 
(0.49) 
9.50 
(0.71) 
53.97 
(4.98) 
2.28   
(0.32) 
22.10 8.80 21.80 Ib 0.60 0.08 
46 Scotland Europe Risk-based 0.87 99.00 3,311 7.00 8.00 24.9 1.79   
(0.18) 
29.90 14.90 21.00 III 0.25 0.13 
47 Singapore 
City 
Asia Screening 0.91 
(0.00) 
100.00 
(0.00) 
3,578 11.50 1.73 
(0.31) 
16.00 
(0.00) 
1.28   
(0.05) 
29.80 11.00 14.10 III 2.47 1.36 
48 Slovenia Europe Screening 0.88 
(0.00) 
100.00 
(0.00) 
2,595 7.50 6.00 19.00 
(0.00) 
1.54   
(0.09) 
28.90 13.70 18.50 Ib 6.22 0.85 
49 Sofia Europe Risk-based 0.78   
(0.00) 
100.00 
(0.00) 
1,213 7.50 18.44 
(1.10) 
33.00 
(0.00) 
1.52  
(0.01) 
26.60 9.80 1.70 Ib, III 6.22 0.85 
50 Soweto Sub-Saharan 
Africa 
Risk-based 0.66 92.50 
(1.64) 
1,121 18.00 
(0.00) 
17.53 
(1.14) 
20.60 
(0.00) 
2.57   
(0.13) 
22.50 12.60 28.40 III, Ia 9.66 2.42 
51 Spain Europe Screening 0.86   
(0.02) 
97.92 
(0..95) 
2,846 6.97 
(0.45) 
7.00   
(1.41) 
26.04 
(0.93) 
1.31  
(0.07) 
29.30 17.20 15.90 III 4.23 1.57 
52 St Augustine Latin America 
and the Caribbean 
None 0.70   
(0.03) 
98.43 
(0.79) 
1,663 10.21 
(0.85) 
13.84 
(0.33) 
9.16   
(1.06) 
2.04   
(0.37) 
22.20 107.46 32.80 III 0.60 0.08 
53 Switzerland Europe Screening 0.93  
(0.00) 
100  
(0.00) 
6,187 7.26 
(0.11) 
2.28   
(0.02) 
32.95   
(0.10) 
1.52 
(0.00) 
30.00 18.17 18.70 III 8.50 0.50 
54 Tokyo Asia Screening 0.89    
(0.00) 
100.00  
(0.00) 
3,741 15.33 
(2.29) 
20.32   
(3.15) 
33.69 
(2.01) 
  1.35   
(0.04) 
29.90 49.88 
 
22.40 III 16.15 7.60 
55 Tunis North Africa and 
the Middle East 
Risk-based 0.72   
(0.00) 
74.00 
(0.00) 
1,663 9.25 8.29   
(0.95) 
35.28   
(3.06) 
1.80 
(0.00) 
24.50 14.30 13.00 V 9.66 2.42 
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No Area Region GBS prevention 
strategy 
Mean 
HDI 
(SD) 
Mean 
skilled 
delivery 
(SD)  
Mean 
government 
expenditure 
on health (SD) 
Mean 
preterm 
births  
(SD) 
Mean low 
birthweights 
(SD) 
Mean 
caesarean 
section  
(SD) 
Mean 
fertility 
rate 
(SD) 
Mean 
maternal 
age  
(SD) 
Mean 
multiple or 
twin births 
(SD) 
Mean 
maternal 
GBS  
(SD) 
Most 
prevalent 
GBS 
strain 
Mean 
PROMs 
(SD)  
Mean 
intrapartum 
fever  
(SD) 
56 United 
Kingdom and 
the Republic 
of Ireland 
Europe Risk-based 0.87 99.00 3,311 7.00 8.00 25.84 1.79 
(0.18) 
29.90 14.90 21.00 III 0.25 0.13 
57 United States 
of America 
North America Screening 0.90   
(0.02) 
98.76 
(0.44) 
9,146 11.75 
(0.77) 
8.00 
(0.00) 
32.68   
(0.54) 
2.01 
(0.06) 
25.00 16.40 18.80 Ia, II 7.20 3.30 
58 Wales Europe Risk-based 0.87 99.00 3,311 7.00 8.00 21.50 1.78 
(0.18) 
29.90 14.90 21.00 III 0.25 0.13 
59 Zagreb Europe Screening 0.81 
(0.00) 
100.00 
(0.00) 
1,517 7.38 
(0.93) 
3.10 
(0.53) 
23.97 1.52   
(0.00) 
27.10 29.49 18.50 Ia 6.22 0.85 
E. coli Escherichia coli, GBS group B Streptococcus, HDI human development index, PROMs prolonged rupture of membranes, SD standard deviation 
Notes:  
- All outcomes are percentages, except multiple or twin births, which are per 1,000 livebirths, and government expenditure on health, which is in PPP int $.  
- Number is bold are from surveys while numbers not in bold are from international websites.  
- Numbers in italics are imputed from the closest neighbouring geographical area. 
- GBS prevention strategy refers to the most recently reported strategy during the period that outcome data were reported.
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11. THE IMPACT OF UNIVERSAL GBS SCREENING ON 
THE TRENDS OF ANNUAL EOGBS INCIDENCE 
This chapter presents the results for the ecological trend analysis study that combines 
international data to explore the impact of universal GBS screening on the trends of annual 
EOGBS incidence, compared with other GBS prevention strategies. While I discussed the 
methodology used to address this study in Chapter 9, here I will first present the study specific 
aim and objectives followed by some study specific methodological procedures. I will then 
present the detailed results from the statistical analyses: first the MICE imputation results, 
then the descriptive statistics, followed by the unadjusted analyses, the main adjusted model, 
the sensitivity analyses and the multi-level analysis model. Finally, I will summarise the 
principal findings and how they relate to previous literature.  
 
11.1 Aims and objectives 
The aim of this chapter is to measure the effect of universal GBS screening on the trend of 
annual EOGBS incidence across time, compared with other GBS prevention strategies, in a 
statistical model that combines data from geographical areas with different prevention 
strategies, and adjusts for compositional differences between the areas.  
The research objectives are to:  
a) Describe the frequency of the GBS prevention strategy as well as the mean or 
frequency of the compositional covariates in general (irrespective of EOGBS 
incidence); 
b) Describe the mean EOGBS incidence across time, geographical areas, world regions 
and GBS prevention strategies; 
c) Investigate the unadjusted relationship between universal GBS screening and the 
trend of annual EOGBS incidence across time compared with other prevention 
strategies, using linear regression; 
d) Investigate the unadjusted relationship between each compositional covariate and the 
mean EOGBS incidence across time, using linear regression; 
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e) Investigate the relationship between universal GBS screening and the trend of annual 
EOGBS incidence across time compared with other prevention strategies, using linear 
regression and adjusting for the compositional covariates; 
f) Examine the stability of the adjusted relationship between universal GBS screening 
and the trend of annual EOGBS incidence across time compared with other prevention 
strategies in a range of sensitivity analyses, if the relationship was statistically 
significant; and 
g) Investigate the multi-level unadjusted relationship between universal GBS screening 
and the trend of annual EOGBS incidence across time compared with other prevention 
strategies, using a multi-level growth curve model to account for the structure of the 
data. (Note that this was an unadjusted analysis as multi-level multiple imputation did 
not work and there were few fully observed covariates). 
 
11.2 Methods 
I have detailed the methodology used for this study in Chapter 9. Here, I describe the data 
selected to perform the analysis.  
11.2.1 Geographical data included 
As discussed in Chapter 10, there were annual EOGBS data from 55 geographical areas. 
However, some of them overlapped with one another in terms of coverage, giving rise to the 
potential of double-counting. These were: Alberta and Ontario that overlapped with multi-
centre data across Canada; data from Barcelona versus multiple centres across Spain; 
voluntary versus enhanced surveillance from England; two hospitals from Johannesburg 
versus data from the township of Soweto; data from multiple centres versus enhanced 
surveillance in New Zealand; two different multi-centre sources for Australia; and enhanced 
surveillance from the United Kingdom and Republic of Ireland versus data from each of the 
five countries in the British Isles. I included the following data sources (and excluded the 
others): Alberta and Ontario as both had population-based surveillance, and Alberta in 
particular had mandatory surveillance; multi-centres from Spain to have broader national 
coverage; the enhanced surveillance for England and individual UK countries instead of the 
United Kingdom and Republic of Ireland overall as the EOGBS incidence varies across the 
countries; Soweto over the two hospitals in Johannesburg for population and wider coverage; 
the enhanced surveillance for New Zealand; and the multi-centre data that had a larger number 
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of years for Australia. This left 47 geographical areas. However, after analysing the EOGBS 
incidence across the years and countries, I excluded Mansoura City in Egypt where the 
EOGBS incidence for 2014 was 28.99 per 1,000 livebirths. This was an extreme outlier and 
was vastly different from incidence rates in the UK. This left data from a total of 46 
geographical areas in the analyses that follow. 
Further descriptive analyses also revealed that St. Augustine had a strong influence on the 
descriptive trends of EOGBS incidence over time. However, as the incidence rates themselves 
were not extreme outliers, there is a separate unadjusted and adjusted linear regression, multi-
level regression and sensitivity analyses with and without St. Augustine.  
 
11.3 Results 
11.3.1 Multiple imputation for compositional covariates 
There were 60 (16%) observations that had complete compositional covariate data for every 
year. The proportion of missing data is shown in Table 18. The covariate with the largest 
number of missing years was the human development index, which had 63% of years missing. 
The covariate with the least amount of missing data was skilled attendance at delivery, which 
had 7% of years missing. 
Table 18. Proportion of missing data in compositional covariates for the EOGBS dataset 
Variable Observed (%) Missing (%) 
Preterm births 153 (40) 231 (60) 
Low birthweights 175 (46) 209 (54) 
Caesarean section 302 (79) 82 (21) 
Skilled attendance at delivery 347 (93) 37 (7) 
Human development index 142 (37) 242 (63) 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
There were multiple patterns of missing data. The most common pattern was for skilled 
attendance at delivery and caesarean section to be observed, with the remaining three variables 
not observed. This was followed by all covariates observed, all but the human development 
index observed, only skilled delivery observed, and less frequent patterns. The logistic 
regression for whether the missingness of a variable was related to the other variables, 
revealed that missingness of preterm births was only related to multiple births. Missingness 
of low birthweights was related to year, fertility rate, EOGBS definition, maternal GBS 
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colonisation, GBS serotype, prolonged rupture of membranes, most recently reported GBS 
prevention strategy, geographical coverage and geographical region. Missingness of caesarean 
section was related to year, fertility rate, multiple births, prolonged rupture of membranes, 
intrapartum fever, geographical coverage and geographical region. Missingness for the human 
development index was related to year and EOGBS incidence. Finally, missingness of skilled 
attendance at delivery was related to year, EOGBS incidence, multiple births, maternal GBS 
colonisation and most recently reported GBS prevention strategy. As data were missing 
because they were available from some years but not others and their missingness was related 
to other data, the mechanism for the missing data was ‘missing at random’. 
As mentioned in Chapter 9, there were 100 imputations because of the large amount of missing 
data and the results showed that convergence was reached within these imputations. 
Additionally, the largest fraction of missing information (FMI) from the analysis models was 
below 67%, confirming that the number of imputations was sufficient. Below, I present the 
descriptive statistics for some of the imputed datasets and the original dataset for comparison. 
11.3.2 Descriptive analysis (objectives a & b) 
This section presents the mean EOGBS incidence across time, geographical areas, world 
regions and GBS prevention strategies (objective b) as well as the frequency of the GBS 
prevention strategy and the mean or frequency of the compositional covariates in general 
(irrespective of EOGBS incidence) (objective a).  
EOGBS incidence 
The mean EOGBS incidence across 384 observations (46 geographical areas, 27 years 
between 1989 and 2015) was 0.49 per 1,000 livebirths (SD 0.62, range: 0.00 to 5.40). Across 
the years, EOGBS incidence varied between 0.28 and 5.04 per 1,000 livebirths. The incidence 
varied between the years, but there was no overall trend (see Table 19). Figure 11 shows the 
scatterplot of all EOGBS incidence observations by year, demonstrating that the range of 
EOGBS incidence was wider and higher in the earlier years. Seven observations before 2002 
were above 2.00 to 5.00 per 1,000 livebirths, while the majority were below 2.0 per 1,000 
livebirths. As the years progressed, these rates reduced and stabilised at a lower rate. As 
evident from Table 19, the geographical areas that contributed to each year varied, therefore, 
the patterns may be reflective of those over time or a result of different areas reporting during 
different time periods.  
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Table 19. EOGBS incidence per 1,000 livebirths across the years 
 
 
 
 
 
 
 
 
 
 
 
 
EOGBS early-onset group B Streptococcus disease 
 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
Each dot represents the EOGBS incidence for one year for one geographical area  
Figure 11. Scatterplot of EOGBS incidence by year 
Year Number of 
geographical areas 
Mean livebirths 
(Standard deviation) 
Mean EOGBS incidence 
(Standard deviation) 
1989 1 5,731.00 5.40 
1990 2 5,547.00 3.18 (2.38) 
1991 2 5,214.00 (3063.19) 0.46 (0.27) 
1992 3 86,181.00 (139,365.30) 0.28 (0.23) 
1993 3 6,669.50 (4,891.06) 1.01 (0.66) 
1994 3 6,707.33 (4,570.78) 1.64 (2.35) 
1995 6 55,007.40 (79,601.10) 0.54 (0.40) 
1996 10 85,310.77 (136,912.90) 0.83 (1.00) 
1997 12 110,751.70 (143,861.70) 0.64 (0.63) 
1998 11 125,676.70 (152,557.00) 0.41 (0.23) 
1999 12 126,738.90 (165,442.10) 0.37 (0.19) 
2000 18 128,990.20 (187,815.40) 0.63 (0.64) 
2001 12 144,928.40 (178573.20) 0.39 (0.30) 
2002 14 125,956.50 (167,647.50) 0.48 (0.70) 
2003 16 115,542.60 (165,273.50) 0.37 (0.19) 
2004 18 111,318.20 (167,775.50) 0.32 (0.33) 
2005 21 96,630.87 (15,9638.70) 0.39 (0.44) 
2006 22 95,396.27 (160,016.10) 0.30 (0.29) 
2007 24 87,147.15 (153,155.20) 0.35 (0.37) 
2008 24 83,339.56 (155,873.10) 0.60 (0.59) 
2009 25 78,781.24 (151,121.20) 0.36 (0.38) 
2010 26 77,229.19 (143,812.00) 0.42 (0.34) 
2011 28 70,159.65 (135,949.40) 0.48 (0.53) 
2012 26 75,572.28 (140,237.60) 0.40 (0.40) 
2013 27 66,003.58 (135,981.50) 0.51 (0.63) 
2014 17 82,560.06 (193,064.80) 0.48 (0.54) 
2015 1 2,195.00 0.46 
Total 384 observations  
(46 areas, 27 years) 
90,967.03 (151,485.80) 0.49 (0.62) 
Years
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When plotting the EOGBS incidence by year for every geographical area, we see that the early 
trend of high EOGBS incidence that dramatically decreased in the seven observations above 
2.0 per 1,000 livebirths is from one geographical area of St. Augustine in Trinidad and Tobago 
(see Appendix 15-A). Indeed, besides Mansoura City which was excluded, the highest mean 
EOGBS incidence per 1,000 livebirths across years was found in St. Augustine (3.74 [SD 
1.14]), followed by Sofia in Bulgaria (0.78 [SD 0.25]). Three areas reported zero cases of 
EOGBS across years: Cordoba in Argentina, Podgorica in Montenegro and Slovenia (this 
might be a result of diagnostic related issues, voluntary surveillance or too small a sample size 
to detect cases). Otherwise, the lowest mean EOGBS incidences per 1,000 livebirths across 
years were found in Bangalore (0.15 [SD 0.26]), Buenos Aires (0.14 [SD 0.20]), and Manila 
(0.15) (see Table 20). These are the averages across the years for each geographical area but, 
as can be seen in Appendix 15-A, for many areas the rates of EOGBS fluctuated from the first 
year to the last.  
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Table 20. EOGBS incidence per 1,000 livebirths by geographical area 
 
Geographical area 
Number 
of years 
Mean number of livebirths 
(Standard deviation) 
Mean EOGBS incidence  
(Standard deviation) 
Alberta 11 47,896.00 (4,854.45) 0.25 (0.10) 
Australia 11 29,199.82 (4,802.03) 0.38 (0.16) 
Bangalore 3 4,044.33 (1,605.77) 0.15 (0.26) 
Brno 1 6,415.00 0.31 
Buenos Aires 18 6,473.22 (923.54) 0.14 (0.20) 
Cordoba 2 1,573.00 (152.74) 0.00 (0.00) 
Denmark 15 63,296.47 (3,182.94) 0.17 (0.05) 
Emilia-Romagna 11 38,686.09 (2,477.04) 0.26 (0.07) 
England 2 668,696.00 (68,071.76) 0.54 (0.06) 
Finland 19 58,658.79 (1,898.58) 0.55 (0.14) 
Flanders 6 - 0.21 (0.08) 
France 18 570,199.50 (57,015.64) 0.36 (0.17) 
Guangzhou 4 2,097.50 (265.54) 0.61 (0.29) 
Kaunas 7 3,524.86 (194.83) 1.13 (0.50) 
Kingston 16 2,744.69 (360.63) 0.69 (0.40) 
Kuala Terengganu 9 12,578.56 (1.141.11) 0.26 (0.25) 
Kuwait 10 11,074.1 (486.46) 1.14 (0.76) 
Macau 10 2,667.7 (697.83) 0.64 (0.70) 
Manila 1 6,682.00 0.15 
Mauritius 1 12,986.00 1.46 
Mexico City 19 5,055.11 (594.00) 0.27 (0.22) 
Netherlands 19 190,186.70 (9,833.44) 0.17 (0.04) 
New Zealand 2 119,768.00 (10,417.10) 0.36 (0.19) 
Northern Ireland 2 24,866.00 2,207.59 0.69 (0.06) 
Norway 18 59,343.44 (1,936.13) 0.44 (0.12) 
Ontario 17 135,098.60 (4,563.32) 0.27 (0.06) 
Panama City 2 131,288.00 (163,749.00) 0.40 (0.53) 
Podgorica 2 3,216 52. (3,259.00) 0.00 (0.00) 
Portugal 7 109,472.90 (4,266.57) 0.24 (0.13) 
Republic of Ireland 2 65,921.50 (10,129.30) 0.40 (0.08) 
Riga 1 2,060.00 0.49 
Santo Domingo 1 18,000.00 2.33 
Sao Paolo 15 8,332.67 (4,881.71) 0.44 (0.25) 
Scotland 2 59,475.50 (2,795.19) 0.35 (0.20) 
Singapore city 14 2,658.64 (399.24) 0.26 (0.40) 
Slovenia 5 21,839.00 (448.82) 0.00 (0.00) 
Sofia 6 3,894.17 (229.22) 0.78 (0.25) 
Soweto 6 29,064.50 (2,561.84) 1.50 (0.16) 
Spain 16 96,036.63 (13,710.00) 0.50 (0.32) 
St Augustine 7 5,145.00 (375.28) 3.74 (1.14) 
Switzerland 3 81,901.00 (988.11) 0.06 (0.05) 
Tokyo 11 1,627.73 (192.70) 0.39 (0.63) 
Tunis 3 3,818.00 (115.17) 1.14 (0.32) 
US 18 422,561.70 (52,171.40) 0.53 (0.43) 
Wales 2 35,126.00 (1,715.44) 0.41 (0.08) 
Zagreb 6 4,254.50 (102.26) 0.35 (0.13) 
Total 384 90,967.03 (151,485.80) 0.49 (0.62) 
EOGBS early-onset group B Streptococcus disease, US United States of America 
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Taking a wider global perspective, the highest mean EOGBS incidence was reported in Sub-
Saharan Africa (1.50 per 1,000 livebirths [SD 0.15]) whereas the lowest was reported in Asia, 
Europe, North America and Oceania which all showed a mean rate of 0.38 per 1,000 livebirths 
(see Table 21). Again, these rates vary across time and, within regions may fluctuate by year 
as shown in the scatterplots of EOGBS incidence by world region presented in Appendix 15-
B.  
Table 21. EOGBS incidence per 1,000 livebirths by region 
Region Number of 
observations/ years (%) 
Mean EOGBS incidence 
(standard deviation) 
Asia 52 (13.54) 0.38 (0.50) 
Europe 170 (44.27) 0.38 (0.29) 
Latin America and the Caribbean 80 (20.83) 0.68 (1.08) 
North Africa and the Middle East 13 (3.39) 1.14 (0.67) 
North America 49 (12.76) 0.38 (0.31) 
Oceania 13 (3.39) 0.38 (0.16) 
Sub-Saharan Africa 7 (1.82) 1.50 (0.15) 
Total 384 (100.00) 0.49 (0.62) 
EOGBS early-onset group B Streptococcus disease 
Finally, the mean EOGBS incidence by most recently reported GBS prevention strategy is 
presented in Table 22. The highest mean EOGBS incidence per 1,000 livebirths was reported 
under no prevention (0.99 [SD 1.42]), followed by risk-based prevention (0.54 [SD 0.48]), 
either risk-based or screening prevention (0.48 [SD 0.16]) and the lowest mean rate was 
reported under universal screening (0.35 [SD 0.35]). Figure 12 shows the scatterplots for 
EOGBS incidence by the most recently reported GBS prevention strategy, highlighting a 
potential increase in EOGBS incidence in areas that reported a risk-based strategy. By 
contrast, there is a potential decrease in areas that reported no prevention, a smaller decrease 
in areas that reported universal screening and an even smaller decrease in areas that reported 
either risk-based or screening prevention. Again, it seems that under no prevention there may 
be a substantial impact of the drastic decrease in EOGBS incidence in St. Augustine, as the 
plot shows the same pattern; removing these observations might reveal a different pattern. 
Table 22. EOGBS incidence per 1,000 livebirths by recently reported GBS prevention strategy 
Most recent GBS prevention strategy Number of observations/ 
years (%) 
Mean EOGBS incidence 
(standard deviation) 
No prevention 42 (10.94) 0.99 (1.42) 
Risk-based prevention  116 (30.21) 0.54 (0.48) 
Screening prevention 196 (51.04) 0.35 (0.35) 
Either risk-based or screening prevention 30 (7.81) 0.48 (0.16) 
Total 384 (100.00) 0.49 (0.62) 
EOGBS early-onset group B Streptococcus disease, GBS group B Streptococcus 
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EOGBS early-onset group B Streptococcus disease, GBS group B Streptococcus 
Each dot represents the EOGBS incidence for one year for one geographical area  
Figure 12. Scatterplot of EOGBS incidence by recently reported GBS prevention strategy  
Predictor and compositional covariates (objective a) 
Most geographical areas (and observations) recently reported a universal screening strategy 
(51% of observations and 46% of areas), followed by risk-based prevention (30% of 
observations and 37% of areas), no prevention (11% of observations and 13% of areas) and 
either risk-based or screening prevention (8% of observations and 4% of areas) (see Table 23 
and Table 17). With respect to world region, the majority of observations were from Europe 
(44%) and the fewest were from Sub-Saharan Africa (2%) (see Table 21). 
Table 23. Frequencies of the recently reported GBS prevention strategy for the EOGBS dataset 
Most recent GBS prevention strategy Frequency 
(%) 
No prevention 6 (13.04) 
Risk-based prevention  17 (36.96) 
Screening prevention 21 (45.65) 
Either risk-based or screening prevention 2 (4.35) 
Total 46 (100.00) 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
The mean values for the compositional covariates that were multiple imputed are presented in 
Table 24. Averages are provided for the data with no imputation, followed by imputed datasets 
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1 and 100, to provide an indication of how well the multiple imputation performed. The mean 
percentage of preterm births across the years in the original dataset was 9.40% (SD 4.25) and 
the imputed means were around 8.70% and, therefore within 0.7% of the original mean. 
Similarly, the mean percentage of low birthweights was 10.17% (SD 7.25) and the imputed 
mean values were around 8.5% to 8.6%, thus, within 1.7% of the original mean and not as 
close to the original data as the other covariates. The mean percentage of caesarean section 
deliveries was 26.80% (SD 10.42) and the imputed mean values were within 0.6%. The mean 
skilled attendance at delivery was 97.85% (SD 5.20) and the imputed mean values were within 
0.13%. Finally, the mean human development index across the data was 0.83 (SD 0.08) and 
were identical in the other two sample datasets. 
Table 24. Mean values for the multiple imputed covariates in the EOGBS dataset 
Covariate Original dataset 
Mean (SD) 
Imputed dataset 1 
Mean (SD) 
Imputed dataset 2 
Mean (SD) 
Preterm births (%) 9.40 (4.25)  8.73 (3.51) 8.70 (3.35) 
Low birthweights (%) 10.17 (7.25) 8.50 (5.89) 8.57 (5.74) 
Caesarean delivery (%) 26.80 (10.42) 26.42 (10.57) 26.24 (10.70) 
Skilled attendance at delivery (%) 97.85 (5.20) 97.96 (4.96) 97.98 (4.96) 
Human development index 0.83 (0.08) 0.83 (0.08) 0.83 (0.08) 
EOGBS early-onset GBS disease, GBS group B Streptococcus, SD standard deviation 
The mean values for compositional covariates that only had one value across all of the years 
and, thus, were not multiple imputed are presented in Table 25. Across the geographical areas, 
mothers were 26 years old at first child (SD 3.41) and had an average of 1.86 children (SD 
0.44). Eighteen percent of births were multiple or twin births (SD 14.34), maternal 
colonisation of GBS was approximately 21% (SD 10.68), mean percentage of prolonged 
rupture of membranes was 6.80% (SD 6.20) and intrapartum fever was 1.28% (SD 1.95). 
Mean government expenditure on health per capita was $3,348.76 (SD 2,163.51). Table 25 
also presents the frequency and percentage of the observations for each category of the 
categorical compositional covariates. The most frequent GBS serotype was serotype III 
(74%), followed by Ib (17%), Ia (8%) and V (1%). Most data covered one centre only and 
approximately the same amount of data was from mandatory/enhanced (18%) or voluntary 
(19%) population surveillance or multiple centres (18%). After data from one centre, most 
data covered a country (43%), a region (10%) or were city or town-wide (2%). Finally, the 
most common definition of EOGBS was 5/6/7 days or less (67%), followed by 2/3 days (28%), 
vertical onset (4%) and was not stated in 0.5%. 
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Table 25. Mean values for the un-imputed covariates for the EOGBS dataset 
Covariate Descriptive statistic 
Continuous variables Mean (SD) 
Fertility rate 1.86 (0.44) 
Average maternal age 26.11(3.41) 
Multiple or twin births (per 1,000 livebirths) 18.16 (14.34) 
Per capita government expenditure on health (PPP int $) 3,348.76 (2,163.51) 
Maternal GBS colonisation 21.02 (10.68) 
Prolonged rupture of membranes 6.80 (6.20) 
Intrapartum fever 1.28 (1.95) 
  
Categorical variables Frequency (%) 
Most prevalent GBS serotype  
Ia 31 (8.07) 
Ib 65 (16.93) 
III 285 (74.22) 
V 3 (0.78) 
Surveillance type  
Mandatory or enhanced population surveillance 70 (18.23) 
Voluntary population surveillance 74 (19.27) 
Multiple centres/counties 69 (17.79) 
One centre 171 (44.53) 
Geographical coverage  
National 165 (42.97) 
Regional 39 (10.16) 
City/town wide 9 (2.34) 
One centre in a city/town 171 (44.53) 
EOGBS definition  
2/3 days or less 108 (28.13) 
5/6/7 days or less 258 (67.19) 
Vertical onset 16 (4.17) 
Not stated 2 (0.52) 
EOGBS early-onset GBS disease, GBS group B Streptococcus, SD Standard deviation 
11.3.3 Unadjusted linear regression analysis (objective c & d) 
This section presents the results of the linear regression analysis showing the unadjusted 
relationship between the most recently reported GBS prevention strategy and the trends of 
annual EOGBS incidence across time for all data and then for the data excluding St. Augustine 
(objective c). This is followed by the linear regression analysis showing the unadjusted 
relationship between each compositional covariate and mean EOGBS incidence (objective d).  
Most recently reported GBS prevention strategy: all data  
The results of the unadjusted analysis are summarised in see Table 26 and Figure 13 for all 
data. Contrary to expectation, there was a continuous decrease in annual EOGBS incidence in 
areas with no prevention. Similarly, there was a decrease in annual EOGBS incidence in 
screening prevention and ‘either prevention’ (i.e. risk-based or screening) areas. Compared 
with screening prevention areas, the EOGBS incidence decreased by 0.082 (95% CI -0.108 to 
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-0.055) yearly in no prevention areas. However, the incidence of EOGBS increased by 0.037 
(95% CI 0.016 to 0.059) yearly in risk-based prevention areas compared with screening areas. 
There was no statistically significant difference in the trends of annual EOGBS incidence 
between screening and ‘either prevention’ areas.   
Most recently reported GBS prevention strategy: excluding data from St. Augustine  
The results of excluding St. Augustine from the analysis (as it had much higher EOGBS rates 
and a trend that drastically decreased) are shown in Table 26 and Figure 14. When St 
Augustine data were excluded, there were decreases in annual EOGBS incidence in both 
screening and ‘either prevention’ areas, and increases in annual EOGBS incidence in no 
prevention and risk-based prevention areas. Compared with screening prevention areas, the 
EOGBS incidence increased by 0.042 (95% CI 0.018 to 0.066) and 0.037 (95% CI 0.022 to 
0.053) yearly for no prevention and risk-based prevention areas respectively. There was no 
statistically significant difference in the trends of annual EOGBS incidence between screening 
prevention and ‘either prevention’ areas.   
 
Table 26. Unadjusted linear regression analyses of the average annual change in EOGBS 
incidence by recently reported GBS prevention strategy 
Most recent reported GBS prevention  
(baseline: screening prevention) 
Average annual change in EOGBS 
incidence (95% confidence interval) 
p-value 
All data   
Screening prevention (reference)  
No prevention  -0.082 (-0.108 to -0.055) 0.000 
Risk-based prevention 0.037 (0.016 to 0.059) 0.001 
Either screening or risk-based prevention 0.004 (-0.037 to 0.05) 0.855 
Excluding St. Augustine    
Screening prevention (reference)  
No prevention 0.042 (0.018 to 0.066) 0.001 
Risk-based prevention 0.037 (0.022 to 0.053) 0.000 
Either screening or risk-based prevention 0.004 (-0.026 to 0.034) 0.803 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
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 EOGBS early-onset group B Streptococcus disease 
Figure 13. Unadjusted trends of annual EOGBS incidence for each recently reported GBS 
prevention strategy using linear regression analysis 
 EOGBS early-onset group B Streptococcus disease 
Figure 14. Unadjusted trends of annual EOGBS incidence for each recently reported GBS 
prevention strategy using linear regression analysis excluding St. Augustine 
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Compositional covariates 
Compared with North America, the EOGBS incidence per 1,000 livebirths was higher in Latin 
America and the Caribbean (0.301, 95% CI 0.093 to 0.510), North Africa and the Middle East 
(0.758, 95% CI 0.398 to 1.116) and Sub-Saharan Africa (1.114, 95% CI 0.649 to 1.579) (see 
Table 27). Compared with national and mandatory surveillance, EOGBS incidence per 1,000 
livebirths was higher in surveillance from one centre (0.280 95% CI 0.151 to 0.410 and 0.230 
95% CI 0.062 to 0.397 respectively). As preterm births increased by one percent, EOGBS 
incidence increased by 0.048 per 1,000 livebirths (95% CI 0.027 to 0.070). As low 
birthweights increased by one percent, the rate of EOGBS incidence increased by 0.02 per 
1,000 livebirths (95% CI 0.009 to 0.031). For a one unit increase in fertility rate, EOGBS 
incidence increased by 0.148 per 1,000 livebirths (95% CI 0.007 to 0.290) while a one percent 
increase in multiple births led to an increase of 0.026 per 1,000 livebirths (95% CI 0.023 to 
0.030). A one percent increase in the prevalence of maternal GBS colonisation led to an 
increase in EOGBS incidence of 0.010 per 1,000 livebirths (95% CI 0.004 to 0.015).  
By contrast, EOGBS incidence per 1,000 livebirths decreased by 0.008 (95% CI -0.014 to -
0.003) with a one percent increase in caesarean sections and by 0.045 (95% CI -0.063 to -
0.028) when average maternal age increased by one year (see Table 27). EOGBS incidence 
per 1,000 livebirths decreased by 0.00005 (95% CI -0.00008 to -0.00002) when government 
health expenditure increased by one unit and by 2.522 (95% CI -3.314 to -1.731) as the human 
development index increased by one unit. The percentages of skilled attendance at delivery, 
prolonged rupture of membranes, EOGBS definition and intrapartum fever were not 
statistically associated with EOGBS incidence. There was no statistically significant 
difference in EOGBS incidence between serotype Ia and the other most prevalent GBS 
serotypes, however, as serotype V was below p=0.2, the most prevalent GBS serotype was 
taken forward into the adjusted analysis.   
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Table 27. Unadjusted linear regression analyses of EOGBS incidence per 1,000 livebirths by 
compositional covariates 
Covariate EOGBS coefficient  
(95% confidence interval) 
p-value  
Region    
North America (reference)  
Asia -0.004 (-0.233 to 0.225) 0.970 
Europe 0.000 (-0.186 to 0.187) 0.999 
Latin America and the Caribbean 0.301(0.093 to 0.510) 0.005 
North Africa and the Middle East 0.758 (0.398 to 1.116) 0.000 
Oceania -0.003 (-0.362 to 0.356) 0.985 
Sub-Saharan Africa 1.114 (0.649 to 1.579) 0.000 
Preterm births  0.048 (0.027 to 0.070) 0.000 
Low birthweights 0.020 (0.009 to 0.031) 0.001 
Caesarean section -0.008 (-0.014 to -0.003) 0.005 
Fertility rate 0.148 (0.007 to 0.290) 0.040 
Skilled attendance at delivery -0.003 (-0.016 to 0.010) 0.631 
Average maternal age -0.045 (-0.063 to -0.028) 0.000 
Multiple or twin birth 0.026 (0.023 to 0.030) 0.000 
Per capita government expenditure on health -0.00005 (-0.00008 to -0.00002) 0.001 
Human development index -2.522 (-3.314 to -1.731) 0.000 
Maternal GBS colonisation 0.010 (0.004 to 0.015) 0.001 
Prolonged rupture of membranes 0.004 (-0.006 to 0.014) 0.459 
Intrapartum fever 0.002 (-0.030 to 0.034) 0.911 
Most prevalent GBS serotype    
Ia (reference)  
Ib -0.019 (-0.286 to 0.247) 0.887 
III 0.060 (-0.0171 to 0.290) 0.612 
V 0.695 (-0.043 to 1.433) 0.065 
Surveillance type    
Mandatory population surveillance (reference)  
Voluntary population surveillance -0.201 (-0.398 to 0.004) 0.046 
Multiple centres/counties -0.031 (-0.233 to 0.169) 0.761 
One centre 0.230 (0.062 to 0.397) 0.007 
Geographical coverage   
National  (reference)  
Regional -0.116 (-0.327 to 0.096) 0.282 
City/town wide -0.192 (-0.598 to 0.214) 0.354 
One centre in a city/town 0.280 (0.151 to 0.410) 0.000 
EOGBS definition    
2/3 days or less (reference)  
5/6/7 days or less 0.113 (-0.027 to 0.253) 0.114 
Vertical onset 0.085 (-0.243 to 0.412) 0.612 
Not stated -0.412 (-1.283 to 0.459) 0.353 
EOGBS early-onset GBS disease, GBS group B Streptococcus   
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11.3.4 Adjusted linear regression analysis (objective e) 
This section presents the results of the linear regression analysis showing the relationship 
between the most recently reported GBS prevention strategy and the trends of annual EOGBS 
incidence across time adjusted for the compositional covariates (objective e): first for all data 
and then for the data excluding St. Augustine. 
All data 
Given the results of the unadjusted linear regression analyses and the a priori list of covariates, 
I included all of the covariates with the exception of skilled attendance at delivery in the initial 
adjusted regression analysis. As I removed statistically non-significant covariates (p>0.05), 
this left the minimal and final model shown in Table 28. The results of the adjusted analysis 
are summarised in Table 28 and Figure 15 for all data. In contrast with the unadjusted analysis, 
when compositional covariates were accounted for, there was no longer a decrease in annual 
EOGBS incidence in no prevention areas compared with screening prevention areas, nor a 
statistically significant difference in the trends of annual EOGBS incidence between no 
prevention and screening areas. In line with the unadjusted analyses, compared with screening 
prevention areas, the incidence of EOGBS increased by 0.040 (95% CI 0.026 to 0.055) yearly 
in risk-based prevention areas. In line with the unadjusted analysis, there was a decrease in 
annual EOGBS incidence in screening and ‘either prevention’ areas. However, the decrease 
of EOGBS incidence in screening prevention areas was larger than compared with ‘‘either 
prevention’’ areas, by 0.017 (95% CI 0.002 to 0.031) yearly. There was also a statistically 
significant difference in the trends of annual EOGBS incidence between risk-based prevention 
areas and no prevention areas (p<0.0001). The mean adjusted R2 for this model was 73%. 
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Table 28. Adjusted linear regression analyses of annual EOGBS incidence per 1,000 livebirths 
by recently reported GBS prevention strategy 
Most recent reported GBS prevention  Average annual change in EOGBS 
incidence (95% confidence interval) 
p-value 
All data   
Screening prevention (reference)  
No prevention 0.023 (-0.012 to 0.058) 0.194 
Risk-based prevention 0.040 (0.026 to 0.055) 0.000 
Either screening or risk-based prevention 0.017 (0.002 to 0.031) 0.026 
Excluding St Augustine    
Screening prevention (reference)  
No prevention 0.050 (0.022 to 0.078) 0.000 
Risk-based prevention 0.038 (0.023 to 0.053) 0.000 
Either screening or risk-based prevention 0.014 (-0.0002 to 0.029) 0.055 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
Models adjusted for region, preterm births, low birthweights, maternal GBS colonisation, prolonged rupture of 
membranes, intrapartum fever, human development index, multiple or twin births, geographical coverage, 
surveillance type, and EOGBS definition 
 
Excluding St. Augustine data 
The results of the final model excluding St. Augustine from the analysis are shown in Table 
28 and Figure 16. In line with the unadjusted analysis, there was a decrease in annual EOGBS 
incidence in screening prevention and ‘either prevention’ areas, and an increase in annual 
EOGBS incidence in no prevention and risk-based prevention areas. Compared with screening 
prevention areas, EOGBS incidence increased by 0.038 (95% CI 0.023 to 0.053) yearly in 
risk-based prevention areas and 0.050 (95% CI 0.022 to 0.078) yearly in no prevention areas. 
The difference in the trends of annual EOGBS incidence between no prevention areas and 
risk-based prevention areas was also statistically significant (p<0.0001). The difference in the 
trends of annual EOGBS incidence between screening prevention and ‘either prevention’ 
areas was not statistically significant. The mean adjusted R2 for this second model was 53%. 
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EOGBS early-onset group B Streptococcus disease 
Figure 15. Adjusted trends of annual EOGBS incidence for each recently reported GBS 
prevention strategy using linear regression analysis 
 
EOGBS early-onset group B Streptococcus disease 
Figure 16. Adjusted trends of annual EOGBS incidence for each recently reported GBS 
prevention strategy using linear regression analysis excluding St. Augustine   
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11.3.5 Sensitivity analysis of the adjusted linear regression analysis (objective f) 
This section presents the results of the sensitivity analyses for the model with all of the data 
and then for the model without St. Augustine data, as the adjusted relationship between 
universal GBS screening and the trend of annual EOGBS incidence across time was 
statistically different to other prevention strategies.  
All data 
Alterations in the analysis with all of the EOGBS data changed the results comparing no 
prevention or ‘either prevention’ areas with screening prevention areas. Analysing the most 
frequently reported GBS prevention strategy across the years instead of the most recently 
reported GBS prevention strategy (0.033 95% CI 0.013 to 0.054) and only including 
geographical areas with four or more years of data (0.051 95% CI 0.008 to 0.093) caused the 
difference in trends of annual EOGBS incidence between no prevention and screening 
prevention areas to become statistically significant. Both sensitivity analyses also made the 
difference in the trends of annual EOGBS incidence between screening prevention areas and 
‘either prevention’ areas to lose statistical significance (0.028 95% CI -0.009 to 0.065 and 
0.015 95% CI -0.0009 to 0.032, respectively). Similarly, removing outer fence box plot 
outliers (0.036 95% CI 0.011 to 0.060) and removing data from only centre (0.275 95% CI 
0.136 to 0.414) caused the difference in the trends of annual EOGBS incidence between no 
prevention areas and screening prevention areas to become statistically significant, possibly 
due to the removal of St. Augustine data. Removing outer fence box plot outliers also caused 
the difference in the trends of annual EOGBS incidence in ‘either prevention’ or screening 
prevention areas to lose statistical significance (0.010 95% CI -0.004 to 0.023).  
There were further sensitivity analyses that only caused the difference in the trends of annual 
EOGBS incidence between no prevention and ‘either prevention’ areas to lose statistical 
significance. One of these analyses was only including covariates with less than 10% of data 
imputed from another country (0.016 95% CI -0.001 to 0.0334). This also changed the 
direction of the trends in annual EOGBS incidence for no prevention areas (in line with the 
unadjusted analysis), although this did not reach statistical significance (-0.037 95% CI -0.099 
to 0.0245). The other analyses were: only keeping data defining EOGBS as 5/6/7 days or less 
(0.020 95% CI -0.0002 to 0.041), only using survey data (0.012 95% CI -0.003 to 0.026), 
using alternative geographical areas where more than one data source was available (0.014 
95% CI -0.004 to 0.033) and altering the maternal GBS colonisation rate to a lower rate where 
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ranges were available (0.016 95% CI, -0.0004 to 0.033). On the other hand, altering maternal 
GBS colonisation to a higher rate did not alter the results. 
Excluding St. Augustine data 
There were only three changes to the analysis excluding St Augustine that changed the results. 
All of the following changes caused a statistically significant difference in the trends of annual 
EOGBS incidence between screening prevention and ‘either prevention’ areas: only keeping 
data from more than one centre (0.025, 95% CI 0.010 to 0.040), only including variables with 
less than 10% of data imputed from other countries (0.015, 95% CI 0.0008 to 0.029), and only 
keeping the data defining EOGBS as 5/6/7 days or less (0.021, 95% CI 0.002 to 0.040). None 
of the other sensitivity analyses altered the results. 
11.3.6 Unadjusted multi-level repeated measures analysis (objective g) 
This section presents the results of the multi-level repeated measures regression analysis 
showing the unadjusted relationship between the most recently reported GBS prevention 
strategy and the trends of annual EOGBS incidence across time, accounting for the 
hierarchical structure of the data (objective g). Again, there was one analysis for all data and 
another for the data excluding St. Augustine.  
All data 
The results of the unadjusted multi-level analysis are summarised in Table 29 and Figure 17 
for all data. In contrast to the linear regression analyses, there were no statistically significant 
differences in the trends of annual EOGBS incidence between screening prevention areas and 
other prevention areas. The between-geographical area intercept variance (σ2u0) indicated that 
the estimated variability in the EOGBS incidence at year 2005 between geographical areas 
was 0.163 (95% CI 0.087 to 0.304). The between-geographical area slope variance (σ2u1) 
indicated that the variability in the pattern of EOGBS incidence between geographical areas 
was 0.003, (95% CI 0.002 to 0.006). Finally, the joint intercept-slope (σu01) covariance was -
0.013 (95% CI -0.024 to -0.002). The negative intercept-slope covariance with the positive 
estimates implies that geographical areas with lower than average EOGBS incidence at first 
year tended also to increase the most over the observation period. By contrast, geographical 
areas with higher than average EOGBS incidence at baseline tended to show above average 
decreases. The within geographical area variance (σ2e) shows that the variability in EOGBS 
incidence across the years within geographical areas was 0.067 (95% CI 0.057 to 0.079). The 
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statistically non-significant trends of EOGBS incidence shown in Figure 17 for each 
prevention area closely resembled each of the trends found in the adjusted linear regression.   
Table 29. Multi-level growth curve analysis on annual EOGBS incidence per 1,000 livebirths by 
recently reported GBS prevention strategy 
Variable Coefficient  
(95% confidence intervals) 
All data  
Fixed effects (Measures of association)  
GBS prevention strategy    
Screening prevention (reference) 
No prevention 0.016 (-0.048 to 0.080) 
Risk-based prevention 0.037 (-0.008 to 0.082) 
Either screening or risk-based prevention 0.010 (-0. 080 to 0.100) 
Random effects (Measures of variation)  
Between geographical area  
Between intercept variance 0.163 (0.087 to 0.304) 
Between slope variance 0.003 (0.002 to 0.006) 
Between intercept-slope variance -0.013 (-0.024 to -0.002) 
Within geographical area 0.067 (0.057 to 0.079) 
  
Excluding St Augustine data  
Fixed effects (Measures of association)  
GBS prevention strategy   
Screening prevention (reference) 
No prevention 0.078 (0.032 to 0.125) 
Risk-based prevention 0.030 (0.009 to 0.069) 
Either screening or risk-based prevention 0.009 (-0.051 to 0.069) 
Random effects (Measures of variation)  
Between geographical Area  
Intercept variance 0.0815 (0.041 to 0.161) 
Slope variance 0.001 (0.0006 to 0.003) 
Intercept-slope variance 0.0008 (-0.005 to 0.006) 
Within geographical area 0.066 (0.056 to 0.078) 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
Adjusted model adjusted for preterm births, maternal GBS, prolonged rupture of membranes, intrapartum fever, 
GBS serotype, surveillance type, geographical coverage, EOGBS definition  
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EOGBS early-onset group B Streptococcus disease 
Figure 17. Unadjusted trends of annual EOGBS incidence for each recently reported GBS 
prevention strategy using multi-level analysis 
Excluding St. Augustine data 
The results excluding St. Augustine data from the analysis are shown in Table 29 and Figure 
18. Similar to the adjusted linear regression analysis, there were decreases in annual EOGBS 
incidence in both screening and ‘either prevention’ areas, and increases in annual EOGBS 
incidence in both no prevention and risk-based prevention areas. Compared with screening 
prevention areas, the EOGBS incidence increased by 0.030 (95% CI 0.009 to 0.069) yearly in 
risk-based prevention areas and by 0.078 (95% CI 0.032 to 0.125) yearly in no prevention 
areas. The difference in the trends of annual EOGBS incidence between risk-based areas and 
no prevention areas was also statistically significant (p=0.0012). The difference in the trends 
of annual EOGBS incidence between screening prevention areas and ‘either prevention’ areas 
was not statistically significant. The between-geographical area intercept variance indicated 
that the estimated variability in the EOGBS incidence at year 2005 between geographical areas 
was 0.0815 (95% CI 0.041 to 0.161). The between-geographical area slope variance indicated 
that the variability in the pattern of EOGBS incidence between geographical areas was 0.001 
95% (CI 0.0006 to 0.003). However, the joint intercept-slope covariance was not (0.0008 95% 
CI -0.005 to 0.006). The within-geographical area variance shows that the variability in 
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EOGBS incidence across the years within geographical areas was 0.066 (95% CI 0.056 to 
0.078). 
 
EOGBS early-onset group B Streptococcus disease 
Figure 18. Unadjusted trends of annual EOGBS incidence for each recently reported GBS 
prevention strategy using multi-level analysis and excluding St Augustine 
 
11.4 Discussion 
In this discussion, I will summarise the findings of this study and compare the findings with 
previous literature. In Chapter 14, I will discuss the strengths and the limitations as well as the 
research and policy implications related to this study.  
11.4.1 Principal findings  
In this study, I aimed to investigate whether GBS prevention strategies, particularly universal 
screening, have an impact on the trends of annual EOGBS incidence across countries, 
adjusting for country differences. The findings suggest that the international trends of EOGBS 
may indeed be related to some prevention strategies. However, there was substantial 
uncertainty in the key results that follow. The most consistent trends across analyses were that 
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EOGBS incidence increased in areas that (most recently) reported risk-based prevention 
whereas it decreased in areas that reported universal screening. Based on the available 
evidence, the predicted values in risk-based prevention areas showed that EOGBS incidence 
increased from approximately 0.10 to 0.5 per 1,000 livebirths in the adjusted linear regression 
and approximately 0.3 to 0.75 per 1,000 livebirths in the unadjusted multi-level analysis 
during the study period. The predicted values in screening prevention areas showed that 
EOGBS incidence reduced from approximately 0.8 to 0.9 per 1,000 livebirths to 0.2 to 0.3 per 
1,000 livebirths in the unadjusted linear regression and from approximately 0.66 to 0.19 per 
1,000 livebirths in the unadjusted multi-level analysis during the study period. The difference 
in the trends of annual EOGBS incidence between risk-based and screening areas were 
statistically different in most analyses.  
By contrast, there was little evidence for a difference in the trends of annual EOGBS incidence 
between areas that reported universal screening and those that reported ‘either prevention’ 
strategy, as EOGBS incidence decreased across time in both. Results comparing no prevention 
with universal screening were complicated by greater uncertainty across the analyses, as 
different assumptions and models revealed conflicting EOGBS trends. When the countries’ 
contexts were not accounted for in the analyses, areas reporting no prevention showed a 
decrease in EOGBS incidence that was statistically different to those reporting universal 
screening. However, when countries’ contexts or time were accounted for, areas reporting no 
prevention either had an upward (and not a downward) trend that was statistically different to 
areas reporting universal screening, or little change in annual EOGBS incidence, which was 
not statistically different to screening.  
When comparing no prevention with screening, the inclusion of data from one centre in St. 
Augustine, that had no prevention, had a strong influence on the results. Including St. 
Augustine in the linear and multi-level regression analyses resulted in either a steeper decrease 
of EOGBS incidence in areas that most recently reported no prevention compared with 
universal screening, or no difference. In the adjusted linear regression and the unadjusted 
multi-level analysis, the predicted values identified the following trends in areas that reported 
no prevention during the study period, which were not different to universal screening: 
EOGBS incidence decreased from around 0.84 per 1,000 livebirths in 1990 to 0.74 in 2015, 
while in the adjusted linear regression EOGBS incidence decreased from 0.94 to 0.91 per 
1,000 livebirths. On the other hand, removing St. Augustine from the analyses showed that 
EOGBS incidence increased over time in areas that reported no prevention. The predicted 
values indicated that EOGBS incidence increased from 0.44 in 1990 to 1.11 per 1,000 
livebirths in 2015 in the adjusted linear regression and from -0.48 to 1.0 per 1,000 livebirths 
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in the unadjusted multi-level analysis, which were statistically significant compared with areas 
that reported universal screening. Data from St. Augustine were unusual as the rate of EOGBS 
incidence started at 5.41 per 1,000 livebirths in 1989. The EOGBS incidence in approximately 
90% of the observations was below 1.00 per 1,000 livebirths. The rate of EOGBS then reduced 
dramatically to 2.79 per 1,000 livebirths by 2002; the magnitude of this change was also higher 
than that observed in any other area.  
The findings on the EOGBS trends under risk-based versus universal screening prevention 
were more stable than no prevention compared with screening. All of the analyses showed 
that EOGBS incidence increased in areas that most recently reported risk-based prevention 
whereas it decreased under screening. However, in the multi-level analysis with all of the data 
(including St. Augustine), the difference between the increase under risk-based prevention 
was not statistically different to the decrease under screening. This may indicate that when 
accounting for the variance between geographical areas (which showed different intercepts, 
slopes and intercept-slopes for EOGBS incidence between areas), there is no difference 
between risk-based prevention and universal screening. On the other hand, when St. Augustine 
was removed from the multi-level analyses the difference in the trends of the two strategies 
were statistically different. Furthermore, if the multi-level analysis is re-run with the 
compositional covariates, the results might vary. Likewise, in general there was no difference 
in the downward trends in EOGBS incidence between screening and ‘either prevention.’ 
Although in the adjusted linear regression with all data, the difference in the trends of EOGBS 
incidence between universal screening and ‘either prevention’ reached statistical significance, 
in nine out of the 10 sensitivity analyses for this model, the statistical significance was lost.  
The results in this study when including St. Augustine may also be due to a statistical 
phenomenon known as regression to the mean, where an outcome that is extreme on the first 
measurement will be closer to the centre of the distribution for subsequent measurements.403, 
404The distribution of EOGBS incidence in this study was left-skewed with a group of 
observations that would be considered extreme. In this group was St. Augustine that had 
extreme incidence on the first measurement and then decreased closer towards the mean in 
subsequent years. Further supporting this possibility is the result in the multi-level unadjusted 
analysis including St. Augustine, which showed that geographical areas with lower than 
average EOGBS incidence at first year tended to increase the most over the observation period 
(which is the pattern found in risk-based prevention) and that areas with higher than average 
EOGBS incidence at baseline tended to show above average decreases (which is the pattern 
found in the remaining areas when all data are included). Therefore, it is possible that the 
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yearly changes that occurred over time were due to this statistical bias as opposed to a change 
as a result of any or no prevention strategy. 
Given these inconsistent findings, it is difficult to reach a conclusion on the association 
between GBS prevention strategy and EOGBS incidence. On the one hand, there are results 
from linear regression analyses with a reasonable sample size that did not account for the data 
structure (time nested within geographical area). On the other hand, there are results from 
multi-level analysis that did account for the data structure but did not account for confounding 
factors. All of these analyses have revealed different results. Screening consistently showed a 
downward trend of EOGBS incidence across the analyses while risk-based prevention 
consistently showed an upward trend. It is also likely that there is no difference in the EOGBS 
trends between screening and ‘either prevention’. However, there are important 
inconsistencies and uncertainties in these results. 
11.4.2 Comparison with previous literature 
As discussed in Chapter 2, there have been a number of studies comparing the rate of EOGBS 
incidence within an area, before and after changing the GBS prevention strategy from no or 
risk-based prevention to screening. Many of these studies show conflicting results; some in 
support of the findings from this study and some against. A meta-analysis in 2011 compared 
the rates of GBS sepsis during a screening period with a period of no or risk-based prevention 
that preceded screening, in eight studies published between 1994 and 2006. The authors found 
that across the US, Austria, Australia, Italy and Switzerland, there was less neonatal GBS 
sepsis compared with the periods of no (OR 0.43 95% CI 0.25 to 0.73) and risk-based 
prevention (OR 0.25, 95% CI 0.16 to 0.37).16 Similarly, another meta-analysis of seven studies 
across Turkey, Australia and the US in 2013 also found that the odds of EOGBS under risk-
based prevention were higher than under screening (OR 0.45, 95% CI 0.37 to 0.53).17 One of 
the main limitations of the reviews is that these figures were not adjusted for other differences 
during the screening and non-screening periods. In the current study, I have attempted to adjust 
for differences between areas with different prevention strategies, and the results on risk-based 
prevention compared with screening are in line with the reviews. Risk-based prevention does 
indeed appear to have higher and increasing rates of EOGBS compared with screening. The 
results without St. Augustine are also in line with review findings that under screening there 
is a lower EOGBS incidence than under no prevention. The current results conflict with the 
review when including St. Augustine. This may imply that other factors, possibly wider than 
GBS prevention, such as health system or gynaecology and obstetrics care improvements, can 
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contribute to a decrease in EOGBS incidence, especially in countries that have previously had 
very high rates. 
Related to this, a relatively recent study comparing EOGBS infections in a teaching hospital 
in Hungary between a period with no prevention and a period with screening, found decreases 
in the incidence of all EOGBS infections (0.36, 95% CI 0.26 to 0.49), GBS sepsis (0.27, 95% 
CI 0.12 to 0.58), and GBS pneumonia (0.19, 95% CI 0.11 to 0.32) (p=0.001 for all three 
comparisons).173 The rate of EOGBS reduced from a high of 7.55 to 2.44 per 1,000 livebirths. 
The rates of EOGBS in the Hungarian study were closest to the trends found in St. Augustine 
in this study, which showed a high rate of EOGBS that drastically reduced over time. 
However, in St. Augustine, this was not a result of prevention intervention. In the Hungarian 
study, no adjustment was made for confounding variables, therefore factors beyond the 
screening programme could have contributed to the decrease, as opposed to screening. 
Likewise, the decrease under screening could be due to regression to the mean bias as 
explained above.403, 404 
There has also been a recent review that pooled the rate of EOGBS incidence by the different 
GBS prevention strategies across countries, but did not statistically compare the rates. This 
review found that the pooled incidence of EOGBS across countries was 0.44 per 1,000 
livebirths (95% CI 0.36 to 0.51), which is similar to the mean incidence of EOGBS found in 
this study, 0.49 per 1,000 livebirths. The authors found that countries that adopted both 
screening in addition to risk-based policies had the lowest incidence at 0.38 per 1,000 
livebirths (95% CI 0.25 to 0.51), followed by screening only at 0.45 (95% CI 0.31 to 0.59), 
and the highest incidence was for countries adopting a risk-based prevention strategy (0.49, 
95% CI 0.34 to 0.65).405 Although, in this study, I did not categorise screening prevention into 
those that screen and offer IAP for risk factors, and those that only offer IAP based on the 
screening test, the results are comparable. Both screening or screen and risk-based prevention 
show lower rates than risk-based prevention alone.  
Since the pooled meta-analytic comparisons on risk-based versus screening prevention, 
smaller studies have reported inconsistent findings. In line with this study, research in the US 
found lower odds of developing EOGBS in NICU admissions during the screening period 
compared with the either risk-based or screening period in adjusted analyses (OR 0.69 
p<0.001).172 This analysis was adjusted for gestational age, sex, race, inborn status, 5-min 
APGAR, ventilator support on first postnatal data, prenatal steroid expose, prenatal antibiotic 
exposure and mode of delivery. In contrast to the results of this study, unadjusted results from 
another US study found that the incidence of EOGBS decreased after the introduction of a 
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risk-based strategy (2.06 to 0.96 per 1,000 livebirths) but did not reduce further in the era of 
screening (1.11 per 1,000 livebirths).170 Likewise, a recent study in one UK maternity unit 
found that EOGBS fell from 0.99 per 1,000 livebirths in the risk-based period to 0.33 per 
1,000 livebirths during the screening period; however, this did not reach statistical 
significance in unadjusted analyses (p=0.08).34 Recently, a model developed by the NSC 
based on the best available evidence and expert opinion, found that the number of EOGBS 
cases would be lower under screening and risk-based prevention as it would prevent 52 to 57 
cases compared with risk based prevention alone.177 
Overall, the existing evidence from literature on the impact of GBS prevention strategies on 
EOGBS incidence reflects the inconsistency and uncertainty found in this study. Trends in 
EOGBS incidence might indeed decrease under screening compared with risk-based and no 
prevention, however, whether this decrease is statistically or clinically significant is not clear. 
 
11.5 Conclusions for this chapter 
 Findings from this chapter have highlighted that GBS prevention strategies may be 
associated with international trends of EOGBS incidence per 1,000 livebirths. 
 In areas that most recently reported a risk-based prevention, EOGBS incidence 
increased by around 0.4 to 0.5 per 1,000 livebirths in 27 years. In areas that most 
recently reported universal screening, there was a decrease in EOGBS incidence by 
approximately 0.5 to 0.6 per 1,000 livebirths in 27 years, while in those that reported 
‘either prevention’ strategy, there was a decrease of around 0.2 per 1,000 livebirths.  
 These trends were quite consistent across the analyses and, in general, the differences 
in the average change in annual EOGBS incidence between risk-based prevention and 
screening were statistically significant across most analyses. However, the difference 
between universal screening and ‘either prevention’ in the majority of the analyses 
was not.  
 While the comparison of adopting universal screening with risk-based prevention was 
relatively consistent, the result must be treated with caution as it contains important 
limitations and some instability across the analyses.  
 Areas that most recently reported no GBS prevention displayed conflicting findings, 
with some analyses showing an increase and others a decrease in EOGBS incidence. 
Further examination showed that this might be due to outlying data trends and/or other 
factors contributing to EOGBS incidence.   
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12. THE IMPACT OF UNIVERSAL GBS SCREENING ON 
THE TRENDS OF ANNUAL EARLY-ONSET SEPSIS 
INCIDENCE 
This chapter presents the results for the ecological trend analysis study that combines 
international data to explore the impact of universal GBS screening on the trends of annual 
early-onset sepsis incidence, compared with other GBS prevention strategies. While I 
discussed the methodology used to address this study in Chapter 9, here I will first present the 
study specific aim and objectives followed by some study specific methodological procedures. 
I will then present the detailed results from the statistical analyses: first the MICE imputation 
results, then the descriptive statistics, followed by the unadjusted analyses and the main 
adjusted model. Finally, I will summarise the principal findings and how they relate to 
previous literature.  
 
12.1 Aims and objectives 
The aim of this chapter is to measure the effect of universal GBS screening on the trend of 
annual early-onset sepsis incidence across time, compared with other GBS prevention 
strategies, in a statistical model that combines data from geographical areas with different 
prevention strategies, and adjusts for compositional differences between the areas.  
The research objectives are to:  
a) Describe the frequency of the GBS prevention strategy as well as the mean or 
frequency of the compositional covariates in general (irrespective of early-onset 
sepsis incidence); 
b) Describe the mean early-onset sepsis incidence across time, geographical areas, world 
regions and GBS prevention strategies; 
c) Investigate the unadjusted relationship between universal GBS screening and the 
trend of annual early-onset sepsis incidence across time compared with other 
prevention strategies, using linear regression; 
d) Investigate the unadjusted relationship between each compositional covariate and the 
mean early-onset sepsis incidence across time, using linear regression; 
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e) Investigate the relationship between universal GBS screening and the trend of annual 
early-onset sepsis incidence across time compared with other prevention strategies, 
using linear regression and adjusting for the compositional covariates; and 
f) Examine the stability of the adjusted relationship between universal GBS screening 
and the trend of annual early-onset sepsis incidence across time compared with other 
prevention strategies in a range of sensitivity analyses, if the relationship was 
statistically significant. 
 
12.2  Methods 
I have detailed the methodology used for this study in Chapter 9. Here, I describe the data 
selected to perform the analysis.  
12.2.1 Geographical data included 
As discussed in Chapter 10, there were annual early-onset sepsis data from 28 geographical 
areas. However, some of them overlapped in terms of coverage, giving rise to the potential of 
double-counting. These were: Alberta that overlapped with multi-centre data across Canada; 
data from Barcelona versus multiple centres across Spain; and data from multiple centres 
versus enhanced surveillance in New Zealand. I chose Alberta as it had population-based and 
mandatory surveillance; multi-centres from Spain to have broader national coverage; and the 
enhanced surveillance for New Zealand. This left 25 geographical areas. However, after 
analysing the early-onset sepsis incidence across the years and countries, I excluded Mansoura 
City in Egypt where the rate of early-onset sepsis incidence for 2014 was 72.46 per 1,000 
livebirths. This rate was an extreme outlier from the remaining data and was vastly different 
from the incidence rates in the UK. This left data from a total of 24 geographical areas in the 
analyses that follow. 
Further descriptive analyses also revealed that Mexico City had a strong influence on the 
descriptive trends of early-onset sepsis incidence over time. However, as the incidence rates 
themselves were not extreme outliers, I ran the unadjusted and adjusted linear regression 
separately with and without Mexico City.  
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12.2.2 Compositional covariates included 
The list of compositional covariates included in the analyses that follow was shorter than the 
list in the EOGBS analyses in Chapter 11, as the sample size was considerably smaller, thus, 
the model needed to be simplified. I prioritised the following compositional covariates that 
were theoretically most important and investigated them in the unadjusted analyses, while the 
others mentioned in Chapter 11 were excluded: preterm births, low birthweights, maternal 
GBS colonisation, prolonged rupture of membranes and intrapartum fever (as they are strong 
risk factors for neonatal sepsis and EOGBS) and the human development index, world region, 
surveillance type, geographical coverage and early-onset sepsis definition (to account for 
crucial limitations in the data collection methods). 
 
12.3 Results 
12.3.1 Multiple imputation for compositional covariates 
There were 32 (20%) observations that had complete compositional covariate data for every 
year. The proportion of missing data is shown in Table 30. Of the covariates that were included 
in the analyses, preterm births had the largest amount of missing data with 63% of years 
missing. This was followed closely by the human development index, which had 60% of years 
missing, and, finally, low birthweights with 51% of years missing.  
Table 30. Proportion of missing data in compositional covariates used for the early-onset sepsis 
dataset 
 
 
There were multiple patterns of missing data. The most common pattern was for none of the 
covariates to be observed, followed by all covariates observed, only low birthweights to be 
observed, both only the human development index to be observed and only low birthweights 
and preterm births to be observed, low birthweights and the human development index to be 
observed, only preterm births to be observed and finally the human development index and 
preterm births to be observed. The logistic regression for whether the missingness of a variable 
was related to the other variables revealed that the missingness of preterm births was related 
to early-onset sepsis definition and multiple births. Missingness of low birthweights was 
Variable Observed (%) Missing (%) 
Preterm births 60 (37) 102 (63) 
Low birthweights 79 (49) 83 (51) 
Human development index 64 (40) 98 (60) 
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related to year and early-onset sepsis definition. Missingness of the human development index 
was related to year. As data were missing because they were available from some years but 
not others and their missingness was related to other data, the mechanism for the missing data 
was ‘missing at random’. 
As mentioned in Chapter 9, there were 100 imputations because of the large amount of missing 
data and the results showed that convergence was reached within these imputations. 
Additionally, the largest fraction of missing information (FMI) from the analysis models was 
68%, confirming that the number of imputations was sufficient. Below, I present the 
descriptive statistics for some of the imputed datasets and the original dataset for comparison. 
12.3.2 Descriptive analysis (objectives a & b) 
This section presents the mean early-onset sepsis incidence across time, geographical areas, 
world regions and GBS prevention strategies (objective b) as well as the frequency of the GBS 
prevention strategy and the mean or frequency of the compositional covariates in general 
(irrespective of early-onset sepsis incidence) (objective a).  
Early-onset sepsis incidence 
The mean early-onset sepsis incidence across 162 observations (24 geographical areas, 22 
years between 1992 and 2015) was 4.87 per 1,000 livebirths (SD 8.00, range: 0.00 to 39.95). 
Across the years, early-onset sepsis incidence varied between 1.09 and 11.74 per 1,000 
livebirths (see Table 31). Figure 19 shows the scatterplot of all early-onset sepsis incidence 
observations by year. It shows that there were two patterns within the data: one with rates of 
early-onset sepsis lower than 10 per 1,000 livebirths that increased over time, and another with 
a random scatter between 10 to 40 cases of early-onset sepsis per 1,000 livebirths. These 
patterns may be reflective of trends over time or a result of different geographical areas that 
contributed to each year (see Table 31).   
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Table 31. Early-onset sepsis incidence per 1,000 livebirths across the years 
 
Each dot represents the early-onset sepsis incidence for one year for one geographical area 
Figure 19. Scatterplot of early-onset sepsis incidence by year 
Year Number of 
geographical areas 
Mean livebirths 
(Standard deviation) 
Mean early-onset sepsis incidence 
(Standard deviation) 
1992 1 247,076.00 1.09 
1995 2 4,425.50 (1,918.38) 8.06 (8.17) 
1996 5 17,810.40 (29,733.50) 4.90 (4.64) 
1997 4 24,977.75 (40,981.75) 7.31 (9.21) 
1998 3 4,445.00 (1,410.28) 11.74 (17.28) 
1999 4 24,303.75 (39,162.95) 9.60 (15.70) 
2000 4 23,055.00 (36,951.62) 9.45 (16.20) 
2001 2 37,205.67 (54,612.31) 8.37 (12.79) 
2002 4 37,479.25 (46,222.46)  8.20 (13.48) 
2003 6 29,135.00 (33,907.51) 5.53 (9.99) 
2004 6 25,592.83 (29,493.70) 5.28 (9.75) 
2005 10 64,389.90 (139,861.70) 3.88 (8.52) 
2006 11 62,819.36 (135,090.70) 3.26 (6.94) 
2007 12 59,229.42 (133,392.60) 2.62 (4.41) 
2008 14 57,883.00 (124,832.50) 3.87 (6.63) 
2009 13 25,184.85 (36,798.35) 3.59 (5.91) 
2010 13 34,245.85 (45,417.99) 3.97 (6.62) 
2011 12 33,406.92 (40,865.52) 5.47 (11.11) 
2012 14 39,306.21 (48,879.46) 4.06 (8.06) 
2013 13 20,173.77 (30,923.28) 4.02 (3.38) 
2014 7 4,554.71 (3,458.30) 6.24 (3.68) 
2015 1 2,195.00 6.38 
Total 162 observations  
(24 areas, 22 years) 
37,738.85 (78,582.26) 4.87 (8.00) 
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Plotting the early-onset sepsis incidence by year reveals that the pattern of high early-onset 
sepsis incidence above 10 per 1,000 livebirths increasing to almost 40 per 1,000 livebirths is 
from one geographical area of Mexico City (see Appendix 16-A). Excluding Mansoura City, 
the highest mean early-onset sepsis incidence per 1,000 livebirths across years was found in 
Mexico City (24.52 [SD 8.20]) followed by St. Augustine in Trinidad and Tobago (10.18). 
Removing Mexico City gave a mean early-onset sepsis incidence of 2.26 per 1,000 livebirths 
(SD 2.34, range 0.00 to 10.18). The lowest mean early-onset sepsis incidence per 1,000 
livebirths across years was found in Alberta (0.21 [SD 0.08]) followed by Switzerland (0.30 
[SD 0.18]) (see Table 32). These are the averages across the years for each geographical area 
but, as can be seen in Appendix 16-A, for many areas the rates fluctuated from the first year 
to the last.  
Table 32. Early-onset sepsis incidence per 1,000 livebirths by geographical area 
Geographical area Number 
of years 
Mean number of livebirths 
(Standard deviation) 
Mean early-onset sepsis incidence 
(Standard deviation) 
Alberta 11 47,896.00 (4,854.45) 0.21 (0.08) 
Australia 11 29,199.82 (4,802.03) 2.24 (0.51) 
Bangalore 3 4,044.33 (1,605.77) 5.68 (0.72) 
Buenos Aires 18 6,473.22 (923.54) 0.68 (0.32) 
Cordoba 2 1,573.00 (152.74) 6.12 (4.80) 
Emilia-Romagna 1 146,682.00 0.61 
Guangzhou 3 2,109.33 (323.93) 7.24 (3.00) 
Kaunas 7 3,524.86 (194.83) 5.18 (2.15) 
Kingston 12 2,619.58 (326.72) 2.59 (1.03) 
Kuala Terengganu 4 11,637.50 (755.55) 0.92 (0.42) 
Kuwait 10 11,074.10 (486.46) 3.52 (1.14) 
Macau 10 2,667.70 (697.83) 0.84 (0.77) 
Manila 1 6,682.00 10.18 
Mexico City 19 5,055.11 (593.10) 24.52 (8.20) 
New Zealand 1 127,134.00 0.49 
Panama City 1 247,076.00 1.09 
Portugal 6 95,824.83 (8,100.16) 5.13 (0.20) 
Riga 1 2,060.00 9.71 
Spain 16 96,036.63 (13,710.00) 1.35 (0.51) 
St Augustine 1 4,910.00 10.18 
Switzerland 3 81,901.00 (988.11) 0.30 (0.18) 
Tokyo 11 1,627.73 (192.71) 1.05 (0.93) 
US 4 464.044.30 (9,575.21) 0.35 (0.06) 
Zagreb 6 4,254.50 (102.26) 3.22 (2.52) 
Total 162 37,738.85 (78,582.26) 4.87 (8.00) 
US United States of America 
Taking a broader global perspective, the highest mean early-onset sepsis per 1,000 livebirths 
was reported in Latin America and the Caribbean (10.05 [SD 12.08]), probably due to the 
influence of high incidences from Mexico City. The lowest incidence was reported in North 
America (0.25 per 1,000 livebirths [SD 0.10]), which was much lower than incidences found 
in the other regions. Asia, Europe, Oceania and North Africa and the Middle East had early-
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onset sepsis rates around two to four per 1,000 livebirths (see Table 33). Again, these rates 
vary across time and, within regions, may fluctuate by year as shown in the scatterplots of 
early-onset sepsis incidence by world region presented in Appendix 16-B.  
Table 33. Early-onset sepsis incidence per 1,000 livebirths by region 
Region Number of observations/ 
years (%) 
Mean early-onset sepsis incidence 
(standard deviation) 
Asia 32 (19.75) 2.27 (2.83) 
Europe 40 (24.69) 2.98 (2.48) 
Latin America and the Caribbean 53 (32.72) 10.05 (12.08) 
North Africa and the Middle East 10 (6.17) 3.52 (1.14) 
North America 15 (9.26) 0.25 (0.10) 
Oceania 12 (7.41) 2.10 (0.70) 
Total 162 (100.00) 4.87 (8.00) 
 
Finally, the mean early-onset sepsis incidence by most recently reported GBS prevention 
strategy is presented in Table 34. The highest mean incidence per 1,000 livebirths was reported 
under no prevention (14.78 [SD 12.81]), which was much higher than the other prevention 
strategies. This was followed by risk-based prevention (2.88 [SD 1.95]), which was closely 
followed by either risk-based or screening prevention (2.24 [SD 0.51]) and finally screening 
prevention (2.03 [SD 2.46]), all of which had relatively similar incidences. Figure 20 shows 
the scatterplot for early-onset sepsis incidence by the most recently reported GBS prevention 
strategy. There was a potential increase in early-onset sepsis incidence in areas that reported 
universal screening and a potential decrease in areas that reported either risk-based or 
screening prevention. There was a mixed pattern in areas that reported risk-based prevention 
whereby incidence initially increased until 1998, then decreased until 2000, followed by a 
period of no data until approximately 2005, after which there was an increase. Under no 
prevention, there was a random pattern and a substantial impact of data from Mexico City as 
the plot shows the same pattern. 
Table 34. Early-onset sepsis incidence per 1,000 livebirths by recently reported GBS prevention 
strategy 
Most recent GBS prevention  Number of 
observations/years 
(%) 
Mean early-onset sepsis 
incidence (standard 
deviation) 
No prevention 34 (20.99) 14.78 (12.81) 
Risk-based prevention  28 (17.28) 2.88 (1.95) 
Screening prevention 89 (54.94) 2.03 (2.46) 
Either risk-based and screening 
prevention 
11 (6.79) 2.24 (0.51) 
Total 162 (100) 4.87 (8.00) 
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Each dot represents the early-onset incidence for one year for one geographical area.  
Figure 20. Scatterplot of early-onset sepsis by most recently reported GBS prevention strategy 
 
Predictor and compositional covariates 
Most geographical areas (and observations) recently reported a screening strategy (55% of 
observations and 54% of areas), followed by no prevention (21% of observations and 21% of 
areas), risk-based prevention (17% of observations and 21% of areas) and risk-based or 
screening prevention (7% of observations and 4% of areas) (see Table 35 and Table 17). With 
respect to world region, the majority of observations were from Latin America and the 
Caribbean (33%) and the fewest were from North Africa and the Middle East (6%). There 
were no data from Sub-Saharan Africa (see Table 33).  
Table 35. Frequency of geographical areas for recently reported GBS strategy for the early-
onset sepsis dataset 
Most recent GBS prevention strategy Frequency (%) 
No prevention 5 (21) 
Risk-based prevention  5 (21) 
Screening prevention 13 (54) 
Either risk-based and screening prevention 1 (4) 
Total 24 (100) 
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The mean values for the compositional covariates that were multiple imputed are presented in 
Table 36. Averages are provided for the data with no imputation, followed by imputed datasets 
1 and 100, to provide an indication of how well the multiple imputation performed. The mean 
percentage of preterm births across the years in the original dataset was 10.91% (SD 5.32) and 
the imputed means were around 9.27% to 9.37%, therefore, within 1.64% of the original mean. 
Similarly, the mean percentage of low birthweights was 12.93% (SD 8.39) and the imputed 
mean values were around 10.5% and 11%, thus, within 2.4% of the original mean. By contrast, 
the imputation for the human development index performed better, as the mean value was the 
same across the datasets at 0.81 (SD 0.08). 
Table 36. Mean values for multiple imputed compositional covariates for the early-onset sepsis 
dataset 
Covariate Original dataset 
Mean (SD) 
Imputed dataset 1 
Mean (SD) 
Imputed dataset 2 
Mean (SD) 
Preterm births (%) 10.91 (5.32) 9.27 (4.08) 9.37 (4.32) 
Low birthweights (%) 12.93 (8.39) 10.49 (7.32) 11.02 (8.53) 
Human development index 0.81 (0.08) 0.81 (0.08) 0.81 (0.08) 
 
The mean values for compositional covariates that only had one value across all of the years 
and, thus, were not multiple imputed are presented in Table 37. Across the geographical areas, 
maternal colonisation of GBS was approximately 16.45% (SD 10.28), the mean percentage of 
prolonged rupture of membranes was 7.09% (SD 6.28) and intrapartum fever was 1.92% (SD 
2.53). Most data covered one centre only (65.43%), followed by multiple centres (27.16%) 
and mandatory/enhanced surveillance (7.41%). After data from one centre, most data covered 
a country (25.31%), a region (7.41%) or were city or town-wide (1.85%). Finally, the most 
common definition of early-onset sepsis was 2/3/4 days or less (45.06%), followed by 5/6/7 
days or less (41.36%) and vertical onset/mother-acquired (13.58%).   
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Table 37. Mean values for un-imputed compositional covariates for the early-onset sepsis 
dataset 
Covariate Descriptive statistic 
Continuous variables Mean (SD) 
Maternal GBS colonisation 16.45 (10.28) 
Prolonged rupture of membranes 7.09 (6.28) 
Intrapartum fever 1.92 (2.53) 
  
Categorical variables Frequency (%) 
Surveillance type  
     Mandatory or enhanced population surveillance 12 (7.41) 
     Multiple centres/counties 44 (27.16) 
     One centre 106 (65.43) 
Geographical coverage  
     National 41 (25.31) 
     Regional 12 (7.41) 
     City/town wide 3 (1.85) 
     One centre in a city/town 106 (65.43) 
Early-onset sepsis definition  
     2/3/4 days or less 73 (45.06) 
     5/6/7 days or less 67 (41.36) 
     Vertical onset/Mother-acquired 22 (13.58) 
 
12.3.3 Unadjusted linear regression analysis (objective c & d) 
This section presents the results of the linear regression analysis showing the unadjusted 
relationship between most recently reported GBS prevention strategy and the trends of annual 
early-onset sepsis incidence across time for all data and then for the data excluding Mexico 
City (objective c). This is followed by the linear regression analysis showing the unadjusted 
relationship between each compositional covariate and mean early-onset sepsis incidence 
(objective d).  
Most recently reported GBS prevention strategy  
The results of the unadjusted analysis are summarised in Table 38 and Figure 21. Contrary to 
expectation, there was a continuous decrease in annual early-onset sepsis incidence in areas 
with no prevention. Compared with screening prevention areas, the early-onset sepsis 
incidence decreased by 0.706 (95% CI -1.130 to -0.281) yearly in no prevention areas. There 
were no statistically significant differences in the trends of annual early-onset sepsis incidence 
in screening prevention areas compared with risk-based prevention or ‘either prevention’ 
areas. When Mexico City was excluded, there was still a continuous decrease in annual early-
onset sepsis incidence in no prevention areas compared with screening areas (-0.047 95% CI 
-0.419 to -0.003), however, the slope was no longer as steep as the analysis including Mexico 
City (see Figure 22). 
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Table 38. Unadjusted and adjusted linear regression analyses on the average annual change in 
early-onset sepsis incidence per 1,000 livebirths by recently reported GBS prevention strategy  
Most recent reported GBS prevention 
 
Average annual change in early-
onset sepsis (95% confidence 
interval) 
p-value 
Unadjusted analysis   
     Screening prevention (reference)  
     No prevention  -0.706 (-1.130 to -0.281) 0.001 
     Risk-based prevention -0.051 (-0.559 to 0.456) 0.842 
Either risk-based and screening 
prevention 
-0.289 (-1.458 to 0.880) 0.626 
Adjusted analysis    
     Screening prevention (reference)  
     No prevention 0.002 (-0.834 to 0.838) 0.996 
     Risk-based prevention -0.089 ( -0.449 to 0.271) 0.625 
Either risk-based and screening 
prevention 
-0.244 (-0.597 to 0.110) 0.174 
GBS group B Streptococcus  
Adjusted analysis adjusted for region, preterm births, low birthweights, maternal GBS colonisation, human 
development index, geographical coverage, surveillance type, and early-onset sepsis definition. 
 
 
Figure 21. Unadjusted trends of annual early-onset sepsis incidence by recently reported GBS 
prevention strategy  
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Figure 22. Unadjusted trends of annual early-onset sepsis incidence by recently reported GBS 
prevention strategy excluding Mexico City 
Compositional covariates  
Compared with North America, the early-onset sepsis incidence was 9.803 per 1,000 livebirths 
higher in Latin America and the Caribbean (95% CI 5.643 to 13.963), though this may have 
been because of Mexico City (see Table 39). As low birthweights increased by one percent, 
the rate of early-onset sepsis incidence increased by 0.641 per 1,000 livebirths (95% CI 0.446 
to 0.836). Compared with national and mandatory surveillance, early-onset sepsis incidence 
per 1,000 livebirths was higher in surveillance from one centre (4.550 95% CI 1.745 to 7.354 
and 6.235 95% CI 1.615 to 10.892, respectively). By contrast, early-onset sepsis incidence 
decreased by 44.525 as the human development index increased by one unit (95% CI -59.338 
to -29.711). Early-onset sepsis also decreased by 0.311 per 1,000 livebirths (95% CI -0.423 to 
-0.200) when maternal GBS colonisation increased by one percent; by 0.483 per 1,000 
livebirths (95% CI -0.667 to -0.299) when prolonged rupture of membranes increased by one 
percent; and by 0.846 (95% CI -1.322 to -0.370) when intrapartum fever increased by one 
percent. This may be a result of antibiotics given for these factors. Finally, compared with 
2/3/4 days or less, early-onset sepsis was lower when defined as 5/6/7 days or less (-6.446 
95% CI -8.936 to -3.996) or vertical onset/mother-acquired (-5.972 CI -9.522 to -2.422). The 
percentage of preterm births was not statistically associated with early-onset sepsis incidence.  
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Table 39. Unadjusted linear regression analyses of early-onset sepsis incidence per 1,000 
livebirths by compositional covariate 
Covariate Early-onset sepsis coefficient  
(95% confidence interval) 
p-value 
Region    
North America (reference)  
Asia 2.019 (-2.432 to 6.470 0.372 
Europe 2.731 (-1.576 to 7.037) 0.212 
Latin America and the Caribbean 9.803 (5.643 to 13.963) 0.000 
North Africa and the Middle East 3.267 (-2.541 to 9.074) 0.268 
Oceania 1.848 (-3.661 to 7.357) 0.509 
Preterm births  -0.015 (-0.488 to 0.183) 0.370 
Low birthweights 0.641 (0.446 to 0.836) 0.000 
Human development index -44.525 (-59.338 to -29.711) 0.000 
Maternal GBS colonisation -0.311 (-0.423 to -0.200) 0.000 
Prolonged rupture of membranes -0.483 (-0.667 to -0.299) 0.000 
Intrapartum fever -0.846 (-1.322 to -0.370) 0.001 
Surveillance type     
Mandatory population surveillance (reference)  
Multiple centres/counties 1.958 (-3.002 to 6.917) 0.437 
One centre 6.253 (1.615 to 10.892) 0.009 
Geographical coverage    
National (reference)  
Regional -1.703 (-6.707 to 3.301) 0.502 
City/town wide 3.727 (-5.391 to 12.846) 0.421 
One centre in a city/town 4.550 (1.745 to 7.354) 0.002 
Early-onset sepsis definition    
2/3/4 days or less (reference)  
5/6/7 days or less -6.466 (-8.936 to -3.996) 0.000 
Vertical onset/Mother-acquired -5.972 (-9.522 to -2.422) 0.001 
 
12.3.4 Adjusted linear regression analysis (objective e) 
This section presents the results of the linear regression analysis showing the relationship 
between the most recently reported GBS prevention strategy and the trends of annual early-
onset sepsis incidence adjusted for the compositional covariates (objective e).  
Given the results of the unadjusted linear regressions and the a priori list, I included all of the 
covariates in the initial adjusted analysis. As I removed statistically non-significant covariates 
(p>0.05), this left the minimal and final model shown in Table 38. As shown in Figure 23, 
when the compositional covariates were accounted for, the trends in annual early-onset sepsis 
incidence decreased in ‘either prevention’ areas, increased in no prevention and screening 
prevention areas and remained stable in risk-based prevention areas. However, compared with 
screening prevention areas, the trends of annual early-onset sepsis in any of the other 
prevention areas were not statistically different (see Table 38). In contrast with the unadjusted 
analysis, the difference in the trends in annual early-onset sepsis incidence between no 
prevention and screening prevention areas lost statistical significance (0.002 95% CI -0.834 
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to 0.838). These results did not change when Mexico City was removed from the model. The 
mean adjusted R2 for this model was 82%. As the adjusted relationship between universal GBS 
screening and the trend of annual early-onset sepsis incidence across time was not statistically 
different to other prevention strategies, I did not explore sensitivity analyses (objective f).  
 
Figure 23. Adjusted trends of annual early-onset sepsis incidence by recently reported GBS 
prevention strategy 
 
12.4 Discussion  
In this discussion, I will summarise the findings of this study and compare the findings with 
previous literature. In Chapter 14, I will discuss the strengths and the limitations as well as the 
research and policy implications related to this study.  
12.4.1 Principal findings  
In this study, I aimed to investigate whether GBS prevention strategies, particularly universal 
screening, have an impact on the trends of annual early-onset sepsis incidence across 
countries. The key finding was that international trends of early-onset sepsis are unrelated to 
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any of the prevention strategies. Based on the available evidence, the predicted values showed 
that early-onset sepsis increased from approximately 2.5 to 4 per 1,000 livebirths in screening 
prevention areas and from approximately -0.1 to 1.0 per 1,000 livebirths in no prevention 
areas, during the study period. In risk-based prevention areas, the predicted values showed 
that early-onset sepsis remained stable across time whereas in ‘either prevention’ areas it 
decreased. However, none of these differences between the different prevention areas and 
screening areas were statistically significant. 
There are many possible explanations for the findings of this study. It could be that the most 
recent GBS prevention strategy has no relationship with the trends in early-onset sepsis. While 
universal GBS screening might reduce EOGBS incidence (as shown in some of the results in 
Chapter 11), it may have no impact on the trends of overall early-onset sepsis. The differences 
in the findings between the two chapters may reflect IAP in the blood preventing GBS 
detection or IAP producing changes in the organisms causing early-onset sepsis. However, 
the results of this study could equally be due to the lack of statistical power from the small 
sample size in this study. As identified in Chapter 9, 63 observations in each prevention 
strategy provided an 80% chance to detect a change of 0.1 per 1,000 livebirths. Accounting 
for the imbalances between the observations in each prevention group, the sample size 
achieved was 20 per prevention group for the comparison of either versus screening 
prevention, 41 for risk-based versus screening prevention, and 48 for no versus screening 
prevention. With these sample sizes, there was only a 50% or lower chance of observing a 
statistically significant annual difference of 0.1 per 1,000 livebirths between the interventions. 
The annual differences found between the prevention strategies were below 0.1 per 1,000 
livebirths and, therefore, the sample size may have been too small for these differences to be 
statistically significant.  
To conclude, the results indicate that universal GBS screening or other prevention strategies 
may not have an impact on the trends of annual early-onset sepsis incidence. However, this 
study was statistically under-powered and the resulting findings are uncertain. Alternative 
results might be found if a larger sample size were analysed. 
12.4.2 Comparison with previous literature 
While the results of this study are uncertain, there is evidence that supports the finding that 
GBS screening does not reduce neonatal sepsis. For example, the first multi-state population 
study exploring the rates of early-onset sepsis in the US under universal screening found that 
the incidence remained constant at around 0.77 per 1,000 livebirths between 2005 and 2008.175 
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Another multi-state US study published in 2016 also reported a stable incidence of early-onset 
sepsis between 0.77 and 0.79 per 1,000 livebirths from 2005 to 2014.87 In the UK, a multi-
centre study reported that the incidence of early-onset sepsis in NICU admissions was steady 
under risk-based prevention, with no differences across 2006, 2007, and 2008  (p>0.1).99 
Earlier multi-centre studies in the US during the 1990s where either risk-based or screening 
strategies were implemented have shown similar stable trends.406, 407 However, all of these 
neonatal sepsis trends were during periods of one particular GBS prevention strategy and did 
not compare the trends in one strategy with another.  
One of the early multi-centre studies compared a period of no prevention (1991 to 1993) with  
risk-based or screening prevention (1998 to 2000) in 15 centres across the US, finding no 
difference between the periods (19.3 per 1,000 livebirths in the no prevention period and 15.4 
per 1,000 livebirths in the risk-based or screening period).20 However, this study was only in 
the low birthweight population (<1500g) and may not be generalisable to all neonates. On the 
other hand, another study in the US found that the average annual percent decrease in neonatal 
sepsis hospitalisations for term infants during 1996 to 2001 when risk-based prevention or 
universal screening were recommended was statistically significant (-3.6%, 95% CI -5.1 to 
2.0%), however after 2002 when only universal screening was introduced the average annual 
percent change was not statistically significant.174 Although these results are in contrast to 
those found in this study, the authors of this study did not adjust the analysis for any 
confounding factors beyond the GBS prevention strategy which might be the reason for the 
differences in results. Alternatively, it may because this study lacked statistical power in this 
study or that this analysis was on all neonatal sepsis. Indeed, when using a proxy for early-
onset sepsis (term infants diagnosed with sepsis during delivery with admission and discharge 
within ten days of birth), the authors found no difference in the average annual percent change 
between 1988 and 2006. However, when comparing the average incidence of ‘early-onset’ 
sepsis hospitalisations per 1,000 livebirths in the periods of universal screening (10.3) and 
‘either prevention’ (11.4) with no prevention (14.3), the differences were statistically 
significant. Annual differences in early-onset sepsis may not be large enough to reach 
statistical significance.  
Trends in early-onset sepsis might not reduce in screening programmes as widespread IAP 
may decrease EOGBS, yet increase gram-negative organisms causing sepsis, resulting in no 
overall reduction. There has been increasing evidence investigating sepsis caused by E. coli, 
the largest gram-negative organism causing neonatal sepsis. Two US studies in neonates with 
low birthweight found that early-onset E. coli increased in risk-based and screening periods 
compared with no prevention,20, 187 For example, early-onset E. coli increased from 2.83 per 
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1,000 NICU admissions during no prevention to 7.12 during risk-based prevention and 10.22 
during screening.187 By contrast, studies in all (term and preterm) neonates have not found 
changes in early-onset E. coli incidence during the period of GBS prevention,406, 407 87 while 
others have found that IAP usage increased the odds of early-onset E. coli infection in 
unadjusted but not adjusted analyses when factors such as gestational age were accounted 
for.188, 189 To inform whether early-onset sepsis trends are unaffected by GBS prevention 
strategies as a result of increasing gram-negative organisms, an investigation comparing E. 
coli in countries with different GBS prevention strategies will be investigated in Chapter 13.  
The results of this study did not clarify the conflicting findings in the literature on the impact 
of universal GBS screening or other GBS prevention strategies on the trends of annual early-
onset sepsis. As shown in this study and in the literature, it is possible that early-onset sepsis 
incidence may not decrease under screening, however, this could be due to factors beyond the 
GBS prevention strategy.  
 
12.5 Conclusions for this chapter 
 The findings in this chapter are suggestive of universal GBS screening having no 
impact on the trends of annual early-onset sepsis incidence compared with risk-based 
prevention, ‘either prevention’ and no prevention. 
 One of the reasons for a stable trend in early-onset sepsis under GBS screening may 
be that, although EOGBS incidence decreases, the incidence of gram-negative sepsis, 
such as E. coli, increases. 
 Importantly, this study did not have a sufficient sample size, therefore the findings 
might be a result of low statistical power as opposed to no true difference. 
 The evidence remains inconclusive and larger sample sizes are required to determine 
the impact of universal GBS screening on early-onset sepsis trends across countries. 
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13. THE IMPACT OF UNIVERSAL GBS SCREENING ON 
THE TRENDS OF LOGBS, EARLY-ONSET E. COLI, 
AND NEONATAL GBS ANTIBIOTIC RESISTANCE  
This chapter presents the results for the final ecological trend analysis study that combines 
international data to explore the impact of universal GBS screening and widespread IAP on 
the trends of six potential harms, compared with other GBS prevention strategies. While I 
discussed the methodology used to address this study in Chapter 9, here I will first present the 
study specific aim and objectives followed by some study specific methodological procedures. 
I will then present the detailed results from the statistical analyses: first the MICE imputation 
results, then the descriptive statistics, followed by the unadjusted analyses, the main adjusted 
model and the sensitivity analyses. Finally, I will summarise the principal findings and how 
they relate to previous literature.  
 
13.1 Aims and objectives 
The aim of this chapter is to measure the effect of universal GBS screening and widespread 
IAP on the trend of six potential harms across time, compared with other GBS prevention 
strategies, in a statistical model that combines data from geographical areas with different 
prevention strategies, and adjusts for compositional differences between the areas. The six 
potential harmful outcomes investigated were: annual LOGBS incidence, annual early-onset 
E. coli incidence, the annual percentage of EOGBS cases resistant to clindamycin, the annual 
percentage of EOGBS cases resistant to erythromycin, the annual percentage of neonatal GBS 
cases resistant to clindamycin and the annual percentage of neonatal GBS cases resistant to 
erythromycin. 
The research objectives are to:  
a) Describe the frequency of the GBS prevention strategy as well as the mean or 
frequency of the compositional covariates in general (irrespective of harms); 
b) Describe the mean for each harmful outcome across time, geographical areas, world 
regions and GBS prevention strategies; 
Antenatal screening for group B Streptococcus in the UK	
	 223 
c) Investigate the unadjusted relationship between universal GBS screening and the 
trend of each harmful outcome across time compared with other prevention strategies, 
using linear regression; 
a) Investigate the unadjusted relationship between each compositional covariate and the 
mean of each harmful outcome across time, using linear regression; 
b) Investigate the relationship between universal GBS screening and the trend of each 
harmful outcome across time compared with other prevention strategies, using linear 
regression and adjusting for the compositional covariates; and 
d) Examine the stability of the adjusted relationship between universal GBS screening 
and the trend of each harmful outcome across time compared with other prevention 
strategies in a range of sensitivity analyses, if the relationships were statistically 
significant. 
 
13.2 Methods 
I have detailed the methodology used for this study in Chapter 9. Here, I describe the data 
selected to perform the analysis.  
13.2.1 Geographical data included 
As discussed in Chapter 10, there were annual LOGBS data from 47 geographical areas. 
However, some of them overlapped in terms of coverage, giving rise to the potential of double-
counting. These were: voluntary versus enhanced surveillance from England, two hospitals 
from Johannesburg versus data from the township of Soweto, data from multiple centres 
versus enhanced surveillance in New Zealand, two different multi-centre sources for 
Australia, and enhanced surveillance from the United Kingdom and Republic of Ireland versus 
data from each of the five countries in the British Isles. I included the following data sources 
(and excluded the others): the enhanced surveillance for England and individual UK countries 
instead of the United Kingdom and Republic of Ireland overall as the EOGBS incidence across 
the countries varies; Soweto over the two hospitals in Johannesburg for population and wider 
coverage; the enhanced surveillance for New Zealand; and the multi-centre data that had a 
larger number of years for Australia. This left 42 geographical areas. However, after analysing 
the LOGBS incidence across the years and countries, I excluded Mansoura City in Egypt 
where the rate of LOGBS incidence for 2014 was 24.15 per 1,000 livebirths. This was an 
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extreme outlier and was vastly different from the incidence rates in the UK. This left data from 
a total of 41 geographical areas in the analyses. 
For early-onset E. coli, data were available from 28 geographical areas and the areas with 
overlapping data were: Ontario that overlapped with multi-centre data across Canada and data 
from multiple centres versus enhanced surveillance in New Zealand. I included Ontario as it 
had population-based surveillance, and the enhanced surveillance for New Zealand (and 
excluded the others). This left 26 geographical areas. However, I excluded Mansoura City in 
Egypt where the rate of early-onset E. coli incidence for 2014 was 28.99 per 1,000 livebirths 
as it was an extreme outlier from the remaining data and was vastly different from the 
incidence rates in the UK. This left data from a total of 25 geographical areas in the analyses. 
For EOGBS cases resistant to clindamycin, data were available from 23 areas and for EOGBS 
cases resistant to erythromycin, data were available from 24 areas. For neonatal GBS cases 
resistant to clindamycin, data were available from 17 areas and for neonatal GBS cases 
resistant to erythromycin data were available from 19 areas. For all, data only overlapped for 
Alberta and one or two sources of multi-centre data across Canada. I chose Alberta as the data 
were from mandatory population surveillance. This left data from a total of 21 geographical 
areas for EOGBS cases resistant to erythromycin, 22 areas for EOGBS cases resistant to 
erythromycin, 16 areas for neonatal GBS cases resistant to clindamycin and 18 areas for 
neonatal GBS cases resistant to erythromycin.  
 
13.3 Results 
13.3.1 Multiple imputation for compositional covariates 
Table 40 summarises of the proportion of missing data for each compositional covariate in 
each dataset. There were 63 (20%) observations that had complete compositional covariate 
for every year in the dataset on LOGBS, 43 (21%) on E. coli, 19 (16%) on EOGBS 
clindamycin resistance, 19 (17%) on EOGBS erythromycin resistance, 18 (16%) on neonatal 
GBS clindamycin resistance and 19 (17%) on neonatal GBS erythromycin resistance. The 
covariate with the largest number of missing years across the datasets was the human 
development index, which had 51% to 61% of years missing. The covariate with the least 
amount of missing data was skilled delivery which had 11% to 17% of years missing. There 
were more than 20 different patterns of missing data for the LOGBS dataset, 18 for E. coli, 22 
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for EOGBS clindamycin resistance and erythromycin resistance, and 15 for neonatal GBS 
clindamycin and erythromycin resistance.  
Across all datasets, the missingness of each compositional covariate was related to at least one 
variable. The exception was for the missingness of skilled delivery which did not converge in 
the early-onset E. coli dataset or the EOGBS and neonatal clindamycin and erythromycin 
datasets, and caesarean section which did not converge in the EOGBS and neonatal 
clindamycin and erythromycin datasets. As data were missing because they were available 
from some years but not others and their missingness was related to other data, the mechanism 
for the missing data was ‘missing at random’. 
As mentioned in Chapter 9, I set the number of imputations at 100 because of the large amount 
of missing data and the results showed that convergence was reached within these imputations. 
Additionally, the largest fraction of missing information (FMI) from of the analysis models was 
below 79%, confirming that the number of imputations was sufficient. Below, I present the 
descriptive statistics of some of the imputed datasets and the original dataset for comparison. 
Table 40. Proportion of missing data in compositional covariates for each dataset 
E. coli Escherichia coli, GBS group B Streptococcus, LOGBS late-onset GBS 
 
 
 
Variable LOGBS Early-onset 
E. coli 
Early-onset GBS Neonatal GBS 
clindamycin 
resistance 
erythromycin 
resistance 
clindamycin 
resistance 
erythromycin 
resistance  
Observe
d (%) 
Missing 
(%) Observed (%) Missing (%) Observed (%) Missing (%) Observed (%) Missing (%) Observed (%) Missing (%) Observed (%) Missing (%) 
Preterm 
births 
153 
(49) 
158 
(51) 
100 
(48) 
109 
(52) 
59 
(49) 
62 
(51) 
59 
(51) 
56 
(49) 
63 
(57) 
47 
(43) 
64 
(59) 
45 
(41) 
Low 
birthweights 
153 
(51) 
158 
(49) 
119 
(57) 
90 
(43) 
78 
(64) 
43 
(36) 
72 
(63) 
43 
(37) 
77 
(70) 
33 
(30) 
75 
(69) 
34 
(31) 
Caesarean 
section 
257 
(83) 
54 
(17) 
165 
(79) 
44 
(21) 
108 
(89) 
13 
(11) 
102 
(89) 
13 
(11) 
 
102 
(93) 
8 
(7) 
100 
(92) 
9 
(8) 
Skilled 
attendance at 
delivery 
276 
(89) 
35 
(11) 
178 
(85) 
31 
(15) 
102 
(84) 
19 
(16) 
96 
(83) 
19 
(17) 
92 
(84) 
18 
(16) 
91 
(83) 
18 
(17) 
Human 
development 
index 
120 
(39) 
191 
(61) 
84 
(40) 
125 
(60) 
55 
(45) 
66 
(55) 
50 
(43) 
65 
(57) 
44 
(40) 
66 
(60) 
43 
(39) 
66 
(61) 
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13.3.2 Descriptive analysis for the predictor and compositional covariates (objective a)  
This section presents the frequency of the GBS prevention strategy and the mean or frequency 
of the compositional covariates for each outcome dataset (objective a).  
The majority of geographical areas across the datasets most recently reported a universal 
screening strategy 39% to 56% areas), followed by risk-based prevention (21% to 37%), no 
prevention (12% to 19%) and ‘either prevention’ (0% to 4%) (see Table 41). With respect to 
world region, the majority of observations were from Europe across all datasets (36.84% to 
51.44%). The world region with the fewest observations varied across datasets. For LOGBS 
incidence, the fewest observations were from North Africa and the Middle East (0.96%); for 
early-onset E. coli incidence, there were no data from Sub-Saharan Africa followed by 
Oceania (5.74%); for EOGBS resistance, the fewest observations were also from Oceania 
(0.83% for clindamycin and 0.87% for erythromycin); and for neonatal GBS resistance they 
were from North Africa and the Middle East (0.91% for clindamycin and 0.92% for 
erythromycin). 
Table 41. Frequencies of recently reported GBS prevention strategy for each dataset 
Most recent 
reported GBS 
prevention 
strategy 
Dataset 
LOGBS 
(%) 
E. coli 
(%) 
EOGBS 
clindamycin and 
erythromycin (%) 
Neonatal GBS 
clindamycin 
(%) 
Neonatal GBS 
erythromycin 
(%) 
No prevention 6 
(13.04) 
4 
(12.12) 
4 
(18.18) 
3 
(18.75) 
3 
(16.67) 
Risk-based 
prevention  
17 
(36.96) 
7 
(21.21) 
8 
(36.36) 
4 
(25.00) 
5 
(27.78) 
Screening 
prevention 
21 
(45.65) 
13 
(39.39) 
10 
(45.45) 
9 
(56.25) 
10 
(55.56) 
Either 
prevention 
2 
(4.35) 
1 
(3.03) 
0 
(0.00) 
0 
(0.00) 
0 
(0.00) 
Total 46 
(100.00) 
33 
(100.00) 
22 
(100.00) 
16 
(100.00) 
18 
(100.00) 
E. coli Escherichia coli, GBS group B Streptococcus, LOGBS late-onset GBS 
The mean values for the compositional covariates that were multiple imputed for each dataset 
are presented in Table 42. Averages are provided for the data with no imputation, followed by 
imputed datasets 1 and 100. The mean percentage of preterm births across the years in the 
original datasets ranged from 9.39% (SD 4.22) to 10.32% (SD 4.61) and the imputed means 
were from 8.71% (SD 3.52) to 9.40% (SD 3.89). The mean percentage of low birthweights 
ranged from 9.88% (SD 7.26) to 11.94% (SD 7.86) and the imputed mean values were from 
8.56% (SD 6.09) to 10.46% (SD 7.36). The mean percentage of caesarean section deliveries 
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ranged from 26.62% (SD 8.74) to 28.33% (SD 9.31) and the imputed mean values ranged 
from 25.97% (SD 8.87) to 27.78% (SD 8.57). The mean skilled attendance at delivery ranged 
from 96.58% (SD 6.26) to 97.54% (SD 5.77) and the imputed mean values ranged from 
96.71% (SD 5.81) to 97.67% (SD 5.47). Finally, the mean human development index across 
the data ranged from 0.82 (SD 0.08) to 0.83 (0.09) and the imputed mean values also ranged 
from 0.82 to 0.83. Similar to the previous multiple imputations, in general, the imputed mean 
values for the human development index were the closest to the original mean, whereas, the 
mean values for low birthweights were the furthest from the original mean.  
Table 42. Mean values for multiple imputed compositional covariates for each dataset 
Dataset Mean % 
preterm 
births (SD) 
Mean % low 
birthweights 
(SD) 
Mean % 
Caesarean 
delivery (SD) 
Mean % skilled 
attendance at 
delivery (SD) 
Mean HDI 
(SD) 
LOGBS      
Original 9.39 (4.22) 9.88 (7.26) 27.09 (10.11) 97.54 (5.77) 0.83 (0.09) 
Imputed 1 8.71 (3.52) 8.63 (5.92) 26.72 (10.11) 97.60 (5.49) 0.83 (0.08) 
Imputed 100 8.83 (3.49) 8.56 (6.09) 26.55 (10.12) 97.67 (5.47) 0.83 (0.08) 
E. coli      
Original 9.83 (4.30) 10.29 (7.53) 28.33 (9.31) 97.28 (6.74) 0.82 (0.08) 
Imputed 1 9.12 (3.53) 9.24 (6.58) 26.75 (9.30) 97.56 (6.26) 0.82 (0.07) 
Imputed 100 9.09 (3.34) 8.96 (6.63) 26.70 (9.29) 97.62 (6.27) 0.82 (0.08) 
EOGBS clindamycin 
resistance 
     
Original 9.93 (4.46) 11.94 (7.86) 27.87 (8.42) 97.04 (5.70) 0.82 (0.08) 
Imputed 1 9.08 (3.53) 10.30 (7.37) 27.34 (8.15) 97.32 (5.33) 0.82 (0.08) 
Imputed 100 9.11 (3.61) 10.33 (7.30) 27.49 (8.21) 97.42 (5.32) 0.83 (0.08) 
EOGBS erythromycin 
resistance 
     
Original 10.02 (4.46) 11.65 (7.91) 27.84 (8.76) 96.58 (6.26) 0.82 (0.08) 
Imputed 1 9.24 (3.72) 10.06 (7.27) 27.78 (8.57) 96.71 (5.81) 0.83 (0.07) 
Imputed 100 9.28 (3.72) 10.13 (7.17) 27.33 (8.79) 97.03 (5.84) 0.83 (0.08) 
Neonatal GBS 
clindamycin resistance 
     
Original 10.28 (4.63) 11.46 (7.88) 26.62 (8.74) 97.18 (5.45) 0.82 (0.08) 
Imputed 1 9.28 (3.91) 9.93 (7.44) 25.97 (8.87) 97.57 (5.07) 0.82 (0.08) 
Imputed 100 9.18 (4.02) 10.46 (7.36) 27.01 (8.85) 97.25 (0.11) 0.82 (0.08) 
Neonatal GBS 
erythromycin 
resistance 
     
Original 10.32 (4.61) 11.81 (7.92) 26.77 (8.97) 97.15 (5.48) 0.82 (0.08) 
Imputed 1 9.38 (4.14) 10.18 (7.60) 26.90 (9.11) 96.94 (5.23) 0.82 (0.09) 
Imputed 100 9.40 (3.89) 10.19 (7.52) 26.65 (8.94) 97.33 (5.04) 0.82 (0.09) 
E. coli Escherichia coli, GBS group B Streptococcus, HDI human development index, LOGBS late-onset GBS 
The mean values for compositional covariates that only had one value across all of the years 
and were not multiple imputed are presented in Table 43. Across the datasets, on average 
mothers were 26 years old at first child and had an average of 1.83 (SD 0.48) to 1.92 (SD 
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0.47) children. Multiple or twin births ranged from 16.41% (SD 7.96) to 18.16% (SD 14.34), 
maternal colonisation of GBS from 16.48% (SD 9.70) to 21.02% (SD 10.68), mean percentage 
of prolonged rupture of membranes from 5.85% (SD 6.17) to 6.80% (SD 6.20) and intrapartum 
fever from 1.21% (SD 1.70) to 1.58% (SD 2.32). Mean government expenditure on health per 
capita ranged from $2,610.91 (SD 1,523.16) to $3,348.76 (SD 2,163.51). The most frequent 
GBS serotype was serotype III (72.73% to 84.45%) and most data covered one centre only 
(44.53% to 62.68%). The commonest definition for LOGBS was 5/6/7/8 days onwards 
(67.19%), for E. coli it was <5/6/7/8 days (51.20%), for EOGBS it was <5/6/7 days (74.38% 
for clindamycin and 72.17% for erythromycin), and for neonatal GBS definition it was 
<89/90/132 days (50% for clindamycin and 51.38% for erythromycin).   
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Table 43. Mean values for un-imputed compositional covariates for each dataset 
Covariate Dataset 
LOGBS 
(%) 
E. coli 
(%) 
EOGBS 
clindamycin  
(%) 
EOGBS 
erythromycin 
(%) 
Neonatal GBS 
clindamycin 
(%) 
Neonatal GBS 
erythromycin 
(%) 
Continuous variables  Mean (SD) 
Fertility rate 1.86 
(0.44) 
1.86 
(0.49) 
1.89 
(0.47) 
1.92 
(0.47) 
1.83 
(0.48) 
1.84 
(0.47) 
Average maternal age 26.11 
(3.41) 
25.71 
(3.82) 
25.86 
(3.38) 
25.83 
(3.45) 
26.02 
(3.50) 
26.10 
(3.48) 
Multiple or twin births  
(per 1,000 livebirths) 
18.16 
(14.34) 
17.59 
(9.56) 
16.41 
(7.96) 
16.85 
(7.94) 
16.86 
(9.54) 
17.03 
(9.48) 
Per capita government 
expenditure on health (PPP int $) 
3,348.76 
(2,163.51) 
2,697.45 
(1,694.25) 
2610.91 
(1523.16) 
2,694.58 
(1,516.29) 
2,631.35 
(1,627.50) 
2,668.64 
(1,609.80) 
Maternal GBS colonisation 21.02 
(10.68) 
17.28 
(9.38) 
16.48 
(9.70) 
17.52 
(9.34) 
16.88 
(9.39) 
17.34 
(9.41) 
Prolonged rupture of membranes 6.80 
(6.20) 
5.85 
(6.17) 
6.13 
(5.98) 
5.98 
(5.95) 
6.41 
(6.80) 
6.10 
(6.56) 
Intrapartum fever 1.28 
(1.95) 
1.58 
(2.32) 
1.25 
(1.73) 
1.29 
(1.78) 
1.21 
(1.70) 
1.22 
(1.71) 
Categorical variables Frequency (%) 
Most prevalent GBS serotype       
Ia 31 
(8.07) 
10 
(4.78) 
8 
(6.61) 
8 
(6.96) 
8 
(7.27) 
8 
(7.34) 
Ib 65 
(16.93) 
36 
(17.22) 
23 
(19.01) 
17 
(14.78) 
7 
(6.36) 
7 
(6.42) 
III 285  
(74.22) 
160 
(76.56) 
88 
(72.73) 
87 
(75.65) 
94 
(85.45) 
93 
(85.32) 
V 3 
(0.78) 
3 
(1.44) 
2 
(1.65) 
3 
(2.61) 
1 
(0.91) 
1 
(0.92) 
Surveillance type       
Mandatory or enhanced 
population surveillance 
70 
(18.23) 
1 
(0.48) 
12 
(9.92) 
13 
(11.30) 
11 
(10.00) 
12 
(11.01) 
Voluntary population 
surveillance 
74 
(19.27) 
52 
(24.88) 
32 
(26.45) 
32 
(27.83) 
32 
(29.09) 
32 
(29.36) 
Multiple centres/counties 69 
(17.79) 
25 
(11.96) 
2 
(1.65) 
2 
(1.74) 
1 
(0.91) 
2 
(1.83) 
One centre 171  
(44.53) 
131 
(62.68) 
75 
(61.98) 
68 
(59.13) 
66 
(60.00) 
63 
(57.80) 
Geographical coverage       
National 165  
(42.97) 
57 
(27.27) 
34 
(28.10) 
35 
(30.43) 
33 
(30.00) 
35 
(32.11) 
Regional 39 
(10.16) 
18 
(8.61) 
12 
(9.92) 
12 
(10.43) 
11 
(10.00) 
11 
(10.09) 
City/town wide 9 
(2.34) 
3 
(1.44) 
- - - - 
One centre in a city/town 171 (44.53) 131 
(62.68) 
75 
(61.98) 
68 
(59.13) 
66 
(60.00) 
63 
(57.80) 
EOGBS definition       
1 108  
(28.13) 
96 
(45.93) 
31 
(25.62) 
32 
(27.83) 
17 
(15.45) 
17 
(15.60) 
2 258  
(67.19) 
107 
(51.12) 
90 
(74.38) 
83 
(72.17) 
55 
(50.00) 
56 
(51.38) 
3 16 
(4.17) 
6 
(2.87) 
- - - - 
4 2 
(0.52) 
- - - 38 
(34.55) 
36 
(33.03) 
E. coli Escherichia coli, GBS group B Streptococcus, LOGBS late-onset GBS 
LOGBS definition: 1, 2/3/4 days onwards, 2, 5/6/7/8 days onwards, 3, 48 hours to 6 days, 4, Not stated; E. coli 
definition 1, <2/3/4 days, 2, <5/6/7/8 days, 3, mother infected; Early-onset GBS definition 1, 2/3 days or less, 2, 
5/6/7 days or less; Neonatal GBS definition 1, <28/30/31/44 days, 2, <89/90/132 days, 4 Not stated 
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13.3.3 Descriptive analysis for outcomes (objective b) 
This section presents the mean values for each outcome across time, geographical areas, world 
regions and GBS prevention strategies (objective b).  
LOGBS incidence  
The mean LOGBS incidence across 311 observations (41 geographical areas, 26 years 
between 1990 and 2015) was 0.29 per 1,000 livebirths (SD 0.49, range 0.00 to 3.28).  Across 
the years, LOGBS incidence varied between 0.00 and 0.94 per 1,000 livebirths (see Table 44). 
Figure 24 demonstrates that LOGBS increased across the years and that the range of LOGBS 
incidence was wider during the latter years. As evident from Table 44, this could be as a result 
of more geographical areas contributing to the later years compared with the earlier years. 
 
 
 LOGBS early-onset group B Streptococcus disease 
Each dot represents the LOGBS incidence for one year for one geographical area 
Figure 24. Scatterplot of LOGBS incidence by year 
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Table 44. LOGBS incidence per 1,000 livebirths across the years 
LOGBS early-onset group B Streptococcus disease 
The highest mean LOGBS incidence was found in Soweto in South Africa at 1.20 per 1,000 
livebirths (SD 0.13), followed by Mexico City at 0.99 per 1,000 livebirths (1.40), and 
Guangzhou in China at 0.97 per 1,000 livebirths (SD 0.45). Brno, Cordoba, Manila, 
Podgorica, Riga, Slovenia, Tunis and Zagreb reported zero cases, which may be a result of 
diagnostic related issues, small sample size or voluntary surveillance. Besides these areas, the 
lowest LOGBS incidences were in New Zealand at 0.02 per 1,000 livebirths, Kuala 
Terengganu at 0.03 per 1,000 livebirths (0.04), and Ho Chi Minh at 0.04 per 1,000 livebirths 
(0.03) (see Table 45). These are averages across the years but as shown in Appendix 17-A, 
for many areas the rates of LOGBS fluctuated from year to year.   
Year Number of 
geographical areas 
Mean livebirths 
(Standard deviation) 
Mean LOGBS incidence 
(Standard deviation) 
1990 1 - 0.35 
1991 1 3,048.00 0.00 
1992 2 125,055.00 (172,563.80) 0.34 (0.46) 
1993 1 3,211.00 0.31 
1994 1 3,187.00 0.94 
1995 4 65,607.75 (87,745.83) 0.21 (0.15) 
1996 7 108,579.50 (160,043.80) 0.16 (0.12) 
1997 9 135,492.70 (158,860.40) 0.21 (0.21) 
1998 9 139,151.10 (165,591.30) 0.25 (0.26) 
1999 10 141,895.10 (178,065.50) 0.42 (0.93) 
2000 15 148,593.60 (200,307.40) 0.16 (0.11) 
2001 10 163,196.50 (190,437.60) 0.48 (0.99) 
2002 11 149,873.00 (181,548.60) 0.14 (0.10) 
2003 14 125,212.30 (174,464.60) 0.13 (0.10) 
2004 15 120,529.90 (176,675.60) 0.42 (0.63) 
2005 17 107,191.90 (170,848.10) 0.38 (0.73) 
2006 18 103,838.50 (170,763.30) 0.40 (0.73) 
2007 19 98,528.13 (165,631.40) 0.48 (0.71) 
2008 19 94,391.52 (169,069.50) 0.25 (0.31) 
2009 19 92,636.31 (166,652.50) 0.31 (0.60) 
2010 21 89,700.53 (157,026.10) 0.24 (0.40) 
2011 25 75,302.52 (142,072.70) 0.24 (0.31) 
2012 23 81,802.23 (147,133) 0.25 (0.33) 
2013 25 72,104.59 (139,968.60) 0.24 (0.38) 
2014 14 98,904.64 (210,339.50) 0.27 (0.28) 
2015 1 2,195.00 0.00 
Total 311 103,862.30 (162,717.10) 0.29 (0.49) 
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Table 45. LOGBS incidence per 1,000 livebirths by geographical area 
 
Geographical area 
Number 
of years 
Mean number of livebirths 
(Standard deviation) 
Mean LOGBS incidence  
(Standard deviation) 
Alberta 11 47,896.00 (4,854.45) 0.24 (0.09) 
Australia 11 29,199.82 (4,802.03) 0.20 (0.12) 
Bangalore 3 4,044.33 (1,605.77) 0.07 (0.11) 
Barcelona 18 1,776.89 (247.95) 0.10 (0.23) 
Brno 1 6,415 0.00 
Cordoba 2 1,573 (152.74) 0.00 
Denmark 15 63,296.47 (3,182.94) 0.13 (0.05) 
Emilia-Romagna 11 38,686.09 (2,477.04) 0.30 (0.10) 
England 2 668,696.00 (68,071.76) 0.31 (0.08) 
Finland 19 58,658.79 (1,898.58) 0.25 (0.09) 
France 18 570,199.50 (57,015.64) 0.22 (0.04) 
Guangzhou 4 2,097.50 (265.54) 0.97 (0.45) 
Ho Chi Minh 3 45,589.33 (5,934.90) 0.04 (0.03) 
Kaunas 7 3,524.86 (194.83) 0.79 (0.90) 
Kingston 16 2,744.69 (360.63) 0.33 (0.32) 
Kuala Terengganu 9 12,578.56 (1,141.11) 0.03 (0.04) 
Macau 10 2,667.70 (697.83) 0.68 (0.66) 
Manila 1 6,682.00 0.00 
Mauritius 1 12,986.00 0.39 
Mexico City 19 5,055.11 (594.00) 0.99 (1.40) 
Netherlands 19 190,186.70 (9,833.44) 0.10 (0.04) 
New Zealand 1 127,134.00 0.02 
Northern Ireland 2 24,866 (2,207.59) 0.26 (0.12) 
Norway 18 59,343.44 (1,936.13) 0.22 (0.08) 
Ontario 17 135,098.60 (4,563.32) 0.08 (0.03) 
Panama City 2 131,288.00 (163,749.00) 0.30 (0.40) 
Podgorica 2 3,216.00 (52.33) 0.00 
Portugal 7 109,472.90 (4,266.57) 0.13 (0.08) 
Republic of Ireland 2 65,921.50 (10,129.30) 0.27 (0.02) 
Riga 1 2,060.00 0.00 
Santo Domingo 1 18,000.00 0.83 
Sao Paolo 1 13,749.00 0.15 
Scotland 2 59,475.50 (2,795.19) 0.32 (0.15) 
Slovenia 5 21,839.00 (448.82) 0.00 
Soweto 6 29,064.50 (2,561.84) 1.20 (0.13) 
Switzerland 3 81,901.00 (988.11) 0.13 (0.10) 
Tokyo 11 1,627.73 (192.70) 0.12 (0.26) 
Tunis 3 3,818.00 (115.17) 0.00 
US 19 422,561.70 (52,171.40) 0.33 (0.03) 
Wales 2 35,126.00 (1,715.44) 0.35 (0.16) 
Zagreb 6 4,254.50 (102.26) 0.00 
Total 311 103862.30 (162717.10) 0.29 (0.49) 
LOGBS late-onset group B Streptococcus disease, US United States of America 
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The highest mean LOGBS incidence was reported in Sub-Saharan Africa (1.09 per 1,000 
livebirths [SD 0.33]) whereas the lowest was reported in Oceania (0.19 per 1,000 livebirths 
[SD 0.12]) after North Africa and the Middle East that both reported zero cases (Table 46). 
Again, these are the averages but they vary across the years (as shown in Appendix 17-B) as 
do the number of geographical areas contributing to each region.  
Table 46. LOGBS incidence per 1,000 livebirths by region  
Region Number of 
observations/ years (%) 
Mean LOGBS incidence 
(standard deviation) 
Asia 41 (13.18) 0.30 (0.50) 
Europe 160 (51.44) 0.20 (0.25) 
Latin America and the Caribbean 41 (13.18) 0.63 (1.02) 
North Africa and the Middle East 3 (0.96) 0.00 (0.00) 
North America 47 (15.11) 0.22 (0.12) 
Oceania 12 (3.86) 0.19 (0.12) 
Sub-Saharan Africa 7 (2.25) 1.09 (0.33) 
Total 311 0.29 (0.49) 
LOGBS late-onset group B Streptococcus disease 
The mean LOGBS incidence by most recently reported GBS prevention strategy is presented 
in Table 47. The highest mean LOGBS incidence per 1,000 livebirths was reported under no 
prevention 0.72 [SD 1.09]), followed by risk-based prevention (0.24 [SD 0.30]), either risk-
based or screening prevention (00.23 [SD 0.10]), and the lowest mean rate was reported under 
screening prevention (0.22 [SD 0.31]). In Figure 25, it is clear that under no prevention there 
is a random scatter of LOGBS, which is similar to risk-based prevention and ‘either 
prevention’, while under screening it appears that there may be an increase.  
Table 47. LOGBS incidence per 1,000 livebirths by recently reported GBS prevention strategy 
Most recent reported GBS prevention  Number of 
observations/ years 
(%) 
Mean LOGBS 
incidence (standard 
deviation) 
No prevention 38 (12.22) 0.72 (1.09) 
Risk-based prevention  99 (31.83) 0.24 (0.30) 
Screening prevention 144 (46.30) 0.22 (0.31) 
Either risk-based and screening 
prevention 
30 (9.65) 0.23 (0.10) 
Total 311 0.29 (0.49) 
GBS group B Streptococcus, LOGBS late-onset GBS  
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LOGBS Late-onset group B Streptococcus 
Each dot represents the LOGBS incidence for one year for one geographical area 
Figure 25. LOGBS incidence by recently reported GBS prevention strategy   
 
Early-onset E. coli incidence 
The mean early-onset E. coli incidence across 209 observations (25 geographical areas, 22 
years between 1992 and 2015) was 0.29 per 1,000 livebirths (SD 0.54, range 0.00 to 4.72).  
Across the years, E. coli incidence varied between 0.00 and 0.71 per 1,000 livebirths. Figure 
26 demonstrates that E. coli increased across the years, which could be as a result of more 
geographical areas contributing to the later years compared with the earlier years (see Table 
48).    
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E. coli Escherichia coli 
Each dot represents the E. coli incidence for one year for one geographical area 
Figure 26. Scatterplot of E. coli incidence by year 
Table 48. Early-onset E. coli incidence per 1,000 livebirths across the years 
E. coli Escherichia coli 
Year Number of 
geographical areas 
Mean livebirths 
(Standard deviation) 
Mean E. coli incidence 
(Standard deviation) 
1992 1   247,076.00  0.22 
1995 3 66,454.67 (107,446.20) 0.18 (0.29) 
1996 5 40,823.00 (83,140.41) 0.39 (0.56) 
1997 6 56,736.67 (84,232.87) 0.26 (0.61) 
1998 7 135,572.70 (220,338.60) 0.29 (0.41) 
1999 7 133,834.70 (215,842.30) 0.07 (0.09) 
2000 7 131,765.90 (210,393.30) 0.10 (0.22) 
2001 6 151,850.70 (218,136.90) 0.09 (0.08) 
2002 7 134,902.70 (204,644.20) 0.17 (0.21) 
2003 8 120,915.60 (203,303.20) 0.11 (0.17) 
2004 8 121,319.00 (209,308.10) 0.15 (0.21) 
2005 11 90,234.91 (184,481.30) 0.21 (0.29) 
2006 12 85,995.75 (183,266.90) 0.17 (0.20) 
2007 13 81,349.69 (181,923.50) 0.29 (0.50) 
2008 16 127,689.90 (25,7438.50) 0.30 (0.54) 
2009 15 77,910.47 (174,012.70) 0.48 (0.79) 
2010 16 82,513.25 (172,096.10) 0.25 (0.27) 
2011 17 74,571.06 (167,350.00) 0.40 (0.48) 
2012 18 78,634.39 (164,302.60) 0.28 (0.48) 
2013 18 66,908.00 (157,958.20) 0.39 (0.60) 
2014 7 5,643.27 (5,065.38) 0.71 (1.77) 
2015 1 2,195.00   0.00 
Total 209 91,558.10 (17,7403.70) 0.28 (0.54) 
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The highest mean E. coli incidence was reported in Guangzhou in China at 2.30 per 1,000 
livebirths (SD 1.66), followed by Mexico City at 0.96 per 1,000 livebirths (SD 0.84) and 
Kaunas in Lithuania at 0.81 per 1,000 livebirths (SD 0.30). Bangalore, Cordoba and Riga 
reported zero cases (could be a result of diagnostic related issues, small sample size or 
voluntary surveillance). Besides these areas, the lowest LOGBS incidences were in Ontario at 
0.003 per 1,000 livebirths (SD 0.004), Kuala Terengganu at 0.02 per 1,000 livebirths (SD 
0.03) and the Netherlands at 0.03 per 1,000 livebirths (SD 0.02) (see Table 49). For some 
areas such as Barcelona, Guangzhou and Mexico City, the incidence of E. coli fluctuated from 
year to year whereas for other areas such as Bangalore, Cordoba, Kuala Terengganu and the 
Netherlands, they were stable across time (see Appendix 18-A).  
Table 49. Early-onset E. coli incidence per 1,000 livebirths by geographical area 
 
Geographical 
area 
Number 
of years 
Mean number of livebirths 
(Standard deviation) 
Mean E. coli incidence  
(Standard deviation) 
Australia 11 29,199.82 (4,802.03) 0.34 (0.12) 
Bangalore 3 4,044.33 (1,605.77) 0.00 (0.00) 
Barcelona 18 1,776.89 (247.95) 0.25 (0.33) 
Buenos Aires 18 6,473.22 (923.54) 0.13 (0.12) 
Cordoba 2 1,573.00 (152.74) 0.00 (0.00) 
Emilia-Romagna 1 146,682.00 0.13 
England 16 629,548.60 (46,740.74) 0.14 (0.04) 
Guangzhou 4 2,097.50 (265.54) 2.30 (1.66) 
Kaunas 7 3,524.86 (194.83) 0.81 (0.30) 
Kingston 12 2,619.58 (326.72) 0.18 (0.40) 
Kuala Terengganu 9 12,578.56 (1,141.11) 0.02 (0.03) 
Kuwait 10 11,074.10 (486.46) 0.43 (0.28) 
Macau 10 2,667.70 (697.83) 0.08 (0.17) 
Mexico City 19 5,055.11 (594.00) 0.96 (0.84) 
Netherlands 19 190,186.70 (9,833.44) 0.03 (0.02) 
New Zealand 1 127,134.00 0.09 
Ontario 17 135,098.60 (4,563.32) 0.003 (0.004) 
Panama city 1 247,076.00 0.22 
Portugal 6 95,824.83 (8,100.16) 0.21 (0.03) 
Riga 1 2,060.00   0.00 
Switzerland 3 81,901.00 (988.11) 0.04 (0.05) 
Tokyo 11 1627.73 (192.71) 0.12 (0.26) 
Tunis 3 3,818.00 (115.17) 0.18 (0.31) 
US 1 858,000.00 0.19 
Zagreb 6 4,254.50 (102.26) 0.27 (0.23) 
Total 209 91,558.10 (177,403.70) 0.28 (0.54) 
E. coli Escherichia coli, US United States of America 
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The highest mean E. coli incidence was reported in Latin America and the Caribbean (0.44 
per 1,000 livebirths [SD 0.67]) and the lowest was reported in North America (0.01 per 1,000 
livebirths [SD 0.04]) (see Table 50). Again, the rates vary across the years (in Appendix 18-
B) and the number of geographical areas contributing to them. 
Table 50. Early-onset E. coli incidence per 1,000 livebirths by region  
Region Number of 
observations/ years (%) 
Mean E. coli incidence 
(standard deviation) 
Asia 37 (17.70)  0.31 (0.87) 
Europe 77 (36.84) 0.21 (0.28) 
Latin America and the Caribbean 52 (24.88) 0.44 (0.67) 
North Africa and the Middle East 13 (6.22) 0.37 (0.30) 
North America 18 (8.61) 0.01 (0.04) 
Oceania 12 (5.74) 0.32 (0.14) 
Total 209 (100.00) 0.28 (0.54) 
E. coli Escherichia coli 
With respect to the most recent GBS prevention strategy, the highest mean E. coli incidence 
per 1,000 livebirths was reported under no prevention 0.58 [SD 0.78]), followed by ‘either 
prevention’ (0.34 [SD 0.12]), screening prevention (0.28 [SD 0.59]) and the lowest mean rate 
was reported under risk-based prevention (0.15 [SD 0.24]) (see Table 51). Under all strategies 
besides ‘either prevention’, early-onset E. coli incidence increased across time (see Figure 
27).  
Table 51. Early-onset E. coli incidence per 1,000 livebirths by recently reported GBS prevention 
strategy 
Most recently reported GBS 
prevention  
Number of 
observations/ years (%) 
Mean E. coli incidence 
(sta38ndard deviation) 
No prevention 33 (15.79) 0.58 (0.78) 
Risk-based prevention  70 (33.49) 0.15 (0.24) 
Screening prevention 95 (45.45) 0.28 (0.59) 
Either risk-based and screening 11 (5.26) 0.34 (0.12) 
Total 209 (100.00) 0.28 (0.54) 
E. coli Escherichia coli, GBS group B Streptococcus 
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E. coli Escherichia coli, GBS group B Streptococcus 
Each dot represents the E. coli incidence for one year for one geographical area 
Figure 27. E. coli incidence by recently reported GBS prevention strategy 
EOGBS resistance  
The mean percentage of EOGBS cases resistant to clindamycin across 121 observations (22 
geographical areas, 20 years between 1995 and 2014) was 13.83% (SD 24.90), while the mean 
percentage of EOGBS cases resistant to erythromycin across 115 observations (22 
geographical areas, 20 years between 1995 and 2014) was 16.21 (SD 24.45). Both outcomes 
ranged from 0% to 100%, which could be a result of small numbers of the EOGBS cases in 
the denominator. Across the years, the percentage of EOGBS cases resistant to clindamycin 
varied between 0.00% and 36.54% (SD 45.57) while erythromycin resistance varied between 
0.00% and 31.09% (SD 40.99). From Table 52, Figure 28 and Figure 29 it is clear that EOGBS 
resistance to clindamycin and erythromycin increased across the years, although this could be 
a result of more geographical areas contributing to the later years compared with the earlier 
years.  
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Table 52. Percentage of EOGBS resistance across the years 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
 
 EOGBS early-onset GBS disease, GBS group B Streptococcus 
Each dot represents the % of EOGBS cases resistant to clindamycin for one year for one geographical area  
Figure 28. Scatterplot of EOGBS cases resistant to clindamycin by year 
Year Clindamycin resistance Erythromycin resistance 
 No. 
areas 
Mean 
EOGBS cases 
(SD) 
Mean % cases 
resistant  
(SD) 
No. 
areas 
Mean EOGBS 
cases 
(SD) 
Mean % cases 
resistant 
(SD) 
1995 1 3.00 0.00 1 3.00 0.00 
1996 2 4.00 (1.41) 0.00 (0.00) 2 4.00 (1.41) 0.00 (0.00) 
1997 2 1.00 (0.00) 0.00 (0.00) 2 1.00 (0.00) 0.00 (0.00) 
1998 2 35.50 (28.99) 1.79 (2.53) 2 98.00 (59.40) 1.61 (0.25) 
1999 3 5.67 (8.08) 2.22 (3.85) 3 38.67 (65.24) 0.58 (1.01) 
2000 2 10.00 (11.31) 2.78 (3.93) 2 55.50 (75.66) 0.46 (0.65) 
2001 3 3.67 (4.62) 0 .00 (0.00) 3 38.33 (64.66) 1.18 (2.04) 
2002 1   19.00 0.00 1 135.00 3.70 
2003 4 9.75 (13.00) 0.86 (1.73) 4 38.50 (70.36) 1.91 (3.82) 
2004 4 20.00 (15.49) 5.36 (10.71) 4 51.50 (68.65) 7.99 (10.24) 
2005 8 12.00 (15.57) 8.50 (12.16) 8 24.88 (44.17) 11.22 (15.17) 
2006 7 13.14 (17.81) 16.70 (37.10) 7 30.43 (58.41) 29.55 (40.57) 
2007 9 13.56 (14.50) 5.47 (0.50) 9 28.33 (52.81) 10.84 (14.83) 
2008 11 17.09 (21.97) 5.59 (8.96) 11 27.64 (52.42) 13.34 (20.35) 
2009 9 15.33 (18.68) 12.85 (10.78) 8 31.00 (57.43) 18.38 (16.04) 
2010 13 20.38 (31.44) 17.57 (27.58) 12 31.00 (57.75) 18.56 (18.46) 
2011 11 18.55 (24.54) 18.57 (28.61) 10 29.60 (53.18) 30.38 (35.44) 
2012 11 16.73 (25.99) 21.88 (30.35) 10 27.10 (53.22) 20.15 (30.47) 
2013 11 17.27 (26.05) 26.58 (34.18) 11 24.91 (45.91) 21.83 (28.43) 
2014 7 6.43 (8.32) 36.54 (45.57) 5 7.60 (9.84) 31.09 (40.99) 
Total 121 14.83 (20.60) 13.83 (24.90) 115 30.57 (51.49) 16.21 (24.45) 
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 EOGBS early-onset GBS disease, GBS group B Streptococcus 
Each dot represents the % of EOGBS cases resistant to erythromycin for one year for one geographical area  
Figure 29. Scatterplot of EOGBS cases resistant to erythromycin by year 
Tunis had the highest mean percentage of EOGBS cases resistant to clindamycin (100%), 
however, this was only for one case. Thereafter, the highest mean resistance for clindamycin 
was 66.67% in Guangzhou (SD 57.74) and Macau (SD 42.49) followed by 27.10% (SD 28.39) 
in the Denmark. The highest mean resistance for erythromycin was 83.33% in Santo Domingo, 
66.67% (SD 57.74) in Guangzhou and 60.00% (SD 56.57) in Tunis. No clindamycin 
resistance was reported in Barcelona, Brno, Mexico City, Riga and Zagreb and no 
erythromycin resistance was reported in Barcelona, Brno, Mauritius, Mexico City, Riga, 
Tokyo and Zagreb. Some of this may be the result of the small number of cases in the 
denominator (see Table 53). Besides these areas, the lowest resistances were reported in 
Soweto (0.39% [SD 0.88]), Sofia (1.00 [SD 2.45]) and Kuala Terengganu (3.17% [SD 8.40]) 
for clindamycin resistance, and New Zealand (1.79%), Soweto (5.74% [SD 4.32]) and 
England (9.46 [SD 7.04]) for erythromycin resistance. Resistance fluctuated yearly in some 
countries while it remained stable in others (see Appendix 19-A).  
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Table 53. Percentage of EOGBS resistance across geographical areas 
EOGBS early-onset GBS disease, GBS group B Streptococcus, US United States of America 
 
Asia reported the highest percentage of cases resistant to clindamycin (34.50% [SD 45.53]) 
while Latin America and the Caribbean reported the lowest (0.28 [SD 1.15]). North America 
reported the highest percentage of cases resistant to erythromycin (37.14 [SD 17.87]) and 
Oceania reported the lowest (1.79%) (see Table 54). As shown in Appendix 19-B, resistance 
increased across time in North America, Europe, Asia and North Africa and the Middle East, 
was stable in Sub-Saharan Africa and Latin America and the Caribbean, while Oceania only 
had one observation from 1998.   
Area Clindamycin resistance Erythromycin resistance 
 No. 
years 
Mean 
EOGBS cases 
(SD) 
Mean % cases 
resistant  
(SD) 
No. 
years 
Mean 
EOGBS cases 
(SD) 
Mean % cases 
resistant 
(SD) 
Alberta 11 12.18 (5.10) 20.85 (11.05) 11 12.18 (5.10) 36.17 (18.41) 
Barcelona 8 1.25 (0.71) 0.00 (0.00) 8 1.25 (0.71) 0.00 (0.00) 
Brno 1 2.00 0.00 1 2.00 0.00        
Denmark 9 9.44 (5.36) 27.10 (28.39) 9 9.44 (5.36) 26.80 (29.26) 
Emilia-Romagna 1 21.00 23.81 1 24.00 16.67 
England 16 43.31 (29.66) 5.91 (5.07) 16 151 (26.13) 9.46 (7.04) 
France 7 27.86 (5.55) 14.90 (8.42) 7 27.86 (5.55) 23.27 (9.16) 
Guangzhou 3 1.33 (0.58) 66.67 (57.74) 3 1.33 (0.58) 66.67 (57.74) 
Kuala Terengganu 7 4.14 (2.85) 3.17 (8.40) 7 4.14 (2.85) 19.05 (26.23) 
Kuwait 10 12.40 (8.04) 16.31 (12.20) 10 12.40 (8.04) 15.44 (10.60) 
Macau 5 3.40 (2.30) 66.67 (42.49) 3 2.00 (1.73) 33.33 (57.74) 
Mansoura City 1 12.00 16.67 1 12.00 25.00 
Mauritius - - - 1 19.00 0.00 
Mexico City  16 1.69 (1.14) 0.00 (0.00) 16 1.69 (1.14) 0.00 (0.00) 
New Zealand 1 56.00 3.57 1 56.00 1.79 
Riga 1 1.00 0.00 1 1.00 0.00 
Santo Domingo 1 42.00 4.76 1 42.00 83.33 
Sofia 6 3.00 (0.89) 1.00 (2.45) - - - 
Soweto 5 42.80 (5.26) 0.39 (0.88) 5 42.80 (5.26) 5.74 (4.32) 
Tokyo 4 1.75 (0.96) 25.00 (50.00) 4 1.75 (0.96) 0.00 (0.00) 
Tunis 1 2.00 100.00 2 4.00 (1.41) 60.00 (56.57) 
US 1 92.00 26.09 1 92.00 47.83 
Zagreb 6 1.50 (0.55) 0.00 (0.00) 6 1.50 (0.55) 0.00 (0.00) 
Total 121 14.83 (20.60) 13.83 (24.90) 115 30.57 (51.49) 16.21 (24.45) 
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Table 54. Percentage of EOGBS resistance by region  
Region Clindamycin resistance Erythromycin resistance 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
Asia 19 (15.70) 34.50 (45.53) 17 (14.78) 25.49 (40.02) 
Europe 55 (45.45) 8.59 (15.23) 49 (42.61) 11.68 (16.69) 
Latin America and the 
Caribbean 
17 (14.05) 0.28 (1.15) 17 (14.78) 4.90 (20.21) 
North Africa and the 
Middle East 
12 (9.92) 23.32 (26.55) 13 (11.30) 23.03 (25.04) 
North America 12 (9.92) 21.29 (10.64) 12 (10.43) 37.14 (17.87) 
Oceania 1 (0.83) 3.57 1 (0.87) 1.79 
Sub-Saharan Africa 5 (4.13) 0.39 (0.88) 6 (5.22) 4.78 (4.52) 
Total 121 13.83 (24.90) 115 16.21 (24.45) 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
With respect to the most recently reported GBS prevention strategy, the highest mean 
resistance to clindamycin was reported under screening (15.90% [SD 25.99]), followed by no 
prevention (15.42% [SD 33.22]) and finally risk-based prevention (11.55 [SD 19.82]). The 
highest mean resistance to erythromycin was also under screening (19.19% [26.19]), followed 
by risk-based prevention (16.29% [SD 21.29]) and no prevention (9.92% [SD 27.84]) (see 
Table 55). From Figure 30 and Figure 31 it is clear that there were increases in antibiotic 
resistance under all prevention strategies. It is also evident that the rates go from 0% in the 
earlier years to 100% in the later years, probably a result of small numbers.  
Table 55. Percentage of EOGBS resistance by recently reported GBS prevention strategy 
Most recent 
reported GBS 
prevention  
Clindamycin resistance Erythromycin resistance 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
No prevention 23 (19.00) 15.42 (33.22) 21 (18.26) 9.92 (27.84) 
Risk-based 
prevention  
55 (45.45) 11.55 (19.82) 51 (44.35) 16.29 (21.29) 
Screening 
prevention 
43 (35.54) 15.90 (25.99) 43 (37.39) 19.19 (26.19) 
Total 121 (100.00) 13.83 (24.90) 115 16.21 (24.45) 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
Antenatal screening for group B Streptococcus in the UK	
	 243 
EOGBS early-onset GBS disease, GBS group B Streptococcus 
Each dot represents the % of EOGBS cases resistant to clindamycin for one year for one geographical area  
Figure 30. EOGBS clindamycin resistance by recently reported GBS prevention strategy 
 EOGBS early-onset GBS disease, GBS group B Streptococcus 
Each dot represents the % of EOGBS cases resistant to erythromycin for one year for one geographical area  
Figure 31. EOGBS erythromycin resistance by recently reported GBS prevention strategy 
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Neonatal GBS resistance 
The mean percentage of neonatal GBS cases resistant to clindamycin across 110 observations 
(16 geographical areas, 20 years between 1995 and 2014) was 14.45% (SD 25.39) while the 
mean percentage of neonatal GBS cases resistant to erythromycin across 109 observations (18 
geographical areas, 20 years between 1995 and 2014) was 13.83% (SD 20.55). Similar to 
EOGBS resistance, the ranges went from 0 to 100% which could be a result of small 
denominators. Across years, the mean percentage of neonatal GBS cases resistant to 
clindamycin varied between 0.00% and 36.97% (SD 44.56) while erythromycin resistance 
varied between 0.00% and 25.62% (SD 39.40). From Table 56,  Figure 32 and Figure 33, it is 
clear that neonatal GBS resistance to clindamycin and erythromycin increased across the 
years, although this could be a result of more geographical areas contributing to the later years 
compared with the earlier years, as mentioned previously. 
Table 56. Percentage of neonatal GBS resistance across the years 
GBS group B Streptococcus  
Year Clindamycin resistance Erythromycin resistance 
 No. 
areas 
Mean GBS 
cases 
(SD) 
Mean % cases 
resistant  
(SD) 
No. 
areas 
Mean GBS 
cases 
(SD) 
Mean % cases 
resistant 
(SD) 
1995 1 5.00 0.00 1 5.00 0.00 
1996 2 4.50 (2.12) 0.00 (0.00) 2 4.50 (2.12) 0.00 (0.00) 
1997 2 1.50 (0.71) 0.00 (0.00) 2 1.50 (0.71) 0.00 (0.00) 
1998 2 10.50 (3.44) 0.00 (0.00) 2 104.00 (145.66) 0.97 (1.36) 
1999 3 13.67 (11.68) 1.39 (2.41) 3 64.33 (97.00) 0.57 (0.98) 
2000 2 11.50 (12.02) 2.50 (3.54) 2 77.00 (104.65) 0.66 (0.93) 
2001 3 11.67 (9.29) 0.00 (0.00) 3 59.00 (86.16) 0.84 (1.46) 
2002 1 27.00 0.00         1 195.00 3.08 
2003 4 13.50 (17.02) 1.32 (2.63) 4 55.75 (100.95) 1.45 (2.90) 
2004 5 28.40 (23.80) 3.87 (7.25) 5 66.20 (92.32) 5.28 (7.63) 
2005 7 23.71 (29.19) 5.94 (8.71) 7 48.43 (78.26) 7.78 (11.34) 
2006 6 26.83 (31.22) 18.94 (39.90) 6 61.17 (101.83) 25.62 (39.40) 
2007 10 28.50 (32.13) 16.56 (31.00) 9 54.44 (88.91) 10.96 (12.50) 
2008 11 31.09 (39.87) 9.18 (13.97) 12 49.50 (85.14) 18.54 (22.16) 
2009 9 27.33 (38.96) 9.43 (9.70) 9 48.78 (96.72) 12.38 (14.83) 
2010 12 38.58 (60.19) 24.18 (30.27) 12 53.58 (98.69) 22.50 (21.24) 
2011 8 36.00 (50.27) 15.20 (19.76) 8 56.00 (102.66) 12.49 (12.20) 
2012 8 35.63 (53.00) 29.48 (37.55) 8 52.25 (97.76) 24.26 (34.02) 
2013 9 37.89 (3.72) 24.08 (31.17) 9 51.56 (83.21) 18.49 (21.60) 
2014 5 6.60 (8.85) 36.97 (44.56) 4 6.75 (10.21) 23.48 (31.53) 
Total 110 27.00 (38.78) 14.45 (25.39) 109 52.54 (85.54) 13.83 (20.55) 
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 GBS group B Streptococcus 
Each dot represents the % of neonatal GBS cases resistant to clindamycin for one year for one geographical area  
Figure 32. Scatterplot of neonatal GBS cases resistant to clindamycin by year 
 
GBS group B Streptococcus 
Each dot represents the % of neonatal GBS cases resistant to erythromycin for one year for one geographical area  
Figure 33. Scatterplot of neonatal GBS cases resistant to erythromycin by year 
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Macau had the highest mean percentage of neonatal GBS resistant to clindamycin (79.17% 
[SD 21.08]), followed by Guangzhou (43.75% [SD 33.69]) and Denmark (23.48% [SD 
29.13]). The highest mean resistance for erythromycin was 49.71% in the US, followed by 
43.75% (SD 33.69) in Guangzhou and 32.94% (SD 14.80) in Alberta (see Table 57). No 
clindamycin resistance was reported in Barcelona, Brno, Mexico City, Riga and Zagreb, and 
no erythromycin resistance was reported in Barcelona, Brno, Mauritius, Mexico City, Riga, 
Tokyo and Zagreb (probably a result of small denominator). Besides these areas, the lowest 
resistances were reported in Soweto (0.23% [SD 0.51]), Kuala Terengganu (3.17% [SD 8.40]) 
and England (6.44% [SD 4.88]) for clindamycin, and Soweto (3.41% [SD 2.66)]), England 
(8.79% [SD 6.48)]) and France (16.58% [SD 3.04]) for erythromycin. Resistance fluctuated 
across time in some countries and was stable across time in others (Appendix 20-A).  
Table 57. Percentage of neonatal GBS resistance across geographical areas 
EOGBS early-onset GBS, GBS group B Streptococcus, US United States of America 
  
Area Clindamycin resistance Erythromycin resistance 
 No. 
years 
Mean 
EOGBS cases 
(SD) 
Mean % 
cases 
resistant  
(SD) 
No. 
years 
Mean 
EOGBS 
cases 
(SD) 
Mean % 
cases 
resistant 
(SD) 
Alberta 11 24.00 (9.26) 19.51 (10.12) 11 24.00 (9.26) 32.94 (14.80) 
Barcelona 9 1.44 (0.73) 0.00 (0.00) 9 1.44 (0.73) 0.00 (0.00) 
Brno 1 2.00 0.00 1 2.00 0.00 
Denmark 9 17.00 (8.65) 23.48 (29.13) 9 17.11 (8.75) 24.79 (28.82) 
England 16 71.19 (51.79) 6.44 (4.88) 16 239.69 
(55.25) 
8.79 (6.48) 
France 7 82.86 (16.51) 10.35 (5.09) 7 82.86 (16.51) 16.58 (3.04) 
Guangzhou 8 3.00 (1.41) 43.75 (33.69) 8 3.00 (1.41) 43.75 (33.69) 
Kuala 
Terengganu 
7 4.57 (2.82) 3.17 (8.40) 7 4.57 (2.82) 19.73 (27.69) 
Macau 6 6.00 (3.03) 79.17 (21.08) 3 6.33 (1.53) 17.78 (16.78) 
Mansoura city 1 22.00 18.18 1 22.00 27.27 
Mauritius - - - 1 24.00 0.00 
Mexico City  16 7.88 (7.31) 0.00 (0.00) 16 7.88 (7.31) 0.00 (0.00) 
Portugal - - - 1 53.00 30.19 
Riga 1 1.00 0.00 1 1.00 0.00 
Soweto 5 77.80 (8.90) 0.23 (0.51) 5 77.80 (8.90) 3.41 (2.66) 
Tokyo 6 1.50 (0.84) 16.67 (40.82) 6 1.50 (0.84) 0.00 (0.00) 
US 1 171.00 21.64 1 171.00 49.71 
Zagreb 6 1.50 (0.55) 0.00 (0.00) 6 1.50 (0.55) 0.00 (0.00) 
Total 110 27.00 (38.78) 14.45 (25.39) 109 52.54 (85.54) 13.83 (20.55) 
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Asia reported the highest percentage of cases resistant to clindamycin (35.08% [SD 39.39]) 
and Latin America and the Caribbean reported the lowest (0.00% [0.00]) followed by Sub-
Saharan Africa (0.23% [SD 0.51]). North America reported the highest percentage of cases 
resistant to erythromycin (34.34% [SD 14.92]) and Latin America and the Caribbean (0.00% 
[SD 0.00]) followed by Sub-Saharan Africa (2.84% [SD 2.76]) reported the lowest (see Table 
58). As shown in Appendix 20-B, the rates fluctuated by year in North America and Europe, 
were relatively stable in Sub-Saharan Africa and Latin America and the Caribbean. There was 
only one observation from North Africa and the Middle East in 2015.  
Table 58. Percentage of neonatal GBS resistance by region  
Region Clindamycin 
resistance 
Erythromycin resistance 
 Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
Asia 27 (24.55) 35.08 (39.39) 24 (22.02) 22.56 (29.40) 
Europe 49 (44.55) 7.89 (14.88) 50 (45.87) 10.20 (15.47) 
Latin America and the 
Caribbean 
16 (14.55) 0.00 (0.00) 16 (15.09) 0.00 (0.00) 
North Africa and the 
Middle East 
1 (0.91) 18.18 1 (0.92) 27.27 
North America 12 (10.91) 19.69 (9.67) 12 (11.01) 34.34 (14.92) 
Sub-Saharan Africa 5 (4.55) 0.23 (0.51) 6 (5.50) 2.84 (2.76) 
Total 110 (100.00) 14.45 (25.39) 109 (100.00) 13.83 (20.55) 
 
With respect to the most recent prevention strategy, the highest mean resistance to 
clindamycin was reported under no prevention (21.44% [SD 36.67]), followed by screening 
(15.17% [SD 24.04]) and risk-based prevention (9.13% [SD 16.82]). The highest mean 
resistance to erythromycin was under screening (17.81% [SD 23.05]), followed by risk-based 
prevention (13.66% [SD 19.71]) and no prevention (4.03 ([SD 0.08]) (see Table 59). Figure 
34 and Figure 35 show that resistance increased in all prevention strategies. Similar to EOGBS 
resistance rates, the neonatal GBS resistance rates also go from 0% in the earlier years to 100% 
in the later years, probably a result of small numbers.  
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Table 59. Percentage of neonatal GBS resistance by recently reported GBS prevention strategy 
Most recent reported 
GBS prevention  
Clindamycin resistance Erythromycin resistance 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
Number of 
observations/ 
years (%) 
Mean % 
cases 
resistant  
(SD) 
No prevention 23 (20.90) 21.44 (36.67) 20 (18.35) 4.03 (10.08) 
Risk-based prevention  37 (33.64) 9.13 (16.82) 38 (34.86) 13.66 (19.71) 
Screening prevention 50 (45.45) 15.17 (24.04) 51 (46.79) 17.81 (23.05) 
Total 110 (100.00) 14.45 (25.39) 109 (100.00) 13.83 (20.55) 
 
GBS group B Streptococcus 
Each dot represents the % of neonatal GBS cases resistant to clindamycin for one year for one geographical area  
Figure 34. Neonatal GBS clindamycin resistance by recently reported GBS prevention strategy 
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 GBS group B Streptococcus 
Each dot represents the % of neonatal GBS cases resistant to erythromycin for one year for one geographical area 
Figure 35. Neonatal GBS clindamycin resistance by recently reported GBS prevention strategy 
13.3.4 Unadjusted linear regression analysis (objectives c & d)  
This section presents the results of the linear regression analysis showing the unadjusted 
relationship between the most recently reported GBS prevention strategy and the trends of 
each harmful outcome across time. This is followed by the linear regression analysis showing 
the unadjusted relationship between each compositional covariate and mean EOGBS 
incidence (objective d).  
Most recently reported GBS prevention strategy 
The results of the unadjusted analyses are summarised in Table 60 and Figure 36 to Figure 41. 
Again, contrary to expectation, there was a decrease in annual early-onset E. coli incidence in 
areas with no prevention. Compared with screening prevention areas, the early-onset E. coli 
incidence decreased by 0.036 (95% CI -0.072 to -0.001) yearly in no prevention areas. 
Similarly, compared with screening prevention areas, the percentage of neonatal GBS cases 
resistant to clindamycin increased yearly by 2.71% (95% CI -5.25 to -0.18) lower in risk-
based prevention areas. There were no other statistically significant differences in the trends 
of harms between different prevention areas.  
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The statistically non-significant trends in harmful outcomes were as follows. LOGBS 
incidence remained relatively stable in screening and risk-based prevention areas, while it 
increased yearly in ‘either prevention’ areas and decreased yearly in no prevention areas. 
Early-onset E. coli incidence increased yearly in screening prevention and risk-based 
prevention areas whereas it decreased under ‘either prevention’ areas. With the exception of 
the trend in EOGBS resistant to clindamycin in risk-based prevention areas, the percentage of 
EOGBS cases resistant to clindamycin and erythromycin increased across time at similar rates 
in all areas. Likewise, the percentage of neonatal GBS cases resistant to clindamycin increased 
steeper under no prevention and screening prevention areas compared with risk-based 
prevention areas. Finally, the percentage of neonatal GBS cases resistant to erythromycin 
increased steeper under screening compared with risk-based and no prevention areas. 
Table 60. Unadjusted linear regression analyses on the average annual change for the harms by 
recently reported GBS prevention strategy 
Most recent reported GBS prevention  Average annual change in 
outcome 
(95% confidence interval) 
p-value 
LOGBS per 1,000 livebirths   
     Screening prevention (reference)  
     No prevention  -0.034 (-0.055 to 0.003) 0.080 
     Risk-based prevention -0.002 (-0.024 to 0.019) 0.822 
     Either screening or risk-based prevention .0051308 (-0.032 to 0.042) 0.785 
Early-onset E. coli per 1,000 livebirths    
     Screening prevention (reference)  
     No prevention -0.036 (-0.072 to -0.001) 0.044 
     Risk-based prevention -0.015 (-0.046 to 0.016) 0.339 
     Either screening or risk-based prevention -0.048 (-0.147 to 0.052) 0.346 
EOGBS clindamycin resistance (%)    
No prevention (reference)  
Risk-based prevention -1.829 (-4.083 to 0.425) 0.111 
Screening prevention -0.654 (-2.976 to 1.667) 0.578 
EOGBS erythromycin resistance (%)    
No prevention (reference)  
Risk-based prevention -0.352 (-2.742 to 2.038) 0.771 
Screening prevention 0.044 (-2.386 to 2.475) 0.971 
Neonatal GBS clindamycin resistance (%)    
No prevention (reference)  
Risk-based prevention -2.712 (-5.247 to -0.177) 0.036 
Screening prevention -1.371 (-3.617 to 0.876) 0.229 
Neonatal GBS erythromycin resistance (%)    
No prevention (reference)  
Risk-based prevention 0.096 (-2.056 to 2.247) 0.930 
Screening prevention 1.188 (-0.765 to 3.141) 0.230 
E. coli Escherichia coli, EOGBS early-onset GBS, GBS group B Streptococcus, LOGBS late-onset GBS 
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LOGBS Late-onset group B Streptococcus  
Figure 36. Unadjusted trends of annual LOGBS incidence for each recently reported GBS 
prevention strategy using linear regression analysis 
 
E. coli Escherichia coli, GBS group B Streptococcus 
Figure 37. Unadjusted trends of annual early-onset E. coli incidence for each recently reported 
GBS prevention strategy using linear regression analysis 
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EOGBS early-onset group B Streptococcus  
Figure 38. Unadjusted trends of the annual percentage of EOGBS cases resistant to clindamycin 
for each recently reported GBS prevention strategy using linear regression analysis 
EOGBS early-onset group B Streptococcus  
Figure 39. Unadjusted trends of the annual percentage of EOGBS cases resistant to erythromycin 
for each recently reported GBS prevention strategy using linear regression analysis 
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GBS group B Streptococcus  
Figure 40. Unadjusted trends of the annual percentage of neonatal GBS cases resistant to 
clindamycin for each recently reported GBS prevention strategy using linear regression analysis 
 GBS group B Streptococcus  
Figure 41. Unadjusted trends of the annual percentage of neonatal GBS cases resistant to 
erythromycin for each recently reported GBS prevention strategy using linear regression analysis
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Compositional covariates 
The results of the unadjusted linear regression analyses between the compositional covariates 
and the six outcomes are shown in Table 61. To summarise the key relationships, Latin 
America and the Caribbean reported a higher incidence of LOGBS (0.409, 95% CI 0.217 to 
0.601) and early-onset E. coli per 1,000 livebirths (0.428, 95% CI 0.142 to 0.715) compared 
with North America. Sub-Saharan Africa had also had a higher incidence of LOGBS (0.870, 
95% CI 0.505 to 1.234). Compared with North America, Latin America and the Caribbean 
reported a lower percentage of antibiotic resistance across those tested, and Europe and Sub-
Saharan Africa had a lower percentage of erythromycin resistance for both EOGBS and 
neonatal GBS cases tested. A one percent increase in preterm births was associated with: a 
0.033 (95% CI 0.015 to 0.051) per 1,000 livebirths increase in LOGBS incidence; a 0.061 
(95% CI 0.038 to 0.084) per 1,000 livebirths increase in early-onset E. coli incidence; a 2.87% 
(95% CI 1.698 to 4.0458) increase in the percentage of EOGBS cases resistant to 
erythromycin; and a 1.62% (95% CI 0.578 to 2.653) increase in the percentage of neonatal 
GBS cases resistant to erythromycin. A one percent increase in low birthweights was 
associated with an increase of 0.027 (95% CI 0.018 to 0.035) per 1,000 livebirths in LOGBS 
incidence and a 0.034 per 1,000 livebirths (95% CI 0.023 to 0.044) in early-onset E. coli 
incidence. A one percent increase in caesarean sections was also associated with an increase 
in LOGBS (0.007, 95% CI 0.002 to 0.013) and early-onset E. coli (0.019, 95% CI 0.011 to 
0.026) incidence.  
By contrast, a unit increase in the human development index reduced LOGBS by 2.112 (-95% 
CI -2.761 to -1.464) and early-onset E. coli by 1.815 (95% CI -2.778 to -0.853) per 1,000 
livebirths. Likewise, a percentage increase in maternal GBS colonisation reduced LOGBS by 
0.007 (95% CI -0.012 to -0.002) and early-onset E. coli by 0.016 (95% CI -0.024 to -0.009) 
per 1,000 livebirths. A one unit increase in the percentage of prolonged rupture of membranes 
was associated with increases in all resistance outcomes. Similar to other findings, data from 
one centre compared with national surveillance and/or mandatory surveillance influenced the 
results. 
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Table 61. Unadjusted linear regression analyses of the harms by compositional covariates 
Covariate LOGBS/1000 
coefficient  
(95% confidence 
interval [CI]) 
Early-onset E. 
coli/1000 
coefficient  
(95% CI) 
% EOGBS 
resistance to 
clindamycin  
(95% CI) 
% EOGBS 
resistance to 
erythromycin (95% 
CI) 
% Neonatal GBS 
resistance to 
clindamycin (95% 
CI) 
% Neonatal GBS 
resistance to 
erythromycin 
(95% CI) 
Region        
North America (reference) (reference) (reference) (reference) (reference) (reference) 
Asia 0.088  
(-0.105 to 0.280) 
0.296  
(-0.005 to 0.597) 
13.213 
(-3.390 to 29.815) 
-11.653 
(-28.776 to 5.471) 
15.391 
(-26.083 to 2.486) 
-11.778 
(-24.538 to 0.982) 
Europe -0.021  
(-0.170 to 0.128) 
0.196 
(-0.078 to 0.470) 
-12.700 
(-27.045 to 1.646) 
-25.468 
(-40.096 to -10.839) 
-11.799 
(-26.083 to 2.486) 
-24.137  
(-35.739 to -12.536) 
Latin America and the 
Caribbean 
0.409  
(0.217 to 0.601) 
0.428 
(0.142 to 0.715) 
-21.010 
(-37.986 to -4.034) 
-32.241 
(-49.364 to -15.117) 
-19.691 
(-36.628 to -2.755) 
-34.337 
(-48.120 to -20.555) 
North Africa and the Middle 
East 
-0.217  
(-0.753 to 0.319) 
0.361 
(-0.020 to 0.742) 
2.0264 
(-16.355 to 20.408) 
-14.109 
(-32.290 to 4.072) 
-1.509 
(-47.670 to 44.652) 
-7.064 
(-44.629 to 30.500) 
Oceania -0.031  
(-0.322 to 0.260) 
0.306  
(-0.085 to 0.696) 
-17.719 
(-64.583 to 29.145) 
-35.357 
(-82.628 to 11.914) 
- - 
Sub-Saharan Africa 0.870 
(0.505 to 1.234) 
- -20.898 
(-44.864 to 3.069) 
-32.358 
 (-55.066 to -9.650) 
-19.464 
 (-43.071 to 4.143) 
-31.495 
(-49.541 to -13.450) 
Preterm births  0.033 
(0.015 to 0.051) 
0.061 
(0.038 to 0.084) 
1.262 
(-0.137 to 2.66) 
2.872 
(1.698 to 4.0458) 
1.077 
(-0.251 to 2.405) 
1.616 
(0.578 to 2.653) 
Low birthweights 0.027 
(0.018 to 0.035) 
0.034 
(0.023 to 0.044) 
-0.561 
(-1.170 to 0.048) 
-0.521 
(-1.150 to 0.108) 
-0.517 
(-1.162 to 0.127) 
-0.449 
(-0.988 to 0.091) 
Caesarean section 0.007 
(0.002 to 0.013) 
0.019 
(0.011 to 0.026) 
0.296 
(-0.248 to 0.839) 
0.230 
(-.293 to 0.753) 
0.232 
(-0.331 to 0.795) 
-0.045 
(-0.488 to 0.398) 
Fertility rate 0.277  
(0.148 to 0.405) 
0.126 
(-0.023 to 0.274) 
-13.293 
(-22.598 to -3.988) 
-5.420 
(-15.143 to 4.304) 
-18.890 
(-28.407 to -9.373) 
-5.742 
(-14.131 to 2.647) 
Skilled attendance at delivery -0.008 
(-0.018 to 0.002) 
-0.003 
(-0.015 to 0.009) 
0.094 
(-0.758 to 0.945) 
-0.003 
(-0.787 to 0.7806) 
0.999 
(0.079 to 1.918) 
0.652 
(-0.108 to 1.412) 
Average maternal age -0.046 
(-0.062 to -0.031) 
-0.032 
(-0.051 to -0.013) 
-0.246 
(-1.583 to 1.092) 
-0.193 
(-1.514 to 1.127) 
-0.879 
(-2.255 to 0.497) 
-0.155 
(-1.284 to 0.975) 
Multiple or twin birth -0.008 
(-0.015 to -0.002) 
-0.005  
-(0.013 to 0.003) 
0.007 
(-0.561 to 0.575) 
-0.421 
(-0.990 to 0.147) 
-0.330 
(-0.834 to 0.174) 
-0.389  
(-0.798 to 0.0199) 
Per capita government 
expenditure on health 
-0.00004  
(-0.00007 to 
0.00002) 
-0.00009 
(-0.0001 to -
0.00005) 
0.0009 
(-0.002 to 0.004) 
0.003 
(0.0001 to 0.006) 
-0.001 
(-0.004 to 0.002) 
0.003 
(0.0002 to 0.005) 
Human development index -2.112  -1.815 -9.981 14.032 -51.141 32.865 
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Covariate LOGBS/1000 
coefficient  
(95% confidence 
interval [CI]) 
Early-onset E. 
coli/1000 
coefficient  
(95% CI) 
% EOGBS 
resistance to 
clindamycin  
(95% CI) 
% EOGBS 
resistance to 
erythromycin (95% 
CI) 
% Neonatal GBS 
resistance to 
clindamycin (95% 
CI) 
% Neonatal GBS 
resistance to 
erythromycin 
(95% CI) 
(-2.761 to -1.464) (-2.778 to -0.853) (-68.338 to 48.377) (-48.942 to 77.006) (-111.49 to 9.208) (-22.842 to 88.573) 
Maternal GBS colonisation -0.007 
(-0.012 to -0.002) 
-0.016 
(-0.024 to -0.009) 
0.118 
(-0.348 to 0.583) 
0.404 
(-0.079 to 0.886) 
-0.204 
(-0.718 to 0.311) 
0.193 
(-0.224 to 0.610) 
Prolonged rupture of membranes -0.0002 
(-0.009 to 0.009) 
0.006 
(-0.006 to 0.017) 
2.098 
(1.445 to 2.750) 
1.153 
(0.418 to 1.888) 
2.141 
(1.557 to 2.725) 
0.915 
(0.341 to 1.489) 
Intrapartum fever -0.016  
(-0.043 to 0.011) 
-0.009 
(-0.041 to 0.023) 
1.695 
(-0.900 to 4.290) 
-0.727 
(-3.286 to 1.833) 
1.419 
(-1.414 to 4.252) 
-0.825 
(-3.117 to 1.468) 
Most prevalent GBS serotype        
Ia (reference) (reference) (reference) (reference) (reference) (reference) 
Ib -0.198 
(-0.485 to 0.089) 
0.196 
(-0.184 to 0.575) 
1.315 
(-18.400 to 21.030) 
-13.561 
(-33.945 to 6.824) 
-5.482 
(-31.452 to 20.487) 
-23.475 
(-44.326 to -2.624) 
III 0.113 
(-0.066 to 0.292) 
  0.280 
(-0.066 to 0.626) 
9.183 
(-8.554 to 26.920) 
-6.739 
(-24.305 to 10.826) 
10.768 
(-7.712 to 29.248) 
-9.575 
(-24.419 to 5.269) 
V -0.206 
(-0.784 to 0.372) 
0.147 
(-0.553 to 0.846) 
52.295 
(14.323 to 90.267) 
25.688 
(-6.500 to 57.876) 
12.699 
(-40.522 to 65.921) 
3.797  
(-38.935 to 46.529) 
Surveillance type        
Mandatory population 
surveillance 
(reference) (reference) (reference) (reference) (reference) (reference) 
Voluntary population 
surveillance 
-0.139 
(-0.296 to 0.018) 
-0.073 
(-1.115 to 0.968) 
-7.267 
(-24.088 to 9.554) 
-14.532 
(-30.162 to 1.098) 
-7.429 
(-25.211 to 10.354) 
-15.201 
(-28.251 to -2.151) 
Multiple centres/counties -0.032 
(-0.213 to 0.149)  
0.086 
(-0.966 to 1.138) 
-6.271 
(-44.224 to 31.682) 
-7.083 
(-43.178 to 29.012) 
2.123 
(-51.017 to 55.264) 
9.753 
(-19.692 to 39.199) 
One centre 0.168 
 (0.027 to 0.308) 
0.260 
(-0.776 to 1.295) 
-8.459 
(-23.909 to 6.991) 
-19.465 
(-33.850 to -5.080) 
-4.870 
(-21.439 to 11.700) 
-20.897 
(-33.040 to -8.754) 
Geographical coverage       
National  (reference) (reference) (reference) (reference) (reference) (reference) 
Regional -0.015 
(-0.185 to 0.156) 
-0.135 
(-0.414 to 0.145) 
7.208 
(-9.405 to 23.822) 
17.260 
(1.521 to 32.998) 
7.139 
(-10.500 to 24.779) 
16.948 
(3.613 to 30.284) 
City/town wide -0.137 
(-0.687 to 0.414) 
-0.145 
(-0.757 to 0.467) 
- - - - 
One centre in a city/town 0.225 
(0.109 to 0.340) 
0.245 
(0.081 to 0.408) 
-1.251 
(-11.480 to 8.978) 
-4.863 
(-14.650 to 4.925) 
2.270 
(-8.532 to 13.072) 
-6.694  
(-14.827 to 1.439) 
Definition        
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Covariate LOGBS/1000 
coefficient  
(95% confidence 
interval [CI]) 
Early-onset E. 
coli/1000 
coefficient  
(95% CI) 
% EOGBS 
resistance to 
clindamycin  
(95% CI) 
% EOGBS 
resistance to 
erythromycin (95% 
CI) 
% Neonatal GBS 
resistance to 
clindamycin (95% 
CI) 
% Neonatal GBS 
resistance to 
erythromycin 
(95% CI) 
1 (reference) (reference) (reference) (reference) (reference) (reference) 
2 -0.278 
(-0.409 to -0.148) 
-0.307 
(-0.451 to -0.163) 
3.743 
(-6.545 to 14.032) 
  1.674 
(-8.449 to 11.797) 
-7.422 
(-21.448 to 6.604) 
-4.358 
(-15.388 to 6.673) 
3 -0.493 
(-1.442 to 0.456) 
-0.241 
(-0.672 to 0.190) 
- - - - 
4 -0.508 
(-1.185 to 0.168) 
- - - -7.025 
(-21.773 to 7.723) 
-13.675 
(-25.3972 to -1.952) 
E. coli Escherichia coli, GBS group B Streptococcus, LOGBS late-onset GBS 
LOGBS definition: 1, 2/3/4 days onwards, 2, 5/6/7/8 days onwards, 3, 48 hours to 6 days, 4, Not stated 
E. coli definition 1, <2/3/4 days, 2, <5/6/7/8 days, 3, mother infected 
Early-onset GBS definition 1, 2/3 days or less, 2, 5/6/7 days or less 
Neonatal GBS definition 1, <28/30/31/44 days, 2, <89/90/132 days, 4 Not stated 
Numbers in bold are p<0.05 
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13.3.5 Adjusted linear regression analysis (objective e) 
This section presents the results of the adjusted linear regression analysis showing the 
relationship between the most recently reported GBS prevention strategy and the trends of 
each harmful outcome across time adjusted for the compositional covariates (objective e).  
As statistically non-significant covariates were removed, this left the minimal final models 
shown in Table 62, Figure 42 to Figure 47. In contrast with the unadjusted analysis, when 
compositional covariates were adjusted for, there was an increase in annual LOGBS incidence 
in all prevention areas. However, compared with screening prevention areas, LOGBS 
incidence increased by 0.079 (95% CI 0.013 to 0.146) yearly in no prevention areas and 0.016 
(95% CI 0.001 to 0.031) yearly in risk-based prevention areas. The trends in annual LOGBS 
incidence between risk-based areas and no prevention areas were also statistically different 
(p=0.0241). There were no other statistically significant differences in the trends of other 
harmful outcomes between different prevention areas.  
The statistically non-significant trends in the harmful outcomes were as follows. Early-onset 
E. coli incidence increased in no, risk-based and screening prevention areas whereas it 
decreased in ‘either prevention’ areas. The percentage of EOGBS cases resistant to 
clindamycin increased at a similar rate in all prevention areas, while the percentage of EOGBS 
cases resistant to erythromycin increased more steeply in no prevention areas followed by 
screening and risk-based prevention areas. The percentage of neonatal GBS cases resistant to 
clindamycin remained steady in no prevention areas, whereas it increased in risk-based 
prevention areas and screening areas. The percentage of neonatal GBS cases resistant to 
erythromycin remained steady in risk-based prevention areas, whereas it increased in no 
prevention and screening prevention areas.  
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Table 62. Adjusted linear regression analyses on the average annual change for the harms by 
recently reported GBS prevention strategy 
Most recent reported GBS prevention  Coefficient by year 
(95% confidence 
interval) 
p-value 
LOGBS per 1,000 livebirths   
     Screening prevention (reference)  
     No prevention  0.079 (0.013 to 0.146) 0.020 
     Risk-based prevention 0.016 (0.001 to 0.031) 0.035 
     Either prevention 0.010 (-0.008 to 0.028) 0.277 
Early-onset E. coli per 1,000    
     Screening prevention (reference)  
     No prevention 0.021 (-0.029 to 0.072) 0.406 
     Risk-based prevention 0.005 (-0.012 to 0.023) 0.564 
     Either prevention -0.036 (-0.075 to 0.003) 0.072 
EOGBS clindamycin resistance (%)    
No prevention (reference)  
Risk-based prevention 0.207 (-1.857 to 2.272) 0.842 
Screening prevention 0.175 (-2.780 to 3.130) 0.907 
EOGBS erythromycin resistance (%)    
No prevention (reference)  
Risk-based prevention -1.401 (-3.668 to 0.865) 0.219 
Screening prevention -0.608 (-2.578 to 1.361) 0.536 
Neonatal GBS clindamycin resistance    
No prevention (reference)  
Risk-based prevention 0.449 (-2.655 to 3.553) 0.774 
Screening prevention 1.429 (-1.571 to 4.428) 0.346 
Neonatal GBS erythromycin resistance (%)   
No prevention (reference)  
Risk-based prevention -0.209 (-1.684 to 1.266) 0.777 
Screening prevention 0.812 (-0.877 to 2.501) 0.339 
LOGBS late-onset group B Streptococcus, E. coli Escherichia coli,  
a. LOGBS adjusted for percentage preterm births, low birthweights, human development index, region, 
prolonged rupture of membranes, maternal GBS colonisation, geographical coverage, surveillance type, and 
definition  
b. E. coli adjusted for percentage preterm births, low birthweights, human development index, region, maternal 
GBS colonisation, geographical coverage, surveillance type, and definition 
c. EOGBS clindamycin resistance adjusted for region, human development index, percentage preterm births, low 
birthweight, surveillance type, geographical coverage, and definition 
d. EOGBS erythromycin resistance adjusted for region, human development index, percentage preterm births, 
low birthweight, surveillance type, geographical coverage, and definition 
e. Neonatal GBS clindamycin resistance adjusted for region, human development index, percentage preterm 
births, prolonged rupture of membranes, low birthweight, surveillance type, and definition 
f. Neonatal GBS clindamycin resistance adjusted for region, human development index, percentage preterm 
births, low birthweight, surveillance type, and definition 
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LOGBS Late-onset group B Streptococcus  
Figure 42. Adjusted trends of annual LOGBS incidence for each recently reported GBS 
prevention strategy using linear regression analysis 
  
E. coli Escherichia coli, GBS group B Streptococcus 
Figure 43. Adjusted trends of annual early-onset E. coli incidence for each recently reported GBS 
prevention strategy using linear regression analysis 
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EOGBS early-onset group B Streptococcus  
Figure 44. Adjusted trends of the annual percentage of EOGBS cases resistant to clindamycin for 
each recently reported GBS prevention strategy using linear regression analysis 
EOGBS early-onset group B Streptococcus  
Figure 45. Adjusted trends of the annual percentage of EOGBS cases resistant to erythromycin 
for each recently reported GBS prevention strategy using linear regression analysis 
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GBS group B Streptococcus  
Figure 46. Adjusted trends of the annual percentage of neonatal GBS cases resistant to 
clindamycin for each recently reported GBS prevention strategy using linear regression analysis 
GBS group B Streptococcus  
Figure 47. Adjusted trends of the annual percentage of neonatal GBS cases resistant to 
erythromycin for each recently reported GBS prevention strategy using linear regression analysis  
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13.3.6 Sensitivity analysis for LOGBS trends (objective f) 
The results from final model on the trends of annual LOGBS incidence were sensitive to 
alterations in the assumptions and data in the model. The difference in the yearly trends of 
LOGBS incidence between risk-based prevention and screening prevention areas lost 
statistical significance when using the most frequently reported GBS prevention across the 
years instead of the most recently reported GBS prevention (0.011, 95% CI -.001 to 0.024). 
This comparison also lost statistical significance when only including geographical areas with 
four or more years of data (0.015, 95% CI -0.002 to 0.033) and when removing outer fence 
box plot outliers (0.007, 95% CI -0.002 to 0.017). Removing data from only one centre caused 
the difference in trends between no prevention and screening prevention areas to lose 
statistical significance (0.021, 95% CI -0.087 to 0.129). Removing outer fence box plot 
outliers (0.012, 95% CI 0.0003 to 0.023) and data from only one centre (0.009, 95% CI 0.0003 
to 0.0174) also caused the trends in annual LOGBS incidence between ‘either prevention’ 
areas to become statistically different to screening prevention areas.  
Altering the maternal GBS colonisation rate to a lower rate (where ranges were available) 
caused the trends in annual LOGBS incidence in both risk-based (0.014, 95% CI -0.0003 to 
0.029) and no prevention areas (0.055, 95% CI -0.003 to 0.114) compared with screening 
prevention areas to lose statistical significance. Altering maternal GBS colonisation to a 
higher rate only caused the difference in trends between no prevention and screening 
prevention areas to just miss statistical significance (0.059, 95% CI -0.0005 to 0.118). 
Similarly, all of the following changes caused the trends of annual LOGBS incidence in both 
no and risk-based prevention areas compared with screening prevention areas to lose statistical 
significance: only including covariates with less than 10% of data imputed from another 
country (no prevention: 0.043, 95% CI -0.017 to 0.103; risk based prevention: 0.007, 95% CI 
-0.007 to 0.021); only using survey data (no prevention: 0.008, 95% CI -0.049 to 0.065; risk 
based prevention: 0.005, 95% CI -.0008 to  0.017); and using alternative geographical areas 
where more than one data source was available (no prevention: 0.012, 95% CI -0.050 to 0.074, 
risk-based prevention: 0.004, 95% CI -0.009 to 0.016). Only including data defined as 7 days 
onwards did not change the results and none of the sensitivity analyses changed the direction 
of the results.  
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13.4 Discussion 
In this discussion, I will summarise the findings of this study and compare the findings with 
previous literature. In Chapter 14, I will discuss the strengths and the limitations as well as the 
research and policy implications related to this study.  
13.4.1 Principal findings 
In this study, I aimed to investigate whether GBS prevention strategies, particularly universal 
screening, have an impact on the trends of potential harmful outcomes of GBS screening 
programmes across countries. These harmful outcomes were incidences of LOGBS and early-
onset E. coli and the percentages of EOGBS and neonatal GBS cases resistant to clindamycin 
and erythromycin. The findings suggest that the international trends of LOGBS incidence may 
indeed be related to GBS prevention strategies. LOGBS incidence increased under screening, 
however, contrary to expectations, it increased at a higher rate under no and risk-based 
prevention compared with screening. Based on the available evidence, the predicted values 
showed that LOGBS incidence increased from approximately 0.075 to 0.30 per 1,000 
livebirths under screening prevention areas, 0.10 to 0.73 per 1,000 livebirths in risk-based 
prevention areas, and -1.45 to 0.74 per 1,000 livebirths in no prevention areas. The trends for 
the remaining harmful outcomes under risk-based, ‘either’ or no prevention were not different 
to universal screening. This would imply that there is no evidence that LOGBS, early-onset 
E. coli and antibiotic resistance would increase by adopting a GBS screening programme. 
Instead, LOGBS incidence would increase more under a risk-based or no prevention strategy, 
compared with screening. However, aside from the LOGBS analysis, the sample size in the 
remaining analyses was not sufficiently large, therefore, this evidence is inconclusive.   
The difference in the trends of LOGBS incidence between risk-based and no prevention areas 
compared with screening areas was unstable across the sensitivity analyses. While I chose the 
most methodologically robust available options in selecting the data and generating the 
variables for the model, there were serious limitations in the data collected, thus, unstable 
results have important implications. Seven of the 10 sensitivity analyses caused the LOGBS 
differences between screening and risk-based prevention areas to lose statistical significance, 
while six caused the difference between screening and no prevention areas to lose statistical 
significance. As the direction of the results did not change, screening still had a smaller 
increase in LOGBS incidence compared with risk-based and no prevention. However, whether 
the predicted trends can be expected under each of the GBS prevention strategies in different 
populations or settings is uncertain. Nevertheless, for the purposes of this study investigating 
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whether universal screening has a harmful impact of increasing LOGBS incidence, the 
implication that screening does not increase LOGBS incidence compared with other 
strategies, remains unchanged. The main model and the sensitivity analyses showed that 
LOGBS incidence under screening did not increase more than other strategies.   
The findings of early-onset E. coli incidence and the percentages of EOGBS and neonatal 
GBS cases resistant to clindamycin and erythromycin are not clear. While the statistically non-
significant results could be genuine and screening may not increase these outcomes compared 
with other prevention strategies, similar to Chapter 12,  they could also be due to the lack of 
statistical power from the small sample sizes in these analyses. As identified in Chapter 9, 63 
observations in each prevention strategy provided an 80% chance to detect a change of 0.1 per 
1,000 livebirths. Accounting for the imbalances between the observations in each prevention 
group, for the E. coli analysis, the sample size I achieved was 19 per prevention group for the 
comparison of either versus screening prevention, 80 for risk-based versus screening 
prevention, and 48 for no versus screening prevention. The annual differences in early-onset 
E. coli between the prevention strategies were well below 0.1 per 1,000 livebirths, therefore, 
the sample size was not large enough for these differences to be statistically significant. For 
the analyses on GBS resistance, the sample sizes achieved ranged from 26 to 31 in each 
prevention group and the resulting statistical power was less than 50%.  
The lack of statistical power is especially important for the analyses on early-onset E. coli 
incidence and the percentage of neonatal GBS cases resistant to erythromycin. The trends in 
these outcomes were considerably different for each of the prevention strategies yet there was 
no statistically significant difference. Compared with screening, which showed an upward 
trend in early-onset E. coli incidence, ‘either prevention’ areas showed a decreasing yearly 
trend. Similarly, the predicted values show that the percentage of neonatal GBS cases resistant 
to erythromycin increased at a much steeper rate in screening prevention areas from 
approximately 3% to 22.5% during the study period, whereas it changed from around 13% to 
16% in no prevention areas, and remained steady in risk-based prevention areas at around 11% 
to 12%. This may imply that erythromycin resistance increases at higher rate under screening 
programmes than risk-based programmes or no prevention, even though this did not reach 
statistical significance.  
Overall, there is evidence that universal screening does not lead to an unintended increase in 
LOGBS incidence compared with other prevention strategies. Furthermore, there was no 
evidence that universal GBS screening has an impact on the trends of annual early-onset E. 
coli incidence or GBS resistance compared with other strategies, however, these analyses were 
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statistically under-powered to confirm this. Of particular importance, trends in neonatal GBS 
resistance to erythromycin showed a considerably higher but statistically non-significant 
increase over time in screening prevention areas compared with risk-based areas. This might 
have been statistically significant if larger sample sizes were analysed. 
13.4.2 Comparison with previous literature 
In this section, I separately compare the study findings with existing literature for each 
outcome (LOGBS, early-onset E. coli and antibiotic resistance). The trends of LOGBS are not 
as well documented as EOGBS. In line with the study findings, in the US, multi-state 
population surveillance from the CDC reported stable rates of LOGBS ranging from 0.29 to 
0.39 per 1,000 livebirths from 1990 to 2008.408, 409 During this time, the GBS prevention 
strategy changed from no to ‘either’ to screening prevention. Most recently, in 2015 the 
LOGBS incidence was 0.34 per 1,000 livebirths.57 Under GBS screening in Italy, LOGBS has 
remained steady at 0.32 per 1,000 livebirths with no statistically significant variation from 
2003 to 2010.410 By contrast, Bauserman et al. (2013) found that LOGBS incidence increased 
from 0.8 to 1.1 per 1,000 NICU admissions between 1997 to 2001 (‘either prevention’) and 
2002 to 2010 (universal screening).172 Also in agreement with the study findings, literature 
from countries that have adopted risk-based prevention have shown increases in LOGBS 
incidence over time.411 For example, in the UK under risk-based prevention, LOGBS 
incidence has increased from 0.24 per 1,000 livebirths in 2000/01 to 0.37 per 1,000 livebirths 
in 2014/15.5 Similarly, in the Netherlands under risk-based prevention, LOGBS incidence 
increased from 0.03 to 0.13 per 1,000 livebirths over time.66 However, from the report it is not 
clear but likely that the surveillance was voluntary, thus, the increase could be attributable to 
increases in reporting. The findings of this study mirror the existing evidence: increases in 
LOGBS incidence under risk-based prevention were more evident in this study and more 
consistent in the literature, whereas increases in LOGBS incidence under screening were 
smaller in this study and vary in the literature.  
In agreement with the study findings, Stoll et al. (2002) in the US found no difference in all-
cause sepsis and early-onset E. coli sepsis between very low birth neonates whose mothers 
were treated with IAP and those who were not.20 Likewise, although Schrag et al. (2006) found 
that IAP increased the odds of early-onset E. coli infection in unadjusted analyses, IAP did 
not remain associated with early-onset E. coli when other factors were accounted for. In 
Taiwan, Tsai et al. (2012) also found that early-onset E. coli was not associated with antibiotic 
use after adjusting for gestational age.188 Analysing trends over time, Bauserman et al. (2013) 
found that early-onset E. coli remained stable from the period of ‘either prevention’ to the 
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period of screening at 1.4 per 1,000 admissions.172 Likewise, in Australia and New Zealand, 
Daley et al. (2004) found that early-onset E. coli decreased from 1992 to 2001 during either 
or risk-based prevention, which was not statistically significant.72 An older Australian study 
showed similar results.190 Contrary to the findings of  this study, Bizzarro et al. (2008) found 
that early-onset E. coli in very low birthweight neonates (<1500g) increased from 2.83 per 
1,000 admissions (no prevention) to 7.12 per 1,000 admissions (risk-based prevention) to 
10.22 per 1,000 admissions (screening).187 Similarly, in the study by Stoll et al. (2002) the rate 
of early-onset E. coli infections increased from 3.2 to 6.8 per 1000 livebirths in low 
birthweight infants between 1998 to 2000 during ‘either’ prevention.20 Despite the low 
statistical power in this study, the majority of the current evidence in the literature supports 
the finding that screening does not lead to an increase in early-onset E. coli in all neonates. 
However, the evidence is limited as these are observational before and after studies subject to 
bias.  
In the literature, antibiotic resistance in countries offering IAP prevention programmes for 
neonatal GBS prevention have increased over time. It is important to note, that GBS remains 
almost universally susceptible to penicillin as mentioned in Chapters 2 and 7,86 although there 
are recent reports from small studies in Ethiopia and in Italy with evidence of penicillin 
resistance in GBS isolated from pregnant women.179-181 In the US in 2005, 0.2% of GBS 
isolates had reached the upper level of susceptibility for beta-lactams.182, 18 Similarly, in Japan, 
5% to 15% of GBS isolates were reported to have reduced penicillin susceptibility;183 
approximately half of these were susceptible under European breakpoints and came from 
populations where chronic antibiotic exposure is likely to be common (due to chronic 
respiratory disease). The clinical significance of increased minimum inhibitory concentrations 
close to breakpoint is also uncertain.  
However, in the last 20 years, both clindamycin and erythromycin resistance have increased 
in countries with risk-based prevention and universal screening.14, 81 In countries adopting 
universal screening, reported rates of resistance have been higher compared with countries 
with risk-based prevention, though no formal comparison has been performed in neonates. In 
the US, where universal screening is adopted, resistance to erythromycin was reported at 48% 
and resistance to clindamycin was reported at 27% in EOGBS cases in 2010.57 By contrast, in 
the UK in 2010 where risk-based prevention is adopted, erythromycin was reported at 15% in 
EOGBS81 and clindamycin resistance at 9% though this included all GBS cases.184 However, 
in an Italian study of 75 neonatal GBS strains, erythromycin resistance was reported at only 
12% and clindamycin resistance was 7% under screening.412 For neonatal GBS isolates in 
Tanzania where there is no prevention strategy, sensitivity to erythromycin was reported at 
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approximately 81% and sensitivity to clindamycin was 88%.413 This population included all 
invasive and colonising strains. Although the difference in erythromycin trends in this study 
were not statistically significant, the increases were much steeper in screening areas compared 
with the increases risk-based prevention areas for both EOGBS and neonatal GBS. Indeed, in 
a time-trend population study in the US from 1996 to 2003 where prevention strategies 
changed from ‘either prevention’ to universal screening, erythromycin resistance increased 
from 15.8% to 32.8% and clindamycin resistance increased from 10.5% to 15%, although this 
analysis included invasive strains from adult populations.414 With respect to ‘either 
prevention’, in Australia, there are low resistance rates of 6.4% erythromycin and 4.2% of 
clindamycin resistance, which did not increase between 1982 to 2001 (before ‘either 
prevention’ guidelines) and 2002 to 2006 (after ‘either prevention’ guidelines).185 From the 
literature, it is difficult to draw conclusions on the impact of universal GBS screening on GBS 
resistance to clindamycin and erythromycin. Generally, there are higher rates of clindamycin 
and erythromycin resistance in countries that adopt universal screening compared with 
countries that adopt risk-based prevention, ‘either prevention’ or have no prevention. 
However, whether these differences or increases in resistance rates between different 
strategies are clinically or statistically significant remains unanswered in the literature, and in 
this study, as a result of low statistical power.  
 
13.5 Conclusions for this chapter 
 The findings in this chapter show that universal GBS screening has no harmful impact 
on the trends of LOGBS incidence compared with risk-based prevention, ‘either 
prevention’ and no prevention. 
 The trends of LOGBS incidence increased over time in all areas, and were higher in 
risk-based and no prevention areas compared with screening areas. However, these 
higher rates were unstable under different assumptions.  
 There was also no evidence that early-onset E. coli incidence and the percentage of 
GBS cases resistant to clindamycin and erythromycin are higher under universal GBS 
screening and widespread IAP treatment compared with other strategies. 
 Importantly, these analyses did not have a sufficient sample size, therefore, the results 
might be a result of low statistical power as opposed to no true difference.  
 The evidence remains inconclusive and larger sample sizes are required to determine 
the impact universal GBS screening has on the trends of early-onset E. coli and GBS 
resistant to clindamycin and erythromycin across countries.  
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14. DISCUSSION 
In this discussion, I will summarise the key findings, strengths and the limitations as well as 
the research and policy implications related to part III of this thesis overall.  
14.1 Summary of the findings from research questions 4 to 6 
The research aim of this part of the thesis was to investigate whether the international data on 
the benefits and harms of universal GBS screening, compared with other prevention strategies, 
can be adjusted for country-level differences, to inform the clinical effectiveness of universal 
GBS screening. I conducted two ecological trend analysis studies investigating the benefits of 
universal GBS screening on the trends of annual EOGBS incidence (research question 4) and 
early-onset sepsis incidence (research question 5), compared with other prevention strategies. 
Based on the available evidence, EOGBS incidence decreased by 0.5 to 0.6 per 1,000 
livebirths over 27 years, whereas in risk-based prevention, EOGBS increased by 0.4 to 0.5 per 
1,000 livebirths over that time. In general, there was no difference between the trends of 
EOGBS incidence between screening and ‘either prevention’, as the incidence also decreased 
in areas reporting ‘either strategy’. Finally, the results comparing no prevention with screening 
prevention were conflicting and depended on the data included and the assumptions generated 
for the analysis. The results of the study on early-onset sepsis showed that the international 
trends of early-onset sepsis do not differ by prevention strategy. However, the sample size in 
this study was not large enough to make firm conclusions.  
I conducted a third ecological trend analysis study investigating the harms of universal GBS 
screening on the trends of early-onset E. coli incidence, LOGBS incidence, and clindamycin 
and erythromycin resistance in early-onset and neonatal GBS disease across time, compared 
with other prevention strategies (research question 6). There was consistent evidence that 
universal GBS screening did not lead to increases in LOGBS incidence compared with other 
prevention strategies. There was also no evidence that universal GBS screening impacts the 
trends of annual early-onset E. coli incidence or GBS resistance. However, these analyses 
were also statistically under-powered to confirm this.  
Although screening consistently showed a downward trend of EOGBS incidence across the 
analyses, risk-based prevention consistently showed an upward trend, and LOGBS 
consistently did not increase under screening compared with other prevention strategies, there 
are numerous limitations and uncertainties in these results, as discussed below.  
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14.2 Strengths and limitations 
These studies were one of the first attempts to compare the benefits and harms of universal 
GBS screening across different geographical areas and different times with other prevention 
strategies. In these studies, I collected data covering all world regions for most variables, 
resulting in the beginning of an international database which maps out EOGBS incidence 
across 46 geographical areas, early-onset sepsis incidence across 24 areas, LOGBS incidence 
across 41 areas, early-onset E. coli across 25 geographical areas, and neonatal GBS resistance 
across 23 geographical areas. In addition, I adjusted for confounding variables when 
comparing prevention programmes, which is the case in only a few studies. I controlled for 
compositional differences across the geographical areas, including maternal risk factors for 
GBS. I also adjusted for methodological differences between the areas due to the limitations 
in secondary data collection. Therefore, I was able to reduce bias from these factors. To avoid 
bias from missing data, I utilised MICE imputation and achieved convergence for the 
compositional covariates across the years. Finally, I also attempted to account for the multi-
level structure of the data in a multi-level growth curve model for EOGBS incidence.  
However, there are a number of limitations in these study that need to be considered in relation 
to the findings. Firstly, across the studies only a maximum of 41 out of 194 countries were 
represented (minimum 16 countries). It is suggested that, for self-completion questionnaires, 
a rate of below 50% would be a low response rate.350 This risk of selection bias raises concerns 
about the external validity of the sample I achieved in these studies, how representative they 
are, and how generalisable the findings are. The small sample size may also be the reason why 
the results are varied across some analyses; a larger sample size may prevent the instability. 
Collecting data on the outcomes was a difficult task as they were not readily available from 
national surveillance institutions or collated into one dataset, as for other conditions. 
Contacting busy institutions across countries and asking for the completion of survey 
questionnaires was labour intensive and, although at initial contact institutions were interested 
in participating, due to their busy schedules and other commitments, they were not able to 
provide any data. I did manage to collect data from areas of every world region for most of 
the outcomes. It was particularly difficult for early-onset sepsis, possibly as sepsis is 
diagnosed clinically in hospitals and is not necessarily collected by national laboratories, 
making population surveillance more complicated. However, non-response bias is an 
important issue when using survey questionnaires350 and the number of countries from each 
world region was not balanced. In particular, there were few countries from Sub-Saharan 
Africa, North Africa and the Middle East. Furthermore, there was no data from the UK for 
early-onset sepsis and no data from Oceania for resistance rates. There was also a higher 
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representation of areas that were from high income countries. In summary, survey 
questionnaires have these limitations and I may not have obtained a random or representative 
sample, leading to selection bias. Similarly, the quality of the data I collected across countries 
varied and in some cases institutions reported zero cases of disease outcomes in their area. 
This might be a result of poor diagnostic facilities or procedures, surveillance being voluntary 
in that area, or because the population that the institution covered was too small to allow 
identification of a case. I did attempt to control for this by adjusting for regional and economic 
differences as well as the coverage of the data.  
The lack of data was particularly important for the analyses of early-onset sepsis and E. coli 
incidences as well as the GBS resistance rates as I was unable to achieve the calculated sample 
size required to provide sufficient statistical power for the analysis. Having a low sample size 
and low statistical power reduces the likelihood of detecting a true effect of the 
interventions.415 With fewer than 63 observations per prevention group, the probability of 
finding a true difference of 0.1 per 1,000 livebirths per year between the prevention groups 
was reduced from 80% to 50% or lower. Therefore, the small sample size increased the 
probability of incorrectly not rejecting the null hypothesis and concluding that there is no 
effect of one GBS prevention strategy compared with another, also known as a type II error.416 
The differences in early-onset sepsis and E. coli incidences found between the groups in these 
studies were in fact lower than 0.1 per 1,000 livebirths and the chance of these differences 
being statistically significant, with the sample size achieved, are even lower. Therefore, no 
differences in the trends under screening compared with other GBS prevention strategies may 
be a result of the low sample size and statistical power, as opposed to no true difference. Low 
sample size bias may also make the results unreliable and they may not be reproducible in 
future studies.  
Similarly, the lack of a representative or random sample increases the risk of the findings 
reflecting regression to the mean bias. As explained in Chapter 11, regression to the mean can 
occur in a group of observations if an outcome is extreme on the first measurement, as it will 
become closer to the mean for subsequent measurements irrespective of exposures and 
interventions.403, 404 This was particularly important for EOGBS incidence, as St. Augustine 
had an extreme incidence on the first measurement, which then decreased closer towards the 
mean in subsequent years. In addition, the multi-level unadjusted analysis in Chapter 11, 
showed that geographical areas with lower than average incidence at first year tended to 
increase the most over the observation period and that areas with higher than average 
incidence at baseline tended to show above average decreases. Therefore, it is possible that 
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the yearly changes that occurred over time were due to the regression to the mean bias, as 
opposed to a change as a result of any or no prevention strategy. 
Related to small sample size, to compare EOGBS and neonatal GBS resistance rates, I 
converted the raw numbers of resistant cases into percentages of EOGBS and neonatal GBS 
cases resistant to the antibiotics. This made the resistances across geographical areas and years 
more readily comparable as their baseline sample sizes or totals were different. While this 
made the comparisons more meaningful, the drawback is that for some percentages, the 
denominator for resistances were fewer than five. Neonatal GBS is a rare condition and data 
from one centre are not large enough to have a sufficient number of EOGBS cases. For such 
observations in the data, the representation of resistance may be blurred as small numbers 
become exaggerated, i.e. an observation where there was 0% or 100% resistance yet this only 
represented one case. Nevertheless, the majority of the data did not have denominators as 
small, and analysing raw numbers would also not have been comparable, as 1 in 4 cases and 
2 in 30 cases are also not equivalent. A potential follow-up of this study would be to analyse 
the raw numbers instead of the percentages so that the results can be compared.  
Secondly, although I tried to account for the most important compositional factors that had a 
valid theoretical foundation to be included, there were a range of challenges and weaknesses 
in the adjustments made. In particular for the analysis on early-onset sepsis, I was unable to 
account for compositional covariates of interest such as caesarean sections, fertility rate, 
skilled attendance at delivery, average maternal age, multiple or twin births, per capita 
government expenditure on health and GBS serotype. I had to reduce the number of covariates 
of interest to avoid overfitting the regression model to the small amount of data. Overfitting a 
model may result in the poor prediction for additional subjects, in this case areas, that were 
not in the original model and could overestimate the R2 of the model.417 In the literature there 
have been varying rules of thumb on how many covariates can be analysed in accordance with 
the sample size. Some have suggested five observations per covariate,418 some 10 
observations,419 and others have suggested the number lies between 15 to 20 observations,420 
To keep a balance between the number of covariates to include and overfitting the model, I 
included 19 variables (continuous and categorical variables) for 162 observations in the largest 
model. More recent research has demonstrated, that for linear regression models, a minimum 
of two observations per covariate is adequate to estimate regression coefficients, standard 
errors and confidence intervals.417 If these further covariates were included in the analysis the 
results might have been different.  
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In the remaining analyses, while I attempted to collect data on maternal risk factors, there 
were some I was unable to collect data for and had to exclude from the analysis. For example, 
preterm premature rupture of membranes is an important risk factor but I was not able to 
collect enough data to include it. Likewise, although I accounted for the total number of 
caesarean section in the study, I did not have enough data to break this down into elective and 
emergency caesarean sections, which have different implications for EOGBS. An elective 
caesarean section would reduce the risk of GBS transmission whereas an emergency caesarean 
section could increase it.86 Similarly, I did not manage to collect enough data to adjust for the 
percentage of women who were tested and treated within the prevention programmes of each 
area. Although I was interested in the impact of having a guideline in place (irrespective to 
how well it is implemented), the differences in how well it is implemented could absolutely 
influence the incidence of diseases and could account for the patterns in incidence. I was also 
unable to include information on the testing methods used in screening programmes, for 
example, the type of culture media used, the sites swabbed, the use of rapid testing in addition 
to culture as well as the clinical risk factors that are used to offer IAP. These could equally 
influence the number of women treated, the incidence of diseases, therefore, the trends in the 
diseases. In particular, whether IAP is offered to all preterm births or not, is crucial because 
the burden of GBS is higher in preterm than term births,5 however, the majority of preterm 
births would not be eligible for screening at 35 to 37 weeks. Treating all preterm births could 
have a substantial impact in areas that did so as part of their screening and/or risk-based 
prevention. In addition, there could be a wide range of compositional variables which I may 
not have considered as they have not been mentioned in the literature, yet could be accounting 
for the results. Any of these factors, beyond those controlled for in the study, may account for 
the results I found. 
Even for the compositional covariates that I did adjust for in the analyses, many were not 
available across the different areas, or years, and were limited to their secondary and cross-
sectional nature. For many covariates, especially maternal risk factors, such as GBS 
colonisation, prolonged rupture of membranes and intrapartum fever, I used a one point 
estimate for each geographical area. Although this provided some adjustment for these factors 
across geographical areas, there may have been a fluctuation of these factors across the years, 
which could influence the trends in outcomes. Secondly, for prolonged rupture of membranes 
and intrapartum fever in particular, I imputed the majority of the data from other countries, as 
most institutions did not provide this information. Therefore, the rates across many countries 
were the same for each world region. This was the best available alternative to include these 
factors in the models, however, it may not represent the specific context or burden of risk 
factors for each country. The definition of the compositional covariates may also have differed 
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in cases where the institutions provided the data which could affect the results. I could not 
account for this in the analysis as that would have resulted in too large a number of covariates. 
These limitations are expected and commonly seen in secondary research.   
I was also unable to adjust the multi-level analysis for the compositional covariates due to the 
missing data across the years and the inability to impute them accounting for the data structure. 
Running this model without imputation would have reduced the sample size to below 50% of 
that achieved. Should this study be re-run, I would use the most recent data values across each 
of the years for each of the compositional covariates (not perform any imputation) and perform 
the multi-level repeated measures model on all of the completed cases (as they would no 
longer have missing data) to assess how this would alter the results.  
Thirdly, the predictor variable of GBS prevention strategy also contains some weakness. I set 
out to investigate the relationship between the trend in annual EOGBS incidence with the 
annual prevention strategy, which would allow me to account for the change in prevention 
strategy and the impact this had on the outcomes. I tried to collect the GBS prevention strategy 
by year, or when it changed across the years, however, I did not receive data on this for every 
geographical area. Furthermore, for institutions that provided national guidelines, it was 
difficult to link these guidelines to the year when the hospitals covered changed their 
guidelines. Consequently, I chose the least biased strategy, to use the most recent GBS strategy 
during the period that data were provided. There are limitations in using this method as the 
most recent strategy may have only been in use for a short while. For example, the recent GBS 
strategy may have only been in place for a year as opposed to majority of the period where 
EOGBS incidence data were provided. Similarly, the majority of observed trends in EOGBS 
incidence might have actually been during the period where the previous GBS prevention 
strategy was used and may not be entirely attributable to the recent strategy. For example, in 
the US, there was a drastic decline between the 1990s and 2002, when either a risk-based or 
screening guideline was adopted, followed by a lower decrease thereafter when a screening 
guideline was adopted. In this case, we know that the initially drastic decline was during either 
guideline and not during screening. However, in this analysis, the decrease would be attributed 
to screening, as this is the recent guideline. In this study, the following areas changed guideline 
more than once. Only the US changed from no prevention to ‘either prevention’ to screening, 
and only two areas (Buenos Aires and Sao Paolo) changed from no prevention to risk-based 
prevention to screening. The others moved directly from one strategy to another. In addition, 
during the period of ‘either prevention’ in the US as well as geographical areas in this study, 
it is not clear which prevention was used more widely across institutions. 
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Fourthly, there are weaknesses in the definitions of the outcomes. As discussed throughout 
this chapter, different areas defined outcomes differently and I made an attempt to account for 
this in the analysis with respect to the number of days. In the survey, I requested the definition 
in terms of positive/negative culture, however, it was not completed by many institutions. 
Therefore, the definitions in this respect may have differed across geographical areas in this 
study. In the areas that did provide information about definition, the majority stated that it was 
positive sterile culture. As discussed in Chapter 2, a related limitation, that must be kept in 
mind for the EOGBS analysis, is that, although culture-proven EOGBS is the standard 
outcome, it is likely to underestimate the true burden of the disease due to IAP given to 
women. This would, consequently, overestimate the impact of prevention interventions. 
Another limitation is that I considered the rate of EOGBS in all births not in term births alone. 
Term births (37 weeks onwards) are the group who are eligible for screening and for whom 
screening could have an impact, as the recommended time for testing is 35 to 37 weeks. The 
results comparing GBS prevention strategies may be different if trends are assessed in term 
births alone. 
For antibiotic resistance, different methods can be used to test susceptibility/resistance and 
different guidelines can be used to interpret antibiotic sensitivities/resistances.421, 422 Due to a 
lack of time and resources as well as an overwhelming questionnaire, the differences in the 
testing and interpreting methods between geographical areas were not accounted for. Different 
methods can produce different results and different guidelines define resistance differently.421, 
422 While attempts are in progress to harmonise the guidelines, consensus has not yet been 
reached and countries in Europe and North America use different guidelines.422 The lack of 
these adjustments in this study put the findings at risk of bias as the differences in methods 
and guidelines could be contributing to the higher increases under screening prevention. 
Nevertheless, in one meta-analysis on antibiotic resistance in paediatric urinary tract 
infections caused by E. coli, there were no differences in resistance rates by antibiotic 
sensitivity guidelines reported or not in studies.423 A broader drawback of this study 
investigating the harms from screening is that I was unable to account for the many potential 
harms that were identified in the systematic review in Chapter 7. In particular, the key harms 
of gut microbiota changes, cerebral palsy, penicillin resistance and maternal anaphylaxis could 
not be explored as they require a long follow-up and/or can be very rare and were therefore 
not feasible. While I performed the analysis on the best available outcomes and data that could 
be practically collected, there are other potential harms from GBS screening and this study is 
not comprehensive.  
Antenatal screening for group B Streptococcus in the UK	
	 276 
Another statistical limitation of the analyses except for EOGBS incidence was that I was 
unable to account for the hierarchical structure of the data in the analysis. The data for each 
year were nested in the geographical area from which they originated; however, I combined 
all of the data across different geographical areas for each year to present the annual trends. 
The outcomes over time within each geographical area may be correlated with each other, 
thus, they are not independent. An important assumption of linear regression techniques is 
that the observations are independent. A consequence of not accounting for the hierarchical 
structure is that I may have underestimated the standard errors of the regression coefficients, 
which usually results in the overestimation of the statistical significance.424 When setting out 
to undertake this study, I did attempt to account for the hierarchical structure by performing a 
multi-level model, however, with so few completed observations it was not possible. 
As a result of all of these limitations, the predicted values particularly for the incidences of 
early-onset sepsis, LOGBS, E. coli and the percentages antibiotic resistance started with 
negative values below zero. While this is technically or statistically plausible as in linear 
probability models predicted values can lie outside zero, these values are implausible for the 
range of the outcomes, and not be a representation of the truth.  
Finally, there are wider weaknesses of epidemiological ecological studies. The purpose of this 
study was to investigate the effect of GBS prevention strategy on the universal GBS screening 
outcomes at the population or ecological level. Therefore, these findings must be interpreted 
at this level and care must be taken not to fall into the ecological fallacy. This occurs when 
one makes conclusions about individuals based on analysis of group data.425 I did not collect 
data at the individual level, in particular, on the type of tests women received or whether they 
received tests or treatment at all, therefore, interpretations of the impact of GBS prevention 
strategies for individuals cannot be made. Likewise, epidemiological studies are observational 
in their nature and are, therefore, not as robust as RCTs. Due to the observational nature, a 
causal link cannot be determined between GBS prevention strategies and the outcomes 
explored. My intention was to find an alternative to RCTs but, as a result of the limitations 
listed above that are common to observational studies, survey questionnaires and secondary 
data collection methods, I could not account for many factors. These factors, within and 
beyond the prevention strategy, could have caused the results. 
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14.3 Research and policy implications 
Despite the potential implications of these ecological trend analyses on the strategies to adopt 
for the prevention of EOGBS, there is substantial uncertainty around the effectiveness and 
harms of universal GBS screening compared with other, or no prevention strategies. This 
uncertainty stems from the instability observed in the analyses, insufficient sample sizes as 
well as a series of unavoidable limitations in the data collected. Therefore, it is imperative to 
be cautious as no firm conclusion can be drawn about the impact of GBS prevention strategies. 
There was instability in the comparison of EOGBS incidence in universal screening with other 
prevention strategies (research question 4), particularly no prevention. Nevertheless, in all the 
analyses, screening showed a decreasing trend in EOGBS incidence. Furthermore, from the 
predicted values it appears that countries adopting a risk-based prevention strategy may be 
experiencing an increase in EOGBS of approximately 0.01 to 0.02 per 1,000 livebirths every 
year, as also shown in the UK5 and Netherlands.66 By switching to universal screening, these 
countries may be able to prevent EOGBS cases and reduce their incidence by 0.02 per 1,000 
livebirths every year (as estimated from the predicted values). Again, it is important to bear 
the instability in the analyses and the limitations in mind, which mean these estimations are 
not certain. Furthermore, it is not clear how these changes relate to the mortality or long-term 
disability from EOGBS.  
As discussed in Chapter 2, focusing on culture-proven EOGBS as the outcome is likely to 
underestimate the true burden of the GBS disease due to IAP given to women. As an 
alternative, when investigating the impact of universal GBS screening on the trends of early-
onset sepsis incidence (research question 5), there was a low sample size and statistical power. 
Therefore, conclusions cannot be reached and the implications for the clinical practice of 
universal screening, or other prevention strategies, remain unknown. A larger sample size is 
needed to determine whether, or not, screening is useful in reducing early-onset sepsis. Should 
a larger sample reproduce the same results, the implication would be that universal GBS 
screening has no impact on early-onset sepsis. Therefore, the findings on the effectiveness of 
screening reducing EOGBS incidence may be over-estimated due to IAP in the blood. Equally, 
while universal screening may reduce EOGBS, it may increase other organisms causing 
infection in neonates, balancing out any effects, or it could be a result of changes occurring in 
the environment beyond GBS screening. Overall, it would mean that universal screening is 
not supported by the evidence. By contrast, if the statistically non-significant trends in this 
study reached statistical significance with a larger sample, they would show that, under 
screening early-onset sepsis increases over time, whereas under risk-based prevention it 
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remains relatively stable. This would imply that risk-based prevention may be a safer option 
than universal screening. However, for now these are hypotheses and the research question 
remains unanswered.  
With respect to the harms of universal GBS screening (research question 6), the ecological 
trend analysis found that screening did not lead to an increase in LOGBS, and there was no 
evidence that it increased early-onset E. coli and clindamycin and erythromycin resistance in 
neonatal GBS isolates, compared with other GBS prevention strategies. The findings for 
LOGBS incidence per 1,000 livebirths were based on a sufficient sample size and the main 
model and all sensitivity analyses showed that incidence was not higher under screening 
compared with other prevention strategies. This implies that if countries choose to adopt 
universal screening, LOGBS would not increase over time as a result of the programme. The 
main model suggests that countries adopting risk-based prevention may be experiencing an 
increase in LOGBS incidence that is larger than the increase seen in screening. The predicted 
values showed that on average LOGBS under risk-based prevention would increase by around 
0.024 per 1,000 livebirths per year. Similarly, LOGBS under no prevention would also 
increase by around 0.08 per 1,000 livebirths. By contrast, LOGBS under screening would 
increase at a lower rate around 0.009 per 1,000 livebirths per year. Whether these lower rates 
would occur by changing prevention strategies is uncertain and should be treated with caution, 
as the higher rate in risk-based and no prevention strategies compared with screening lost 
statistical significance in the sensitivity analyses. What is more certain is that LOGBS would 
not increase more highly if countries adopted screening compared with other or no prevention 
strategies.  
Given the low statistical power in the analyses for the remaining harms, it is difficult to reach 
implications on whether universal GBS screening increases early-onset E. coli and GBS 
resistance. A larger sample size is needed to determine whether screening would impact these 
outcomes. Should a larger sample reproduce the same results, the implications would be that 
universal screening does not lead to a larger increase in early-onset E. coli and GBS resistance 
compared with other prevention strategies, and does not pose this harm. This might be more 
convincing for early-onset E. coli and clindamycin resistance that increased at similar rates 
for screening and risk-based prevention. For neonatal GBS cases resistant to erythromycin 
there were marked differences between screening and particularly risk-based prevention. 
According to the predicted values, neonatal GBS resistance would increase under screening 
by around 0.95% every year, whereas under risk-based prevention it would only change by 
0.05% and under no prevention by 0.15%. These differences might be clinically significant 
and could also be statistically significant in a larger sample size. However, in terms of 
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informing national policy, local epidemiology of the resistance rates within a country and the 
predominant circulating clones might be most important.  
Given the limitations of these studies, further research could build on the work that has already 
been covered here, with improvements made on the data. The instability in the EOGBS and 
LOGBS results might be due to the small sample size achieved. Although the sample size met 
the power requirements to detect an annual difference of 0.1 per 1,000 livebirths, the 
differences observed between the years was lower than this and may still be clinically 
significant. Therefore, increasing the sample size could lead to more stable results. Likewise, 
for the remaining studies, the sample size was not sufficient to determine the impact of 
universal GBS screening. A larger sample size is needed to assess early-onset sepsis and the 
harms from screening, one that is even larger than 63 observations per group, so that clinically 
meaningful differences that are below 0.1 per 1,000 livebirths per year between strategies can 
be detected. Funding and time constraints also meant that I was unable to obtain data on the 
screening strategy by year or the compositional variables by year. Likewise, I was unable to 
collect data for maternal risk factors for many geographical areas. If all of this information 
could be collected, adjustment could be more comprehensive and informative, and conclusive 
answers might be reached about the impact of universal GBS screening versus other 
prevention strategies. 
Ultimately, RCT evidence with a long-term follow up is needed to inform the benefits and 
harms of universal GBS screening. The current data that are available have many weaknesses, 
making it difficult to combine and analyse together. It might possible to perform an RCT for 
GBS screening in another country with a higher incidence of EOGBS (such as countries across 
Africa and Latin America). The incidence in the UK is low, and so whilst an RCT is possible 
and would answer the question, it would require an a very large sample size. On the other 
hand, as mentioned in Chapter 2, the positive predictive value of the screening test would be 
very low and overtreatment high, even if a large enough sample size was reached. An 
alternative strategy to RCT evidence and ecological comparisons between countries, would 
be a study combining international datasets on the outcomes of screening, risk-based and no 
prevention data at the individual level. If this is done for as many countries as possible, a 
sufficient sample size could be achieved for a quasi-experimental study. I initially attempted 
this method for this thesis and sought databases containing such data in the US and UK, 
however, they were not available or permission was not granted. For the meantime, the 
screening criteria that there should be evidence proving the clinical effectiveness of screening, 
and evidence that the benefits should outweigh the harms, are not met. The results from these 
studies contain some instability and numerous limitations in the data, all of which contribute 
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to substantial uncertainty. Trends in EOGBS incidence might decrease under screening 
compared with risk-based prevention, however, whether this decrease is clinically significant 
and outweighs the harms, remains unanswered.  
 
14.4 Conclusions for this chapter 
 The ecological trend analysis studies highlighted that EOGBS incidence declined by 
approximately 0.02 per 1,000 livebirths per year under universal GBS screening, 
whereas it increased by approximately 0.01 to 0.02 per 1,000 livebirths per year under 
risk-based prevention.  
 There was little evidence of a difference in the trends of EOGBS incidence between 
screening and ‘either prevention’. Areas that currently do not have GBS prevention 
displayed conflicting findings, with some analyses showing an increase, and others a 
decrease, in EOGBS incidence.  
 There was no harmful impact of universal GBS screening on the trends of LOGBS 
incidence compared with risk-based prevention, ‘either prevention’ or no prevention. 
 There was no evidence of universal GBS screening having an impact on annual early-
onset sepsis trends compared with other, or no prevention strategies; however, this 
study did not have a sufficient sample size.  
 There was also no evidence that early-onset E. coli incidence and the percentage of 
GBS cases resistant to clindamycin and erythromycin increase under universal 
screening and widespread IAP treatment, compared with risk-based or no prevention. 
Importantly, these analyses also did not have a sufficient sample size.  
 Therefore, the last two results might be a result of low statistical power as opposed to 
no true difference.  
 All of the remaining results must also be treated with caution as they contain some 
instability across the analyses and numerous limitations in the data, all of which 
contribute to substantial uncertainty in the findings.  
 The evidence on the benefits and harms of universal GBS screening compared with 
other, or no prevention strategies remains inconclusive. Larger sample sizes with 
better data may be able to provide more conclusive answers.  
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15. DISCUSSION & CONCLUSION 
15.1 Original research aims restated 
EOGBS is a rare but important health condition affecting 0.57 per 1,000 livebirths with a case 
fatality rate of 5.2%5 and 9% to 16% suffering from long-term disability.8, 54, 7 To prevent the 
transmission of GBS colonisation from mother to neonate and the progression to EOGBS, 
currently in the UK, a risk-based strategy is adopted where women who appear with known 
GBS risk factors are offered intrapartum antibiotic prophylaxis. As EOGBS incidence has 
risen across time in the UK and more than 30% of cases do not have risk factors, many 
advocate introducing universal GBS screening. In 2012, the UK NSC reviewed and 
recommended against introducing a universal GBS screening programme, concluding that 
there was insufficient evidence to ensure that the benefits of screening would outweigh the 
harms.23 The review identified the following three key gaps in the literature.  
Firstly, there was lack of evidence on the natural history as to why around 36% of mothers 
transmit GBS colonisation to their neonates and why 1% to 3% develop EOGBS (NSC criteria 
1). Secondly, there was a lack of evidence on the harms from IAP and expanding its use in a 
screening programme (NSC criteria 13). Thirdly, with no RCT evidence, there was much 
uncertainty on the effectiveness of GBS screening (NSC criteria 11). With large sample size 
requirements, RCTs might not be feasible and a method was required to assess the impact of 
GBS (and other screening programmes of rare conditions) in their absence. Beyond these gaps, 
there was also a lack of information on the wider context on how policy decisions for screening 
programmes, such as GBS, are made. In this thesis, I addressed these research gaps to examine 
whether the GBS screening programme meets the screening criteria when these gaps are 
addressed, and whether the UK should introduce the programme as a result.  
 
15.2 Research aims addressed 
In this section, I will first present the findings on the systems and policy-making processes for 
screening in general and then in relation to GBS (research question 1). I will combine the 
findings from the literature review, the systematic reviews and the ecological trend analyses 
to assess universal GBS screening against each of the key international screening criteria. I 
will present the thesis findings that addressed criteria on the natural history of the condition 
(research question 2), the effectiveness of universal GBS screening (research question 4 and 
Antenatal screening for group B Streptococcus in the UK	
	 283 
5) and whether the benefits of universal GBS screening and large scale IAP outweigh the 
harms (research question 3 and 6). To present a comprehensive assessment of GBS screening, 
I will also discuss the criteria on the epidemiology of the condition, the test accuracy of 
selective rectovaginal culture at 35 to 37 weeks and the effectiveness of IAP treatment, based 
on the literature review findings (Chapter 2).  
15.2.1 Screening policy-making (research question 1) 
Findings from the systematic review on the systems and policy-making processes for 
screening (research question 1, Chapter 5) across 14 countries showed that all countries had a 
national body responsible for screening recommendations. These organisations assessed 
scientific evidence for a screening programme against a list of screening criteria or a list of 
key questions and a framework to judge whether the benefits of screening outweigh the harms 
from the programme. However, once these national screening recommendations were 
formulated, they were not enforced in all countries. Screening recommendations became 
regulations that required national implementation only in some countries. In other countries, 
the recommendations were similar to best practice guidelines, and local and regional health 
authorities could decide all or some of the screening programmes for their citizens. Therefore, 
screening practices may vary within countries. 
Interestingly, in 15 of the 17 countries, the screening recommendations for GBS were not 
developed by the organisations that were nationally responsible for screening. With the 
exception of Canada and the UK, in the majority of countries, recommendations were 
produced by professional medical societies. In the US, they have been developed by the CDC, 
which is a preventative health organisation, but not the USPSTF, which is responsible for 
screening recommendations. It is not known whether these organisations took the key 
screening principles into account, and this may have implications on whether the critical and 
likely unseen harms of GBS screening have been considered.  
There was also divergence with respect to the specific screening criteria that were utilised 
across countries. One of the most important criteria was that different countries required 
different levels of scientific evidence. Unlike the UK, 10 of the countries did not specifically 
require RCT evidence to prove screening effectiveness in reducing morbidity and mortality. 
Canada, Sweden, and the US may fulfil this need with the use of GRADE or similar tools for 
quality appraisal and strength of recommendation. The difference in evidence approach may 
reflect the decision-making structures for screening within the countries. Requiring RCT 
evidence may be more appropriate in countries where national screening decisions are similar 
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to regulations, whereas GRADE methodology may be more appropriate in countries where 
the recommendations are guidelines that regional or local health authorities decide to follow. 
This difference could have implications on whether programmes are introduced or not, as 
evidence other than RCT contain biases that could overestimate the benefits of screening. 
Another striking criterion that was not utilised in any country was the requirement where, if 
quality assurance is not met, the screening programme should be stopped. Sweden stated in 
their manual, that there should be criteria of when to stop a programme but this was not 
reflected in their criteria statement and how this should be done was not mentioned.  
The differences in the organisations making GBS screening recommendation as well as the 
differences in the criteria and evidence requirements might explain why some countries 
recommend and implement universal GBS screening while others do not. With screening 
decisions not requiring adherence and many national screening bodies not having a GBS 
screening recommendation, lower level authorities may develop their own policies.  
15.2.2 EOGBS condition, epidemiology and natural history (criterion 1) 
Natural history  
From the literature review (Chapter 2), the best evidence reported that 21% of pregnant 
women (approximately 150,806 in a year) are colonised with GBS in the UK. Without 
treatment, the best available estimate is that 36.4% would transmit GBS to their neonates and 
1% to 3% of colonised neonates would develop EOGBS. The systematic review investigating 
whether bacterial load or bacterial molecular markers are associated with GBS transmission 
from mother to neonate, or progression from neonatal colonisation to EOGBS disease, 
(research question 2, Chapter 6) suggested that the natural history of maternal GBS 
colonisation has not been extensively researched and is still in its infancy. In addition to 
bacterial load, only three bacterial markers have been investigated.  
Of all the evidence in the systematic review, the most promising finding was the association 
between high bacterial load and GBS transmission or EOGBS. This association was evident 
across different definitions of bacterial load and across study settings. Women colonised with 
heavier GBS bacterial load were approximately two to three times more likely to have a 
neonate with GBS colonisation compared with mothers with lighter GBS bacterial load. 
Neonates colonised with heavier compared with lighter GBS bacterial load were also at higher 
risk of developing EOGBS. While the association between bacterial load and 1) vertical 
transmission of GBS colonisation, and 2) neonatal colonisation versus invasive EOGBS was 
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consistent, evidence on the association between bacterial load and transition from maternal 
GBS colonisation to EOGBS was not as clear, possibly due to the small number of EOGBS 
cases in each study.  
With respect to serotype, the pooled results from the meta-analysis estimated that neonates 
colonised with serotype III were approximately 1.5 to two times more likely to develop 
EOGBS than neonates with serotype Ia and II, respectively. However, the sensitivity analysis 
identified that the results may not be stable, especially for serotype III versus serotype II. The 
results of the meta-analysis were heavily influenced by one study, and removing it led to 
statistically non-significant results. Besides a potential lack of power, as confounding 
variables were not adequately adjusted for, there could have been specific population 
characteristics in the study setting for Madzivhandila et al. (2011) that contributed to the 
statistically significant findings.39 Another study found that reaction to C-protein was not 
associated with EOGBS compared with asymptomatic colonisation in neonates, and neither 
was antigen type when serotype was accounted for.  
Despite the evidence on the potential value of these factors to predict GBS colonisation or 
EOGBS, the risk of bias across the evidence was high or moderate. No study was at low risk 
of bias for all domains and the overall relationships identified in this systematic review could 
be partly, or completely, a result of confounding factors. The majority of the evidence is also 
published before the year 2000 and may have limited applicability to today’s context.  
Epidemiology (Chapter 2) 
With IAP treatment, under the risk-based strategy, recent surveillance reported that the overall 
incidence of EOGBS is 0.57 per 1,000 livebirths in the UK and case fatality was 5.2% in 
2014/15. Although the rates vary, studies have reported that between 9% and 16% of EOGBS 
survivors suffer from long-term disability. The rate of GBS-related stillbirth in the UK was 
approximately 4.0 per 100,000 total births in 2014; about half occurred before 37 weeks of 
gestation. Approximately 1% of all stillbirths in the UK were mostly or partly attributed to 
GBS. 
Regarding the risk factors associated with EOGBS, recent surveillance in 2014/15 reported 
that approximately 22% of EOGBS cases were in preterm deliveries. In England and Wales, 
EOGBS incidence was inversely associated with gestational age at birth, decreasing from 4.42 
per 1,000 livebirths before 28 weeks of gestation to 0.41 per 1,000 livebirths after 37 weeks. 
Prematurity was also an independent risk factor for death. Risk factors based on NICE and 
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2012 RCOG guidelines were present in 41.3% and 35.4% of EOGBS cases, respectively, but 
only 44% of those with RCOG risk factors were treated with IAP. The percentage of neonates 
with EOGBS born at term to mothers without any RCOG or NICE risk factors was 63% to 
67%. As these cases would not be detected by the risk-based prevention strategy and would 
be born after 37 weeks, this is the cohort that universal GBS screening would try to detect. 
Thirty-seven percent of EOGBS deaths had at least one RCOG risk factor for GBS; only one 
mother of the 27 EOGBS babies who died received IAP. There were 10 deaths in babies with 
EOGBS born after 35 weeks’ gestation; 60% to 70% of them did not have any maternal risk 
factors based on NICE and RCOG risk factors, respectively. Similarly, of the nine EOGBS 
deaths in neonates born after 37 weeks, the number without any maternal risk factors was 
between 56% to 67% of EOGBS deaths. These are the deaths that would not be prevented by 
the risk-based strategy, which universal GBS screening would try to prevent. 
Overall, EOGBS is an important health condition, however, the natural history from GBS 
maternal carriage to EOGBS disease remains poorly understood. The most consistent 
evidence was that heavy bacterial load was associated with EOGBS, however, the evidence 
on this and bacterial markers contains uncertainties due to the risk of bias. Therefore, this 
criterion is not met. Research is required to fill the evidence gap on why mothers transmit 
GBS and why neonates develop EOGBS disease.  
15.2.3 Test accuracy (criterion 4) 
The recommended screening test for detecting GBS is selective enriched culture of 
rectovaginal swabs at 35 to 37 weeks gestation; however, it is not accurate in predicting 
EOGBS. Based on the literature review (Chapter 2), I estimated two PPVs for the ability of 
maternal GBS colonisation at 35 to 37 weeks to detect EOGBS using two approaches, and 
found a rate of 0.2% and 0.4%. There are also no agreed PPVs for antenatal culture detecting 
GBS colonisation at birth with a range of values reported. PPVs in the literature review ranged 
from 67.4% to 89.1%. Most studies show that approximately 20% to 30% of pregnant women 
who test positive for GBS at 35 to 37 weeks test negative during labour. Another limitation of 
this test is that it excludes the majority of women with preterm birth who have worse outcomes 
from GBS. Therefore, this criterion is also not met.  
A better test is urgently required, however a poor understanding of the natural history of GBS 
vertical transmission and progression to EOGBS inhibits the ability to identify one. 
Developments are emerging in rapid intrapartum testing with real-time PCR showing the most 
promising results. However, practical limitations of rapid testing prevent its widespread use, 
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including its cost, its complex administration, and its inability to determine antibiotic 
sensitivity to direct the choice of antibiotic for women allergic to penicillin. 
15.2.4 Effectiveness of IAP treatment (criterion 9) 
IAP is currently the recommended treatment for EOGBS prevention. As shown in the 
literature review (Chapter 2), a Cochrane meta-analysis concluded that IAP appears to be 
effective in reducing culture-proven and probable EOGBS by 83%, compared with no 
treatment. However, this was based on three small and old trials at high risk of bias, therefore, 
the extent to which IAP decreases EOGBS disease and related morbidity and mortality is 
uncertain. In addition, there was no evidence that IAP reduced the incidence of all-cause 
mortality, mortality from GBS infection or from infections other than GBS. Observational 
findings have also suggested that the timing and duration of IAP have an impact on its 
effectiveness, with rates of EOGBS and clinical sepsis higher in mothers who received IAP 
for less than 4 hours compared with those who received it for four or more hours. Patients 
who received substandard IAP of clindamycin due to reported penicillin-allergy also showed 
a reduced effectiveness of IAP. As a result of the uncertainty in the effectiveness of IAP, this 
criterion is also not met. Higher quality evidence is required to address this, although RCTs 
may not be feasible when IAP has become the recommended treatment. 
15.2.5 Effectiveness of universal GBS screening (criteria 11) 
The literature review (Chapter 2) showed that the evidence on the effectiveness of universal 
GBS screening is limited. There have been no RCTs assessing the effects of screening on 
EOGBS and in their absence, it is difficult to quantify the impact of adding universal screening 
to current practice. Instead, there are observational studies using historical controls and 
comparing EOGBS incidence in different periods of time in which different GBS prevention 
strategies were adopted. The control periods (no prevention and/or risk-based strategies) 
precede the universal screening periods. Risk of bias from this kind of approach is well 
documented as participants in the study and control group are not contemporaneous, data are 
collected retrospectively and confounding factors are not usually considered adequately. The 
majority of the studies as well as pooling of the studies show that universal screening reduces 
the risk of EOGBS compared with no prevention and risk-based prevention, however, there 
have been some inconsistencies (Chapter 2). Finally, as most studies have not controlled for 
confounding variables, results may be country-specific.  
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In the absence of RCT data, in Chapter 11, I attempted to find an alternative approach to assess 
the potential impact of universal screening on EOGBS (research question 4). The approach 
was to combine ecological data from different countries and compare the trends of EOGBS 
incidence under the different strategies, while controlling for confounding factors. This proved 
to be a difficult task due to the differences in the data across countries and the limitations of 
retrospective data collection. As a result, there was substantial uncertainty around the impact 
of universal GBS screening on the trends of annual EOGBS incidence compared with other, 
and no GBS prevention strategies. 
Bearing this caution in mind, the majority of the analyses showed that there was a decrease in 
in annual EOGBS incidence in areas that adopted screening whereas there was an increase in 
annual EOGBS incidence in areas that adopted risk-based prevention. In areas that adopted 
screening, the predicted values during the study period showed that EOGBS incidence 
decreased from around 0.8 to 0.9 per 1,000 livebirths in 1990 to 0.2 to 0.3 in 2015 in the 
adjusted linear regression, and from around 0.66 per 1,000 livebirths in 1990 to 0.19 in 2015 
in the multi-level unadjusted regression. On average, EOGBS incidence decreased at around 
0.02 per 1,000 livebirths yearly under screening. By contrast, in areas adopting risk-based 
prevention, the predicted values during the study period showed that EOGBS incidence 
increased from 0.1 per 1,000 livebirths in 1990 to 0.50 in 2015 in the adjusted linear regression 
and from 0.3 per 1,000 livebirths to 0.75 in the unadjusted multi-level regression. On average, 
EOGBS incidence increased by around 0.01 to 0.02 per 1,000 livebirths under risk-based 
prevention. Trends in EOGBS incidence in areas that adopted ‘either prevention’ strategy 
decreased by around 0.02 per 1,000 livebirths every year, and when compared with the trends 
in areas that adopted screening, there was no statistical significance in the majority of the 
analyses. 
Results in areas with no prevention were complicated by greater uncertainty across the 
analyses as different assumptions and models revealed conflicting trends in EOGBS 
incidence. In particular, there was a strong influence of data from St. Augustine, which had 
extremely high EOGBS incidence that dramatically decreased. When St. Augustine was 
included in the analysis, there was no statistically significant difference in the trends of 
EOGBS incidence between areas that adopted screening and areas with no prevention. In the 
unadjusted multi-level analysis, EOGBS incidence decreased from around 0.84 per 1,000 
livebirths in 1990 to 0.74 in 2015 during the study period, while in the adjusted linear 
regression EOGBS incidence decreased from 0.94 to 0.91 per 1,000 livebirths. By contrast, 
when these data were excluded from the analyses, trends of EOGBS incidence increased from 
0.44 in 1990 to 1.11 per 1,000 livebirths in 2015 in the adjusted linear regression and from -
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0.48 to 1.0 per 1,000 livebirths in the unadjusted multi-level analysis, which were statistically 
significant. Therefore, in countries with extremely high EOGBS incidence, there may be 
reasons in their context, beyond the GBS prevention strategy, that cause the high and drastic 
change in EOGBS incidence.  
While these trends provide some useful exploratory information, it remains difficult to 
quantify the potential impact of screening, as there were many limitations in this study (see 
Section 15.3 for a more thorough account). A lack of a random sample with an extreme 
EOGBS incidence from St. Augustine at first observation that reduced closer to the mean in 
subsequent observations, may reflect regression to the mean for results including these data. 
In addition, the prevention strategy analysed was the most recently adopted prevention 
strategy and the reduction across time might be attributable previous strategies. The results 
were also on all livebirths, including preterm births who would not be eligible for screening. 
Finally, there were limitations in the confounding variables accounted for in this study as some 
were not available annually and some were imputed from other countries. Therefore, there is 
a considerable risk of bias in this study.  
Most studies in the literature focus on culture-proven EOGBS (which is the standard 
outcome), however, any changes may reflect a decreased likelihood of neonatal cultures being 
positive due to IAP use, with the culture negative cases of EOGBS being undetected. Findings 
on early-onset sepsis have been more inconsistent than that on EOGBS, making the impact of 
universal screening difficult to assess (Chapter 2). Using the same approach, in Chapter 12, I 
combined ecological data from different countries and compared the trends of early-onset 
sepsis incidence under the different GBS prevention strategies, while controlling for 
confounding factors (research question 5). These results showed that there was no difference 
in the early-onset sepsis incidence by GBS prevention strategy. However, the sample size in 
this study was not large enough to make any reasonable conclusions. Alternatively, studies 
from the literature review have shown similar results that early-onset sepsis incidence does 
not decrease under screening. Early-onset sepsis incidence may not reduce in screening 
programmes (even if EOGBS incidence reduces) because of the selection pressure from IAP 
changing the profile of the organisms causing sepsis. Widespread IAP might decrease EOGBS 
yet increase gram-negative organisms causing infection, resulting in no overall reduction 
(Chapter 2).  
Overall, this methodological approach could not be an alternative to RCT evidence, due to the 
lack of adequate data on GBS related variables across countries. As a result of the limitations 
in the available data, there is a substantial risk of bias in this study, and it remains difficult to 
Antenatal screening for group B Streptococcus in the UK	
	 290 
assess the impact of implementing universal GBS screening. Furthermore, the impact of 
universal screening on EOGBS related mortality and long-term disability was not estimated 
in this study due to the small sample size. Therefore, the effectiveness of universal GBS 
screening is not known and the criterion remains unmet.  
15.2.6 Benefits of screening programme outweigh the harms (criteria 13)  
As indicated above, it is not possible to quantify the benefits of screening, therefore, it is not 
possible to assess whether the benefits would outweigh the harms. Consequently, this criterion 
is unmet. Nevertheless, an examination of the potential harms is a standard part of the 
assessment of any screening proposal. As approximately 150,800 pregnant women would be 
eligible for IAP, of whom approximately at least 99% will gain no health benefit, it is 
particularly important in this context. Therefore, I attempted to quantify the harms side of the 
screening equation and in this section, I will summarise the findings on the harms of universal 
GBS screening, particularly from expanding IAP. 
Findings from the systematic review (research question 3, Chapter 7) and the ecological study 
(Chapter 13) show that the harms from universal GBS screening and IAP expansion are 
unclear and cannot be quantified. The systematic review (Chapter 7) showed that the 
occurrence of harmful outcomes from IAP and their clinical importance has not been well 
explored. The systematic review resulted in a wide range of adverse events reported in 17 
observational studies and 13 RCTs, including gut microbiota, antibiotic resistance, maternal 
thrush, bowel problems, cerebral palsy, functional impairment and neonatal infection. 
However, there was little high-quality evidence to determine the frequency of adverse events 
from IAP for neonatal GBS disease prevention. The studies were small and at high risk of risk 
bias. More importantly, there was a substantial evidence gap around the long-term effects of 
IAP.  
There was only one study that assessed the long-term impact on the effects of IAP in women, 
on their children at age seven. This RCT showed an increased risk of serious consequences, 
such as cerebral palsy as well as bowel problems and functional impairment. However, the 
applicability of these findings is uncertain, as the drugs investigated were erythromycin or 
amoxicillin-clavulanate given for 10 days or until birth to a population in preterm labour. The 
drug recommendation for GBS IAP treatment is penicillin or clindamycin, given for shorter 
durations, at or near, term labour (Chapter 2). In this trial, the effect size was also small, and 
with multiple statistical comparisons on the same population, the probability of a chance result 
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is increased. Furthermore, the plausible biological mechanisms through which IAP can cause 
the development of cerebral palsy are not known.  
On the other hand, studies with improved applicability that explicitly included IAP for GBS 
prevention consistently found that IAP could alter gut microbiota. However, all of these 
studies were observational and populations in these studies were not followed to clinical 
outcomes. Therefore, whether microbiota alterations from IAP are associated with any short 
or long-term health problems is not known. 
There was also evidence that IAP may increase the risk of neonatal infections compared with 
no treatment, however, the evidence was at high risk of bias and inconsistent across studies. 
One study reported that IAP can increase the proportion of late-onset bacterial infections in 
infants, however, the indication was not stated and when the analysis was restricted to 
penicillin, the results were no longer statistically significant. In the ecological study on the 
harms from screening (Chapter 13), I investigated the impact of different prevention strategies 
on LOGBS incidence. While LOGBS incidence increased in areas adopting screening, the 
magnitude of this increase was lower than in areas adopting risk-based or no prevention. 
According to the predicted values, while LOGBS increased by around 0.02 per 1,000 
livebirths on average every year under risk-based prevention and by around 0.08 per 1,000 
livebirths on average under no prevention, it increased by around 0.009 per 1,000 livebirths 
on average under screening. While the statistical significance of the results varied in the 
sensitivity analysis, the direction did not change. Therefore, there was no evidence from this 
study that there is harm of increasing LOGBS incidence from introducing a screening 
programme. However, the limitations of the ecological study on the effectiveness of screening 
(in Section 15.2.5 above) apply here as well. While these were the best available data, there 
were limitations in the predictor variable of prevention strategy and the confounding variables, 
resulting in a substantial risk of bias in this study.  
In addition to late-onset infections, one study in the systematic review found no difference in 
early-onset E. coli sepsis between neonates whose mothers were treated with IAP compared 
with those who were not (Chapter 7). In the ecological study (Chapter 13), I investigated the 
impact of different prevention strategies on early-onset E. coli incidence. In this study, there 
was no evidence of any differences in the trends of early-onset E. coli by prevention strategy. 
However, this study had a small sample size and did not have sufficient statistical power for 
confirmatory results. Therefore, similar to the results from the study on early-onset sepsis, 
these results may not be representative and a larger sample size may show different findings. 
The majority of the current evidence in the literature supports the findings in this study that 
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screening does not lead to an increase in early-onset E. coli, however, this evidence is limited 
as these studies are observational before and after studies and thus subject to bias (Chapter 2). 
It is not clear whether universal GBS screening would impact early-onset E. coli incidence or 
not.  
The final key finding from the systematic review (Chapter 7) was increased antibiotic 
resistance in infants whose mothers were treated with IAP compared with those who were not. 
In one RCT there was evidence of azithromycin resistance in S. aureus and S. pneumoniae 
strains, however this was from azithromycin treatment. Two observational studies showed a 
higher proportion of ampicillin resistant organisms in infants whose mothers were treated 
compared with untreated mothers. Two further studies did not find differences in the 
cephalosporin or ampicillin resistance and amoxicillin resistance between treated and 
untreated groups. However, this observational evidence was at high or unclear risk of bias due 
to confounding variables and not all of the evidence was not related to IAP treatment for GBS.  
In the ecological study (Chapter 13), the differences between the percentages of EOGBS and 
neonatal GBS cases resistant to clindamycin and erythromycin were not statistically 
significant by GBS prevention strategy. However, similar to early-onset E. coli incidence, the 
sample size achieved in this study lacked statistical power, therefore, it is difficult to reach 
conclusions as to whether adopting a universal GBS screening would have an impact on 
resistances rates or not. Larger sample sizes may find different results, especially for neonatal 
GBS resistance to erythromycin, where areas adopting screening increased more steeply from 
approximately 3% to 22.5% whereas areas adopting risk-based prevention had a steady rate 
and areas with no prevention changed by around 3%. Literature on the topic generally shows 
that rates of resistance are higher in countries adopting screening compared with countries that 
have adopted risk-based prevention strategies. However, there have been no formal 
comparisons on neonatal resistance across different strategies. Based on the literature and this 
study, conclusions about the impact of antibiotic resistance from universal GBS screening are 
not known. Nevertheless, GBS does remains almost universally susceptible to penicillin,14 
although there are recent small and poor quality studies in Ethiopia and in Italy with evidence 
of penicillin resistance in GBS isolated from pregnant women 179-181 and in the US, GBS 
isolates have shown reduced susceptibility to beta-lactams while in Japan, GBS isolates are 
showing reduced susceptibility to penicillin.182, 18  
Overall, the harms from universal GBS screening and large scale IAP cannot be quantified. 
However, the scale of the overtreatment and range of plausible harms require a better 
understanding before IAP can be safely expanded. In the era of antibiotic resistance, such a 
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widespread IAP strategy may also be challenging in relation to the Department of Health’s 
antibiotic resistance strategy to reduce unnecessary use of antibiotics.426  
 
15.3 Thesis strengths and limitations  
Throughout this thesis, I have discussed the strengths and limitations for each chapter’s 
methodology and findings. Here, I will discuss the strengths and limitations for the thesis as a 
whole.  
One of the strengths of this thesis is that the research aims and objectives were based on an 
extensive literature review and attempted to address a critical evidence gap, not only for GBS 
screening, but for screening as a whole. The systematic review on the policies and screening 
systems across countries was the first study of its kind; no previous literature had mapped the 
screening criteria or other processes used across countries. In addition, there are many 
nominated diseases for screening programmes that are rare and RCTs may never be available, 
thus, alternative methods to assess the effectiveness of screening are required. Specific to 
universal GBS screening, I addressed the key gaps in the evidence surrounding GBS that had 
not been previously researched. In the systematic reviews and the ecological studies, a range 
of experts were involved in the project to review the work and advise on microbiology, 
infectious disease, obstetrics and gynaecology, screening, statistics and epidemiology. This 
ensured the project had clinical and methodological validity. Finally, I performed sensitivity 
analyses to test the stability of any statistically significant findings throughout this thesis.  
The searches for the systematic reviews were extensive with no date limit in order to cast a 
wide net and capture as much of the data as possible. To quality assure the search and ensure 
I found all documents, subject area experts reviewed the strategies and included articles. To 
assure the quality of all the review processes, each was duplicated and checked by a second 
reviewer.  
The ecological studies were the first attempts to compare the temporal relationship of the 
benefits and harms of universal GBS screening across different GBS prevention strategies in 
different geographical areas. In addition to culture-proven EOGBS, to assess the benefits of 
screening I also assessed early-onset sepsis due to the limitations in assessing culture-proven 
EOGBS. I also assessed the key harms that were feasible to collect data for, including 
antibiotic resistance and neonatal infections other than EOGBS. I undertook an exhaustive 
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data collection process in an attempt to obtain the best available data on the GBS benefits and 
harms across countries. The findings from the studies were also adjusted for some of the key 
confounding variables including preterm births and low birthweights, as well as the 
methodological differences between the areas due to the limitations in retrospective data 
collection. Finally, by imputing data using statistical processes, I was able to perform the 
analyses using all of the collected data. Therefore, I attempted to reduce as much bias as 
possible from the methodological limitations, confounding variables and missing data.  
As with all research projects, there are limitations that must be considered. While I attempted 
to obtain as much data as possible, for both the systematic reviews and the ecological studies, 
some data may be missing. In the systematic review on screening policy-making, using GBS 
may have limited the number of countries found from low and middle-income countries. 
Likewise, in the systematic reviews on the natural history of GBS and on the adverse events 
from IAP, I excluded articles not in English, case reports and case series. This could have 
increased the amount of data included from the literature, as there are laboratory studies and 
patient reports on small numbers of cases. Nevertheless, I excluded these studies as they have 
very little conclusive implications for patient outcomes and clinical practice, as the exposed 
groups with disease cannot be compared with control groups.  
Similarly, in the ecological studies, although I undertook an exhaustive data collection 
processes, only 42 of 194 countries were included. In particular, there were few countries from 
Sub-Saharan Africa, North Africa and the Middle East that are less likely to have GBS 
prevention programmes. There was also a higher representation of areas that were from high 
income countries that are more likely to have prevention programmes. These limitations raise 
the risk of selection bias and the external validity of the findings. In the ecological studies, I 
did attempt to account for selection bias by adjusting for regional and economic differences 
in the study. For the analysis on EOGBS incidence, a non-random sample may also have 
resulted in regression to the mean bias. 
The lack of collected data was more problematic for early-onset sepsis, early-onset E. coli and 
antibiotic resistance where the sample sizes were not sufficient to ensure internal validity of 
the studies. The lack of power means the statistically non-significant results could be incorrect 
as the probability of incorrectly not rejecting the null hypothesis or the type II error is 
increased. For these studies, as well as LOGBS, I was also unable to account for the 
hierarchical structure of the data in the analysis due to the lack of data, which may 
underestimate the standard errors of the regression coefficients and overestimate statistical 
significance.  
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Another consequence of the small number of observations is that I could not account for all 
of the important confounding variables that had a valid theoretical foundation. In particular, I 
did not manage to collect enough data to adjust for factors within the GBS prevention 
programmes such as the percentage of women who were tested and treated, testing methods 
used, and clinical risk factors used to offer IAP especially offering IAP to all preterm births 
with no other risk factors. As term births are the group for whom screening would be provided 
and could have an impact, results separated for term births only would have been more 
informative. There also were limitations in the adjustments that were made due to 
retrospective data collection methods. Some confounding variables only had a one point cross-
sectional estimate and fluctuations of these factors across the years could influence the trends 
in outcomes. Furthermore, I imputed the majority of the data for prolonged rupture of 
membranes and intrapartum fever from other countries, which may not represent the specific 
context or burden of risk factors for each country. The definition of the confounding variables 
may also have differed and I could not account for this in the analysis.  
Similarly, the quality of the data I collected across countries for the ecological studies varied, 
and some surveillance was only voluntary or hospital data, which could underestimate or 
overestimate incidence rates. I attempted to control for this by adjusting for the coverage of 
the data.  The quality of data could also have varied according to the diagnostic facilities and 
procedures, and I attempted to control for these through economic variables, though this may 
not have been sufficient.  
Most importantly, due to the retrospective data collection, I was unable to collect data on the 
differences in the GBS prevention strategy across the years in each geographical area and 
instead, had to use the most recent GBS strategy during the period that data were provided. 
The recent strategy may not reflect the strategy in place during the majority of the study 
period, and the observed trends might have actually occurred during the period where another 
strategy was used. Finally, the definitions of outcomes also differed across the studies and 
were not identically defined across the institutions that provided data. Due to the retrospective 
and secondary data collection methods, these limitations are expected. Therefore, I attempted 
to adjust for the differences across countries and chose the most appropriate methods for the 
analysis. Furthermore, I conducted sensitivity analyses to assess the stability of results where 
they were statistically significant in the main model. As a result of the limitations in the 
available data across countries, the predicted means included negative values, which were 
outside of the plausible range for the outcomes and not be a representation of the truth.  
Antenatal screening for group B Streptococcus in the UK	
	 296 
An important limitation of the ecological studies is that they were observational in nature, 
therefore, they suggest possible associations between the exposure (GBS prevention strategy) 
and the outcomes, however, the causality cannot be established (as would be possible with an 
RCT). Secondly, while the purpose of the ecological studies was to investigate the effect of 
the GBS prevention strategy on the population or ecological level, care must be taken not to 
fall into the ecological fallacy and make conclusions about the impact of universal GBS 
screening and IAP treatment for individuals.  
Using the best available data and methodology, I addressed the gaps in the evidence on 
universal GBS screening. I am confident that the findings from the systematic review are 
robust and comprehensively demonstrate what is available. However, the ecological studies 
had significant amounts of missing data and issues with both internal and external validity. As 
a result, I was unable to accurately account for confounding variables and time structure, 
making it difficult to draw conclusions from the results.  
 
15.4 Implications for policy and practice in the UK  
This thesis investigated the research gaps in the assessment of universal GBS screening 
identified in the 2012 UK NSC review, namely the natural history of GBS, the effectiveness 
of screening and the adverse events from screening and expanding IAP. This was in an effort 
to inform whether the UK should introduce a GBS screening programme. As discussed in the 
summary of the thesis findings, none of the key research gaps have been addressed in the 
studies in the systematic reviews and the ecological studies in this thesis. As a result, there is 
insufficient evidence to ensure that the benefits of universal GBS screening using mainly 
enriched selective culture at 35 to 37 weeks would outweigh the harms. There were many 
weaknesses in the ecological studies as identified in the section above, which means it was 
not an adequate alternative to RCT data.  
Keeping the limitations in mind, the results of the ecological studies imply that in the UK, 
where the EOGBS incidence is currently 0.57 per 1,000 livebirths under risk-based 
prevention, introducing universal screening would reduce EOGBS incidence by 0.1 per 1,000 
livebirths by five years to 0.47 per 1,000 livebirths. Currently, there are approximately 443 
cases of EOGBS in the UK (0.57/1000 in 776,352 neonates101 born in the UK). Based on the 
predicted values, the expected impact of screening would be a decrease of around 16 cases 
every year, and by five years the number of EOGBS would be reduced to around 365 cases. 
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However, from the results it is not clear how these changes relate to the mortality or long-term 
disability from EOGBS.  
With respect to the harms from screening, there are few policy implications that can be drawn. 
The number of harms that can be expected if countries change from adopting risk-based 
prevention to universal GBS screening remains unknown. Whether there would be an impact 
of universal GBS screening on gut microbiota changes, antibiotic resistance, early-onset E. 
coli and other neonatal infections, or have any long-term health effects, remains unclear. The 
ecological study implied that LOGBS incidence may increase at a slower rate if countries 
switch to universal GBS screening. In the UK, LOGBS incidence is currently 0.37 per 1,000 
livebirths and this equates to 287 cases every year. If universal screening is introduced, 
LOGBS would still continue to increase. It is estimated that the following year LOGBS 
incidence would be 0.379 per 1,000 livebirths and 294 cases. By five years, the incidence of 
LOGBS would be 0.415 per 1,000 livebirths or 322 cases. Based on the surveillance in the 
UK, this is the rate that LOGBS incidence has been increasing under risk-based prevention, 
from 0.11 per 1,000 livebirths in 1991 to 0.29 per 1,000 livebirths in 2010,81 or 0.24 per 1,000 
livebirths in 2000/01 to 0.37 per 1,000 livebirths 2014/15.5 According to the results, LOGBS 
in the UK would continue at around this rate and will not increase greater than it already is.  
Finally, little is still known on the reasons why some GBS colonised women transmit GBS to 
their neonates or why some neonates develop EOGBS. With range of potential harms 
associated with screening and widespread IAP, bacterial factors might provide an opportunity 
for future prevention strategies to target patients with only the hypervirulent strains of GBS. 
Bacterial load and markers could provide innovative opportunities for more efficient 
prevention strategies, limiting the risk of harmful outcomes from widespread IAP. Bacterial 
load is the most promising of the factors, as despite the different measurements it was 
consistently associated with GBS transmission and EOGBS.  
To conclude, GBS infection is an important health condition and its persistence combined 
with the currently poor options for screening tests and the harms from IAP stress the need for 
a better understanding of GBS and more effective prevention. Universal antenatal GBS culture 
screening so far does not meet the key UK NSC criteria needed to introduce screening 
programmes. We do not fully understand the natural history of why some mothers, but not 
others, transmit GBS to their neonates, or which neonates will develop EOGBS or suffer harm 
from EOGBS. Selective culture at 35 to 37 weeks gestation is not an accurate predictor of 
EOGBS. The proposed screening programme would offer all term pregnant women the 
antenatal GBS culture test, and at least 99% of screen-positive and treated mothers (and their 
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babies) would be over-treated. Finally, the effectiveness of IAP is also somewhat uncertain 
and the evidence to support a benefit of universal screening over risk-based prevention is 
inconsistent and confined to observational studies using historical controls. Combining these 
observational data across countries and adjusting for confounding variables did not prove to 
be adequate method to inform the benefits and harms from screening. Given the current 
evidence, we do not know the balance of the benefits and the harms of introducing universal 
GBS screening, therefore, it should not be introduced in the UK. Bacterial load, serotype, 
sequence type, and the more specific isolate characterisation that is feasible with the advent 
of genome sequencing, could potentially be involved in guiding future prevention 
interventions.  
 
15.5 Implications for research   
If we are to better inform the debate around the introduction of universal GBS screening, 
further research is needed that explores the balance of benefits and harms of screening. To 
measure this requires RCT evidence on the impact of universal screening on EOGBS, early-
onset sepsis and the list of potential harms, with economic modelling to evaluate the associated 
costs. Indeed, the UK Department of Health and the Health Technology Assessment has 
recently decided to commission such an RCT in the UK.427 The RCT would require a large 
sample size and need to have a sufficiently long follow-up to explore the harms of expanding 
IAP, which may be missed otherwise. However, it is estimated that 99% of women who test 
positive for GBS in the third trimester would not go on to have a neonate with EOGBS. The 
PPV of such a screening programme would be very low and overtreatment high.  
The current universal screening strategy may be inadequate, and to improve the balance of 
benefits and harms for future proposed screening programmes, more research is needed to 
understand the natural history of GBS. Identifying patients with only the hypervirulent strains 
of GBS could help to reduce the number of women treated with antibiotics who are at low risk 
of having neonates with EOGBS. Although this research is required and is worth exploring, it 
is important to note that it may be unable to identify detectable factors above the current 
known risk factors that could be operationalised to change practice on who receives 
prophylaxis. This work should encompass research to reliably predict which mothers with 
GBS during labour will transmit GBS to the neonate (approximately 36.4% of GBS positive 
women in labour will transmit to the neonate) and which mothers will have a neonate that 
develops EOGBS. The characteristics may include clinical or demographic risk factors in the 
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mother, biochemical or molecular markers or bacterial load. This could also include an 
assessment of the predictive value on a combination of risk-factors and whether a risk-model 
could be used to identify women at highest risk. The work could also explore research to 
reliably predict which neonates with GBS colonisation will progress to EOGBS disease (even 
without IAP only up to 3% of neonates with GBS colonisation might progress to EOGBS 
disease). However, it may be difficult to identify neonates with GBS colonisation who will 
progress to EOGBS in a timely and highly accurate manner to rule out the approximately 99% 
of neonates with colonisation who do not go on to develop disease. There may be infant 
characteristics that give some prediction, although they would have to offer strong NPV to 
justify not treating positive infants.  
Finally, test accuracy research is also needed to reliably detect GBS colonisation and bacterial 
load during labour (approximately 27% of GBS positive women at 35 to 37 weeks were 
negative during labour, and 5% of GBS negative women at 35 to 37 weeks were positive 
during labour). Although the latest in-labour tests have some practical issues, there may be a 
feasible option to more accurately measure who is colonised in labour and how heavily as well 
as developments in the rapid testing of antibiotic resistance. Tests must be timely to ensure 
that women are in the labour ward long enough to be tested and treated with IAP (optimally 
at least 4 hours before delivery), and even if a test is rapid enough, there may be issues around 
the practicality of offering tests to women who have chosen home births or midwife-led care.  
In addition to universal GBS screening, there is a need to explore the risk factors used in risk-
based prevention strategies to identify more EOGBS cases and how effective risk-based 
prevention strategies are according to the factors included. As only 44% of eligible EOGBS 
cases were not treated in the UK, risk-based prevention has not been properly tried or tested. 
Therefore, the reasons for low adherence should be investigated along with the effectiveness 
under higher adherence levels. It may also be interesting to compare the impact of including 
preterm birth as a risk factor to offer IAP compared with not including it on EOGBS incidence 
in both risk-based and screening programmes.  
This thesis has addressed issues relating to the expansion of GBS prevention to include 
universal GBS screening and the beneficial and harmful impact this would have as a result.  
From the findings of this thesis, it is clear that we must tread cautiously as there are significant 
questions yet to be answered in deciding whether to implement a universal antenatal GBS 
screening programme. However, more research is urgently required in this area especially for 
the UK where the burden of EOGBS incidence is increasing. An alternative approach was 
trialled to replace RCT data to make screening decisions when RCT evidence is not available. 
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For GBS, this approach did not answer the question as GBS is a complex bacterium with many 
factors that can influence screening and treatment, and these covariates were poorly collected 
in most countries during the study period. However, beyond GBS screening, there are other 
rare conditions where RCT data are not available and alternative approaches to RCT evidence 
are required to make screening decisions. This ecological approach may work for conditions 
that are less complicated or better documented. On the other hand, methodologists may wish 
to try and combine data at the level of patients from different countries to assess if using data 
in this way could help to inform screening decisions.    
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17. APPENDICES  
Appendix 1. Search strategies for systematic review on screening systems and policy processes 
across countries (objective 1) 
 
Medline 
  # ▲ 
Searches 
  1 exp Mass Screening/ 
  2 exp Policy Making/ or Public Policy/ or Health Policy/ 
  3 exp Guideline/ 
  4 exp Decision Making/ 
  5 exp "review"/ 
  6 health planning/ or exp health planning guidelines/ or exp health planning technical assistance/ or regional health planning/ 
  7 (decision making* or decision-making*).kw,ti. 
  8 National Health Programs/ or Government Programs/ 
  9 "screen*".kw,ti. 
  10 1 or 9 
  11 exp Streptococcus agalactiae/ 
  12 "group b streptococc*".kw,ti. 
  13 "streptococc* agalactiae".kw,ti. 14 11 or 12 or 13 
  15 (polic* or guideline* or program* or strateg* or decision making* or decision-making* or process* or procedure* or review* or plan* or recommend* or committee*).ab,kw,ti. 
  16 exp Government Agencies/ 
  17 2 or 3 or 4 or 5 or 6 or 7 or 8 or 15 or 16 
  18 10 and 14 and 17 
  19 limit 18 to yr="1996 -Current"  
 
 
Embase  
  # ▲ 
Searches 
  1 exp screening/ 
  2 policy/ 
  3 exp health care policy/ 
  4 exp hospital policy/ 
  5 exp practice guideline/ 
  6 exp health program/ 
  7 decision making/ 
  8 process design/ or process development/ or process optimization/ 
  9 procedures/ 
  10 "review"/ 
  11 hospital planning/ or patient care planning/ or planning/ or strategic planning/ or health care planning/ 
  12 program development/ 
  13 exp advisory committee/ 
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  14 "screen*".ti,kw. 
  15 1 or 14 
  16 (polic* or guideline* or program* or strateg* or decision making* or decision-making* or process* or procedure* or review* or plan* or recommend* or committee*).ti,ab,kw. 
  17 exp consensus development/ 
  18 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 16 or 17 
  19 exp Streptococcus agalactiae/ 
  20 "streptococc* agalactiae".ti,ab,kw. 
  21 "group b streptococc*".ti,ab,kw. 
  22 19 or 20 or 21 
  23 15 and 18 and 22 
  24 limit 23 to yr="1996 -Current"   
ASSIA 
screen* AND (streptococci* agalactiae OR group b streptococci*) AND (polic* OR guideline* OR strategy* OR 
program* OR decision making OR decisionmaking OR process* OR procedure* OR review* OR plan* OR 
recommend* OR committee*) 
1996-2013 
 
SSCI 
Title=(screen*) AND Title=(group b streptococc* OR streptococc* agalactiae) AND Topic=(polic* or guideline* 
or program* or strateg* or decision making* or decision-making* or process* or procedure* or review* or plan* 
or recommend* or committee*)  
Timespan=1996-2013. Databases=SCI-EXPANDED.  
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Appendix 2. Data extraction sheet for screening policy-making systems and processes (objective 1) 
 
No
. 
Country/ Level Author Title Year Disease Screening 
body and 
authority  
Criteria 
and how it 
is used 
Stakeholder 
Involvement 
Evidence 
synthesis 
methodology  
Decision-
making 
process 
Other 
  Country/ is it 
regional, 
national, local 
                    
  If research 
article review 
comparing 
countries - put 
comparison 
                    
  If research 
article 
recommending 
processes 
specify 
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Appendix 3. Search strategies for systematic review on bacterial load and markers associated 
with GBS vertical transmission and EOGBS (objective 2) 
 
Medline:  
 
# ▲ Searches 
1 exp Streptococcus agalactiae/ 
2 (group b adj streptococc*).ab,ti,tw. 
3 "streptococc* agalactiae".ab,ti,tw. 
4 1 or 2 or 3 
5 exp Pregnancy/ 
6 exp Parturition/ 
7 exp Labor, Obstetric/ 
8 exp Delivery, Obstetric/ 
9 exp Pregnancy Complications, Infectious/ 
10 exp Infant/ 
11 (newborn* or new-born*).ab,ti,tw. 
12 "infant*".ab,ti,tw. 
13 "neonat*".ab,ti,tw. 
14 (babies or baby).ab,ti,tw. 
15 (antepartum* or ante-partum*).ab,ti,tw. 
16 (intrapartum* or intra-partum*).ab,ti,tw. 
17 (prenatal* or pre-natal*).ab,ti,tw. 
18 (antenatal* or ante-natal*).ab,ti,tw. 
19 "birth*".ab,ti,tw. 
20 "pregnan*".ab,ti,tw. 
21 "matern*".ab,ti,tw. 
22 exp Maternal Health Services/ 
23 exp Obstetric Labor Complications/ 
24 (labor or labour).ab,ti,tw. 
25 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 
20 or 21 or 22 or 23 or 24 
26 exp bacterial load/ 
27 exp Genetic Markers/ 
28 "bacteria* load*".ab,ti,tw. 
29 "bacteria* count*".ab,ti,tw. 
30 Biomarkers/ 
31 Virulence/ 
32 Molecular Epidemiology/ 
33 ((heav* or light* or low* or moderat* or intens*) and (colonis* or coloniz* or 
carriage)).ab,ti,tw. 
34 ((gene* or molecular* or dna or biological or immunological or chromosome) 
adj3 (marker* or biomarker*)).ab,ti,tw. 
35 pathogenicity.ab,ti,tw. 
36 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 
37 4 and 25 and 36 
38 limit 37 to (english language and humans) 
 
 
Medline In-process: 
 
# ▲ Searches 
1 (group b adj streptococc*).ab,ti,tw. 
2 "streptococc* agalactiae".ab,ti,tw. 
3 (newborn* or new-born*).ab,ti,tw. 
4 "infant*".ab,ti,tw. 
5 "neonat*".ab,ti,tw. 
6 (babies or baby).ab,ti,tw. 
7 (antepartum* or ante-partum*).ab,ti,tw. 
8 (intrapartum* or intra-partum*).ab,ti,tw. 
9 (prenatal* or pre-natal*).ab,ti,tw. 
10 (antenatal* or ante-natal*).ab,ti,tw. 
11 "birth*".ab,ti,tw. 
12 "pregnan*".ab,ti,tw. 
13 "matern*".ab,ti,tw. 
14 (labor or labour).ab,ti,tw. 
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15 "bacteria* load*".ab,ti,tw. 
16 "bacteria* count*".ab,ti,tw. 
17 ((heav* or light* or low* or moderat* or intens*) and (colonis* or coloniz* or 
carriage)).ab,ti,tw. 
18 ((gene* or molecular* or dna or biological or immunological or chromosome) 
adj3 (marker* or biomarker*)).ab,ti,tw. 
19 pathogenicity.ab,ti,tw. 
20 1 or 2 
21 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
22 15 or 16 or 17 or 18 or 19 
23 20 and 21 and 22 
24 limit 23 to english language 
 
Embase:  
 
# ▲ Searches 
1 exp Streptococcus agalactiae/ 
2 (group b adj streptococc*).ti,ab,tw. 
3 "Streptococc* agalactiae".ti,ab,tw. 
4 1 or 2 or 3 
5 exp pregnancy/ 
6 exp birth/ 
7 exp labor/ 
8 exp prenatal period/ 
9 exp delivery/ 
10 exp pregnant woman/ 
11 exp newborn/ 
12 exp infant/ 
13 exp maternal care/ 
14 "matern*".ti,ab,tw. 
15 (newborn* or new-born*).ti,ab,tw. 
16 "infant*".ti,ab,tw. 
17 "neonat*".ti,ab,tw. 
18 (babies or baby).ti,ab,tw. 
19 (antenatal* or ante-natal*).ti,ab,tw. 
20 (antepartum* or ante-partum*).ti,ab,tw. 
21 (intrapartum* or intra-partum*).ti,ab,tw. 
22 (prenatal* or pre-natal*).ti,ab,tw. 
23 "birth*".ti,ab,tw. 
24 "pregnan*".ti,ab,tw. 
25 exp labor complication/ 
26 (labor or labour).ti,ab,tw. 
27 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 
20 or 21 or 22 or 23 or 24 or 25 or 26 
28 exp bacterial load/ 
29 exp molecular marker/ 
30 exp genetic marker/ 
31 "bacteria* load*".ti,ab,tw. 
32 "bacteria* count*".ti,ab,tw. 
33 biological marker/ 
34 virulence/ 
35 molecular epidemiology/ 
36 pathogenicity/ 
37 ((gene* or molecular* or dna or biological or immunological or chromosome) 
adj3 (marker* or biomarker*)).ti,ab,tw. 
38 ((heav* or light* or low* or moderat* or intens*) and (colonis* or coloniz* or 
carriage)).ti,ab,tw. 
39 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 
40 4 and 27 and 39 
41 limit 40 to (human and english language) 
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Cochrane:  
 
  
 
 
 
 
 
 
 
Antenatal screening for group B Streptococcus in the UK	
	 330 
 
Web of Science:  
 
  
 
Set 
 
  # 
26 
(#25 NOT #19) AND LANGUAGE: (English) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
25 
#24 AND #20 AND #3 
Indexes=SCI-EXPANDED Timespan=All years 
# 
24 
#23 OR #22 OR #21 OR #17 OR #16 OR #15 
Indexes=SCI-EXPANDED Timespan=All years 
# 
23 
TS=(virulence) OR TI=(virulence) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
22 
TS=(pathogenicity) OR TI=(pathogenicity) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
21 
TS=((gene* or molecular* or dna or biological or immunological or chromosome) NEAR/3 (marker* 
or biomarker*)) OR TI=((gene* or molecular* or dna or biological or immunological or chromosome) 
NEAR/3 (marker* or biomarker*)) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
20 
#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #18 
Indexes=SCI-EXPANDED Timespan=All year 
# 
19 
TS=(animal*) OR TI=(animal*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
18 
TS=(matern*) OR TI=(matern*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
17 
TS=(heav* or light* or low* or moderat* or intens*) AND TS=(colonis* or coloniz* or carriage) OR 
TI=(heav* or light* or low* or moderat* or intens*) AND TI=(colonis* or coloniz* or carriage) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
16 
TS=(bacteria* count*) OR TI=(bacteria* count*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
15 
TS=(bacteria* load*) OR TI=(bacteria* load*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
14 
TS=(infant*) OR TI=(infant*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
13 
TS=(neonat*) OR TI=(neonat*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
12 
TS=(baby or babies) OR TI=(baby or babies) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
11 
TS=(newborn* or new-born* or new born*) OR TI=(newborn* or new-born* or new born*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
10 
TS=(antepartum* or ante-partum* or ante partum*) OR TI=(antepartum* or ante-partum* or ante 
partum*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 9 TS=(intrapartum* or intra-partum* or intra partum*) OR TI=(intrapartum* or intra-partum* or intra 
partum*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 8 TS=(prenatal* or pre-natal* or pre natal*) OR TI=(prenatal* or pre-natal* or pre natal*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 7 TS=(antenatal* or ante-natal* or ante natal*) OR TI=(antenatal* or ante-natal* or ante natal*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 6 TS=(labour or labor) OR TI=(labour or labor) 
Indexes=SCI-EXPANDED Timespan=All years 
# 5 TOPIC: (birth*) OR TITLE: (birth*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 4 TOPIC: (pregnan*) OR TITLE: (pregnan*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 3 #2 OR #1 
Indexes=SCI-EXPANDED Timespan=All years 
# 2 TS=(b near/5 streptococc*) OR TI=(b near/5 streptococc*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 1 TS=("streptococc* agalactiae") OR TI=("streptococc* agalactiae") 
Indexes=SCI-EXPANDED Timespan=All years 
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Appendix 4. Data extraction sheet for systematic review on bacterial load and markers 
associated with GBS vertical transmission and EOGBS (objective 2) 
 
Review Details 
Reviewer  
Study details 
Study ID Number  
First author surname  
Year of publication  
Country  
Number of centers   
Study design  
Study setting  
Total study duration (including length 
of follow up if applicable) 
 
Funding 
(government/private/manufacturer/other 
- specify) 
 
Aim of the study  
Methods of the study 
Recruitment dates  
Inclusion criteria  
Exclusion criteria  
Participants, Exposures and Outcomes definitions 
General definition of the sample: 
Definition and diagnostic methods for 
GBS maternal colonisation  
(e.g. site of swab, time, culture media) 
Definition and diagnostic methods for 
GBS neonatal colonisation  
(e.g. site of swab, time, and culture media) 
Definitions and diagnostic methods for 
EOGBS neonatal disease  
(e.g. site of swab, time, symptoms) 
Exposure 1  
 
(Specify general definition of bacterial loads/molecular markers) 
 Exposed 
group 1 
Exposed 
group 2 
Non-exposed 
group 
Total 
Definition of each group     
Sample size at baseline (total n)     
Sample size (analysed n)     
Lost to follow-up/withdrawals (n)     
Baseline 
characteristics 
Mean (range or SD) 
age (years) 
    
Mean (range or SD) 
gestational age 
(weeks) 
    
Female children (n 
[%]) 
    
Mean birthweight 
(range or SD) 
    
Race/ethnicity (n [%])     
Co-morbidity (n [%])     
Overall (n/N, [% or 
rate]) maternal OR 
neonatal GBS 
colonisation rate 
(specify) 
    
Overall EOGBS rate 
(n/N, [rate per 1000]) 
    
Overall (n/N, [% or 
rate]) transmission or 
transition (specify 
mother to neonatal 
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colonisation OR 
mother to EOGBS 
disease OR neonatal 
colonisation to 
neonatal EOGBS 
disease) 
Any treatments 
received (n [%]) 
Specify treatment (e.g. 
IAP) 
    
Late onset GBS (n 
[%]) 
    
Other     
Exposure 2  
(Specify general definition of bacterial 
loads/molecular markers) 
 
 Exposed 
group 1 
Exposed 
group 2 
Non-exposed 
group 
Total 
Definition of each group     
Sample size at baseline (total n)     
Sample size (analysed n)     
Lost to follow-up/withdrawals (n)     
Baseline 
characteristics 
Mean (range or SD) 
age (years) 
    
Mean (range or SD) 
gestational age 
(weeks) 
    
Female children (n 
[%]) 
    
Race/ethnicity (n [%])     
Co-morbidity (n [%])     
Maternal GBS 
colonisation rate (if 
applicable) 
    
Any treatments 
received (n [%]) 
Specify treatment (e.g. 
IAP) 
    
Late onset GBS (n 
[%]) 
    
Other     
Exposure 3  
(Specify general definition of bacterial 
loads/molecular markers) 
 
 
 Exposed 
group 1 
Exposed 
group 2 
Non-exposed 
group 
Total 
Definitions     
Sample size at baseline (total n)     
Sample size (analysed n)     
Lost to follow-up/withdrawals (n)     
Baseline 
characteristics 
Mean (range or SD) 
age (years) 
    
Mean (range or SD) 
gestational age 
(weeks) 
    
Female children (n 
[%]) 
    
Race/ethnicity (n [%])     
Co-morbidity (n [%])     
Maternal GBS 
colonisation rate (if 
applicable) 
    
Any treatments 
received (n [%]) 
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Specify treatment (e.g. 
IAP) 
Late onset GBS (n 
[%]) 
    
Other     
Add information for more exposures as 
necessary 
    
Outcomes 
GBS outcomes assessed (GBS neonatal 
colonisation, early-onset GBS neonatal 
disease) 
 
Other outcomes (specify)  
Results 
Outcome 
(Specify) 
Exposure 1  
(Specify) 
OR, RR, mean 
difference  (95% CI) 
Covariates 
adjusted for 
Non-
exposed 
(Specify) 
Exposed 
group 1 
(Specify) 
Exposed 
group 2 
(Specify) 
Total 
 
Crude  Adjusted  
Occurred        
Did not occur        
Total        
Outcome 
(Specify) 
Exposure 2 
(Specify) 
OR, RR, mean 
difference  (95% CI) 
Covariates 
adjusted for 
Non-
exposed 
(Specify) 
Exposed 
group 1 
(Specify) 
Exposed 
group 2 
(Specify) 
Total 
 
Crude  Adjusted  
Occurred        
Did not occur        
Total        
Outcome 
(Specify) 
Exposure 3 
(Specify) 
OR, RR, mean 
difference  (95% CI) 
Covariates 
adjusted for 
Non-
exposed 
Exposed 
group 1 
Exposed 
group 2) 
Total 
 
Crude  Adjusted  
Occurred        
Did not occur        
Total        
Add more 2x2 tables for more exposures as necessary 
Authors’ conclusion: 
Reviewer Notes: 
Abbreviations: GBS=group B Streptococcus; EOGBS=early-onset GBS; OR=Odds ratio; RR=Risk ratio; 95% 
CI=95 percent confidence interval; SD=standard deviation; n=number 
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Appendix 5. Full-text studies excluded from systematic review on bacterial load and markers 
associated with GBS vertical transmission and EOGB, with reason (objective 2) 
 
Reference Reason  
Alhhazmi, A., et al. (2016). "Epidemiology of Invasive Group B 
Streptococcal Disease in Alberta, Canada, from 2003 to 2013." Journal 
of Clinical Microbiology 54(7): 1774-1781. 
Not on transmission (from mother to 
baby) or transition (from early-onset 
colonisation to early-onset GBS 
disease) 
Almeida A, Villain A, Joubrel C, et al. Whole-Genome Comparison 
Uncovers Genomic Mutations between Group B Streptococci Sampled 
from Infected Newborns and Their Mothers. Journal of Bacteriology 
2015; 197(20): 3354-66. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Ayoub EM, Swingle H. Pathogenic mechanisms in neonatal GBS 
infection. Antibiot Chemother 1985; 35: 128-41. 
Review 
Berardi A, Rossi C, Creti R, et al. Group B Streptococcal Colonization 
in 160 Mother-Baby Pairs: A Prospective Cohort Study. Journal of 
Pediatrics 2013; 163(4): 1099-+. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Berardi A, Rossi C, Guidotti I, et al. Factors associated with 
intrapartum transmission of group B Streptococcus. Pediatric 
Infectious Disease Journal 2014; 33(12): 1211-5. 
Unable to distinguish data from those 
who received IAP and those who did 
not 
Berner R, Bender A, Rensing C, Forster J, Brandis M. Low prevalence 
of the immunoglobulin-A-binding beta antigen of the C protein among 
Streptococcus agalactiae isolates causing neonatal sepsis.[Erratum 
appears in Eur J Clin Microbiol Infect Dis 2000 Jan;19(1):75]. Eur J 
Clin Microbiol Infect Dis. 1999;18(8):545-50. 
Unable to distinguish data from those 
who received IAP and those who did 
not 
Bidet P, Brahimi N, Chalas C, Aujard Y, Bingen E. Molecular 
characterization of serotype III group B-streptococcus isolates causing 
neonatal meningitis. Journal of Infectious Diseases 2003; 188(8): 
1132-7. 
Unable to distinguish data from early-
onset cases to other cases 
Bisharat N, Jones N, Marchaim D, et al. Population structure of group 
B streptococcus from a low-incidence region for invasive neonatal 
disease. Microbiology-(UK) 2005; 151: 1875-81. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Brigtsen AK, Jacobsen AF, Dedi L, Melby KK, Fugelseth D, Whitelaw 
A. Maternal Colonization with Group B Streptococcus Is Associated 
with an Increased Rate of Infants Transferred to the Neonatal Intensive 
Care Unit. Neonatology 2015; 108(3): 157-63. 
Not on transmission (from mother to 
baby) or transition (from early-onset 
colonisation to early-onset GBS 
disease) and no bacterial load factor or 
bacterial molecular marker 
Campisi, E., et al. (2016). "Serotype IV Streptococcus agalactiae ST-
452 has arisen from large genomic recombination events between 
CC23 and the hypervirulent CC17 lineages." Scientific Reports 6. 
More than 10% of the participants had 
late-onset GBS 
Chan GJ, Modak JK, Mahmud AA, Baqui AH, Black RE, Saha SK. 
Maternal and neonatal colonization in Bangladesh: prevalences, 
etiologies and risk factors. Journal of Perinatology 2013; 33(12): 971-
6. 
No bacterial load factor or bacterial 
molecular marker 
Chatellier S, Huet H, Kenzi S, Rosenau A, Geslin P, Quentin R. 
Genetic diversity of rRNA operons of unrelated Streptococcus 
agalactiae strains isolated from cerebrospinal fluid of neonates 
suffering from meningitis. Journal of Clinical Microbiology 1996; 
34(11): 2741-7. 
More than 10% of the participants had 
late-onset GBS 
Chatellier S, Ramanantsoa C, Harriau P, Rolland K, Rosenau A, 
Quentin R. Characterization of Streptococcus agalactiae strains by 
randomly amplified polymorphic DNA analysis. Journal of Clinical 
Microbiology 1997; 35(10): 2573-9. 
More than 10% of the participants had 
late-onset GBS 
Chaudhry BY, Akhtar N, Balouch AH. Vaginal carriage rate of group 
B Streptococcus in pregnant women and its transmission to neonates. J 
Ayub Med Coll Abbottabad 2010; 22(4): 167-70. 
No bacterial load factor or bacterial 
molecular marker 
D'Urzo N, Martinelli M, Pezzicoli A, et al. Acidic pH Strongly 
Enhances In Vitro Biofilm Formation by a Subset of Hypervirulent ST-
17 Streptococcus agalactiae Strains. Applied and Environmental 
Microbiology 2014; 80(7): 2176-85. 
Unable to distinguish data from early-
onset cases to other cases 
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Reference Reason  
Davies HD, Jones N, Whittam TS, Elsayed S, Bisharat N, Baker CJ. 
Multilocus sequence typing of serotype III group B streptococcus and 
correlation with pathogenic potential. Journal of Infectious Diseases 
2004; 189(6): 1097-102. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
De Francesco MA, Gargiulo F, Negrini R, Gelmi M, Manca N. 
Different sequence strains of Streptococcus agalactiae elicit various 
levels of cytokine production. Immunol Invest 2008; 37(8): 741-51. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Dore N, Bennett D, Kaliszer M, Cafferkey M, Smyth CJ. Molecular 
epidemiology of group B streptococci in Ireland: associations between 
serotype, invasive status and presence of genes encoding putative 
virulence factors. Epidemiology and Infection 2003; 131(2): 823-33. 
Unable to distinguish data from early-
onset GBS cases to others 
Emaneini, M., et al. (2016). "Characterization of virulence factors, 
antimicrobial resistance pattern and clonal complexes of group B 
streptococci isolated from neonates." Microbial Pathogenesis 99: 119-
122. 
Not on transmission (from mother to 
baby) or transition (from early-onset 
colonisation to early-onset GBS 
disease) 
Eskandarian N, Ismail Z, Neela V, van Belkum A, Desa MN, Amin 
Nordin S. Antimicrobial susceptibility profiles, serotype distribution 
and virulence determinants among invasive, non-invasive and 
colonizing Streptococcus agalactiae (group B streptococcus) from 
Malaysian patients. Eur J Clin Microbiol Infect Dis 2015; 34(3): 579-
84. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Fluegge K, Wons J, Spellerberg B, et al. Genetic differences between 
invasive and noninvasive neonatal group B streptococcal isolates. 
Pediatr Infect Dis J 2011;30(12):1027-31. 
Only includes infants with early-onset 
disease. 
Freer J. Preventing perinatal transmission of group B streptococcal 
disease. JAAPA : official journal of the American Academy of 
Physician Assistants 2004; 17(3): 47-50; quiz 1-2. 
Review, and no bacterial load factor or 
bacterial molecular marker 
Friis-Moller A, Busk HE, Korner B, et al. Infections and colonisations 
with haemolytic streptococci group B in a Danish neonatal intensive 
care unit. Dan Med Bull 1984; 31(6): 494-9. 
No bacterial load factor or bacterial 
molecular marker 
Hakansson S, Granlund-Edstedt M, Sellin M, Holm SE. Demonstration 
and characterization of buoyant-density subpopulations of group B 
Streptococcus type III. Journal of Infectious Diseases 1990; 161(4): 
741-6. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Hakansson S, Holm SE, Wagner M. Density profile of group B 
streptococci, type III, and its possible relation to enhanced virulence. 
Journal of Clinical Microbiology 1987; 25(4): 714-8. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Harper IA. The importance of group B streptococci as human 
pathogens in the British Isles. Journal of clinical pathology 1971; 
24(5): 438-41. 
Case-report, and no bacterial load factor 
or bacterial molecular marker 
Helmig R, Halaburt JT, Uldbjert N, Thomsen AC, Stenderup A. 
Increased cell adherence of group B streptococci from preterm infants 
with neonatal sepsis. Obstet Gynecol 1990; 76(5 Pt 1): 825-7. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Hervas JA, Gonzalez L, Gil J, Paoletti LC, Madoff LC, Benedi VJ. 
Neonatal group B streptococcal infection in Mallorca, Spain. Clinical 
Infectious Diseases. 1993;16(5):714-8. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Hooven, T. A., et al. (2016). "The essential genome of Streptococcus 
agalactiae." Bmc Genomics 17. 
Not human/clinical study  
Imperi M, Gherardi G, Berardi A, et al. Invasive neonatal GBS 
infections from an area-based surveillance study in Italy. Clin 
Microbiol Infect 2011; 17(12): 1834-9. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
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Reference Reason  
Islam, M. S., et al. (2016). "Prevalence, Serotype Distribution, and 
Mortality Risk Associated with Group B Streptococcus Colonization of 
Newborns in Rural Bangladesh." Pediatric Infectious Disease Journal. 
Outcome is death and not EOGBS and 
has no bacterial load factor or bacterial 
molecular marker 
Kirmani N, Hafiz S, Jafarey SN, Hassan TJ. Carriage of beta 
haemolytic streptococci (BHS) in pregnant women and acquisition by 
neonates. JPMA J Pak Med Assoc 1994; 44(11): 256-7. 
No bacterial load factor or bacterial 
molecular marker 
Lin FYC, Whiting A, Adderson E, et al. Phylogenetic lineages of 
invasive and colonizing strains of serotype III group B streptococci 
from neonates: A multicenter prospective study. Journal of Clinical 
Microbiology 2006; 44(4): 1257-61. 
Unable to distinguish data from those 
who received IAP and those who did 
not 
Lin FY, Troendle JF. Hypothesis: Neonatal respiratory distress may be 
related to asymptomatic colonization with group B streptococci. 
Pediatr Infect Dis J 2006;25(10):884-8. 
In IAP context. 
Lin F, Sintchenko V, Kong F, Gilbert GL, Coiera E. Commonly used 
molecular epidemiology markers of Streptococcus agalactiae do not 
appear to predict virulence. Pathology 2009; 41(6): 576-81. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Malik, A., et al. (2016). "Neonatal Nasopharyngeal Colonization with 
Group B Streptococcus and its Association with Clinical Sepsis." 
American Journal of Perinatology 33(8): 800-807. 
No bacterial load factor or bacterial 
molecular marker and >10% were 
treated with IAP 
Manning S, Ki M, Marrs CF, et al. The frequency of genes encoding 
three putative group B streptococcal virulence factors among invasive 
and colonizing isolates. Bmc Infectious Diseases 2006; 6. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Marchaim D, Hallak M, Gortzak-Uzan L, Peled N, Riesenberg K, 
Schlaeffer F. Cell wall proteins of group B Streptococcus and low 
incidence of neonatal disease in southern Israel. Journal of 
Reproductive Medicine 2003; 48(9): 697-702. 
No bacterial load factor or bacterial 
molecular marker 
Meehan M, Cunney R, Cafferkey M. Molecular epidemiology of group 
B streptococci in Ireland reveals a diverse population with evidence of 
capsular switching. Eur J Clin Microbiol Infect Dis 2014; 33(7): 1155-
62. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Melchers WJG, Bakkers J, Toonen M, van Kuppeveld FJM, Trijbels 
M, Hoogkamp-Korstanje JAA. Genetic analysis of Streptococcus 
agalactiae strains isolated from neonates and their mothers. FEMS 
Immunol Med Microbiol 2003; 36(1-2): 111-3. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Milligan TW, Baker CJ, Straus DC, Mattingly SJ. Association of 
elevated levels of extracellular neuraminidase with clinical isolates of 
type III group B streptococci. Infect Immun 1978; 21(3): 738-46. 
Unable to distinguish data from early-
onset cases to other cases 
Muller-Vranjes A, Puntaric D, Curzik D, et al. Prevalence and 
significance of vaginal group B streptococcus colonization in pregnant 
women from Osijek, Croatia. Coll Antropol 2011; 35(1): 21-6. 
No bacterial load factor or bacterial 
molecular marker 
Nakstad, B., et al. (2016). "Early detection of neonatal group B 
streptococcus sepsis and the possible diagnostic utility of IL-6, IL-8, 
and CD11b in a human umbilical cord blood in vitro model." Infection 
and Drug Resistance 9: 171-179. 
Not human/clinical study 
Palacios GC, Eskew EK, Solorzano F, Mattingly SJ. Identification of 
the high-virulence clone of group B streptococci in Mexican isolates 
by growth characteristics at 40 degrees C. Curr Microbiol 1999; 38(2): 
126-31. 
Unable to distinguish data from early-
onset cases to other cases 
Palacios GC, Gonzalez MN, Beltran M, Arredondo JL, Torres J, 
Solorzano F. High-virulence clone of group B streptococci unable to 
grow at high temperatures is present in serotypes other than type III. 
Curr Microbiol 2007; 54(1): 42-7. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Palmeiro JK, Dalla-Costa LM, Fracalanzza SE, et al. Phenotypic and 
genotypic characterization of group B streptococcal isolates in 
southern Brazil. Journal of Clinical Microbiology 2010; 48(12): 4397-
403. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
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Reference Reason  
Parker, R. E., et al. (2016). "Association between genotypic diversity 
and biofilm production in group B Streptococcus." BMC Microbiology 
16 (1) (no pagination)(86). 
Not on transmission (from mother to 
baby) or transition (from early-onset 
colonisation to early-onset GBS 
disease) 
Puopolo KM, Draper D, Wi S, et al. Estimating the Probability of 
Neonatal Early-Onset Infection on the Basis of Maternal Risk Factors. 
Pediatrics 2011; 128(5): E1155-E63. 
No bacterial load factor or bacterial 
molecular marker 
Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group 
B streptococci in pregnancy and adverse outcome. VIP Study Group. 
Am J Obstet Gynecol 1996; 174(4): 1354-60. 
Unable to distinguish data from those 
who received IAP and those who did 
not 
Savonius, O., et al. (2016). "Swiftly decreasing cerebrospinal fluid 
cathelicidin concentration predicts improved outcome in childhood 
bacterial meningitis." Journal of Clinical Microbiology 54(6): 1648-
1649. 
More than 10% of the participants had 
late-onset GBS 
Seale, A. C., et al. (2016). "Maternal colonization with Streptococcus 
agalactiae and associated stillbirth and neonatal disease in coastal 
Kenya." Nature Microbiology 1(7): 16067. 
Case series; no control group 
Shabayek, S., et al. (2016). "A streptococcal NRAMP homologue is 
crucial for the survival of Streptococcus agalactiae under low pH 
conditions." Molecular Microbiology 100(4): 589-606. 
Not on transmission (from mother to 
baby) or transition (from early-onset 
colonisation to early-onset GBS 
disease) 
Sheppard, A. E., et al. (2016). "Capsular Typing Method for 
Streptococcus agalactiae Using Whole-Genome Sequence Data." 
Journal of Clinical Microbiology 54(5): 1388-1390. 
Not on transmission (from mother to 
baby) or transition (from early-onset 
colonisation to early-onset GBS 
disease) 
Siauw C, Kobsar A, Dornieden C, et al. Group B streptococcus isolates 
from septic patients and healthy carriers differentially activate platelet 
signaling cascades. Thromb Haemost 2006; 95(5): 836-49. 
Unable to distinguish data from early-
onset cases to other cases 
Smith TC, Roehl SA, Pillai P, Li S, Marrs CF, Foxman B. Distribution 
of novel and previously investigated virulence genes in colonizing and 
invasive isolates of Streptococcus agalactiae. Epidemiology and 
Infection 2007; 135(6): 1046-54. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Teixeira LA, Figueiredo AM, Ferreira BT, et al. Sialic acid content and 
surface hydrophobicity of group B streptococci. Epidemiol Infect 
1993; 110(1): 87-94. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Towers CV, Garite TJ, Friedman WW, Pircon RA, Nageotte MP. 
Comparison of a rapid enzyme-linked immunosorbent assay test and 
the Gram stain for detection of group B streptococcus in high-risk 
antepartum patients. Am J Obstet Gynecol 1990; 163(3): 965-7. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
Valentin-Weigand P, Chhatwal GS. Correlation of epithelial cell 
invasiveness of group B streptococci with clinical source of isolation. 
Microb Pathog 1995; 19(2): 83-91. 
Unable to distinguish data from early-
onset cases to other cases 
van der Mee-Marquet N, Domelier AS, Mereghetti L, et al. Prophagic 
DNA fragments in Streptococcus agalactiae strains and association 
with neonatal meningitis. Journal of Clinical Microbiology 2006; 
44(3): 1049-58. 
Bacterial load or bacterial molecular 
marker not related to transmission (from 
mother to baby) or transition (from 
early-onset colonisation to early-onset 
GBS disease) 
van Elzakker E, Yahiaoui R, Visser C, et al. Epidemiology of and 
prenatal molecular distinction between invasive and colonizing group 
B streptococci in The Netherlands and Taiwan. Eur J Clin Microbiol 
Infect Dis 2009; 28(8): 921-8. 
Unable to distinguish data from early-
onset cases to other cases 
Weindling AM, Hawkins JM, Coombes MA, Stringer J. Colonisation 
of babies and their families by group B streptococci. Br Med J (Clin 
Res Ed) 1981; 283(6305): 1503-5. 
No bacterial load factor or bacterial 
molecular marker 
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Appendix 6. Summary forest plots of each pooled risk ratio by GBS serotype 
 
  
Antenatal screening for group B Streptococcus in the UK	
	 339 
Appendix 7. Sensitivity analyses results for the meta-analysis of EOGBS by colonised serotype  
 
A. Cohort studies only  
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B. Not explicitly selective culture OR EOGBS definition explicitly sterile culture 
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C. Leaving out Madzivhandila et al. (2011) 
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Appendix 8. Search strategies for systematic review of adverse events from intrapartum 
antibiotic prophylaxis (objective 3) 
 
Medline:  
 
# ▲ Searches 
1 exp Parturition/ 
2 exp Labor, Obstetric/ 
3 exp Delivery, Obstetric/ 
4 exp Obstetric Labor Complications/ 
5 exp Maternal Health Services/ 
6 (labour or labor).ab,ti,tw. 
7 (intrapartum* or intra-partum*).ab,ti,tw. 
8 "birth* ".ab,ti,tw. 
9 "matern* ".ab,ti,tw. 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11 "prophyla*".ab,ti,tw. 
12 exp Penicillins/ 
13 exp Erythromycin/ 
14 exp Clindamycin/ 
15 exp Cefazolin/ 
16 "penicillin*".ab,ti,tw. 
17 "erythromycin*".ab,ti,tw. 
18 "clindamycin*".ab,ti,tw. 
19 "cefazolin*".ab,ti,tw. 
20 "ampicillin*".ab,ti,tw. 
21 "vancomycin*".ab,ti,tw. 
22 exp Vancomycin/ 
23 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
24 11 and 23 
25 exp Antibiotic Prophylaxis/ 
26 exp Patient Harm/ 
27 exp Product Surveillance, Postmarketing/ 
28 exp Adverse Drug Reaction Reporting Systems/ 
29 exp Clinical Trials, Phase IV as Topic/ 
30 exp Poisoning/ 
31 exp Substance-Related Disorders/ 
32 exp "Drug-Related Side Effects and Adverse Reactions"/ 
33 exp abnormalities, drug induced/ 
34 exp Drug Monitoring/ 
35 exp Drug Hypersensitivity/ 
36 exp Postoperative Complications/ 
37 exp Intraoperative Complications/ 
38 (toxicity or complication* or noxious or tolerability).ab,ti,tw. 
39 (safe or safety).ab,ti,tw. 
40 "side effect*".ab,ti,tw. 
41 ((adverse or undesirable or harms* or serious or toxic) adj3 (effect* or reaction* or 
event* or outcome*)).ab,ti,tw. 
42 (ae or to or po or co).fs. 
43 exp Drug Resistance/ 
44 exp Microbiota/ 
45 exp Anxiety/co, de [Complications, Drug Effects] 
46 exp Anaphylaxis/ci, co, de [Chemically Induced, Complications, Drug Effects] 
47 exp Overweight/ci, co, de [Chemically Induced, Complications, Drug Effects] 
48 exp Asthma/ci, co, de [Chemically Induced, Complications, Drug Effects] 
49 exp Autistic Disorder/ci, co [Chemically Induced, Complications] 
50 "autis*".ab,ti,tw. 
51 "diabet*".ab,ti,tw. 
52 "obes*".ab,ti,tw. 
53 asthma.ab,ti,tw. 
54 anxiety.ab,ti,tw. 
55 (resistance or resistant).ab,ti,tw. 
56 (microbiome or microbiota).ab,ti,tw. 
57 "anaphyla*".ab,ti,tw. 
58 (overweight or over-weight).ab,ti,tw. 
59 exp Clostridium difficile/de [Drug Effects] 
60 exp Diarrhea/ci, co, po [Chemically Induced, Complications, Poisoning] 
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Medline In-process: 
 
61 ("Clostridium difficile" or "c. diff" or "c. difficile").ab,ti,tw. 
62 (Antibiotic-associated diarrhoea or Antibiotic-associated diarrhea or Antibiotic 
associated diarrhoea or Antibiotic associated diarrhea).ab,ti,tw. 
63 exp Bacterial Infections/ci, co [Chemically Induced, Complications] 
64 exp Sepsis/ci, co, to [Chemically Induced, Complications, Toxicity] 
65 exp "Length of Stay"/ 
66 exp Skin Diseases/ci, co, to [Chemically Induced, Complications, Toxicity] 
67 exp Respiratory Tract Diseases/ci, co, de [Chemically Induced, Complications, Drug 
Effects] 
68 exp Cerebral Palsy/ci, co [Chemically Induced, Complications] 
69 length of stay.ab,ti,tw. 
70 (respiratory illness* or respiratory disease*).ab,ti,tw. 
71 cerebral palsy.ab,ti,tw. 
72 (Neonatal Necrotising Enterocolitis or Neonatal Necrotizing Enterocolitis or 
nec).ab,ti,tw. 
73 exp Candidiasis/ci, co [Chemically Induced, Complications] 
74 exp Enterocolitis, Necrotizing/ci, co [Chemically Induced, Complications] 
75 (yeast infection* or Candidiasis).ab,ti,tw. 
76 (suprainfection* or supra-infection*).ab,ti,tw. 
77 exp Methicillin-Resistant Staphylococcus aureus/de [Drug Effects] 
78 exp Vancomycin-Resistant Enterococci/de [Drug Effects] 
79 exp Inflammatory Bowel Diseases/ci, co [Chemically Induced, Complications] 
80 (Inflammatory bowel disease* or Crohn's disease* or Ulcerative colitis).ab,ti,tw. 
81 exp "Growth and Development"/de [Drug Effects] 
82 (Meticillin-resistant Staphylococcus aureus or Methicillin-resistant Staphylococcus 
aureus or Meticillin resistant Staphylococcus aureus or Methicillin resistant 
Staphylococcus aureus or MRSA).ab,ti,tw. 
83 (skin disease* or dematologic* disease* or skin condition* or dematologic* 
condition*).ab,ti,tw. 
84 (Vancomycin-resistant Enterococci or Vancomycin resistant Enterococci or 
VRE).ab,ti,tw. 
85 (Extended Spectrum Beta-lactamase or Extended Spectrum Beta lactamase or 
ESBL).ab,ti,tw. 
86 (Carbapenem-resistant Organism or Carbapenem resistant Organism or 
CRO).ab,ti,tw. 
87 "antibiotic*".ab,ti,tw. 
88 exp Diabetes Mellitus/ci [Chemically Induced] 
89 (growth adj2 develop*).ab,ti,tw. 
90 11 and 87 
91 24 or 25 or 90 
92 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 
or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 
55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 
or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 
84 or 85 or 86 or 88 or 89 
93 10 and 91 and 92 
94 limit 93 to (english language and humans) 
# ▲ Searches 
1 (labour or labor).ab,ti,tw. 
2 (intrapartum* or intra-partum*).ab,ti,tw. 
3 "birth* ".ab,ti,tw. 
4 "matern* ".ab,ti,tw. 
5 "prophyla*".ab,ti,tw. 
6 "penicillin*".ab,ti,tw. 
7 "erythromycin*".ab,ti,tw. 
8 "clindamycin*".ab,ti,tw. 
9 "cefazolin*".ab,ti,tw. 
10 "ampicillin*".ab,ti,tw. 
11 "vancomycin*".ab,ti,tw. 
12 (toxicity or complication* or noxious or tolerability).ab,ti,tw. 
13 (safe or safety).ab,ti,tw. 
14 "side effect*".ab,ti,tw. 
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Embase:  
 
15 ((adverse or undesirable or harms* or serious or toxic) adj3 (effect* or reaction* or 
event* or outcome*)).ab,ti,tw. 
16 "autis*".ab,ti,tw. 
17 "diabet*".ab,ti,tw. 
18 "obes*".ab,ti,tw. 
19 asthma.ab,ti,tw. 
20 anxiety.ab,ti,tw. 
21 (resistance or resistant).ab,ti,tw. 
22 (microbiome or microbiota).ab,ti,tw. 
23 "anaphyla*".ab,ti,tw. 
24 (overweight or over-weight).ab,ti,tw. 
25 ("Clostridium difficile" or "c. diff" or "c. difficile").ab,ti,tw. 
26 (Antibiotic-associated diarrhoea or Antibiotic-associated diarrhea or Antibiotic 
associated diarrhoea or Antibiotic associated diarrhea).ab,ti,tw. 
27 length of stay.ab,ti,tw. 
28 (respiratory illness* or respiratory disease*).ab,ti,tw. 
29 cerebral palsy.ab,ti,tw. 
30 (Neonatal Necrotising Enterocolitis or Neonatal Necrotizing Enterocolitis or 
nec).ab,ti,tw. 
31 (yeast infection* or Candidiasis).ab,ti,tw. 
32 (suprainfection* or supra-infection*).ab,ti,tw. 
33 (Inflammatory bowel disease* or Crohn's disease* or Ulcerative colitis).ab,ti,tw. 
34 (Meticillin-resistant Staphylococcus aureus or Methicillin-resistant Staphylococcus 
aureus or Meticillin resistant Staphylococcus aureus or Methicillin resistant 
Staphylococcus aureus or MRSA).ab,ti,tw. 
35 (skin disease* or dematologic* disease* or skin condition* or dematologic* 
condition*).ab,ti,tw. 
36 (Vancomycin-resistant Enterococci or Vancomycin resistant Enterococci or 
VRE).ab,ti,tw. 
37 (Extended Spectrum Beta-lactamase or Extended Spectrum Beta lactamase or 
ESBL).ab,ti,tw. 
38 (Carbapenem-resistant Organism or Carbapenem resistant Organism or 
CRO).ab,ti,tw. 
39 1 or 2 or 3 or 4 
40 6 or 7 or 8 or 9 or 10 or 11 
41 5 and 40 
42 (sepsis or septicaemia).ab,ti,tw. 
43 "bacteria* infection*".ab,ti,tw. 
44 "antibiotic*".ab,ti,tw. 
45 (growth adj2 develop*).ab,ti,tw. 
46 5 and 44 
47 41 or 46 
48 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 42 or 43 or 
45 
49 39 and 47 and 48 
50 limit 49 to english language 
# ▲ Searches 
1 (intrapartum* or intra-partum*).ti,ab,tw. 
2 "birth*".ti,ab,tw. 
3 "matern*".ti,ab,tw. 
4 exp birth/ 
5 exp labor/ 
6 exp delivery/ 
7 exp maternal care/ 
8 exp labor complication/ 
9 exp intrapartum care/ 
10 (labor or labour).ti,ab,tw. 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 "prophyla*".ti,ab,tw. 
13 exp Penicillins/ 
14 exp Erythromycin/ 
15 exp Clindamycin/ 
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16 exp Cefazolin/ 
17 "penicillin*".ti,ab,tw. 
18 "erythromycin*".ti,ab,tw. 
19 "clindamycin*".ti,ab,tw. 
20 "cefazolin*".ti,ab,tw. 
21 "ampicillin*".ti,ab,tw. 
22 "vancomycin*".ti,ab,tw. 
23 exp Vancomycin/ 
24 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
25 12 and 24 
26 exp Antibiotic Prophylaxis/ 
27 exp patient harm/ 
28 exp side effect/ 
29 exp adverse drug reaction/ 
30 exp drug toxicity/ 
31 exp intoxication/ 
32 exp drug safety/ 
33 exp drug monitoring/ 
34 exp drug hypersensitivity/ 
35 exp postmarketing surveillance/ 
36 exp drug surveillance program/ 
37 phase 4 clinical trial/ 
38 exp postoperative complication/ 
39 exp peroperative complication/ 
40 "side effect*".ti,ab,tw. 
41 (ae or si or to or co).fs. 
42 exp anaphylaxis/co, si [Complication, Side Effect] 
43 exp microflora/ 
44 exp drug resistance/ 
45 exp anxiety/co [Complication] 
46 exp obesity/co, si [Complication, Side Effect] 
47 exp asthma/co, si [Complication, Side Effect] 
48 exp diabetes mellitus/co, to, si [Complication, Drug Toxicity, Side Effect] 
49 exp autism/co, si [Complication, Side Effect] 
50 (resistance or resistant).ti,ab,tw. 
51 "autis*".ti,ab,tw. 
52 "diabet*".ti,ab,tw. 
53 "obes*".ti,ab,tw. 
54 asthma.ti,ab,tw. 
55 anxiety.ti,ab,tw. 
56 (microbiome or microbiota).ti,ab,tw. 
57 "anaphyla*".ti,ab,tw. 
58 (overweight or over-weight).ti,ab,tw. 
59 ((adverse or undesirable or harm* or serious or toxic) adj3 (effect* or reaction* 
or event* or outcome*)).ti,ab,tw. 
60 (safe or safety).ti,ab,tw. 
61 exp Peptoclostridium difficile/ 
62 ("Clostridium difficile" or "c. diff" or "c. difficile").ti,ab,tw. 
63 (Antibiotic-associated diarrhoea or Antibiotic-associated diarrhea or Antibiotic 
associated diarrhoea or Antibiotic associated diarrhea).ti,ab,tw. 
64 exp bacterial infection/co, si [Complication, Side Effect] 
65 exp sepsis/co, si [Complication, Side Effect] 
66 exp "length of stay"/ 
67 exp skin disease/co, si [Complication, Side Effect] 
68 exp respiratory tract disease/co, si [Complication, Side Effect] 
69 exp cerebral palsy/co, si [Complication, Side Effect] 
70 length of stay.ti,ab,tw. 
71 (respiratory illness* or respiratory disease*).ti,ab,tw. 
72 cerebral palsy.ti,ab,tw. 
73 (Neonatal Necrotising Enterocolitis or Neonatal Necrotizing Enterocolitis or 
nec).ti,ab,tw. 
74 exp necrotizing enterocolitis/co, si [Complication, Side Effect] 
75 exp candidiasis/co, si [Complication, Side Effect] 
76 (yeast infection* or Candidiasis).ti,ab,tw. 
77 (suprainfection* or supra-infection*).ti,ab,tw. 
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Cochrane: 
 
 
78 (Meticillin-resistant Staphylococcus aureus or Methicillin-resistant 
Staphylococcus aureus or Meticillin resistant Staphylococcus aureus or 
Methicillin resistant Staphylococcus aureus or MRSA).ti,ab,tw. 
79 exp vancomycin resistant Enterococcus/ 
80 (Extended Spectrum Beta-lactamase or Extended Spectrum Beta lactamase or 
ESBL).ti,ab,tw. 
81 (Vancomycin-resistant Enterococci or Vancomycin resistant Enterococci or 
VRE).ti,ab,tw. 
82 (Carbapenem-resistant Organism or Carbapenem resistant Organism or 
CRO).ti,ab,tw. 
83 exp inflammatory bowel disease/co, si [Complication, Side Effect] 
84 (Inflammatory bowel disease* or Crohn's disease* or Ulcerative colitis).ti,ab,tw. 
85 exp "growth, development and aging"/ 
86 exp antibiotic associated diarrhea/ 
87 exp methicillin resistant Staphylococcus aureus/ 
88 (skin disease* or dematologic* disease* or skin condition* or dematologic* 
condition*).ti,ab,tw. 
89 exp extended spectrum beta lactamase/ 
90 "antibiotic*".ti,ab,tw. 
91 (growth adj2 develop*).ti,ab,tw. 
92 12 and 90 
93 25 or 26 or 92 
94 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 
41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 
55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 
69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 
83 or 84 or 85 or 86 or 87 or 88 or 89 or 91 
95 11 and 93 and 94 
96 limit 95 to (human and english language) 
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Web of Science:  
 
 
Set 
 
  # 
50 
(#48 NOT #49) AND LANGUAGE: (English) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
49 
TS=(animal) OR TI=(animal) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
48 
#47 AND #46 AND #5 
Indexes=SCI-EXPANDED Timespan=All years 
# 
47 
#43 OR #42 OR #41 OR #40 OR #39 OR #38 OR #37 OR #36 OR #35 OR #34 OR #33 OR #32 OR 
#31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR 
#19 OR #18 OR #17 OR #16 OR #15 
Indexes=SCI-EXPANDED Timespan=All years 
# 
46 
#45 OR #8 
Indexes=SCI-EXPANDED Timespan=All years 
# 
45 
#44 AND #7 
Indexes=SCI-EXPANDED Timespan=All years 
# 
44 
#14 OR #13 OR #12 OR #11 OR #10 OR #9 
Indexes=SCI-EXPANDED Timespan=All years 
# 
43 
TS=("bacteria* infection*") OR TI=("bacteria* infection*") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
42 
TS=("Carbapenem-resistant Organism" or "Carbapenem resistant Organism" or CRO) OR 
TI=("Carbapenem-resistant Organism" or "Carbapenem resistant Organism" or CRO) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
41 
TS=("Extended Spectrum Beta-lactamase" or "Extended Spectrum Beta lactamase" or ESBL) OR 
TI=("Extended Spectrum Beta-lactamase" or "Extended Spectrum Beta lactamase" or ESBL) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
40 
TS=("Vancomycin-resistant Enterococci" or "Vancomycin resistant Enterococci" or VRE) OR 
TI=("Vancomycin-resistant Enterococci" or "Vancomycin resistant Enterococci" or VRE) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
39 
TS=("skin disease*" or "dematologic* disease*" or "skin condition*" or "dematologic* condition*") 
OR TI=("skin disease*" or "dematologic* disease*" or "skin condition*" or "dematologic* condition*") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
38 
(TS=(growth NEAR/2 develop*) OR TI=(growth NEAR/2 develop*)) AND LANGUAGE: (English) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
37 
TS=("Meticillin-resistant Staphylococcus aureus" or "Methicillin-resistant Staphylococcus aureus" or 
"Meticillin resistant Staphylococcus aureus" or "Methicillin resistant Staphylococcus aureus" or 
MRSA) OR TI=("Meticillin-resistant Staphylococcus aureus" or "Methicillin-resistant Staphylococcus 
aureus" or "Meticillin resistant Staphylococcus aureus" or "Methicillin resistant Staphylococcus aureus" 
or MRSA) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
36 
TS=("Inflammatory bowel disease*" or "Crohn's disease*" or "Ulcerative colitis") OR 
TI=("Inflammatory bowel disease*" or "Crohn's disease*" or "Ulcerative colitis") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
35 
TS=(suprainfection* or supra-infection or supra infection) OR TI=(suprainfection* or supra-infection 
or supra infection) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
34 
TS=("yeast infection*" or Candidiasis) OR TI=("yeast infection*" or Candidiasis) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
33 
TS=("Neonatal Necrotising Enterocolitis" or "Neonatal Necrotizing Enterocolitis" or nec) OR 
TI=("Neonatal Necrotising Enterocolitis" or "Neonatal Necrotizing Enterocolitis" or nec) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
32 
TS=("cerebral palsy") OR TI=("cerebral palsy") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
31 
TS=("respiratory illness*" or "respiratory disease*") OR TI=("respiratory illness*" or "respiratory 
disease*") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
30 
TS=("length of stay") OR TI=("length of stay") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
29 
TS=("Antibiotic-associated diarrhoea" or "Antibiotic-associated diarrhea" or "Antibiotic associated 
diarrhoea" or "Antibiotic associated diarrhea") OR TI=("Antibiotic-associated diarrhoea" or 
"Antibiotic-associated diarrhea" or "Antibiotic associated diarrhoea" or "Antibiotic associated 
diarrhea") 
Indexes=SCI-EXPANDED Timespan=All years 
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# 
28 
TS=("Clostridium difficile" or "c. diff" or "c. difficile") OR TI=("Clostridium difficile" or "c. diff" or 
"c. difficile") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
27 
TS=(overweight or over-weight or over weight) OR TI=(overweight or over-weight or over weight) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
26 
TS=(anaphyla*) OR TI=(anaphyla*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
25 
TS=(microbiome or microbiota) OR TI=(microbiome or microbiota) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
24 
TS=(resistance or resistant) OR TI=(resistance or resistant) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
23 
TS=(anxiety) OR TI=(anxiety) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
22 
TS=(asthma) OR TI=(asthma) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
21 
TS=(obes*) OR TI=(obes*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
20 
TS=(diabet*) OR TI=(diabet*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
19 
TS=(autis*) OR TI=(autis*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
18 
TS=(((adverse or undesirable or harms* or serious or toxic) NEAR/3 (effect* or reaction* or event* or 
outcome*)) OR ((adverse or undesirable or harms* or serious or toxic) NEAR/3 (effect* or reaction* or 
event* or outcome*))) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
17 
TS=("side effect*") OR TI=("side effect*") 
Indexes=SCI-EXPANDED Timespan=All years 
# 
16 
TS=(safe or safety) OR TI=(safe or safety) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
15 
TS=(toxicity or complication* or noxious or tolerability) OR TI=(toxicity or complication* or noxious 
or tolerability) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
14 
TS=(vancomycin*) OR TI=(vancomycin*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
13 
TS=(ampicillin*) OR TI=(ampicillin*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
12 
TS=(cefazolin*) OR TI=(cefazolin*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
11 
TS=(clindamycin*) OR TI=(clindamycin*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 
10 
TS=(erythromycin*) OR TI=(erythromycin*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 9 TS=(penicillin*) OR TI=(penicillin*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 8 #7 AND #6 
Indexes=SCI-EXPANDED Timespan=All years 
# 7 TS=(prophyla*) OR TI=(prophyla*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 6 TS=(antibiotic*) OR TI=(antibiotic*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 5 #4 OR #3 OR #2 OR #1 
Indexes=SCI-EXPANDED Timespan=All years 
# 4 TS=(matern*) OR TI=(matern*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 3 TS=(birth*) OR TI=(birth*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 2 TS=(intrapartum* or intra-partum* or intra partum*) OR TI=(intrapartum* or intra-partum* or intra 
partum*) 
Indexes=SCI-EXPANDED Timespan=All years 
# 1 TS=(labour or labor) OR TI=(labour or labor) 
Indexes=SCI-EXPANDED Timespan=All years 
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Appendix 9. Data extraction sheet for systematic review on adverse events from intrapartum 
antibiotic prophylaxis (objective 3) 
 
Review Details 
Reviewer  
Study details 
Study ID Number  
First author surname  
Year of publication  
Country  
Study design  
Study setting  
Number of centers  
Total study duration  (including length of follow up if applicable) 
Funding  (government/private/manufacturer/other - specify) 
Aim of the study  
Methods of the study 
Recruitment dates  
Inclusion criteria  
Exclusion criteria  
Recruitment method (e.g. 
consecutive participants) 
 
Interventions and participants  
General definition of the sample: 
Intervention arm: Antibiotic 
prophylaxis 
No treatment Total 
Dose of antibiotic    
Indication for antibiotic    
Antibiotic given    
Duration of antibiotic    
Sample size at baseline     
Sample size analysed    
Lost to follow-up/withdrawals     
Baseline 
characteristi
cs 
Mean (range or SD) age (years)    
Mean (range or SD) gestational age 
(weeks) 
   
Female children (n [%])    
Race/ethnicity (n [%])    
Elective Caesarean section (n [%])    
Intrapartum fever (n [%])    
Prolonged rupture of membranes (n 
[%]) 
   
Chorioamnionitis (n [%])    
Co-morbidity (n [%]) specify what 
this included 
   
History of allergy from antibiotic 
(n[%]) 
   
Co-intervention (n[%])specify what 
this included 
   
Multiple births (n [%])    
Mean (rage or SD) birth weight (g)    
Smoking (n [%])    
Other (specify)     
Outcomes 
Adverse event name Definition Time 
point: 
Measurement 
    
    
    
Results 
Adverse 
event 1  
(specify) 
Interventio
n (IAP) [n] 
Control 
[n] 
Total  OR, RR, mean difference (95%CI) Covariates 
adjusted for Crude  Adjusted  
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Adverse 
event 1 
(specify)  
Occurred 
      
Adverse 
event 1 
(specify)  
Did not occur 
      
Total       
Adverse 
event 2  
(specify) 
 
Interventio
n (IAP) [n] 
Control 
[n] 
Total 
[n] 
OR, RR, mean difference (95%CI) Covariates 
adjusted for Crude  Adjusted  
Adverse 
event 2 
(specify) 
Occurred 
      
Adverse 
event 2 
(specify) 
Did not occur 
      
Total       
Add more 2x2 tables and statistical results for more adverse events as necessary 
Authors’ conclusion: 
Reviewer Notes: 
Abbreviations: 95% CI=95 percent confidence interval; SD=standard deviation; n=number 
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Appendix 10. Full-text excluded from systematic on adverse events from intrapartum antibiotic 
prophylaxis, with reason (objective 3) 
 
Reference Reason 
Aard LA, Saed F. Low-incidence cesarean section: 12-year experience. Mayo Clin 
Proc 1975; 50(7): 365-9. 
Prophylaxis for Caesarean 
section 
Accordino, F., et al. (2016). Risk factors for cerebral palsy in PPROM and preterm 
delivery with intact membranes<sup>*</sup>. Journal of Maternal-Fetal and 
Neonatal Medicine 29(23): 3854-3859. 
More than 10% had 
symptoms in labour 
(chorioamnionitis)  
Adeniran AS, Aboyeji AP, Fawole AA, Adesiyun OO, Saidu R. Role of Risk-
Based Approach in the Prevention of Vertical Transmission of Neonatal Sepsis. 
Niger Postgrad Med J 2015; 22(2): 88-92. 
More than 10% had 
symptoms in labour 
(intrapartum fever) 
Andrews WW, Hauth JC, Cliver SP, Savage K, Goldenberg RL. Randomized 
clinical trial of extended spectrum antibiotic prophylaxis with coverage for 
Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet 
Gynecol 2003; 101(6): 1183-9. 
Prophylaxis for Caesarean 
section 
Anonymous. Prophylactic antibiotics in caesarean section. Br Med J 1973; 
2(5868): 675-6. 
Consensus statement 
Anonymous. Obesity in pregnancy. Obstet Gynecol 2015; 126(6): e112-e26. Review 
Anteby SO, Birkenfeld A, Weinstein D. Post cesarean section urinary tract 
infections, risk factors and prophylactic antibiotic treatment. Clin Exp Obstet 
Gynecol 1984; 11(4): 161-4. 
Prophylaxis for Caesarean 
section 
Apgar BS, Greenberg G, Yen G. Prevention of group B streptococcal disease in the 
newborn. Am Fam Physician 2005; 71(5): 903-10. 
Review 
Apuzzio JJ, Ganesh VV, Pelosi MA, Frisoli G. The effect of prophylactic 
antibiotics on risk factors for endomyometritis in adolescent patients undergoing 
cesarean section. Journal of adolescent health care : official publication of the 
Society for Adolescent Medicine, 1984.  
Prophylaxis for Caesarean 
section 
Ayangade O. Antibiotic prophylaxis in high-risk obstetrics. J Natl Med Assoc 
1977; 69(11): 793-5. 
Unable to identify timing of 
antibiotics 
Ayangade O. Long vs short-course antibiotic prophylaxis in cesarean section: a 
comparative clinical study. J Natl Med Assoc 1979; 71(1): 71-3. 
Prophylaxis for Caesarean 
section 
Azad, M. B., et al. (2016). Impact of maternal intrapartum antibiotics, method of 
birth and breastfeeding on gut microbiota during the first year of life: A 
prospective cohort study. BJOG: An International Journal of Obstetrics and 
Gynaecology 123(6): 983-993 
More than 10% had 
symptoms in labour 
(prolonged rupture of 
membranes) 
Battarino O, Battarino A. [Short-term antibiotic prophylaxis in cesarean section]. 
Minerva ginecologica, 1988.  
Full-text not in English 
Beattie PG, Rings TR, Hunter MF, Lake Y. Risk factors for wound infection 
following caesarean section. Aust N Z J Obstet Gynaecol 1994; 34(4): 398-402. 
Prophylaxis for Caesarean 
section 
Benigno BB, Ford LC, Lawrence WD, Ledger WJ, Ling FW, McNeeley SG. A 
double-blind, controlled comparison of piperacillin and cefoxitin in the prevention 
of postoperative infection in patients undergoing cesarean section. Surg Gynecol 
Obstet, 1986.  
Prophylaxis for Caesarean 
section 
Benjamin DK, Stoll BJ, Gantz MG, et al. Neonatal Candidiasis: Epidemiology, 
Risk Factors, and Clinical Judgment. Pediatrics 2010; 126(4): E865-E73. 
Unable to distinguish 
intrapartum antibiotics with 
other timings 
Berardi A, Rossi C, Creti R, et al. Group B Streptococcal colonization in 160 
mother-baby pairs: A prospective cohort study. J Pediatr 2013; 163(4): 1099-
104.e1. 
No data on adverse events 
Berardi, A., et al. (2016). "The burden of early-onset sepsis in Emilia-Romagna 
(Italy): a 4-year, population-based study." Journal of Maternal-Fetal and Neonatal 
Medicine 29(19): 3126-3131. 
More than 10% had 
symptoms in labour 
(prolonged rupture of 
membranes) 
Berkeley AS, Hirsch JC, Freedman KS, Ledger WJ. Cefotaxime for cesarean 
section prophylaxis in labor. Intravenous administration vs. lavage. Journal of 
Reproductive Medicine for the Obstetrician and Gynecologist 1990; 35(3): 214-8. 
Prophylaxis for Caesarean 
section 
Bibi M, Megdiche H, Ghanem H, et al. [Antibiotic prophylaxis in a priori cesarean 
sections without a high risk of infection. Experiences of a Tunisian maternity 
department]. Journal de gynécologie, obstétrique et biologie de la reproduction, 
1994. 
Full-text not in English 
Birkenfeld A, Anteby SO. The effect of ampicillin and colistin on post-Caesarean 
section endometritis with identification of possible risk factors. Aust N Z J Obstet 
Gynaecol 1983; 23(4): 204-7. 
Prophylaxis for Caesarean 
section 
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Reference Reason 
Block BS, Mercer LJ, Ismail MA, Moawad AH. Clostridium difficile-associated 
diarrhea follows perioperative prophylaxis with cefoxitin. Am J Obstet Gynecol 
1985; 153(8): 835-8. 
More than 10% prophylaxis 
for Caesarean section 
Boothby R, Benrubi G, Ferrell E. Comparison of intravenous cefoxitin prophylaxis 
with intraoperative cefoxitin irrigation for the prevention of post-cesarean-section 
endometritis. Journal of Reproductive Medicine for the Obstetrician and 
Gynecologist 1984; 29(11): 830-2. 
Prophylaxis for Caesarean 
section 
Bourgeois FJ, Pinkerton JA, Andersen W, Thiagarajah S. Antibiotic irrigation 
prophylaxis in the high-risk cesarean section patient. Am J Obstet Gynecol 1985; 
153(2): 197-201. 
Prophylaxis for Caesarean 
section 
Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal 
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Prophylaxis for Caesarean 
section 
Moberg PJ, Schedvins K. Use of cefuroxime in preventing postcesarean infection 
in high-risk patients. Gynecol Obstet Invest 1989; 28(1): 19-22. 
Prophylaxis for Caesarean 
section 
Moodley J, Zeeman DJ. Prophylactic and antimicrobial therapy using lincomycin 
in patients undergoing emergency caesarean section. S Afr Med J 1981; 59(25): 
911-3. 
Prophylaxis for Caesarean 
section 
Moro M, Andrews M. Prophylactic antibiotics in cesarean section. Obstet Gynecol 
1974; 44(5): 688-92. 
Prophylaxis for Caesarean 
section 
Morrison JC, Coxwell WL, Kennedy BS, Schreier PC, Wiser WL, Fish SA. The 
use of prophylactic antibiotics in patients undergoing cesarean section. Surg 
Gynecol Obstet, 1973.  
Prophylaxis for Caesarean 
section 
Mothilal M, Thivya R, Anjalakshi C, Ramesh A, Damodharan N. Comparison of 
effectiveness of Azithromycin and Cefazolin in post caesarean section infection. 
International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5(SUPPL 3): 
92-4. 
Prophylaxis for Caesarean 
section 
Newton ER, Prihoda TJ, Gibbs RS. A clinical and microbiologic analysis of risk 
factors for puerperal endometritis. Obstet Gynecol 1990; 75(3 Pt 1): 402-6. 
Prophylaxis for Caesarean 
section 
Newton ER, Wallace PA. Effects of prophylactic antibiotics on endometrial flora 
in women with postcesarean endometritis. Obstet Gynecol 1998; 92(2): 262-8. 
Participants had 
endometritis at the 
beginning of study  
Ng NK, Sivalingam N. The role of prophylactic antibiotics in caesarean section--a 
randomised trial. Med J Malaysia 1992; 47(4): 273-9. 
Prophylaxis for Caesarean 
section 
Ngoc NTN, Sloan NL, Thach TS, Liem LKB, Winikoff B. Incidence of postpartum 
infection after vaginal delivery in Viet Nam. J Heatlh Popul Nutr 2005; 23(2): 121-
30. 
No data on adverse events 
and antibiotics given after 
birth 
Nice C, Feeney A, Godwin P, et al. A prospective audit of wound infection rates 
after caesarean section in five West Yorkshire hospitals. J Hosp Infect 1996; 33(1): 
55-61. 
Prophylaxis for Caesarean 
section 
Nokiani FA, Akbari H, Rezaei M. Timing of prophylactic antibiotic administration 
in term cesarean section: A randomized clinical trial. Iranian Journal of Clinical 
Infectious Diseases 2009; 4(2): 71-6. 
Prophylaxis for Caesarean 
section 
O'Leary JA, Mullins JH, Andrinopoulos GC. Ampicillin vs. ampicillin-gentamicin 
prophylaxis in high-risk primary cesarean section. The Journal of reproductive 
medicine, 1986. 
Prophylaxis for Caesarean 
section 
Ogasawara KK, Goodwin TM. Efficacy of azithromycin in reducing lower genital 
Ureaplasma urealyticum colonization in women at risk for preterm delivery. The 
Journal of maternal-fetal medicine, 1999.  
More than 10% had preterm 
premature rupture of 
membranes 
Ogasawara KK, Murphy Goodwin T. The efficacy of prophylactic erythromycin in 
preventing vertical transmission of Ureaplasma urealyticum. Am J Perinatol 1997; 
14(4): 233-7. 
More than 10% preterm 
premature rupture of 
membranes 
Ognissanti F, Bucciero A, Conturso R, et al. A comparison of mezlocillin and 
cefotetan in cesarean section prophylaxis: a prospective, randomized study. 
Preliminary results. J Chemother 1989; 1(4 Suppl): 1030-2. 
Prophylaxis for Caesarean 
section 
Oliva GC, Fratoni A, Papadia LS, Tartaglia E, Mancuso S. Antibiotic prophylaxis 
in emergency and elective cesarean section. J Chemother 1989; 1(4 Suppl): 1020-2. 
Prophylaxis for Caesarean 
section 
Owens SM, Brozanski BS, Meyn LA, Wiesenfeld HC. Antimicrobial Prophylaxis 
for Cesarean Delivery Before Skin Incision. Obstet Gynecol 2009; 114(3): 573-9. 
Prophylaxis for Caesarean 
section 
Padilla SL, Spence MR, Beauchamp PJ. Single-dose ampicillin for cesarean 
section prophylaxis. Obstet Gynecol 1983; 61(4): 463-6. 
Prophylaxis for Caesarean 
section 
Periti P, Mazzei T, Periti E. Prophylaxis in gynaecological and obstetric surgery: a 
comparative randomised multicentre study of single-dose cefotetan versus two 
doses of cefazolin. Chemioterapia : international journal of the Mediterranean 
Society of Chemotherapy, 1988.  
Surgical prophylaxis  
Persaud RR, Azad MB, Chari RS, et al. Perinatal antibiotic exposure of neonates in 
Canada and associated risk factors: a population-based study. J Matern-Fetal 
Neonatal Med 2015; 28(10): 1190-5. 
No data on adverse events 
Peterson CM, Medchill M, Gordon DS, Chard HL. Cesarean prophylaxis: a 
comparison of cefamandole and cefazolin by both intravenous and lavage routes, 
and risk factors associated with endometritis. Obstet Gynecol 1990; 75(2): 179-82. 
Prophylaxis for Caesarean 
section 
Phelan JP, Pruyn SC. Prophylactic antibiotics in cesarean section: a double-blind 
study of cefazolin. Am J Obstet Gynecol 1979; 133(5): 474-8. 
Prophylaxis for Caesarean 
section 
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Reference Reason 
Pitt C, Sanchez-Ramos L, Kaunitz AM. Adjunctive intravaginal metronidazole for 
the prevention of postcesarean endometritis: A randomized controlled trial. Obstet 
Gynecol 2001; 98(5): 745-50. 
Prophylaxis for Caesarean 
section 
Polk BF, Schoenbaum SC. Prophylactic antibiotics in obstetrics. Clin Obstet 
Gynecol 1979; 22(2): 379-84. 
Review 
Pothinam S, Chanpoo T, Lumbiganon P. Post-cesarean section puerperal 
morbidity. The incidence and risk factors at Srinagarind Hospital. J Med Assoc 
Thai 1992; 75(3): 173-7. 
Prophylaxis for Caesarean 
section 
Poulain P, Betremieux P, Donnio PY, Proudhon JF, Karege G, Giraud JR. 
Selective intrapartum anti-bioprophylaxy of group B streptococci infection of 
neonates: A prospective study in 2454 subsequent deliveries. Eur J Obstet Gynecol 
Reprod Biol 1997; 72(2): 137-40. 
More than 10% had 
symptoms in labour 
Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal 
disease in the era of maternal screening. Pediatrics 2005; 115(5): 1240-6. 
No data on adverse events  
Rayburn W, Varner M, Galask R. Comparison of moxalactam and cefazolin as 
prophylactic antibiotics during cesarean section. Antimicrob Agents Chemother 
1985; 27(3): 337-9. 
Prophylaxis for Caesarean 
section 
Raymond J, Lopez E, Bonacorsi S, et al. Evidence for transmission of escherichia 
coli from mother to child in late-onset neonatal infection. Pediatr Infect Dis J 2008; 
27(2): 186-8. 
Case report 
Reggiori A, Ravera M, Cocozza E, Andreata M, Mukasa F. Randomized study of 
antibiotic prophylaxis for general and gynaecological surgery from a single centre 
in rural Africa. The British journal of surgery, 1996.  
Surgical prophylaxis  
Rehu M, Jahkola M. Prophylactic antibiotics in Caesarean section: effect of a short 
preoperative course of benzyl penicillin or clindamycin plus gentamicin on 
postoperative infectious morbidity. Ann Clin Res 1980; 12(2): 45-8. 
Prophylaxis for Caesarean 
section 
Renner RM, Renner A, Schmid S, et al. Efficacy of a strategy to prevent neonatal 
early-onset group B streptococcal (GBS) sepsis. J Perinat Med 2006; 34(1): 32-8. 
No data on adverse events 
Rentz AC, Samore MH, Stoddard GJ, Faix RG, Byington CL. Risk factors 
associated with ampicillin-resistant infection in newborns in the era of group B 
streptococcal prophylaxis. Arch Pediatr Adolesc Med 2004; 158(6): 556-60. 
More than 10% 
symptomatic 
(chorioamnionitis and 
prolonged rupture of 
membranes)  
Rijhsinghani A, Savopoulos SE, Walters JK, Huggins G, Hibbs JR. 
Ampicillin/sulbactam versus ampicillin alone for cesarean section prophylaxis: A 
randomized double-blind trial. Am J Perinatol 1995; 12(5): 322-4. 
Prophylaxis for Caesarean 
section 
Roex AJ, Van Loenen AC. Pharmacokinetics of three-dose cefoxitin prophylaxis in 
caesarean section. Pharm Weekbl Sci 1988; 10(6): 281-3. 
Prophylaxis for Caesarean 
section 
Roex AJM, Puyenbroek JI, Van Loenen AC, Arts NFT. Single- versus three-dose 
cefoxitin prophylaxis in caesarean section: A randomized clinical trial. Eur J Obstet 
Gynecol Reprod Biol 1987; 25(4): 293-8. 
Prophylaxis for Caesarean 
section 
Roth P, Schaal JP, Fromentin C, Guerrier T, Maillet R, Colette C. [Comparative 
study of 2 protocols for antibiotic therapy. Maternal-fetal non-specific bacterial 
infections during labor]. Journal de gynécologie, obstétrique et biologie de la 
reproduction, 1990.  
Full-text not in English 
Rothbard MJ, Mayer W, Wystepek A, Gordon M. Prophylactic antibiotics in 
cesarean section. Obstet Gynecol 1975; 45(4): 421-4. 
Prophylaxis for Caesarean 
section 
Rouse DJ, Hauth JC, Andrews WW, Mills BB, Maher JE. Chlorhexidine vaginal 
irrigation for the prevention of peripartal infection: A placebo-controlled 
randomized clinical trial. Am J Obstet Gynecol 1997; 176(3): 617-22. 
Not systemic prophylaxis 
Rudge MV, Atallah AN, Peracoli JC, Tristao Ada R, Mendonca Neto M. 
Randomized controlled trial on prevention of postcesarean infection using 
penicillin and cephalothin in Brazil. Acta Obstet Gynecol Scand 2006; 85(8): 945-
8. 
Prophylaxis for Caesarean 
section 
Saad A, Finan R, Papas S, Anastabiades E. Evaluation of ceftizoxime in the 
prophylaxis of gynecological surgery. Revue Medicale Libanaise 2004; 16(1): 36-
8. 
Surgical prophylaxis and 
timing of antibiotics also 
unclear. 
Sabir S. Infective morbidity following Caesarean section. Specialist 1996; 13(1): 
29-32. 
Prophylaxis for Caesarean 
section 
Saezllorens X, Ahchu MS, Castano E, et al. Intrapartum Prophylaxis with 
Ceftriaxone Decreases Rates of Bacterial-Colonization and Early-Onset Infection 
in Newborns. Clin Infect Dis 1995; 21(4): 876-80. 
More than 10% 
symptomatic (prolonged 
rupture of membranes) 
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Reference Reason 
Saltzman DH, Eron LJ, Tuomala RE, Protomastro LJ, Sites JG. Single-dose 
antibiotic prophylaxis in high-risk patients undergoing cesarean section. A 
comparative trial. J Reprod Med 1986; 31(8): 709-12. 
Prophylaxis for Caesarean 
section 
Schrag SJ, Cutland CL, Zell ER, et al. Risk factors for neonatal sepsis and perinatal 
death among infants enrolled in the prevention of perinatal sepsis trial, Soweto, 
South Africa. Pediatr Infect Dis J 2012; 31(8): 821-6. 
More than 10% 
symptomatic (prolonged 
rupture of membrane, foul 
smelling vaginal discharge) 
Schrag SJ, Hadler JL, Arnold KE, Martell-Cleary P, Reingold A, Schuchat A. Risk 
factors for invasive, early-onset Escherichia coli infections in the era of widespread 
intrapartum antibiotic use. Pediatrics 2006; 118(2): 570-6. 
More than 10% 
symptomatic (intrapartum 
fever, prolonged rupture of 
membrane) 
Schuchat A, Zywicki SS, Dinsmoor MJ, et al. Risk factors and opportunities for 
prevention of early-onset neonatal sepsis: A multicenter case-control study. 
Pediatrics 2000; 105(1): 21-6. 
More than 10% 
symptomatic (intrapartum 
fever, prolonged rupture of 
membrane) 
Sengupta A, Kohli JK. Antibiotic prophylaxis in cesarean section causing 
anaphylaxis and intrauterine fetal death. J Obstet Gynaecol Res 2008; 34(2): 252-4. 
Case report 
Shrestha B, Marhatha R, Giri A, Jaisi S, Maskey U. Surgical site wound infection 
in relation to antibiotic prophylaxis given before skin incision and after cord 
clamping during cesarean delivery. Nepal Med Coll J 2014; 16(2-4): 148-51. 
Prophylaxis for Caesarean 
section 
Simchen E, Shapiro M, Michel J, Sacks TG. The successful use of antibiotic 
prophylaxis in selected high-risk surgical patients under non-trial, everyday 
conditions. J Hosp Infect 1980; 1(3): 211-20. 
Surgical prophylaxis  
Singleton ML. Group B strep prophylaxis: what are we creating? Midwifery Today 
Int Midwife 2007; (81): 18-20. 
Editorial 
Skjeldestad FE, Bjornholt JV, Gran JM, Erisken HM. The effect of antibiotic 
prophylaxis guidelines on surgical-site infections associated with cesarean 
delivery. International Journal of Gynecology and Obstetrics 2014; 128(2): 126-30. 
Prophylaxis for Caesarean 
section 
Smith AM, Cox CWFM. Necrotising fasciitis following caesarean section. Journal 
of Obstetrics and Gynaecology 1992; 12(4): 246-7. 
Case report 
Spandorfer SD, Graham E, Forouzan I. Postcesarean endometritis. Clinical risk 
factors predictive of positive blood cultures. J Reprod Med 1996; 41(11): 797-800. 
Prophylaxis for Caesarean 
section 
Spreafico P, Scian A, Epis A, Vassen L, Bonazzi C, Lovotti M. Cesarean section: 
antibiotic prophylaxis with ceftezole. Chemioterapia 1987; 6(2 Suppl): 613-6. 
Prophylaxis for Caesarean 
section 
Stage AH, Glover DD, Vaughan JE. Low-dose cephradine prophylaxis in obstetric 
and gynecologic surgery. J Reprod Med 1982; 27(3): 113-9. 
Surgical prophylaxis  
Stark MA, Ross MF, Kershner W, Searing K. Case Study of Intrapartum Antibiotic 
Prophylaxis and Subsequent Postpartum Beta-Lactam Anaphylaxis. Jognn 2015; 
44(5): 610-7. 
Case report 
Stiver HG, Forward KR, Livingstone RA. Double blind placebo-controlled 
multicentre comparison of cefoxitin vs cefazolin prophylaxis against post-cesarean 
section infection. Clinical and Investigative Medicine 1982; 5(2-3): 34B. 
Abstract 
Stiver HG, Forward KR, Livingstone RA. Multicenter comparison of cefoxitin 
versus cefazolin for prevention of infectious morbidity after nonelective cesarean 
section. Am J Obstet Gynecol 1983; 145(2): 158-63. 
Prophylaxis for Caesarean 
section 
Stiver HG, Forward KR, Tyrrell DL, et al. Comparative cervical microflora shifts 
after cefoxitin or cefazolin prophylaxis against infection following cesarean 
section. Am J Obstet Gynecol 1984; 149(7): 718-21. 
Prophylaxis for Caesarean 
section 
Sullivan SA, Smith T, Chang E, Hulsey T, Vandorsten JP, Soper D. Administration 
of cefazolin prior to skin incision is superior to cefazolin at cord clamping in 
preventing postcesarean infectious morbidity: a randomized, controlled 
trial.[Erratum appears in Am J Obstet Gynecol. 2007 Sep;197(3):333]. Am J Obstet 
Gynecol 2007; 196(5): 455.e1-5. 
Prophylaxis for Caesarean 
section 
Suonio S, Saarikoski S, Vohlonen I, Kauhanen O. Risk factors for fever, 
endometritis and wound infection after abdominal delivery. Int J Gynaecol Obstet 
1989; 29(2): 135-42. 
Prophylaxis for Caesarean 
section 
Szalontay AS. [Antibiotic prophylaxis in cesarean section]. Revista medico-
chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i, 1997.  
Full-text not in English 
Tassi PG, Tarantini M, Rampinelli F, et al. Piperacillin in antibiotic prophylaxis: a 
single-dose administration for cesarean section. J Chemother 1989; 1(4 Suppl): 
1025-6. 
Prophylaxis for Caesarean 
section 
Antenatal screening for group B Streptococcus in the UK	
	 362 
Reference Reason 
Tassi PG, Tarantini M, Cadenelli GP, Gastaldi A, Benedetti M. Ceftazidime in 
antibiotic prophylaxis for emergency cesarean section: a randomized prospective 
study. Int J Clin Pharmacol Ther Toxicol 1987; 25(10): 582-8. 
Prophylaxis for Caesarean 
section 
Teo SM, Mok D, Pham K, et al. The Infant Nasopharyngeal Microbiome Impacts 
Severity of Lower Respiratory Infection and Risk of Asthma Development. Cell 
Host Microbe 2015; 17(5): 704-15. 
Unclear when antibiotics 
were given and delivery 
mode 
Thigpen BD, Hood WA, Chauhan S, et al. Timing of prophylactic antibiotic 
administration in the uninfected laboring gravida: a randomized clinical trial. Am J 
Obstet Gynecol, 2005.  
Prophylaxis for Caesarean 
section 
Thurman AR, Anca Y, White CA, Soper DE. Post-cesarean delivery infectious 
morbidity: Focus on preoperative antibiotics and methicillin-resistant 
Staphylococcus aureus. Am J Infect Control 2010; 38(8): 612-6. 
Prophylaxis for Caesarean 
section 
To WW, Lau WN. A protocol of selective antibiotic prophylaxis for caesarean 
section based on risk factors. Aust N Z J Obstet Gynaecol 2001; 41(4): 402-6. 
Prophylaxis for Caesarean 
section 
Towers CV, Cart MH, Padilla G, Asrat T. Potential consequences of widespread 
antepartal use of ampicillin. Am J Obstet Gynecol 1998; 179(4): 879-83. 
Unable to distinguish 
mothers treated in labour 
from mother treated in 
pregnancy as well 
Tsai CH, Chen YY, Wang KG, Chen CY, Chen CP. Characteristics of early-onset 
neonatal sepsis caused by Escherichia coli. Taiwan J Obstet Gynecol 2012; 51(1): 
26-30. 
Unable to distinguish 
women who had emergency 
caesarean section from 
those that had elective 
caesarean section 
Tully JL, Klapholz H, Baldini LM, Friedland GH. Perioperative use of cefoxitin in 
primary cesarean section. J Reprod Med 1983; 28(12): 827-32. 
Prophylaxis for Caesarean 
section 
Tuppurainen N, Hallman M. Prevention of neonatal group B streptococcal disease: 
intrapartum detection and chemoprophylaxis of heavily colonized parturients. 
Obstet Gynecol, 1989.  
No data on adverse events 
Turner MJ. Prophylactic antibiotics for caesarean section and hysterectomy. 
Journal of Obstetrics and Gynaecology 1994; 14(1): 54-5. 
Editorial  
Tzingounis V, Makris N, Zolotas J. Cefuroxime prophylaxis in caesarean section. 
Pharmatherapeutica 1982; 3(2): 140-2. 
Prophylaxis for Caesarean 
section 
van der Linden MC, van Erp EJ, Ruijs GJ, Holm JP. A prospective randomized 
study comparing amoxycillin/clavulanate with cefuroxime plus metronidazole for 
perioperative prophylaxis in gynaecological surgery. Eur J Obstet Gynecol Reprod 
Biol 1993; 50(2): 141-5. 
Surgical prophylaxis  
Van Scoy RE. Prophylactic antibiotic therapy: its use and abuse. Clin Obstet 
Gynecol 1976; 19(3): 721-33. 
Review 
Varner MW, Weiner CP, Petzold CR, Galask RP. Comparison of cefotetan and 
cefoxitin as prophylaxis in cesarean section. Am J Obstet Gynecol, 1986.  
Prophylaxis for Caesarean 
section 
von Mandach U, Huch R, Malinverni R, Huch A. Ceftriaxone (single dose) versus 
cefoxitin (multiple doses): success and failure of antibiotic prophylaxis in 1052 
cesarean sections. J Perinat Med 1993; 21(5): 385-97. 
Prophylaxis for Caesarean 
section 
Wali A, Taj Z, Abbas Z. Chemoprophylaxis in caesarean sections. Journal of the 
College of Physicians and Surgeons Pakistan 2002; 12(2): 78-81. 
Prophylaxis for Caesarean 
section 
Wallace RL, Yonekura ML. The use of prophylactic antibiotics in patients 
undergoing emergency primary cesarean section. Am J Obstet Gynecol 1983; 
147(5): 533-6. 
Prophylaxis for Caesarean 
section 
Wax JR, Hersey K, Philput C, et al. Single dose cefazolin prophylaxis for 
postcesarean infections: before vs. after cord clamping. J Matern Fetal Med 1997; 
6(1): 61-5. 
Prophylaxis for Caesarean 
section 
Wegienka G, Havstad S, Zoratti EM, Kim H, Ownby DR, Johnson CC. Combined 
effects of prenatal medication use and delivery type are associated with eczema at 
age 2 years. Clin Exp Allergy 2015; 45(3): 660-8 
Timing of antibiotics 
unclear and unable to 
distinguish between 
antibiotics and antifungals 
Weinberg M, Fuentes JM, Ruiz AI, et al. Reducing infections among women 
undergoing cesarean section in Colombia by means of continuous quality 
improvement methods. Arch Intern Med 2001; 161(19): 2357-65. 
More than 10% participants 
had elective caesarean 
section 
Weissberg SM, Edwards NL, O'Leary JA. Prophylactic antibiotics in cesarean 
section. Obstet Gynecol 1971; 38(2): 290-3. 
Prophylaxis for Caesarean 
section 
Westen EHMN, Kolk PR, Van Velzen CL, et al. Single-dose compared with 
multiple day antibiotic prophylaxis for cesarean section in low-resource settings, a 
Prophylaxis for Caesarean 
section 
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Reference Reason 
randomized controlled, noninferiority trial. Acta Obstet Gynecol Scand 2015; 
94(1): 43-9. 
Wolfe HM, Gross TL, Sokol RJ, Bottoms SF, Thompson KL. Determinants of 
morbidity in obese women delivered by cesarean. Obstet Gynecol 1988; 71(5): 
691-6. 
Prophylaxis for Caesarean 
section 
Wong R, Gee CL, Ledger WJ. Prophylactic use of cefazolin in monitored obstetric 
patients undergoing cesarean section. Obstet Gynecol 1978; 51(4): 407-11. 
Prophylaxis for Caesarean 
section 
Work BA, Jr. Role of preventive antibiotics in patients undergoing cesarean 
section. South Med J 1977; 70 Suppl 1: 44-5. 
Prophylaxis for Caesarean 
section 
Yip SK, Lau TK, Rogers MS. A study on prophylactic antibiotics in cesarean 
sections - Is it worthwhile? Acta Obstet Gynecol Scand 1997; 76(6): 547-9. 
Prophylaxis for Caesarean 
section 
Yonekura ML, Appleman M, Wallace R, Boucher M, Nakamura R. Predictive 
value of amniotic-membrane cultures for the development of postcesarean 
endometritis. Rev Infect Dis 1984; 6 Suppl 1: S157-64. 
Prophylaxis for Caesarean 
section 
Young BC, Hacker MR, Dodge LE, Golen TH. Timing of antibiotic administration 
and infectious morbidity following cesarean delivery: incorporating policy change 
into workflow. Arch Gynecol Obstet 2012; 285(5): 1219-24. 
Prophylaxis for Caesarean 
section 
Young R, Platt L, Ledger W. Prophylactic cefoxitin in cesarean section. Surg 
Gynecol Obstet 1983; 157(1): 11-4. 
Prophylaxis for Caesarean 
section 
Zhang J, Johnson CD, Hoffman M. Cervical cerclage in delayed interval delivery 
in a multifetal pregnancy: a review of seven case series. Eur J Obstet Gynecol 
Reprod Biol 2003; 108(2): 126-30. 
Review of case series about 
cervical cerclage for 
multiple births 
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Appendix 11. Summary of the included studies in the systematic review on the adverse events from intrapartum antibiotic prophylaxis (objective 3) 
 
Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
Studies investigating outcome as adverse events of IAP  
Aloisio 2014304 
Italy 
Cohort 52 infants  
6-7 days old 
(26 treated 
26 not treated) 
GBS 
prophylaxis 
Intrapartum 2g 
ampicillin at 
least 4h before 
delivery, 
followed by 1g 
every 4h until 
delivery 
Gut microbiota: 
E. coli 
 
Bacteroides fragilis 
 
Bifidobacterium spp. 
 
Clostridium difficile 
 
Lactobacillus spp. 
 
 
M: 8.18  
(R: 4.09-12.70) 
M: 8.17  
(R: 4.68-11.99) 
M: 5.85  
(R: 3.24–7.79) 
M: 3.89  
(R: 3.12–4.80) 
M: 6.69  
(R: 5.40–8.93) 
 
M: 9.03  
(R: 5.61-11.78) 
M: 8.53  
(R: 5.22-11.16) 
M: 7.29  
(R: 4.12–10.95) 
M: 3.70  
(R: 2.85–5.46) 
M: 6.73  
(R: 5.45–8.20) 
 
NS 
 
NS 
 
p=0.001 
 
NS 
 
NS 
 
 
 
None 
Aloisio 2016305 
Italy 
Prospective 
cohort 
20 infants 
6-7 days old  
(10 treated 10 
not treated) 
GBS 
prophylaxis  
Intrapartum 2g 
ampicillin at 
least 4 h before 
delivery, 
followed by 1 g 
every 4 h until 
delivery  
Gut microbiota 
composition: 
Actinobacteria  
Bacteriodetes 
Proteobacteria 
Firmicutes 
 
 
0.4% 
16.0% 
54.7% 
- 
 
 
3.8% 
47.7% 
15.5% 
- 
 
 
p< 0.05 
p< 0.05 
p< 0.05 
- 
 
None 
None 
None 
- 
Gut microbiota 
composition:  
Bifidobacteriaceae 
genus 
Other microbial 
genus  
 
 
0.02% 
 
 
6.469% 
 
p< 0.05 
 
non-significant None 
Gut microbiota: 
Sample richness and 
biodiversity  
Alpha diversity 
The control group showed a more complex microbial profile 
compared with the IAP group who had a reduced level of 
richness and biodiversity: Chao1 and Shannon indexes: 
p=0.0081 and p=0.036, respectively; Bray-Curtis index: p > 
0.05.  
Beta diversity 
Significant phylogenetic and relative abundance difference: 
unweighted UniFrac distance, p< 0.05. Principal coordinate None 
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Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
analysis based on Weighted and Unweighted UniFrac 
distances at genus level shows segregation along axis1 for 
both UniFrac indices, indicating a separation in two clusters 
due to IAP treatment. 
Diversity at bacterial family level 
A more complex profile in control compared with IAP group 
in terms of biodiversity, with a more equal distribution at 
family/genus level. The IAP group had a lower number of 
bacterial families with some cases composed almost 
exclusively by Enterobacteriaceae family members 
(Proteobacteria) that can reach over 90% of relative 
abundance and a few samples are even characterised by the 
presence of Streptococcaceae family (with an average of 
13%). 
Arboleya 2015306 
Spain 
Cohort 27 preterm 
infants  
2-90 days old 
(14 treated, 13 
not treated) 
Indication not 
known 
1 mother 
received a single 
dose of 
penicillin, and 1 
mother received 
1 dose of 
ampicillin every 
6 hours for 3 
days. 12 
mothers 
received 
ampicillin plus 
erythromycin 
[between 2 and 
24 doses of each 
antibiotic) 
 
Gut microbiota 
composition 
Cluster analysis 
Day 2: Higher percentage of sequences from Leuconostaceae 
in controls. 
Day 10: Higher percentage of sequences from 
Micrococcaceae and Propionibacteriaceae in controls. 
Day 30: Higher relative amounts of Comamonadaceae, 
Staphylococcaceae, and unclassified Bacilli in controls. 
Higher Bifidobacteriaceae, Streptococcaceae, unclassified 
Actinobacteria, and unclassified Lactobacillales (p< 0.05) in 
controls. 
Lower percentage of Enterobacteriaceae in controls (p< 0.05) 
Day 90: Most differences disappeared except in 
Ruminococcaceae microbial group (differences unclear) 
Quantitative PCR: 
Day 2 and 10: No significant differences 
Day 30: Higher amounts of Staphylococcaceae in control. 
Lower amounts of Enterobacteriaceae and total bacteria in 
control. 
Day 90: higher amounts of bifidobacteria in control. None 
Arboleya 2016307 
Spain 
Cohort (same 
cohort as 
27 preterm 
infants  
Indication not 
known 
Gut microbiota 
composition 
Day 1: no statistically significant differences on the bacterial 
phyla None 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
above 
Arboleya 
2015 study) 
2-90 days old 
(14 treated, 13 
not treated) 
(same cohort 
as above) 
1 mother 
received a single 
dose of 
penicillin, and 1 
mother received 
1 dose of 
ampicillin every 
6 hours for 3 
days. 12 
mothers 
received 
ampicillin plus 
erythromycin 
[between 2 and 
24 doses of each 
antibiotic) 
Day 30: higher relative frequency of Actinobacteria phylum 
(p< 0.05) and Firmicutes phylum (p< 0.01) in controls. Lower 
frequency of Proteobacteria phylum in controls. Higher levels 
of acetic (p=0.075) and total (p=0.060) short chain fatty acids 
in controls. 
Ashkenazi-
Hoffnung 2011308 
Israel 
Case-control 195 infants  
7-90 days old 
(17 treated, 
178 not 
treated) 
GBS 
prophylaxis 
94% ampicillin 
 
Late-onset serious 
bacterial infections 8 63 
OR per dose of IAP: 
5.19 (0.01-93.11) 
Infant age, 
maternal age 
birth weight, 
gestational age, 
type of delivery, 
and GBS status 
had no 
significant 
effect. 
Number of 
doses, time from 
antibiotic 
administration 
to delivery 
Ampicillin resistant 
late-onset serious 
bacterial infections 
85% = 14.45/17 
(Note: Numbers 
do not add up - 
14 people would 
be 82% and 15 63% = 112/178 p=0.19 
None – 
“Multivariate 
logistic 
regression did 
not identify any 
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Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
people would be 
88%) 
variable that was 
significantly 
associated with 
increased risk of 
resistance to 
ampicillin or 
FGCs” 
First-generation 
cephalosporin 
resistant late-onset 
serious bacterial 
infections 
57% = 9.69/17  
(Note: Numbers 
do not add up - 9 
people would be 
53% and 10 
people would be 
59%) 26% = 46/178 p=0.19 
None – 
“Multivariate 
logistic 
regression did 
not identify any 
variable that was 
significantly 
associated with 
increased risk of 
resistance to 
ampicillin or 
FGCs” 
First-generation 
cephalosporin 
resistance in UTI 
only 
75% (unable to 
calculate 
numbers) 
23.5% (unable to 
calculate 
numbers) p=0.04 None 
Ampicillin resistant 
E. coli only 
100% (unable to 
calculate 
numbers) 
54.5% (unable to 
calculate 
numbers) p=0.14 None 
First-generation 
cephalosporin 
resistant E. coli only 
60% (unable to 
calculate 
numbers) 
22.7% (unable to 
calculate 
numbers) p=0.21 None 
Gentamicin or third 
generation 
cephalosporin 
resistance 0 0 - - 
Balter 2003309 
US 
Retrospective 
cohort 
261 infants  5 minute APGAR 
score 
Median: 8  
IQR: 8-9 
Median: 8  
IQR: 8-9 - 
None 
 
Antenatal screening for group B Streptococcus in the UK	
	 368
Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
(81 treated, 
180 not 
treated) 
 
GBS 
prophylaxis 
(59%) 
Other reasons 
(39%) 
Maternal fever 
(6%) 
Antibiotic not 
reported 
Complete blood 
count 21 17 RR: 2.75(1.53–4.92) 
None 
 
Blood culture drawn 10 10 RR: 2.22 (0.96–5.13) 
None 
 
Urine culture via 
catheterisation 2 1 
RR: 4.44 (0.41-
48.32) 
None 
 
Any urine culture 4 2 
RR: 4.44 (0.83-
23.78) 
None 
 
Chest radiograph 3 8 RR: 0.83 (0.23-3.06) 
None 
 
Infant given 
antibiotics within 7 
days 6 8 RR:  1.67 (0.60-4.65) 
None 
 
Infant given 
intravenous catheter 4 8 RR: 1.11 (0.34-3.58) 
None 
 
Infant in NICU 3 7 RR: 0.95 (0.25-3.59) None 
Mechanical 
ventilation 1 0 - None 
Supplemental oxygen 5 9 RR: 1.23 (0.43-3.57) None 
Hospitalisation ≥ 48 
hours 14 12 RR: 2.59 (1.26-5.35) None 
Hospitalisation > 72 
hours 14 17 RR: 1.83 (0.95-3.53) None 
Length of 
hospitalisation 
56.8 hours 
median 47 hours median p=0.02 None 
Briody 2016310 
US 
Retrospective 
cohort 
165 
intrapartum 
women  
(73 received 
‘appropriate’ 
IAP, 92 
received 
GBS 
prophylaxis 
Appropriate 
IAP:  Penicillin, 
Cefazolin 
Inappropriate 
IAP:  
Clindamycin, 
Neonate placed on 
antibiotics 3 4 RR: 0.94 (0.22-4.09) None 
Hospital stay > 2 
days 25 22 RR: 1.43 (0.88-2.32) None 
Hospital stay > 3 
days 15 16 RR: 1.18 (0.63-2.23) None 
5 minute APGAR 
score M: 9 (R: 5-10) M: 9 (R: 3-10) p=0.24 None 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
‘inappropriate’ 
IAP) 
Erythromycin, 
Vancomycin 
Number of blood 
cultures performed M: 2 (SD: 2.7) M: 9 (SD: 9.9) p=0.11 None 
Corvaglia 2016311  
Italy 
Prospective 
cohort 
84 infants 
7-30 days old 
(35 treated, 49 
not treated) 
GBS 
Prophylaxis 
Intravenous 
ampicillin every 
4 hours until 
delivery (first 
dose 2 g, 
following doses 
1 g each) 
Gut Microbiota 
composition: 
Bifidobacterium spp. 
7 days 
Bifidobacterium spp. 
30 days 
Lactobacillus spp. 
7 days 
Lactobacillus spp. 
30 days 
Bacteroides fragilis 
spp. 
7 days 
Bacteroides fragilis 
spp. 
30 days 
 
Median: 6.01 
(IQR: 5.51–6.98) 
Median: 8.41 
(IQR: 7.71-8.80) 
Median: 5.56 
(IQR: 4.94-6.14) 
Median: 5.29 
(IQR: 4.68-6.01) 
Median: 7.71 
(IQR: 5.80-9.33) 
 
 
Median: 7.36 
(IQR 5.80-9.09) 
 
Median: 7.80 
(IQR: 6.61–8.26] 
Median: 8.39 
(IQR: 7.96-8.86) 
Median: 5.45 
(IQR: 4.81-6.14) 
Median: 5.25 
(IQR: 4.60-6.15) 
Median: 7.75 
(IQR: 5.87-9.61) 
 
 
Median: 8.51 
(IQR: 5.86-9.37) 
 
p=0.000 
 
p=0.363 
 
p=0.872 
 
p=0.932 
 
p > 0.05 
 
 
 
p > 0.05 
 
Feeding 
Cox 1996312 
US 
Randomised 
controlled 
trial 
78 intrapartum 
women  
(39 treated, 39 
not treated) 
Preterm labour 
2g ampicillin 
and 1g 
sulbactam 
parenterally 
every 6 hours 
for 8 doses, 
followed by 
ampicillin-
clavunate 
250mg orally 
every 8 hours 
for 5 days. 
Symptomatic 
vulvovaginitis caused 
by Candida albicans 27 Not stated - - 
Pseudo-membranous 
enterocolitis caused 
by Clostridium 
difficile 1 Not stated - - 
Dinsmoor 2005313 
US 
Retrospective 
cohort 
435 mother-
infant pairs 0-
136 for GBS 
Prophylaxis. 
Other mothers 
Neonatal thrush 
 21 18 OR: 1.87 (0.97-3.63) None 
Maternal thrush 22 17 OR: 2.1 (1.08-4.08) None 
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Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
1 month post-
partum  
(173 treated, 
262 not 
treated) 
received 
antibiotics for 
other indications 
 
Total candidiasis 26 20 OR: 2.14 (1.15-3.97) None 
Glasgow 2005314 
US 
Case-control 182 infants  
7-90 days old 
(62 treated, 
120 not 
treated) 
Indication not 
known 
Penicillin, 
ampicillin, or 
broad spectrum Late-onset serious 
bacterial infection 
37 
Penicillin only: 
10/23 
Broad-spectrum: 
29/39 
53 
80 
 
61 
 
OR: 1.96 (1.05–3.66) 
OR: 0.95 (0.37-2.44) 
 
OR: 4.95 (2.04–
11.98) 
 
Hospital of 
delivery, 
maternal 
chorioamnionitis 
and 
breastfeeding 
Ampicillin-resistant 
late-onset serious 
bacterial infections 
24 
Penicillin only: 
4/9 
Ampicillin only: 
12/18 
Other IAP: 8/10 
13 
33 
 
25 
 
29 
OR: 5.7 (2.3–14.3) 
OR: 2.5 (0.6-10.6) 
 
OR: 6.2 (1.9-19.7) 
 
OR: 12.3 (2.3-65.5) 
Hospital of 
delivery 
Ampicillin resistant 
UTI infections Not reported Not reported OR: 4.3 (1.6–11.7) 
Hospital of 
delivery 
Other serious 
bacterial infections 
(meningitis, 
omphalitis, and 
bacteraemia without 
UTI) Not reported Not reported OR: 25 (1.8–346) 
Hospital of 
delivery 
Gordon 1995315 
US 
Randomised 
controlled 
trial 
117 
intrapartum 
women 
(58 treated, 59 
not treated) 
Preterm labour 
Ceftizoxime for 
5 days or 3 days 
Bleeding 
abnormalities 0 - - - 
Clostridium difficile 
colitis 0 - - - 
Multi-resistant 
bacterial infections 0 - - - 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
Jaureguy 2004316 
France 
Prospective 
cohort 
50 infants  
3 days old  
(25 treated, 25 
not treated) 
GBS 
Prophylaxis 
Intravenous 2g 
amoxicillin at 
the time of 
labour and then 
1g every 4 h 
until delivery 
Gut microbiota: 
Numbers colonised 
with: 
Enterobacteria 
Enterococci 
Staphylococci 
Bacteroides 
Clostridium 
Bifidobacterium 
 
 
 
13 
15 
21 
13 
3 
6 
 
 
 
16 
17 
22 
7 
10 
12 
 
 
p=0.58 
p=0.73 
p=1.00 
p=0.15 
p=0.04 
p=0.18 None 
Gut microbiota 
composition (log 
CFU/gram): 
Enterobacteria 
 
Enterococci 
 
Staphylococci 
 
Bacteroides 
 
Clostridium 
 
Bifidobacterium 
 
 
 
Median: 8.4  
(R: 3.3–9.5) 
Median 8.3  
(R: 3.6–10.3) 
Median: 6.5  
(R: 3.6–8.0) 
Median: 8.0  
(R: 6.3–10.3) 
Median: 5.3  
(R: 4.3–5.8) 
Median: 8.2  
(R: 4.3–9.5) 
 
 
 
Median: 9.2  
(R: 3.3–9.8) 
Median: 7.3  
(R: 3.3–9.5) 
Median: 7.0  
(R: 4.0–9.3) 
Median: 7.9  
(R: 3.6–9.6) 
Median: 6.2  
(R: 3.6–8.1) 
Median: 8.5  
(R: 6.9-10.3) 
 
 
 
p=0.18 
 
p=0.78 
 
p=0.53 
 
p=0.12 
 
p=0.01 
 
p=0.10 None 
Amoxicillin-resistant 
Enterobacteria 10 12 RR: 0.83 (0.44-1.56) None 
Amoxicillin-resistant 
E. coli 6 11 RR: 0.55 (0.24-1.25) 
None 
 
Kampikaho 1993317 
Uganda 
Quasi-
randomised 
controlled 
trial 
660 
intrapartum 
women  
(330 treated, 
330 not 
treated) 
Post-partum 
infection 
prevention 
1g streptomycin 
or 0.8MU 
penicillin Side effects 0 - - - 
Antenatal screening for group B Streptococcus in the UK	
	 372
Reference 
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Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
Keettel 1949319 
US 
Controlled 
trial 
895 
intrapartum 
women  
(465 treated, 
430 not 
treated) 
Post-partum 
infection 
prevention 
300,000/600,000 
units of 
penicillin at the 
indication of 
labour and then 
after 24-hour 
intervals. 
Mild urticaria 7 - - - 
General urticaria 
 
2 (8-12 days, 
600,000 units) - - - 
Local allergic 
manifestations 5 (900,000 units) - - - 
Abscess formations at 
site of injections 
0 
 - - - 
Discomfort following 
injections 
Relatively 
uncommon and 
never severe or 
persistent - - - 
Keettel 1950318 
US 
Controlled 
trial 
773 
intrapartum 
women  
(382 treated, 
391 not 
treated) 
Post-partum 
infection 
prevention 
600,000 units of 
penicillin at the 
indication of 
labour, and then 
after 24-hour 
intervals. 
General urticaria 
 1 (8 days) - - - 
Local allergic 
manifestations 1 - - - 
Abscess formations at 
the site of injections 0 - - - 
Kenyon 2008320 
UK 
Factorial 
randomised 
trial 
3173 children  
0-7 years old 
(numbers 
differ for 
outcomes – 
see treatment 
column) 
Spontaneous 
preterm labour 
375 mg 
amoxicillin–
clavulanate 
(n=763), 250 mg 
erythromycin 
(n=785), 
amoxicillin–
clavulanate and 
erythromycin 
(n=796), double 
placebo (n=735) 
 
Mild functional 
impairment 
 
ERY and AMC: 
181/769 
ERY: 191/785 
AMC: 168/763 
151/735 OR: 1.00 (reference) 
OR: 1.24 (0.96–1.60) 
 
OR: 1.29 (1.00–1.65) 
OR: 1.10 (0.85–1.42) 
Maternal 
baseline, social 
class, and other 
factors 
Moderate functional 
impairment 
 
ERY and AMC: 
91/769 
ERY: 94/785 
AMC: 85/763 
77/735 OR: 1.00 (reference) 
OR: 1.22 (0.88–1.70) 
 
OR: 1.24 (0.89–1.72) 
OR: 1.09 (0.78–1.53) 
Maternal 
baseline, social 
class, and other 
factors 
Severe functional 
impairment 
 
ERY and AMC: 
53/769 
ERY: 48/785 
47/735 OR: 1.00 (reference) 
OR: 1.17 (0.77–1.77) 
 
OR: 1.04 (0.68–1.59) 
Maternal 
baseline, social 
class, and other 
factors 
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IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
AMC: 46/763 OR: 0.97 (0.63–1.49) 
Any functional 
impairment 
 
ERY and AMC: 
325/769 
ERY: 333/785 
AMC: 299/763 
275/735 OR: 1.00 (reference) 
 
OR: 1.22 (1.00–1.51) 
OR: 1.23 (1.00–1.51) 
OR: 1.08 (0.88–1.33) 
Maternal 
baseline, social 
class, and other 
factors 
Three or more 
abnormal attributes 
 
ERY and AMC: 
72/769 
ERY: 59/785 
AMC: 75/763 
74/735 OR: 1.00 (reference) 
 
OR: 0.92 (0.66–1.30) 
OR: 0.73 (0.51–1.04) 
OR: 0.97 (0.69–1.37) 
Maternal 
baseline, social 
class, and other 
factors 
Cerebral palsy 
 
ERY and AMC: 
35/769 
ERY: 18/785 
AMC: 15/763 
12/735 OR: 1.00 (reference) 
 
OR: 2.91 (1.50–5.65) 
OR: 1.42 (0.68–2.98) 
OR: 1.22 (0.57–2.62) 
Maternal 
baseline, social 
class, and other 
factors 
Any 
erythromycin, 
250mg 
(n=1554), no 
erythromycin 
(n=1498) 
Functional 
impairment 
None: 896 
Mild: 372 
Moderate: 185 
Severe: 101 
Any: 658 
Three or more 
abnormal 
attributes: 131 
None: 924 
Mild: 319 
Moderate: 162 
Severe: 93 
Any: 574 
Three or more 
abnormal 
attributes: 149 
OR: 1.00 (reference) 
OR: 1.20 (1.01–1.43) 
OR: 1.18 (0.94–1.48) 
OR: 1.12 (0.83–1.51) 
OR: 1.18 (1.02–1.37) 
OR: 0.83 (0.65–1.07) 
 
 
Maternal 
baseline, social 
class, and other 
factors 
Behaviour 
Emotional 
symptoms: 327 
Conduct 
problems: 480 
Hyperactivity: 
424 
Peer problems: 
405 
Prosocial 
behaviour: 122 
Emotional 
symptoms: 330 
Conduct 
problems: 420 
Hyperactivity: 
415 
Peer problems: 
391 
Prosocial 
behaviour: 99 
OR: 0.94 (0.79–1.12) 
OR: 1.15 (0.98–1.34) 
OR: 0.98 (0.84–1.15) 
 
OR: 1.00 (0.85–1.17) 
OR: 1.20 (0.91–1.59) 
 
OR: 1.03 (0.87–1.21) 
 
OR: 1.13 (0.95–1.35) 
Maternal 
baseline, social 
class, and other 
factors 
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IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
Overall 
difficulties: 384 
Impact on 
families: 334 
Overall 
difficulties: 363 
Impact on 
families: 292 
Any 
erythromycin, 
250mg 
(n=1611), no 
erythromycin 
(n=1562) 
Cerebral palsy 53 27 OR: 1.93 (1.21–3.09) 
Maternal 
baseline, social 
class, and other 
factors 
Seizures 149 116 OR: 1.27 (0.99–1.64) 
Maternal 
baseline, social 
class, and other 
factors 
Seizures on 
prescribed medication 27 17 OR: 1.55 (0.84–2.85) 
Maternal 
baseline, social 
class, and other 
factors 
Hydrocephalus with 
shunt 2 3 OR: 0.65 (0.11–3.87) 
Maternal 
baseline, social 
class, and other 
factors 
ADHD from SDQ or 
parental report 120 116 OR: 1.0 (0.77–1.31) 
Maternal 
baseline, social 
class, and other 
factors 
Other developmental 
problems 10 15 OR: 0.64 (0.29–1.44) 
Maternal 
baseline, social 
class, and other 
factors 
Wheezing in last year 295 295 OR: 0.96 (0.81–1.15) 
Maternal 
baseline, social 
class, and other 
factors 
Medication for chest 
problems in last year 262 280 OR: 0.89 (0.74–1.07) 
Maternal 
baseline, social 
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IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
class, and other 
factors 
Admission to hospital 
in last year 243 202 OR: 1.20 (0.98–1.46) 
Maternal 
baseline, social 
class, and other 
factors 
Admission for chest 
problems 32 38 OR: 0.81 (0.51–1.31) 
Maternal 
baseline, social 
class, and other 
factors 
Diabetes 0 2 - - 
All bowel disorders 64 38 OR: 1.66 (1.10–2.49) 
Maternal 
baseline, social 
class, and other 
factors 
Any 
erythromycin, 
250mg 
(n=2375), no 
erythromycin 
(n=2279) 
Stillbirths 20 24 OR: 0.80 (0.44-1.45) 
Maternal 
baseline, social 
class, and other 
factors 
Deaths in first year 61 41 OR: 1.44 (0.96–2.14) 
Maternal 
baseline, social 
class, and other 
factors 
Deaths after first year 5 5 OR: 0.97 (0.28–3.34) 
Maternal 
baseline, social 
class, and other 
factors 
Total deaths 86 70 OR: 1.19 (0.86–1.63) 
Maternal 
baseline, social 
class, and other 
factors 
Any 
erythromycin, 
250mg 
Educational 
attainment (children 
failing to achieve 
Reading: 377 
Writing: 413 
Maths: 239 
Reading: 367 
Writing: 413 
Maths: 225 
 
 
OR: 1.0 (0.96–1.04) 
Maternal 
baseline, social 
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IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
(n=1641), no 
erythromycin 
(n=1598) 
level 2 or higher in 
national curriculum 
tests) 
OR: 1.0 (0.97–1.04) 
OR: 0.99 (0.96–1.03) 
class, and other 
factors 
Any 
amoxicillin–
clavulanate, 375 
mg (n=1532), no 
amoxicillin–
clavulanate 
(n=1520) Functional 
impairment 
None: 908 
Mild: 349 
Moderate: 176 
Severe: 99 
Any: 624 
Three or more 
abnormal 
attributes: 147 
None: 912 
Mild: 342 
Moderate: 171 
Severe: 95 
Any: 608 
Three or more 
abnormal 
attributes: 133 
OR: 1.00 (reference) 
OR: 1.02 (0.86–1.22) 
OR: 1.03 (0.82–1.30) 
OR: 1.05 (0.78–1.41) 
OR: 1.03 (0.89–1.19) 
OR: 1.11 (0.87–1.42) 
 
 
Maternal 
baseline, social 
class, and other 
factors 
Behaviour 
Emotional 
symptoms: 341 
Conduct 
problems: 454 
Hyperactivity: 
418 
Peer problems: 
396 Prosocial 
behaviour: 112 
Overall 
difficulties: 385 
Impact on 
families: 312 
Emotional 
symptoms: 316 
Conduct 
problems: 446 
Hyperactivity: 
421 
Peer problems: 
400 
Prosocial 
behaviour: 109 
Overall 
difficulties: 362 
Impact on 
families: 314 
OR: 1.09 (0.92–1.30) 
 
OR: 1.01 (0.87–1.18) 
 
OR: 0.98 (0.84–1.15) 
OR: 0.98 (0.83–1.15) 
 
OR: 1.02 (0.78–1.34) 
 
OR: 1.07 (0.91–1.27) 
 
OR: 0.98 (0.82–1.17) 
 
Maternal 
baseline, social 
class, and other 
factors 
Any 
amoxicillin–
clavulanate, 375 
mg (n=1587), no 
amoxicillin–
clavulanate 
(n=1586) 
Cerebral palsy 50 30 OR: 1.69 (1.07–2.67) 
Maternal 
baseline, social 
class, and other 
factors 
Seizures 144 121 OR: 1.21 (0.94–1.56) 
Maternal 
baseline, social 
class, and other 
factors 
Seizures on 
prescribed medication 22 22 OR: 1.0 (0.55–1.81) 
Maternal 
baseline, social 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
class, and other 
factors 
Hydrocephalus with 
shunt 4 1 
OR: 4.01 (0.45–
35.87) 
Maternal 
baseline, social 
class, and other 
factors 
ADHD from SDQ or 
parental report 128 108 OR: 1.20 (0.92–1.57) 
Maternal 
baseline, social 
class, and other 
factors 
Other developmental 
problems 8 17 OR: 0.47 (0.20–1.09) 
Maternal 
baseline, social 
class, and other 
factors 
Wheezing in last year 291 299 OR: 0.97 (0.81–1.16) 
Maternal 
baseline, social 
class, and other 
factors 
Medication for chest 
problems in last year 257 285 OR: 0.88 (0.73–1.06) 
Maternal 
baseline, social 
class, and other 
factors 
Admission to hospital 
in last year 220 225 OR: 0.97 (0.80–1.19) 
Maternal 
baseline, social 
class, and other 
factors 
Admission for chest 
problems 33 37 OR: 0.89 (0.55–1.43) 
Maternal 
baseline, social 
class, and other 
factors 
Diabetes 2 0 - - 
All bowel disorders 54 48 OR: 1.13 (0.76–1.68) 
Maternal 
baseline, social 
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IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
class, and other 
factors 
Any 
amoxicillin–
clavulanate, 
375mg 
(n=2304), no 
amoxicillin–
clavulanate 
(n=2350) 
Stillbirths 20 24 OR: 0.85 (0.47–1.54) 
Maternal 
baseline, social 
class, and other 
factors 
Deaths in first year 49 53 OR: 0.94 (0.63–1.39) 
Maternal 
baseline, social 
class, and other 
factors 
Deaths after first year 6 4 OR: 1.53 (0.43–5.42) 
Maternal 
baseline, social 
class, and other 
factors 
Total deaths 75 81 OR: 0.94 (0.68–1.30) 
Maternal 
baseline, social 
class, and other 
factors 
Any 
amoxicillin–
clavulanate, 375 
mg (n=1608), no 
amoxicillin–
clavulanate 
(n=1631) 
Educational 
attainment (children 
failing to achieve 
level 2 or higher in 
national curriculum 
tests) 
Reading: 366 
Writing: 395 
Maths: 230 
Reading: 378 
Writing: 431 
Maths: 234 
OR: 0.99 (0.95–1.03) 
OR: 0.99 (0.95–1.02) 
OR: 0.99 (0.95–1.03) 
Maternal 
baseline, social 
class, and other 
factors 
Keski-Nisula 
2013321 
Finland 
Prospective 
cohort 
45 mother-
infant pairs 
immediately 
after birth  
(17 treated, 28 
not treated) 
Intrapartum 
antibiotics 
according to 
hospital protocol 
including GBS, 
PROM, 
caesarean 
section, 
chorioamnionitis 
Lactobacillus-
dominant mixed flora 
transmission 1 13 
OR: 0.08 (0.007–
0.80) 
Fetal sex, 
maternal 
smoking during 
pregnancy, 
meconium in 
amniotic fluid, 
duration of 
ruptured 
membranes 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
Intravenous 
penicillin or 
amoxicillin in 
vaginal 
deliveries and 
intravenous 
second-
generation 
cephalosporins 
in Caesarean 
deliveries 
Keuchkerian 
2005322 
Uruguay 
Randomised 
controlled 
trial 
96 intrapartum 
women  
(47 treated, 49 
not treated) 
Preterm labour 
Amoxicillin 
1000 mg 
sulbactam 500 
mg IV every 8 h 
during the first 
48 h and they 
continued to 
receive an oral 
intake of 
amoxicillin 250 
mg sulbactam 
250 mg every 8 
h for 5 days 
Palpitations, flushes, 
nausea and vomiting 2 0 - - 
Asymptomatic 
bacteriuria 0 1 - - 
Urinary infection 1 0 - - 
Lin 2006296 
US 
Retrospective 
cohort 
1594 infants 
(213 treated, 
1378 not 
treated) 
GBS 
prophylaxis  
Penicillin 
Respiratory distress 44 95 RR: 2.62 (1.79–3.83) 
Mother’s race, 
mother’s race 
not known, age 
<20 yr, 
primigravida, 
fever during 
labour, 
caesarean 
delivery, 
Medicaid/public 
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IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
assistance and 
positive prenatal 
culture for GBS, 
missing values 
of rupture of 
membranes and 
prenatal cultures 
the degree of 
colonisation, 
gestational age 
by week, race, 
insulin 
requirement 
during 
pregnancy, 
suspected 
infection during 
labour, 
intrauterine 
catheter, not 
known Pitocin 
use, not known 
prenatal GBS 
culture 
Discharge diagnosis 
of a respiratory 
disorder 12 39 RR: 1.96 (1.04-3.69) 
None 
 
Mazzola 2016194 
Italy 
Prospective 
cohort 
26 infants  
7-30 days old  
(13 treated [7 
breastfed and 
6 mixed fed]  
13 not treated 
[7 breastfed 
GBS 
prophylaxis  
2g ampicillin at 
least 4 h before 
delivery, 
followed by 1g 
to maximum 4g.  Gut microbiota 
composition 
At the phylum level, in breastfed infants, at day 7 
Actinobacteria were not detected in IAP infants and were 
present at 17% in control infants (p< 0.001) and there were 
significantly higher abundances of Proteobacteria in IAP 
infants than controls (p< 0.062).   
IAP infants were dominated by genera belonging to the 
Enterobacteriaceae family (p=0.044), particularly 
Escherichia, which accounted for 52% of the total relative None 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
and 6 mixed 
fed]) 
abundance, compared with 14% in the control group. 
Bifidobacteria were not detected in any of the IAP infants at 
day 7 but 16% of the relative abundance from control infants 
(p=0.001), and control infants also had higher levels of 
Bacteroides than IAP infants (20% vs. 7%), although not 
statistically significant (p=0.078). 
At day 30, Bifidobacteria numbers appeared to have 
recovered in the IAP group accounting for 6% of the relative 
abundance (p=0.025) in both groups; Enterobacteriaceae 
continued to dominate in IAP infants compared with control 
infants (44% vs.16%); Additionally, there was a significantly 
higher level of the Veillonellaceae family in control infants 
compared with IAP infants (p=0.035).  
Veillonella is affected by the antibiotic treatment, as it does 
not increase in the IAP group between 7 and 30 days, whereas 
a strong increase is shown within control samples at the same 
sampling times in control samples.  
At the phylum level, in mixed-fed infants, at day 7 there was a 
higher abundance of Proteobacteria, (37% vs. 17%) and 
Firmicutes (41% versus 29%) in infant and control infants. On 
the other hand, Actinobacteria (8% vs. 1%) and Bacteroidetes 
(36% vs. 21%) were highest in the control compared with IAP 
group.  
At day 7, IAP infants contained high abundances of organisms 
belonging to family Enterobacteriaceae (35% vs. 17%), and 
Streptococcus (32% vs. 10%) compared with the control 
group. Control infants had higher levels of Bacteroides, (32% 
vs. 13%), and Bifidobacterium (5% vs. 1%), compared with 
IAP infants. 
By day 30, Actinobacteria levels increased in the IAP infants 
to 7% and Firmicutes and Proteobacteria reduced to 30% and 
28%. Bacteroidetes were the dominant phylum in both groups, 
representing 26% in control and 34% in IAP treated infants. 
At genus level, the microbiota composition was more uniform 
than that at day 7. Members of the Enterobacteriaceae family 
fall to 28% and Streptococcus was significantly reduced to 8% 
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Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
(p=0.042); The Lachnospiraceae family, absent at day 7 in 
IAP treated infants, was detected at 4% at day 30. 
Bifidobacteria significantly increased in IAP infants from 0% 
at day 7 to 6% at day 30, (p=0.013) and remain highest in 
control infants (19%).  
Gut microbiota 
sample richness and 
biodiversity 
Alpha diversity  
In breastfed infants, at day 7 there was a significantly lower 
diversity in breastfed IAP infants compared with breast fed 
control (Chao1 p=0.012), Simpson p=0.035, Shannon 
p=0.0082 and observed species p=0.021). By day 30 the Chao 
index and observed species increased in the IAP infants, 
although this was not a significant increase, and the Simpson 
and Shannon indices remained largely unchanged. 
In mixed-fed infants, at day 7 there were no significant 
differences in diversity although Chao1, Shannon and 
observed species indices were highest in the control infants. 
At day 30, alpha diversity was similar in both MF groups 
Beta diversity  
In breastfed infants, at day 7, principal coordinate analysis 
(PCoA) plots constructed using unweighted UniFrac distance 
matrices shows clear separation IAP samples from those of 
the Control infants. By day 30, no clear separation was 
observed, suggesting that microbial communities became 
more uniform over time. 
In mixed-fed infants, principal coordinate analysis showed no 
clustering of samples from either IAP or control groups at day 
7 or 30.  None 
Absolute 
quantification of total 
bacteria and 
bifidobacteria  
Total bacteria numbers were similar across the four groups, 
ranging between 9.38 to 9.71 at day 7 and 9.53 to 9.83 log 
CFU/g at day 30, with no significant differences between 
groups observed 
At day 7, Bifidobacterium spp numbers were observed to be 
significantly lower in IAP infants compared with control 
infants (breast fed IAP vs. control: 5.86 log CFU/g vs. 8.16 None 
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IAP treatment 
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Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
log CFU/g, p=0.005; mixed fed IAP vs. control: 5.81 log 
CFU/g vs. 7.19 log CFU/g, p=0.03). 
By day 30, a significant increase was observed in both IAP 
groups (breast fed: 7.72 log CFU/g, p=0.035 and mixed fed: 
8.50 log CFU/g, p=0.036). Numbers remain higher in breast 
fed control infants compared with IAP infants (8.62 log 
CFU/g vs. 7.72 log CFU/g) but this no longer a significant 
difference. Numbers have significantly increased in mixed fed 
control infants to 8.55 log CFU/g (p=0.028) and are similar to 
that of IAP infants, 8.50 log CFU/g. 
McGregor 1986323 
US 
Randomised 
controlled 
trial 
58 intrapartum 
women  
(29 treated, 29 
not treated) 
Preterm labour 
21 enteric-
coated 
erythromycin 
tablets over 7 
days 
Withdrawal from 
study due to 
nausea/and or 
vomiting 1 1 
RR: 1.00 (0.07-
15.24) - 
Rajaei 2006325 
Iran 
Randomised 
controlled 
trial 
80 Intrapartum 
women  
(38 treated, 42 
not treated) 
Preterm labour 
400 mg 
erythromycin 
every 6 h orally 
for 10 days. 
Side effects: nausea, 
vomiting, hot flushes, 
decreased deep 
tendon reflexes, 
emotional 
disturbances or drug 
intolerance - - 
No significant 
difference in side 
effects - 
Roca 2016326 
Gambia 
Randomised 
controlled 
trial  
829 
intrapartum 
women and 
843 infants  
(414 women 
and 419 
infants treated, 
415 women 
and 424 
infants not 
treated) 
Neonatal sepsis 
prevention 
A single dose of 
oral 2g 
azithromycin (4 
tablets of 0.5g) 
Adverse 
events/serious 
adverse events in 
newborns 0 - - - 
Moderate urticarial 
rash 1 - - - 
Newborn GBS 
nasopharyngeal 
samples resistant to 
Azithromycin  
Day 2: 0 
Day 3: 0 
Day 6: 1 (0.3%) 
Day 14: 1 (0.3%) 
Day 28: 1 (0.3%) 
Day 2: 0 
Day 3: 2 (0.5%) 
Day 6: 2 (0.5%) 
Day 14: 1 (0.3) 
Day 28: 0 
- 
- 
PR: 0.51 (0.05–5.62) 
PR: 1.02 (0.06–
16.31) 
- None 
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Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
Newborn S. 
pneumoniae 
nasopharyngeal 
samples resistant to 
Azithromycin 
Day 2: 0 
Day 3: 0 
Day 6: 0 
Day 14: 2 (0.5%) 
Day 28: 8 (2.2%) 
Day 2: 0 
Day 3: 0 
Day 6: 2 (0.5%) 
Day 14: 4 (1.0%) 
Day 28: 8 (2.1%) 
- 
- 
- 
PR: 0.51 (0.009–
2.78) 
PR: 1.04 (0.40–2.75) None 
Newborn S. aureus 
nasopharyngeal 
samples resistant to 
Azithromycin 
Day 2: 3 (0.7%) 
Day 3: 41 
(10.6%) 
Day 6: 48 
(12.7%) 
Day 14: 57 
(15.3%) 
Day 28: 60 
(16.7%) 
Day 2: 4 (1.0%) 
Day 3: 27 (6.8%) 
Day 6: 20 (5.2%) 
Day 14: 13 
(3.4%) 
 
Day 28: 17 
(4.5%) 
 
PR: 0.77 (0.17–3.40)  
PR: 1.56 (0.98–2.48) 
PR: 2.46 (1.49–4.06) 
PR: 4.49 (2.50–8.06) 
 
PR: 3.68 (2.19–6.18) 
 None 
Newborn any bacteria 
nasopharyngeal 
samples resistant to 
Azithromycin 
Day 2: 3 (0.7%) 
Day 3: 41 
(10.6%) 
Day 6: 49 
(13.0%) 
Day 14: 60 
(16.1%) 
Day 28: 69 
(19.2%) 
Day 2: 4 (1.0%) 
Day 3: 29 (7.3%) 
Day 6: 24 (6.2%) 
Day 14: 17 
(4.5%) 
 
Day 28: 25 
(6.7%) 
 
PR: 0.77 (0.17–3.40) 
PR: 1.45 (0.92–2.28) 
PR: 2.09 (1.31–3.34) 
PR: 3.61 (2.15–6.08) 
 
PR: 2.88 (1.86–4.44) 
 None 
Maternal GBS 
nasopharyngeal 
samples resistant to 
Azithromycin  
Day 2: 0 
Day 3: 0 
Day 6: 0 
Day 14: 0 
Day 28: 1 (0.3%) 
Day 2: 0 
Day 3: 0 
Day 6: 0 
Day 14: 0 
Day 28: 1 (0.3%) 
- 
- 
- 
- 
PR: 1.01 (0.06–16.1) None 
Maternal S. 
pneumoniae 
nasopharyngeal 
samples resistant to 
Azithromycin 
Day 2: 6 (1.4%) 
Day 3: 3 (0.8%) 
Day 6: 3 (0.8%) 
Day 14: 7 (1.8%) 
Day 28: 7 (1.8%) 
Day 2: 0 
Day 3: 2 (0.5%) 
Day 6: 4 (1.0%) 
Day 14: 3 (0.8%) 
Day 28: 1 (0.3%) 
- 
PR: 1.51 (0.25–8.97) 
PR: 0.75 (0.17–3.35) 
PR: 2.33 (0.61–8.96) 
PR: 7.09 (0.88–57.4) None 
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Summary measures 
(95%CI) 
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adjusted for in 
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Maternal S. aureus 
nasopharyngeal 
samples resistant to 
Azithromycin 
Day 2: 6 (1.4%) 
Day 3: 16 (4.0%) 
Day 6: 22 (5.6%) 
Day 14: 36 
(9.2%) 
Day 28: 48 
(12.6%) 
Day 2: 11 (2.7%) 
Day 3: 7 (1.7%) 
Day 6: 14 (3.5%) 
Day 14: 12 
(3.1%) 
Day 28: 11 
(2.8%) 
 
PR: 0.55 (0.20–1.46) 
PR: 2.30 (0.96–8.97) 
PR: 1.58 (0.82–3.04) 
PR: 3.00 (1.85–5.68) 
PR: 4.42 (2.33–8.38) 
 None 
Maternal any bacteria 
nasopharyngeal 
samples resistant to 
Azithromycin 
Day 2: 12 (2.9%) 
Day 3: 19 (4.8%) 
Day 6: 25 (6.3%) 
Day 14: 4 
(10.5%) 
Day 28: 56 
(14.7%) 
Day 2: 11 (2.7%) 
Day 3: 9 (2.2%) 
Day 6: 14 (3.5%) 
Day 14: 15 
(3.8%) 
Day 28: 13 
(3.4%) 
 
PR: 1.09 (0.49–2.45)  
PR: 2.12 (0.97–4.63) 
PR: 1.48 (0.81–2.69) 
PR: 2.73 (1.54–4.86) 
PR: 4.36 (2.43–7.85) 
 None 
Maternal GBS 
vaginal samples 
resistant to 
Azithromycin  
Day 2: 1 (0.2%) 
Day 8-10: 6 
(1.5%) 
Day 2: 2 (0.5%) 
Day 8-10: 1 
(0.3%) 
PR: 0.50 (0.05–5.51) 
PR: 6.06 (0.73–50.1) None 
Maternal S. 
pneumoniae vaginal 
samples resistant to 
Azithromycin 
Day 2: 0 
Day 8-10: 0 
Day 2: 0 
Day 8-10: 0 
- 
- None 
Maternal S. aureus 
vaginal samples 
resistant to 
Azithromycin 
Day 2: 0 
Day 8-10: 27 
(6.9%) 
Day 2: 7 (1.7%) 
Day 8-10: 4 
(1.0%) 
 
- 
PR: 6.82 (2.41–19.3) 
 None 
Maternal any bacteria 
vaginal samples 
resistant to 
Azithromycin 
Day 2: 1 (0.2%) 
Day 8-10: 32 
(8.4%) 
Day 2: 9 (2.2%) 
Day 8-10: 5 
(1.3%) 
 
PR: 0.11 (0.01–0.88) 
PR: 6.67 (2.63–16.9) 
 None 
Maternal GBS breast 
milk samples 
Day 3: 1 (0.3%) 
Day 6: 1 (0.3%) 
Day 14: 1(0.3%) 
Day 3: 2 (0.5%) 
Day 6: 2 (0.5%) 
Day 14: 1 (0.3%) 
PR: 0.51 (0.05–5.56)  
PR: 0.50 (0.05–5.52) None 
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resistant to 
Azithromycin  
Day 28: 0 Day 28: 0 PR: 1.00 (0.006–
15.9) 
- 
Maternal S. 
pneumoniae breast 
milk samples 
resistant to 
Azithromycin 
Day 3: 0 
Day 6: 0 
Day 14: 0 
Day 28: 0 
Day 3: 0 
Day 6: 0 
Day 14: 0 
Day 28: 0 
- 
- 
- 
- None 
Maternal S. aureus 
breast milk samples 
resistant to 
Azithromycin 
Day 3: 19 (4.8%) 
Day 6: 20 (5.1%) 
Day 14: 22 
(5.7%) 
Day 28: 14 
(3.7%) 
Day 3: 7 (1.8%) 
Day 6: 8 (2.0%) 
Day 14: 3 (0.8%) 
Day 28: 5 (1.3%) 
PR: 2.75 (1.17–6.47) 
PR: 2.51 (1.12–5.64) 
PR: 7.31 (2.21–24.2) 
PR: 2.82 (1.03–7.76) None 
Maternal any bacteria 
breast milk samples 
resistant to 
Azithromycin 
Day 3: 20 (5.1%) 
Day 6: 20 (5.3%) 
Day 14: 23 
(5.9%) 
Day 28: 14 
(3.7%) 
Day 3: 9 (2.3%) 
Day 6: 10 (2.5%) 
Day 14: 4 (1.0%) 
Day 28: 5 (1.3%) 
PR: 2.25 (1.04–4.88) 
PR: 2.11 (1.01–4.42) 
PR: 5.74 (2.00–16.4) 
PR: 2.82 (1.03–7.76) None 
Salman 2015327 
Gambia 
Sub-study of 
Roca et al.’s 
randomised 
controlled 
trial  
40 infants 
from Roca et 
al.326 (20 
treated, 20 not 
treated) 
Neonatal sepsis 
prevention 
A single dose of 
oral 2g 
azithromycin (4 
tablets of 0.5g) 
Infantile hypertrophic 
pyloric 
Stenosis (IHPS) 
0 0 - - 
419 newborns 
from Roca et 
al.326 (all 
treated) 0 - 
95% CI: 0-
11.3/1,000 cases - 
Sinha 2003328 
US 
Case-control 
study 
228 infants  
0-30 days old 
(114 cases of 
non-GBS 
infection and 
114 controls, 
GBS 
prophylaxis 
Penicillin G 
(41%= 7 
people), 
ampicillin 
Bloodstream 
infection - - RR: 0.20 (0.011-3.6) 
Sex and year of 
birth 
Pneumonia - - RR: 2.5 (0.43-14.0) 
Sex and year of 
birth 
Any infection 
syndrome - - RR: 1.0 (0.38-2.9) 
Sex and year of 
birth 
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Summary measures 
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Factors 
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the analysis 
17 infants 
were treated 
(41%= 7 
people), 
clindamycin 
(18%= 3 people) 
Stoll 200220 
US 
Retrospective 
cohort study 
5447 
intrapartum 
women  
(3554 treated, 
1893 not 
treated) 
Indication not 
known 
Ampicillin 
(49%), penicillin 
(14%), and 
erythromycin 
(13%) 
Early-onset sepsis 63 21 OR: 1.1 (0.6–1.8) 
Gestational age, 
the presence or 
absence of 
intrauterine 
growth 
restriction, birth 
weight, race or 
ethnic group, 
and sex 
E. coli Sepsis or 
death - - 
No association was 
found for any 
maternal antibiotic 
(data were not 
shown). None 
33 infants 
(28 treated, 5 
not treated) 
Indication not 
known 
Ampicillin 
Ampicillin-resistant 
E. coli 26 1 p=0.01 None 
5447 
intrapartum 
women 
Indication not 
known 
IAP within 72 
hours (3399), no 
IAP within 72 
hours (2048) 
Indication not 
known 
Ampicillin IAP 
within 72 hours 
(2348), no 
ampicillin IAP 
within 72 hours 
(3099) 
Early onset sepsis 58 26 OR: 1.0 (0.6–1.6) 
Gestational age, 
the presence or 
absence of 
intrauterine 
growth 
restriction, birth 
weight, race or 
ethnic group, 
and sex 
E. coli sepsis 25 12 p=0.004 
NS 
When 
gestational age 
and interval 
between 
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membrane 
rupture and 
delivery 
adjusted for 
Svare 1997329 
Denmark 
Randomised 
controlled 
trial 
110 
intrapartum 
women  
(59 treated, 51 
not treated) 
Preterm labour 
Ampicillin 2g 
intravenously 
every six hours 
for 24 hours 
followed by 
pivampicillin 
500 mg orally 
every eight 
hours for seven 
days, plus 
metronidazole 
500 mg 
intravenously 
every eight 
hours for 24 
hours followed 
by 
metronidazole 
400 mg orally 
every eight 
hours for seven 
days 
Side effects and 
allergic reactions 
(undefined) 4 1 
RR: 3.46 (0.40-
29.95) None 
Wohl 2015330 
US 
Retrospective 
cohort study 
492 children  
2 years old  
(128 treated, 
364 not 
treated) 
Indication not 
known 
Penicillins 
(108), 
macrolides (16), 
aminoglycosides 
(3), Diagnosing atopic 
dermatitis 
Any IAP 37 
IAP 0-4 hours: 
9/28 
IAP 4-12 hours: 
11/53 
IAP 12-24 hours: 
7/26 
100 RR: 1.03 (0.75–1.41) 
RR 1.17 (0.66–2.06) 
 
RR 0.76 (0.44–1.31) 
 
RR 0.98 (0.51–1.89) 
 
RR 1.99 (1.13–3.49) None 
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cephalosporins 
(1) 
IAP >24 hours: 
6/11 
 
Studies investigating outcomes as IAP benefits in randomised controlled trials that could also be affected by IAP as a harm 
Cox 1996312 
US 
Randomised 
controlled 
trial 
82 infants  
(40 treated, 42 
not treated) 
Preterm labour 
2g ampicillin 
and 1g 
sulbactam 
parenterally 
every 6 hours 
for 8 doses, 
followed by 
ampicillin-
clavunate 
250mg orally 
every 8 hours 
for 5 days. 
5 minute APGAR 
score < 7  1 1 
RR: 1.05 (0.07-
16.23) None 
Neonatal ICU days 
M: 19 (SEM: 
0.2, R: 0-21) 
M: 22 (SEM: 
0.2, R: 0-27) NS None 
Respiratory distress 
ventilation 8  8 
NS (unable to 
calculate RR as some 
missing) None 
Necrotizing 
enterocolitis 0 1 
NS (unable to 
calculate RR as some 
missing) None 
Still birth 0 0 
NS (unable to 
calculate RR as some 
missing) None 
Neonatal death 1 0 
NS (unable to 
calculate RR as some 
missing) None 
Gordon 1995315 
US 
Randomised 
controlled 
trial 
117 
intrapartum 
women  
(58 treated, 59 
not treated) 
Preterm labour 
Ceftizoxime for 
5 days or 3 days 
Maternal infection 2 3 RR: 0.68 (0.12-3.91) None 
Neonatal pneumonia 0 0 NS None 
Neonatal sepsis 0 0 NS None 
Neonatal positive 
cultures 2 2 RR: 1.02 (0.15-6.98) None 
Kampikaho 1993317 
Uganda 
Quasi-
randomised 
controlled 
trial  
660 
intrapartum 
women  
(167 
streptomycin, 
163 penicillin, 
330 not 
treated) 
Post-partum 
infection 
prevention 
1g streptomycin 
(n=167) or 
0.8MU 
penicillin 
(n=163) 
Laboratory-
confirmed post-
partum infection 
Streptomycin: 
14/167 
Penicillin: 
15/163 
  
51/330 
 
 
 
 
1.00 (reference) 
Streptomycin RR: 
0.54 (0.31-0.95) 
Penicillin RR: 0.60 
(0.35-1.03) None 
Keettel 1949319 
US 
Randomised 
controlled 
trial 
895 
intrapartum 
women (465 
Post-partum 
infection 
prevention 
Puerperium fever 66 89 RR: 0.69 (0.51-0 92) None 
Puerperium 
Endometritis 13 40 RR: 0.30 (0.16-0.55) None 
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Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
treated, 430 
not treated) 
300,000/600,000 
units of 
penicillin at the 
indication of 
labour and then 
after 24-hour 
intervals.  
Puerperium Pyelitis 4 1 
RR: 3.70 (0.42-
32.96) None 
Puerperium Mastitis 5 3 RR: 1.54 (0.37-6.41) None 
Stillbirths 9 12 RR: 0.69 (0.30-1.63) None 
Neonatal deaths 12 12 RR: 0.92 (0.42-2.04) None 
Keettel 1950318 
US 
Controlled 
trial 
773 
intrapartum 
women  
(382 treated, 
391 not 
treated) 
Post-partum 
infection 
prevention 
600,000 units of 
penicillin at the 
indication of 
labour, and then 
after 24-hour 
intervals. 
Fever 29 61 RR: 0.49 (0.32-0.74) None 
Stillbirth 5 3 RR: 1.71 (0.41-7.09) None 
Neonatal death 4 2 
RR: 2.05 (0 38-
11.11) None 
Keuchkerian 
2005322 
Uruguay 
Randomised 
controlled 
trial 
96 intrapartum 
women  
(47 treated, 49 
not treated) 
Preterm labour 
Amoxicillin 
1000 mg 
sulbactam 500 
mg IV every 8 h 
during the first 
48 h and they 
continued to 
receive an oral 
intake of 
amoxicillin 250 
mg sulbactam 
250 mg every 8 
h for 5 days 
1 minute APGAR 
score < 7  3  2  RR: 1.57 (0 27-8.94) None 
Respiratory distress 
syndrome 3 3 
RR:  1.04 (0.22-
4.91) None 
Neonatal sepsis 0 0 - - 
Fetal death 1 1 
RR: 1.04 (0.07-
16.19) None 
Neonatal death 0 0 - - 
McGregor 1986323 
US 
Randomised 
controlled 
trial 
17 intrapartum 
women  
(8 treated, 9 
not treated) 
Preterm labour 
21 enteric-
coated 
erythromycin 
Maternal days in 
hospital 
M: 6.1  
(SD: 4.7, R: 3-
15) 
M: 6.3  
(SD: 6.2, R: 2-
18) NS - 
Amniotic fluid 
infection 0 0 - - 
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Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
tablets over 7 
days 
Maternal febrile 
morbidity 0 0 - - 
Initial requirement of 
neonate intermediate 
or intensive care 
nursery  2 3 RR: 0.75 (0.16-3.41) None 
Total days in 
intermediate or 
intensive care nursery 9  62 - - 
Total days in any 
nursery 
M: 3  
(SD: 2.1) 
M: 9.6  
(SD: 13.5) p=0.08 - 
Neonates treated with 
antibiotics 0 1 - - 
Nadiasaukiene 
1996324 
Lithuania  
Randomised 
controlled 
trial 
102 mother-
infant pairs 
(44 treated, 58 
not treated) 
Preterm labour 
2 x 5g 
ampicillin four 
hours apart or 1 
hour before 
delivery if 
labour 
proceeded 
quickly 
1 minute APGAR 
score < 7  
26 40 
RR: 0.86 (0.63-1.16) None 
Neonate did not 
survive first week 
8 12 
RR: 0.88 (0.39-1.96) None 
Neonatal infection 4 38 RR: 0.14 (0.05-0.36) None 
Histological 
chorioamnionitis 
6 28 
RR: 0.28 (0.13-0.62) None 
Puerperal uterine 
infection 
8 26 
RR: 0.41 (0.20-0.81) None 
Rajaei 2006325 
Iran 
Randomised 
controlled 
trial 
80 Intrapartum 
women  
(38 treated, 42 
not treated) 
Preterm labour 
400 mg 
erythromycin 
every 6 h orally 
for 10 days. 
Admission to NICU 14 25 p<0.05 
RR: 0.62 (0.38-1.01) 
Risk difference:  
−22.68% (95% CIs: 
−44.02- −1.34), and 
p=0.043 None 
Roca 2016326 
Gambia 
Randomised 
controlled 
trial  
829 
intrapartum 
women and 
843 infants  
(414 women 
and 419 
infants treated, 
Neonatal sepsis 
prevention 
A single dose of 
oral 2g 
azithromycin (4 
tablets of 0.5g) 
Maternal deaths 0 0 - - 
Puerperal sepsis 1 2 RR: 0.50 (0.05-5.51) - 
Deaths from neonatal 
sepsis, meningitis, 
pneumonia 
3 (all underlying 
conditions) 
4 (no underlying 
conditions) 
RR: 0.76 (0.17- 3.37) - 
Apgar scores at birth 0: 6 
1-6: 8 
0: 6 
1-6: 5 - - 
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Reference 
Country Design Participants 
IAP treatment 
details Outcomes reported 
Findings   
Treatment              Control 
Summary measures 
(95%CI) 
Factors 
adjusted for in 
the analysis 
415 women 
and 424 
infants not 
treated) 
7-10: 402 7-10: 408 
Svare 1997329 
Denmark 
Randomised 
controlled 
trial 
110 
intrapartum 
women  
(59 treated, 51 
not treated) 
Preterm labour 
Ampicillin 
2grams 
intravenously 
every six hours 
for 24 hours 
followed by 
pivampicillin 
500 mg orally 
every eight 
hours for seven 
days, plus 
metronidazole 
500 mg 
intravenously 
every eight 
hours for 24 
hours followed 
by 
metronidazole 
400 mg orally 
every eight 
hours for seven 
days 
Maternal 
Chorioamnionitis - 
endometritis 
3 0 
- None 
5 minute APGAR 
score < 7  5 1 
RR:  4.32 (0.52-
35.79) None 
Admission to 
neonatal department 23/58 32 RR: 0.63 (0.43-0.93) None 
Days in neonatal 
department 
Median: 15.5  
(R: 1-60) 
Median: 27  
(R: 2-121) - - 
Oxygen /NCPAP 
/ventilation 
M: 9.7  
(SD: 15.7) 
M: 10.8  
(SD: 17.2) - - 
Neonatal antibiotic 
days 
M: 5.9  
(SD: 2.8) 
M: 6.6  
(SD: 4.2) - - 
Meningitis, 
septicaemia, 
pneumonia 6/58 11 RR:  0.48 (0.19-1.20) - 
E coli Escherichia coli, CI confidence interval, CFU colony forming units, g grams, GBS group B Streptococcus, IAP intrapartum antibiotic prophylaxis, IQR interquartile range, IV 
intravenous, M mean, NICU national intensive care unit, OR Odds ratio, p probability level, R range, RR relative risk, S. aureus Staphylococcus aureus, S. pneumoniae 
Streptococcus pneumoniae, SEM Standard error of mean, NS not significant, UK United Kingdom, US United States of America, UTI urinary tract infection 
* p=0.037 
Figures in italics have been calculated by myself 
Antenatal screening for group B Streptococcus in the UK	
	 393 
Appendix 12. Study information sheet for ecological studies (objective 4-6) 
 
 STUDY INFORMATION LEAFLET 
Study Title: Importing international data on Group B Streptococcus to inform Group B Streptococcus screening policy in the UK 
Investigator(s): Ms Farah Seedat, Dr Saverio Stranges, Dr Ngianga-Bakwin Kandala, Dr Sian Taylor Phillips 
 
Introduction 
You are invited to take part in a research study. Before you decide, you need to understand why the research is 
being done and what it would involve for you. Please take the time to read the following information 
carefully. Talk to others about the study if you wish. 
 
(Part 1 tells you the purpose of the study and what will happen to you if you take part.  Part 2 gives you more 
detailed information about the conduct of the study) 
Please ask us if there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
 
PART 1 
 
What is the study about? 
When Group B Streptococcus is passed on from a mother to baby during childbirth, there is a small risk that it 
can cause early onset GBS (EOGBS) disease in infants, which has serious life threatening complications. Due 
to the severe complications of GBS in infants, some groups have been campaigning for antenatal screening to 
be introduced. The aim of antenatal screening is to identify GBS colonised mothers for treatment with 
intrapartum antibiotic prophylaxis treatment (IAP). At present the UK National Screening Committee does not 
consider that there is enough evidence that the benefits of antenatal screening would outweigh the harms and 
therefore their policy is not to routinely screen all women in pregnancy. Most importantly, there is a lack of 
randomised controlled trial (RCT) evidence assessing the effectiveness of screening. Other countries take a 
range of approaches to antenatal screening for GBS. As there is no robust RCT evidence on the effectiveness 
of GBS screening, analysis of the approaches taken in different countries and their effectiveness may be an 
important source of information to aid UK decision-making.  In this project, we aim to investigate how data 
on group b streptococcus (GBS) in countries with different screening programmes can be imported and 
factored into policymaking about whether and how to commence screening programmes within the UK. To do 
this, we are kindly asking you to provide aggregate national and regional GBS related outcomes in your 
country.  
 
Do I have to take part? 
It is entirely up to you to decide. We will describe the study and go through this information sheet, which we 
will give you to keep. By sending us any of the data requested, you are giving your consent for the 
information that you have supplied to be used in this study and formal signed consent will not be collected. 
You will be free to withdraw your data at any time, without giving a reason and this will not affect you or 
your circumstances in any way. 
 
What will happen to me if I take part? 
If you agree to take part in the study you will be asked to provide available annual figures for the following 
GBS related outcomes in your country/region: 
Early onset neonatal sepsis incidence (culture positive or negative, < 7 days of life) per 1000 livebirths 
Overall neonatal sepsis incidence (culture positive or negative, < 90 days) per 1000 livebirths 
Early onset GBS incidence (culture positive or negative, < 7 days) per 1000 livebirths 
Overall neonatal GBS incidence (culture positive or negative, <90 days) per 1000 livebirths 
Case fatality from EO (< 7 days)/overall neonatal GBS (as a % of diagnosed cases) 
Case fatality from early-onset (< 7 days)/overall neonatal sepsis (as a % of diagnosed cases) 
Neonatal mortality per 1000 livebirths 
Number and percentage of early-onset (< 7 days)/overall neonatal sepsis cases resistant to different antibiotics  
Number and percentage of EO (< 7 days)/overall neonatal GBS cases resistant to different antibiotics 
Early-onset (< 7 days)/overall neonatal Escherichia coli (E. coli) incidence per 1000 livebirths 
Number and percentage of early-onset (< 7 days)/overall neonatal E. coli resistant to different antibiotics 
Maternal anaphylaxis incidence per 10,000 women treated with IAP 
GBS screening and IAP uptake (as a percentage of all pregnant women offered) 
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GBS maternal colonisation prevalence (as a percentage of all pregnant women) 
Percentage of pregnant women with prolonged rupture of membranes 
Percentage of women with intrapartum fever 
Percentage of women who underwent a caesarean section 
Percentage of women who received clindamycin and % who received penicillin for GBS prevention 
Late onset sepsis incidence (culture positive or negative, 7-89days) per 1000 livebirths 
Late onset group B streptococcus incidence (culture positive or negative, 7-89 days) per 1000 livebirths 
Incidence of peripartum/postpartum clostridium difficile per 1000 deliveries 
GBS prevention protocol 
 
What are the possible disadvantages, side effects, risks, and/or discomforts of taking part in this study? 
There are no risks in providing data for this study. Your rights will not be affected. 
 
What are the possible benefits of taking part in this study? 
By providing data for this study, you may help to influence and improve future GBS healthcare in the UK and 
abroad. For your assistance, your organisation will be acknowledged in all publications of the study and you 
will have access to any intellectual property generated. 
 
Expenses and payments 
Reimbursement is not available for data provision. For your assistance, the organisation will be acknowledged 
in all publications of the study and you will have access to any intellectual property generated. 
 
What will happen when the study ends? 
The data provided will be saved in a database of GBS related outcomes across all countries with available 
data. This database will be securely stored on a password protected laptop that will be stored in a locked 
cabinet overnight in the Department of Health Sciences at the Warwick Medical School campus of University 
of Warwick, and not removed from the site. After the study has finished anonymous data will be stored for in 
the locked cabinets and then archived as per University policy.  
 
Will my taking part be kept confidential? 
Yes.  We will follow strict ethical and legal practice and all information about you will be handled in 
confidence. Further details are included in Part 2. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm that you might 
suffer will be addressed. Detailed information is given in Part 2. 
 
This concludes Part 1. 
If the information in Part 1 has interested you and you are considering participation, please read the 
additional information in Part 2 before making any decision. 
______________________________________________________________________ 
 
PART 2 
Who is organising and funding the study? 
University of Warwick is organising the study. The Principal Investigator is Ms Farah Seedat. The study has 
been reviewed and approved by an independent research ethics committee. The Economic and Social 
Research Council and the UK National Screening Committee funded this study.  
 
What will happen if I don’t want to carry on being part of the study? 
Participation in this study is entirely voluntary. Refusal to participate will not affect you in any way.  
 
If you agree to participate, you may nevertheless withdraw from the study at any time without affecting you in 
any way. 
You have the right to withdraw from the study completely and decline any further contact by study staff after 
you withdraw. Withdrawing from the study will not affect you in any way. 
 
What if there is a problem? 
This study is covered by the University of Warwick’s insurance and indemnity cover.  If you have an issue, 
please contact Jo Horsburgh (details below). 
 
Who should I contact if I wish to make a complaint? 
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Any complaint about the way you have been dealt with during the study or any possible harm you might have 
suffered will be addressed.  Please address your complaint to the person below, who is a Senior University of 
Warwick official entirely independent of this study: 
Jo Horsburgh, Deputy Registrar, Deputy Registrar’s Office, University of Warwick, Coventry, UK, CV4 
8UW. T:  +00 44 (0) 2476 522 713 E: J.Horsburgh@warwick.ac.uk  
 
Will my taking part be kept confidential? 
The data that we require from you are all annual aggregated data at the national or regional level of your 
country therefore it will not contain any patient level data and must be anonymous. Once emailed to us data 
will be saved in an anonymous password protected document. Personal data will not be stored by the research 
team. During the study, this anonymous data file will be stored in a password locked laptops that will be 
stored in a locked cabinet overnight in the Department of Health Sciences at the Warwick Medical School 
campus of University of Warwick, and not removed from the site. The anonymous data will be stored for after 
the study has finished in the locked cabinets and then archived, as per University policy.  
 
What will happen to the results of the study? 
We hope to disseminate the results of the study by publishing it in a peer-reviewed journal and presenting the 
study at relevant conferences.  We also intend to provide reports for the UK National Screening Committee to 
publish on their website and hold a seminar at their premises to communicate specific findings and policy 
recommendations to the staff. We will also send a report to the institutions across the world that provided 
data.  
 
Who has reviewed the study? 
This study has been reviewed and given favourable opinion by the University of Warwick’s Biomedical and 
Scientific Research Ethics Committee (BSREC): REGO-2014-777, 20/06/2014 
 
What if I want more information about the study? 
If you have any questions about any aspect of the study or your participation in it not answered by this 
participant information leaflet, please contact:   
 
Dr Sian Taylor Phillips 
E: S.Taylor-Phillips@warwick.ac.uk 
T:  + 44 (0) 2476 575882   
 
 
 
Thank you for taking the time to read this participant information leaflet.  
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Appendix 13. Questionnaire survey for ecological studies (objective 4-6) 
 
 
 
 
 
 
 
Using International Data To Inform Group B Streptococcus Screening Decisions 
Data Form 
Thank you very much for your interest in collaborating on, and contributing data to, our project investigating the 
contextual predictors of Group B Streptococcus (GBS) disease. We hope the aims and methods of the project, as 
well as the data we are requesting, are clear to you from the introductory emails and study information sheet. If 
you have any questions, please feel free to contact Ms Farah Seedat on f.seedat@warwick.ac.uk or 
+447943826123.  
 
Annual figures on GBS related outcomes 
In the study information sheet you will find the overall list of outcomes we are interested in. We would like to 
know the annual figures for these outcomes. We understand that you may not have data for all of the years, or for 
all of the outcomes. Please feel free to send us data on any of the outcomes across any years, as we are keen to 
compile as much of the available international data as possible. This will not only enable us to perform the 
analysis, but will also be a useful resource in future. 
The table on the next page shows the data that we require. Please complete the table with your data and email it 
back to us. Please fill in the data for each year in separate columns, specifying the year in the first row. For 
outcomes that you do not have data, please put a ‘N’ in the box.  
Alternatively, using the table as a guide, you can send us your corresponding data in whichever format it is in, 
and we can fill out the table with your data.  
 
 
Thank you very much for your time and data.
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Data table 
 
Outcome Cultu
re 
positi
ve, 
negati
ve or 
both 
Definition Setti
ng 
(Cou
ntry, 
regio
n) 
199
6 
199
7 
199
8 
199
9 
 200
0 
200
1 
200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
Number of livebirths                       
 Group B Streptococcus 
Number/percentage of 
pregnant women colonised 
with GBS (by year or overall 
estimated prevalence) 
                      
Number of early-onset group 
B streptococcus cases 
 < x days                     
Number of late-onset group B 
streptococcus cases 
 Specify x-
xx days 
                    
Number of all neonatal group 
B streptococcus cases 
 Specify: 
<xx days 
                    
Number of deaths from early-
onset group B streptococcus  
                      
Number of deaths from late-
onset group B streptococcus  
                      
Number of deaths from all 
neonatal group B 
streptococcus  
                      
Number of early-onset group 
B streptococcus cases 
resistant to clindamycin  
                       
Number of early-onset group 
B streptococcus cases 
resistant to erythromycin 
                      
Number of early-onset group 
B streptococcus cases 
resistant to other antibiotics 
(please specify) 
 Specify 
antibiotic 
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Outcome Cultu
re 
positi
ve, 
negati
ve or 
both 
Definition Setti
ng 
(Cou
ntry, 
regio
n) 
199
6 
199
7 
199
8 
199
9 
 200
0 
200
1 
200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
Number of late-onset group B 
streptococcus cases resistant 
to clindamycin 
                      
Number of late-onset group B 
streptococcus cases resistant 
to erythromycin 
                      
Number of late-onset group B 
streptococcus cases resistant 
to other antibiotics (please 
specify) 
 Specify 
antbiotic 
                    
Number of all neonatal group 
B streptococcus cases 
resistant to clindamycin 
 Specify 
antibiotic  
                    
Number of all neonatal group 
B streptococcus cases 
resistant to erythromycin 
                      
                       
Number of all group B 
streptococcus cases resistant 
to antibiotics (specify each 
antibiotic individually in 
separate rows) 
 Specify 
antibiotic  
                    
 Neonatal Sepsis 
Number of all-cause early 
onset sepsis cases 
 Specify 
early: 
< x days 
                    
Number of all-cause late 
onset sepsis cases 
 Specify 
late: x-x 
days 
                    
Number of all-cause overall 
neonatal sepsis cases 
 Specify: <x 
days 
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Outcome Cultu
re 
positi
ve, 
negati
ve or 
both 
Definition Setti
ng 
(Cou
ntry, 
regio
n) 
199
6 
199
7 
199
8 
199
9 
 200
0 
200
1 
200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
Number of deaths from early-
onset neonatal sepsis  
                      
Number of deaths from late-
onset neonatal sepsis  
                      
Number of deaths from all 
neonatal sepsis  
                      
Number of early-onset 
neonatal sepsis cases resistant 
to antibiotics (specify each 
antibiotic individually in 
separate rows) 
 Specify 
antibiotic  
                    
Number of all neonatal sepsis 
cases resistant to antibiotics 
(specify each antibiotic 
individually in separate rows) 
 Specify 
antibiotic  
                    
Number of all sepsis cases 
resistant to antibiotics 
(specify each antibiotic 
individually in separate rows) 
 Specify 
antibiotic  
                    
 Neonatal Escherichia coli (E. coli) 
Number of early-onset E. coli 
cases 
 Specify 
early: 
< x days 
                    
Number of late-onset E. coli 
cases 
 Specify 
late: x-x 
days 
                    
Number of all neonatal E. 
coli cases 
 Specify: <x 
days 
                    
Number of deaths from early-
onset E. coli 
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Outcome Cultu
re 
positi
ve, 
negati
ve or 
both 
Definition Setti
ng 
(Cou
ntry, 
regio
n) 
199
6 
199
7 
199
8 
199
9 
 200
0 
200
1 
200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
Number of deaths from late-
onset E. coli 
                      
Number of deaths from all 
neonatal E. coli 
                      
Number of early-onset E. coli 
cases resistant to antibiotics 
(specify each antibiotic 
individually in separate rows) 
 Specify 
antibiotic  
                    
Number of all neonatal E. 
coli cases resistant to 
antibiotics (specify each 
antibiotic individually in 
separate rows) 
 Specify 
antibiotic  
                    
Number of all E. coli cases 
resistant to antibiotics 
(specify each antibiotic 
individually in separate rows) 
 Specify 
antibiotic  
                    
 Uptake rates 
GBS screening uptake rate   Definition 
of uptake 
                    
GBS intrapartum antibiotic 
prophylaxis uptake  
 Definition 
of uptake 
                    
Number of women given 
intrapartum antibiotic 
prophylaxis for GBS (if 
different to uptake rate) 
                      
Number of women who 
received penicillin for GBS 
prevention 
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Outcome Cultu
re 
positi
ve, 
negati
ve or 
both 
Definition Setti
ng 
(Cou
ntry, 
regio
n) 
199
6 
199
7 
199
8 
199
9 
 200
0 
200
1 
200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
Number of women who 
received clindamycin for 
GBS prevention 
                      
Number of women who 
received other intrapartum 
antibiotic prophylaxis 
(specify antibiotic)  
 Specify 
antibiotic 
                    
 Other 
Number of preterm deliveries  Specify 
premature
: < xx 
weeks 
                    
Number of low birth weight 
babies 
 Definitio
n of low 
birth 
weight 
                    
Number of 
Peripartum/postpartum 
clostridium difficile cases 
                      
Number of maternal 
anaphylaxis cases 
                      
Number of pregnant women 
with intrapartum prolonged 
rupture of membranes  
 Specify 
rupture 
duration 
                    
Number of women with 
preterm pre-labour rupture of 
membranes  
 Specify 
preterm 
(< xx 
weeks) 
and 
rupture 
duration 
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Outcome Cultu
re 
positi
ve, 
negati
ve or 
both 
Definition Setti
ng 
(Cou
ntry, 
regio
n) 
199
6 
199
7 
199
8 
199
9 
 200
0 
200
1 
200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
Number of women with 
intrapartum fever 
 Specify 
fever 
degree 
                    
Number of women who 
underwent a caesarean 
section 
                      
Most prevalent GBS strain                       
Number of multiple births                       
National/regional GBS 
prevention protocol  (Please 
attach protocol to your email) 
 Universal
, risk-
based, 
combined
, none 
                    
 
Thank you very much for taking the time to fill out this form and providing data. 
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Appendix 14. Ethical approval for ecological studies (objective 4-6) 
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Appendix 15. Scatterplots for EOGBS incidence  
 
A. By geographical area 
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B. By world region 
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Appendix 16. Scatterplots for early-onset sepsis incidence  
 
A. By geographical area
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B. By world region 
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Appendix 17. Scatterplots for late-onset group B Streptococcus incidence 
 
A. By geographical area 
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B. By world region  
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Appendix 18. Scatterplots for Escherichia coli incidence 
 
A. By geographical area 
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B.  By world region 
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Appendix 19. Scatterplots for EOGBS antibiotic resistance  
 
A. By geographical area  
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B. By world region 
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Appendix 20. Scatterplots for neonatal GBS antibiotic resistance 
 
A. By geographical area
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B. By world region  
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